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The two type I genotype T. gondii strains, RH, a lab-adapted strain, and GT1, a 
non-lab-adapted strain, have a genetic difference of only 0.002%, but show remarkable 
phenotypic differences in vitro. For example, it has long been known that RH’s in vitro 
virulence (i.e. plaquing capacity) and extracellular survival is far superior to that of GT1, 
likely due to several decades of adaptation to the in vitro environment (i.e. lab-adaptation). 
The genetic basis of these phenotypes, however, remains largely unknown despite 
previous allele-swapping experiments, thus inspiring two hypotheses: 1) epistatic 
interactions between two or more alleles and/or 2) gene regulatory mechanisms are 
responsible for lab-adaptive phenotypes. Uncovering the molecular basis underlying lab-
adaptive phenotypes will support our growing understanding of T. gondii virulence and 
suggest therapeutic targets that affect the parasites lytic cycle in a host-independent 
manner.  
To answer this question, we applied Evolve and Resequencing (E&R) of GT1 
during the first 1500 generations of its lab-adaptation in order to chronologically identify 
emerging genotype-phenotype correlations. Indeed, lab-adaptation augmented GT1’s in 
vitro virulence by improving its extracellular survival and reinvasion capabilities- both 
extracellular phenotypes of the lytic cycle. DNA-sequencing of parallel GT1 populations 
 
  
at multiple evolutionary timepoints (i.e. passages) identified a polymorphic phospholipid 
flippase gene whose gene expression is critical for in vitro virulence but, unfortunately, 
the evolved mutations could not be functionally characterized due to technical limitations. 
RNA-seq of both intracellular and extracellular parasites across several passages 
identified hundreds of “pro-tachyzoite” differentially expressed genes (DEGs), but only in 
extracellular parasites, paralleling our phenotypic observations. Interestingly, several 
upregulated DEGs are connected to fatty acid biosynthesis. Lastly, genetic KO of five 
seemingly non-related DEGs indicates that GT1’s lab-adaptive in vitro virulence is a 
complex and polygenic phenotype that is largely controlled by mechanisms independent 
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Toxoplasma gondii was co-discovered in 1908, being isolated from Ctenodactylus 
gundi, an African rodent, by Charles Nicolle and Louis Manceaux at the Pasteur Institute 
in Tunisia [1], and from the tissues of a rabbit by Alfonso Splendore in Brazil [2]. 
Throughout the rest of the early 20th century, several suspected human cases of 
toxoplasmosis were reported worldwide, with the first confirmed case being reported in 
1939 by Wolf et al in New York, US [3]. Several reviews excellently summarize these 
historical cases [4, 5]. In 1970, taxonomy classified T. gondii as a member of the 
Apicomplexa, a phylum consisting of over 5,000 unicellular, spore-forming, obligate 
parasitic species [6, 7]. Seven Apicomplexa genera are responsible for human diseases, 
for which immunocompromised or prenatal humans are the most vulnerable: Toxoplasma 
(Toxoplasmosis), Plasmodium (malaria), Cryptosporidium (Cryptosporidiosis), 
Cyclospora (Cyclosporiasis), Isospora (Isosporiasis), Sarcosystis (Sarcocystosis), and, 
more rarely, Babesia (Babesiosis). Due to its ease of culture and genetic manipulation, 
T. gondii is regarded as a model system for studying Apicomplexan biology [8], which has 
advanced our ability to combat human and veterinary diseases, and not to mention the 
annual multi-billion-dollar economic burden on the US [9]. 
 
1.2. Toxoplasma gondii’s life cycle 
T. gondii has evolved to be one of the world’s most ubiquitous parasites, capable of 
infecting any nucleated cell of any warm-blooded organism. Members of the Felidae 
family (i.e. the cat) are considered the definitive host, where sexual reproduction takes 
place, while all other animals are considered intermediate hosts permitting only asexual 
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reproduction [10]. For decades, many scientists have asked, “why the cat”? Well, the 
reason behind this was recently discovered to be the parasites ability to sense linoleic 
acid, which is particularly rich in the serum of cats [11]. As a result, T. gondii have 
developed a complex life cycle comprised of disparate reproductive and parasitic stages. 
Herein, we begin T. gondii’s typical life cycle starting with its definitive host, the cat. 
Infection of the cat commonly begins via oral consumption of chronically infected prey, 
such as a mouse or bird, containing infectious tissue cysts (Figure 1.1); tissue cysts are 
a durable and immunologically-protective vacuolar structure containing up to 3,000 quasi-
dormant parasites called bradyzoites [12, 13]. After their consumption, tissue cysts are 
broken down by digestive enzymes, thereby releasing bradyzoites which subsequently 
invade the enterocytes of the digestive tract [14, 15]. Upon invasion, bradyzoites convert 
into merozoites, a fast and replicative form of T. gondii within the cat that undergo limited 
rounds of asexual reproduction (i.e. endopolygeny) [16, 17]. After this brief parasite 
expansion, merozoites convert into macro- and micro-gametes (i.e. gametogony), 
marking the sexual cycle for T. gondii [16-18]. After gamete fusion and formation of the 
zygote (i.e. fertilization), the oocyst is formed, an environmentally-protective spore 
containing a rigid outer cyst wall. Millions of unsporulated oocysts are shed in the cat’s 
feces and, over a few days, develops into a sporulated oocyst (i.e. sporogony) containing 
eight sporozoites, a dormant form of T. gondii that resides inside the oocyst [17].  
Shed oocysts, particularly on farm land, can contaminate grasslands as well as the 
surface of fruits and vegetables; therefore, infection of an intermediate host commonly 
occurs with the consumption of oocyst-contaminated grasslands or produce (Figure 1.1) 
[19]. Once ingested, sporulated oocysts are broken down by digestive enzymes, thereby 
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releasing the sporozoites [14, 15]. Subsequently, sporozoites invade enterocytes of the 
digestive tract and convert into tachyzoites, a fast and replicative form of T. gondii within 
intermediate hosts that undergo many rounds of asexual reproduction (i.e. endodyogeny) 
[16]. Tachyzoites quickly disseminate to all areas of the body and cause tissue damage 
via its lytic cycle (Figure 1.2a.; see Chapter 1.5) [20-22]. This period of acute infection 
lasts roughly a week, upon which the immune system starts suppressing the infection by 
forcing tachyzoites to convert back into bradyzoites, the quasi-dormant form of T. gondii 
that form tissue cysts, preferentially within muscle and neuronal tissue [13]. This period 
of chronic infection is largely believed to last for the lifetime of the host, albeit parasite 
clearance has been recently observed in mice 20 months post-infection, suggesting 
clearance is eventually possible [23].  
Continued transmission can occur amongst carnivorous intermediates by the 
consumption of rare or undercooked meat containing bradyzoite tissue cysts (e.g. 
predator-prey interactions or steak tartare) (Figure 1.1) [24]. The consumption of tissue 
cysts will release bradyzoites, which subsequently invade the enterocytes of the digestive 
tract. Upon invasion, bradyzoites convert back into tachyzoites, rapidly replicate and 
disseminate throughout the host, and then convert back into the tissue cyst-forming 
bradyzoites. The life cycle of T. gondii comes full circle when tissue cysts from an 
intermediate host (e.g. mouse or bird) are consumed by a cat (Figure 1.1) [13]. 
 
1.3. Population structure and epidemiology 
Since the early 1990’s, >1000 T. gondii isolates from infected human and animals 
have been genotyped by various molecular phylogenetic techniques. Restriction 
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Fragment Length Polymorphism (RFLP) and, more recently, DNA-sequencing have 
identified four clonal (“typical”) genotypes of T. gondii worldwide, termed type I, type II, 
type III, and, more recently, type 12 [25, 26]. Studies estimate the genomic sequence of 
Type I, II, and III to differ only 1-3% [27-29]. More recent studies find all four strain to have 
highly similar multi-locus genotypes, high levels of linkage disequilibrium, and infrequent 
recombination events [26]. Such worldwide clonality appears to be the result of a selective 
sweep that occurred around 10,000 years ago, driven by the emergence of a 
monomorphic chromosome (Chr1a) which enabled T. gondii to infect hosts via oral 
transmission [30, 31]. Consequently, T. gondii can now bypass sexual reproduction in the 
cat and undergo asexual transmission between a myriad of intermediate hosts. 
Furthermore, since the asexual stages are haploid, it is only when multiple genotypes 
infect a single cat that genetic recombination of alleles can actually occur [28]. Taken 
together, this added complexity in the parasites life cycle resulted in the global asexual 
expansion of T. gondii that we see today. 
All four types appear in North America while South America contains many more 
divergent “atypical” strains, categorized into several haplogroups, which include type 12 
[26, 32]. Type I, II, and III are found in Europe [25], whereas Asia appears to be dominated 
by haplogroup 13 [33, 34]. Africa [35], Australia [36, 37], and possibly Antarctica [38] also 
encompass a mixture of typical and atypical genotypes. Severity of infection and 
prevalence of T. gondii genotypes can vary drastically. Type II strains tend to dominate 
the majority of human cases [25, 39-43] while type I and atypical strains tend to be more 
severe pathologically (e.g. ocular toxoplasmosis) [44-46]. Globally, it is estimated that 30-
50% of the human population is infected with T. gondii, but depending on geography, 
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cultural habits, food preparation, and hygiene, prevalence can vary [47, 48]; for example, 
studies report 95% seroprevalence in France [49], 22.5% in US [50], and only 6.7% in 
Korea [51]. Typically, human infection is acquired through the consumption of 
undercooked meat contaminated with tissue cysts or the consumption of unwashed fruits 
and vegetables contaminated with small traces of cat feces containing infectious oocysts 
(Figure 1.1) [52-56]; although rare, oocyst-contaminated water can also be a source of 
infection [57, 58]. Additionally, infection can be acquired congenitally from an 
immunologically naïve mother, or during a patient’s blood transfusion [59] or organ 
transplant (Figure 1.1) [60].  
 
1.4. Toxoplasmosis 
 Toxoplasmosis is the second leading cause of death from foodborne illness in the 
United States (US). The Center for Disease Control (CDC) has named toxoplasmosis as 
one of five neglected parasitic infections due to the number of people infected, severity 
of the disease, and limitations on treatment. It is estimated that 30-50% of the global 
human population is infected with T. gondii [47, 48]. While most individuals are 
asymptomatic, those with compromised immune systems, such as those with AIDS or 
those undergoing chemotherapy, latent or newly acquired toxoplasmosis can be deadly. 
For example, 25% of AIDS patients show cases of Toxoplasma-related encephalitis, with 
about 84% of cases leading to death [61]. T. gondii is capable of migrating through 
biological barriers, such as the blood brain barrier, where it can infect the brain and retina, 
leading to complications in vision (ocular toxoplasmosis) but not cognitive ability [62-65]. 
It is estimated that ~5,000 cases of ocular toxoplasmosis cases occur annually in the US 
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[66]. Furthermore, congenital transmission of the disease, via migration through the 
placental barrier, can cause perinatal mortality or severe birth defects such as blindness 
or mental disability [67]. In the US, an estimated 400-4,000 congenital cases occur every 
year [68]. Currently, there is no vaccine to combat infections; treatment is limited only to 
acute stages of the disease with the co-treatment of pyrimethamine and sulfadiazine, 
although resistance appears to be on the rise in South America [69]. Pathogenesis of the 
disease is the direct result of the tissue damage caused by the tachyzoite’s unchecked 
lytic cycle (Figure 1.2a.), which is discussed in detail next. 
 
1.5. The tachyzoite lytic cycle and its associated virulence traits 
 Acute toxoplasmosis is marked by repeated rounds of the parasite’s lytic cycle 
which causes tissue damage to the host and, if left unchecked, can lead to severe medical 
complications and even death. The lytic cycle consists of several key steps: replication, 
egress, extracellular survival, migration, attachment, and invasion (Figure 1.2a.). An 
impediment or enhancement at any one of these steps can, respectively, stop or speed 
up the parasites lytic cycle; therefore, these steps are viewed as virulence traits (i.e. 
parasitic behaviors critical to pathogenesis). Moreover, throughout its lytic cycle, T. gondii 
encounters both intracellular and extracellular milieu’s, thus these virulence traits can be 
sorted into two categories: extracellular virulence traits and intracellular virulence traits. 
 
1.5.1. Extracellular virulence traits of the lytic cycle: Extracellular survival, motility, 




Extracellular survival is a virulence trait important for local and systemic 
dissemination within a host, although it is still debated whether extracellular parasites in 
the bloodstream can actually disseminate to the peripheral tissues [70-73]. Nevertheless, 
histology shows ~20% of tachyzoites in an infected tissue are extracellular, indicating that 
T. gondii must endure the stress of an extracellular environment during their lytic cycle 
[73]. Previous studies have shown that 4-hour extracellular tachyzoites respond to stress 
by reducing amino acid uptake and inhibiting eukaryotic initiation factor-2α (eIF2α) by 
phosphorylation [74]. Such reduced protein translation, especially by phosphorylation of 
eIF2α, is commonly observed in other parasites, including Plasmodium and 
Trypanosomes [75-78]. Extracellular triggers of stress are largely unknown, but oxygen 
tension appears to be the lead suspect. The partial pressure of oxygen (pO2) can vary 
dramatically between intracellular and extracellular environments (~0.5-20%), as well as 
various tissues (~1-10%), and cell lines (~0.5-17%), and therefore it is considered a major 
cue for environmental sensing by protozoans [79, 80]. Prolyl 4-hydroxylases (PHDs) are 
crucial oxidoreductase enzymes used for O2 sensing [81, 82], and two PHDs, PHYa and 
PHYb, have been described so far in T. gondii: TgPHYa is important for tachyzoite growth 
at low (0.5%) pO2 [83], whereas TgPHYb is important at high (21%) pO2 [84]. Tachyzoite 
growth supported by TgPHYa is also associated with the hydroxylation of S-phase kinase-
associated protein 1 (SKP1) which leads to downstream glycosylation and activation of 
the Skp/Cullin, F-Box containing complex (SCF complex) [85], an E3 ubiquitin ligase that 
marks proteins for proteasomal degradation and regulates protist growth [83, 86, 87]. 
Tachyzoite growth supported by TgPHYb is associated with reduced protein translation 
via the phosphorylation and inhibition of eukaryotic elongation factor 2 (eEF2) [84]. Taken 
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together, these studies indicate oxygen tension as a trigger of extracellular stress 
response pathways that ultimately regulate the proteome of the tachyzoite, which is a 
general stress response mechanism common to eukaryotic cells [88, 89].  
 
Motility:  
During the extracellular state of the lytic cycle, tachyzoites are highly motile as they 
are in search for a host cell to invade. Motility, often described as gliding motility, is 
powered by the glideosome, an actomyosin motor complex tethered to the inner 
membrane complex (IMC) [90, 91]; the IMC is a membrane/cytoskeletal cortex made up 
of multiple flattened alveoli located around the entire periphery of the parasite, just 
underneath the plasma membrane (PM). The glideosome is assembled between the IMC 
and PM (Figure 1.2b.) and consists of a myosin A (MyoA) and myosin light chain (MLC) 
complex immobilized to a set of glideosome associated proteins (GAPs) that anchor 
MyoA/MLC to the IMC [92-94]. The head domain of MyoA binds to the F-actin of the 
cytoskeletal cortex, which has been immobilized to the PM via the glideosome-associated 
connector (GAC) protein [95]. Upon ATP hydrolysis, the IMC-immobilized MyoA motor 
begins to “walk” down the PM-immobilized F-actin, resulting in a “tread-milling” effect of 
the PM, driving the parasite toward the apical direction in a substrate-dependent manner. 
Continued motility is dependent on constitutively-secreted microneme (MIC) proteins that 
are apically-released onto the parasite’s exoplasmic surface and assure strong 
adherence to the substrate (e.g. receptors of a host cell). Notably, constitutive MIC 
secretion and glideosome motility is also crucial for the process of invasion and egress 
 
  10




Essential to T. gondii’s attachment of host cells are the GPI-anchored Surface 
Antigen Glycoproteins (SAGs), otherwise known as SAG-Related Sequence (SRS), 
which coat the surface of parasites and recognize sulfated proteoglycans on the surface 
of host cells [96-99]. There are 161 member of the SRS superfamily that range in 
sequence diversity and gene expression in a genotypically- and developmentally-specific 
fashion [100]. Upon SRS attachment to the host cell, T. gondii re-orients its apical end 
perpendicular to the surface of the host cell and apically-secretes MIC and rhoptry neck 
(RON) proteins through the conoid (Figure 1.2b.) in order to form the moving junction (MJ) 
[101-103]. The MJ is a site of tight parasite-host interaction mediated by the MIC protein 
apical membrane antigen 1 (AMA1) [102], which is anchored to the parasite, and the RON 
proteins RON2 [104], 4 [105], 4L1 [106], 5 [103], and 8 [107], which are anchored in 
complex to the host cell’s PM and cortex [108-110]. Exactly how secreted RON proteins 
become so embedded into the host cell remains enigmatic. After formation of the MJ, T. 
gondii can initiate invasion (Figure 1.2a.). 
  
Invasion: 
Invasion of T. gondii, often described as active penetration, is guided by the MJ 
and powered by the glideosome [90, 91, 111]. During active penetration, which occurs in 
a matter of seconds, the parasite continuously pushes forward into the host cell causing 
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the PM to invaginate around the parasite until the host cells pinches off and forms a 
parasitophorous vacuole (PV) membrane (PVM) around the parasite [112]; at this point, 
the parasite resides inside a PV which too is inside the host cell (Figure 1.2a.) [113]. 
Inside the host cell, the PVM does not fuse with any of the host’s membrane trafficking 
pathways or organelles, or back again with the PM from which it came, protecting the 
parasite from autophagy or exocytosis and promoting a milieu for intracellular replication 
[114, 115]. 
 
1.5.2. Intracellular virulence traits of the lytic cycle: Replication, host manipulation, 
bradyzoite differentiation, and egress 
Replication: 
Asexual replication inside the PV occurs via an internal budding mechanism 
termed endodyogeny–that is, two daughter cells grow inside of the mother cell [114]. 
Concluding cell division, the mother cell has been completely disassembled, with many 
of its proteins, lipids, and organelles being recycled into the two new daughter cells. 
Residuals of the mother cell, such as some mitochondria and acidocalcisomes, are 
usually found in the residual body (RB), a small basal compartment that connects the 
cytoplasm of emerged cells, allowing for recycling, cell-cell communication, and 
synchronized endodyogeny [116, 117].  
The cell cycle of type I tachyzoite endodyogeny will undergo G1 (~3 hours) and S 
phase (~2 hours), then skip the classical G2 phase and go right into M phase (~1 hour), 
which happens to dramatically overlap with cytokinesis, totaling a 6 hours cell division 
cycle [118, 119]. Avirulent type II and type III parasites have slightly longer cell cycles of 
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8-10 hours [119]. During G1 phase, the parasite duplicates the centrosome and Golgi 
apparatus and begins elongation of the apicoplast [120-122]. Continued apicoplast 
elongation and chromosomal duplication marks the S-phase of the cell cycle. Late in S-
phase (1.8N), spindles emerge from two centrosomes and initiate a closed M-phase 
while, simultaneously, the cytoskeletal IMC of the daughter buds appear around this 
scaffold [119, 123, 124]. As M-phase progresses, IMC buds continue to grow and 
incorporate the Golgi, mitochondrion, endoplasmic reticulum (ER), nucleus, and other 
organelles inside the developing bud [125-127]. Organelles such as MICs, rhoptries 
(ROP), and dense granules (GRA) are largely created de novo after the daughter buds 
form [125]. After completion of the daughter cytoskeleton, cytokinesis is completed when 
the PM of the mother cell starts to disassemble and recycles itself onto the emerging 
daughter cells [128]; newly synthesized lipids are produced for the PM as well via the 
apicoplast’s fatty acid synthesis II (FASII) pathway [129]. Upon the dissemination of the 
mother cell and formation of the daughter cell’s PM, the division cycle is completed.  
Transcriptomic analysis identified two signature subtranscriptomes of T. gondii’s 
cell cycle: the G1 and the S/M transcriptome [130]. Combined, these two 
subtranscriptomes represent nearly one third of the parasite’s genome. During the G1 
phase, tachyzoites express many genes involved with biosynthesis and metabolism, 
including RNA polymerases, splicing enzymes, ribosomal proteins, translation factors, 
chromatin modifiers, and a few transcription factors [130]. Additionally, G1 expresses 
metabolic genes associated with the apicoplast (e.g. FASII) and mitochondria (e.g. TCA 
cycle) [130]. During the S/M phase, tachyzoites express many genes involved with the 
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formation of daughter cells, such as DNA polymerases, IMC’s and other cytoskeletal 
proteins, motor proteins, secretory proteins, SRS’s, and transcription factors [130].  
 
Host manipulation: 
Within an in vivo context, parasitic infection naturally triggers a host immune 
response, for which T. gondii has developed sophisticated defensive mechanism to foster 
its continuity. Two major innate cytokine responses for parasite clearance are the 
interferon gamma (IFNγ) [131] and tumor necrosis factor alpha (TNFα) [132, 133] 
pathways. IFNγ-mediated clearance works in several ways: degradation of the PV by up-
regulating autophagy-inducing Immunity Related GTPases (IRGs) [134-136], degradation 
of essential growth nutrients such as tryptophan [137], and activation of other clearance 
pathways via phosphorylation of STAT1 [138, 139]. TNFα-mediated clearance also aims 
to degrade the PV but by up-regulating autophagy-inducing CD40 instead [140]. T. gondii 
has evolved several evasive mechanisms to resist these immune responses in vivo by 
secreting GRA effector proteins that modulate the host cell’s signaling and transcription 
activity [141]. Interestingly, several of these responses contain strain- and host-specific 
virulence factors which are discussed further in Chapter 1.6.2. 
 
Bradyzoite differentiation: 
Within an in vivo context, or under specific laboratory conditions, conversion from 
tachyzoites into bradyzoites is stress induced (e.g. IFNγ effectors, alkaline pH, heat 
shock, nutrient deprivation) [142, 143] and appears to be controlled at the transcriptional 
and translational level [144]. Stress-induced phosphorylation of eIF2α diminishes protein 
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translation and promotes bradyzoite differentiation [74, 145] while pharmacological 
inhibition of eIF2α-specific phosphatases can also induce bradyzoite differentiation [145], 
indicating that phosphorylation of eIF2α is a major determinant of differentiation [144]. 
Moreover, phosphorylation of eIF2α is important for the viability of extracellular parasites 
[74], indicating that halted translation is part of a stress response pathway that likely 
facilitates the conservation of ATP and reprogramming of its transcriptome. 
 Microarray and RNA-seq studies have identified hundreds-to-thousands of 
differentially expressed genes (DEGs) between tachyzoites and bradyzoites, illustrating 
the major reprogramming that underpins bradyzoite differentiation [146]. Many of these 
genes include cyst wall, metabolic, and SRS proteins. Several Apetala 2 (AP2) 
transcription factors have been identified as activators (AP2IV-3 [147], AP2XI-4 [148], and 
AP2Ib-1 [147]) or repressors (AP2IV-4 [149], AP2IX-4 [150], and AP2IX-9 [147, 151]) of 
bradyzoite-associated gene regulation and/or bradyzoite differentiation. Recent progress 
has also identified a Myb-like transcription factor, bradyzoite-deficient factor 1 (BFD1), as 
a master regulator of bradyzoite differentiation [152]. While genetic disruption of AP2 
activators and repressors partially influenced bradyzoite differentiation, disruption of 
BFD1 completely abrogated differentiation, suggesting it as an upstream activator of 
bradyzoite differentiation [152]. Furthermore, conditional BFD1 expression was found to 
recapitulate the transcriptomic profiles of stress-induced bradyzoites while chromatin 






 After several rounds of replication, or recurrence of latent infection, T. gondii will 
exit from the host cell (i.e. egress) (Figure 1.2a.). Several environmental cues can trigger 
egress: a drop in host cytoplasmic K+ (as seen during host apoptosis) [153], a rise in 
phosphatidic acid (PA) on the parasite surface [154], and a decrease in intravacuolar pH 
[155]. While the topography of these cues and their downstream targets are quite complex 
and still developing, they converge onto two crucial intracellular secondary messengers: 
cyclic guanosine monophosphate (cGMP) and Ca2+ [156]. The production of cGMP by 
guanyl cyclase (GC) activates protein kinase G (PKG), a key mediator in the mobilization 
of intracellular Ca2+. The triggered release of Ca2+ from intracellular stores (e.g. 
acidocalcisome, ER) [157, 158] simultaneously activates glideosome motility and MIC 
secretion of perforin-like protein 1 (PLP1) [159-162]. At low pH, PLP1 forms pores within 
the PVM and host cell PM, allowing motile parasites to break free from surrounding 
membranes and become extracellular once again [161, 162]. Upon invasion of a new host 
cell, motility and secretion is turned off by cyclic adenosine monophosphate (cAMP)-
dependent protein kinase A (PKA) which activates cyclic nucleotide phosphodiesterases 
(PDE) to degrade cGMP [163]. As a result, PKG activity and intracellular Ca2+ levels are 
reduced, thereby promoting parasite division and thereby completing the parasite’s lytic 
cycle [164]. 
 
1.6. T. gondii virulence 
1.6.1 Virulence phenotypes in vivo and in vitro  
Virulence, from an in vivo perspective, is defined as the relative capacity of a 
pathogen to cause damage within its host and is often expressed quantitatively as the 
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lethal dose (LD50) or lethal time (LT50) required to kill 50% of test subjects [165, 166]. For 
T. gondii research, test subjects are mouse models, for which the degree of virulence can 
vary depending on the parasite’s genotype. The type I genotype is by far the most virulent, 
with a LD100 of just 1 parasite intraperitoneally (i.p.) injected into healthy mice [167, 168]. 
The type II and type III genotypes are considerably less virulent with a LD50 of ~103 and 
~105, respectively [167]. Type 12 virulence in mice has not been assessed yet. Virulence 
traits such as replication rate [119, 169, 170], immune evasion [171], bradyzoite 
conversion [172], motility [173], and extracellular survival [167] are measurably different 
amongst typical genotypes. Comparatively, type I genotypes display the most enhanced 
virulence traits, resulting in a deadly lytic cycle in mice [174-178]. Notably, virulence 
should be considered not only in the context of parasite genotype, but host species as 
well because T. gondii’s evasion mechanisms (see Chapter 1.6.2) can be host-specific. 
In other words, a virulent genotype in one host may be benign in another. For example, 
i.p. injection of a single type I parasite can kill a healthy mouse but it takes ~104-107 type 
I parasites to kill a healthy rat [177, 179-181]. Fortunately, healthy humans (postnatal) are 
much more resilient to infection as well. Virulence in congenital infections (prenatal) can 
also vary between species, as seen with pregnant sheep [182].  
 Virulence, from an in vitro perspective, is the degree of damage caused to a cell 
cultured host (a cell monolayer), which is commonly visualized by plaque assay and 
quantitatively expressed as plaque size (e.g. mm2). Plaque size of type I, II, and III 
parasites reveal an in vitro virulence that reflects observed in vivo virulence. Interestingly, 
plaque size of eight type I strains (RH, GT1, GIL, FAJI, VEL, ENT, MOR, and PT) all show 
relatively similar levels (~1- to 2-fold) of in vitro virulence with the exception of RH which 
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displays ~5- to 10-fold greater in vitro virulence [168]. The reasons behind RH’s 
dramatically enhanced in vitro virulence has long been a topic of research but the 
mechanism behind it has remained obscure [168, 183].  
 
1.6.2. Genetic virulence factors  
Experimental crosses and QTL analysis of virulent and avirulent strains have 
determined genetic loci and candidate genes that are associated with virulence in mice. 
These mainly consist of ROP- and GRA- secreted proteins that aid parasite virulence by 
modulating the host’s defense mechanisms. Polymorphic ROP16 kinase can 
phosphorylate STAT3 and STAT6 transcription factors and subvert the induction of IFNγ-
mediate defense responses such as host apoptosis [184-186]. Specific ROP5/17 or 
ROP5/18 alleles work in concert to inactivate IFNγ-stimulated IRG-mediated disruption of 
the PV [187-189]. Polymorphic alleles of GRA15, even found within avirulent isolates 
[183], can differentially modulate a host’s NFκB response [190]. Type II alleles of GRA24 
[191] and GRA25 [192] were found to modulate cytokine production and MAPK 
responses, respectively. Other studies aimed at identifying secreted effector proteins 
have identified GRA16 [193], GRA24 [191], and IST1 [194, 195] as direct interactors of 
host cell regulators within the host cell’s nucleus, resulting in the misregulation of the 
host’s p53, MAPK, and IFNγ/β response pathways, respectively. In short, T. gondii has 
successfully evolved many effector proteins for targeting host cell signaling and 
transcription, resulting in successful evasion and established infection [141]. The 
significance of these virulence factors in vitro, however, appear insignificant, suggesting 
they do not interfere with the acute lytic cycle–the driver of disease pathogenesis. 
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Interestingly, evolution of the host-pathogen interaction has resulted in host-
dependent mechanisms of T. gondii’s evasion. For example, both of the type I ROP5/17 
and the ROP5/18 alleles, which are virulent in mice by blocking IRG-mediated clearance, 
are not virulent in humans because we lack many of the ROP-targeted IRGs [187-189, 
196]. Additionally, a host’s defense to T. gondii infection can result in divergent defensive 
mechanisms as well. For example, a family of interferon-inducible GTPases, guanylate 
binding proteins (GBPs), promote parasite clearance in mice by targeting the PV for 
destruction, whereas GBPs in humans do not target the PV and alternatively operate to 
delay the onset of parasite replication [197]. Taken together, these data indicate that the 
evolution of T. gondii’s polymorphic virulence factors can result in host-specific offense 
and defensive mechanisms [196]. Given this diversity in host-pathogen interactions in 
vivo, identifying host-independent virulence factors in T. gondii (such as from an in vitro 
context) could be of great value to human and veterinary medicine. To date, the presence 
of any host-independent polymorphic virulence factors remains unknown.  
 
1.6.3. RH and GT1 at a glance 
Previous studies have elucidated virulence factors involved with in vivo host 
defense modulation, but do not explain the differences in virulence traits observed in vitro. 
Because their in vitro virulence is dramatically different and, yet, their genomes are very 
similar (and readily available), RH and GT1 comparative analysis’ have been the 
traditional approach for uncovering the genetic basis responsible for phenotypic 
differences in vitro.  
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The type I isolate, RH, was first isolated in 1939 from a deceased child with 
toxoplasmosis [198]. It was immediately propagated and maintained by mouse passages 
in vivo until 1977, upon which it was propogated to in vitro cell culture conditions (Figure 
1.3) [198, 199]. The RH strain is the strain of choice used by most laboratories, including 
our own, to understand T. gondii and other apicomplexan biology [8]. As a result of being 
the first isolate available to research, it has experienced several decades of lab-
adaptation [168]. Notably, earlier frozen isolates of RH (RH-JSR), which were passaged 
only in vivo, show remarkably reduced in vitro virulence, similar to that of GT1, indicating 
prolonged lab-adaptation as the driver of augmented in vitro virulence [168]. The other 
type I isolate, GT1, was isolated from an infected goat in 1979. Since then, it has been 
limitedly passaged in vitro and has remained largely cryopreserved until this study (Figure 
1.3).  
Whole genome sequencing (WGS) between RH and GT1 identified 1,394 single 
nucleotide polymorphisms (SNPs), of which 133 encoded nonsynonymous amino acid 
changes and 54 were insertions/deletions (indels) within predicted a coding sequence 
(CDS) (Figure 1.3) [183]. Of these, two SNPs (found in GRA2 and GRA15) were 
individually found to differentially modulate host defense response pathways, but the 
degree to which these two polymorphisms have on in vitro virulence appears minor [183]. 
With relatively few polymorphisms between RH and GT1 and failure to connect them with 
virulent traits of the acute lytic cycle, it is hypothesized that epistatic interactions- the 
specific combination of alleles necessary to bring about a phenotype- may contribute to 
the observed differences in in vitro virulence [183]. For example, the presence of the 
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virulent type I ROP18 allele can only prevent IRG-mediated clearance when it is also in 
the presence of the virulent type I ROP5 allele [187]. 
Epigenetic differences altering gene expression is another plausible hypothesis for 
RH’s superior in vitro virulence. Microarray analysis of RH, RH-JSR, and GT1 has 
provided 113 candidate genes (>2 fold-change) that are differentially expressed between 
RH and GT1/RH-JSR, including several ABC transporters [168] which play a role in 
parasite lipid trafficking [200]; however, none have been validated as differentially 
expressed in vitro virulence factors. Therefore, it is likely that gene regulation may be an 
additional mechanism underlying the difference in observed in vitro virulence traits. 
Altogether, the approach of comparative genomics between lab-adapted, RH, and non-
lab-adapted, GT1, parasites has comprehensively characterized their molecular 
differences, but largely failed to explain the genetic basis of acquired in vitro virulence 
that stems from prolonged lab-adaptation. 
 
1.7. The epigenome 
1.7.1 Epigenetics 
Epigenetics refers to heritable changes in gene expression or phenotype without 
alterations in the DNA sequence. Post-translational modifications (PTM) of genomic DNA 
and PTM of histones, by histone acetyltransferases (HAT) and histone methyltransferase 
(HMT), and the expression of non-coding RNAs (ncRNA), have all been observed in T. 
gondii, although the degree to which these epigenetic mechanisms facilitate parasite 
biology are still being uncovered [201-204]. For example, functional analysis of a T. gondii 
HAT and HMT (GCN5 and CARM1, respectively), uncovered an epigenetic control over 
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life cycle stage differentiation [205]. Furthermore, histone acetylation was found to 
regulate chromatin structure and virulence factors in Plasmodium [206, 207]. Similarly, 
transgenerational epigenetic variation in a variety of other organisms (algae, fungi, and 
insects) has been found to be the basis of adaptive responses [208-212].  
 
1.7.2 The apetala 2 (AP2) transcription factors (TF) 
The apetala 2 (AP2) proteins are a family of transcription factors (TF) that were 
first described back in 1998 in Arabidopsis thaliana and since thought to be plant-
specific [213]. It wasn’t until 2005 when Balaji et al identified a novel series of 
Apicomplexa AP2 (ApiAP2) TF’s in the parasitic protozoan, Plasmodium falciparum 
[214]. Since then, numerous ApiAP2 TF’s have been identified and characterized 
across apicomplexan organisms, including Plasmodium, Eimeria, Sarcocystis, 
Cryptosporidium, and Toxoplasma. In T. gondii, divergent roles for ApiAP2’s have been 
identified such as: association with chromatin remodeling complexes [215] and RNA-
induced silencing complexes (RISC) [204]; binding DNA in a sequence-specific manner 
in order to activate or repress genes critical for parasite virulence and invasion [216, 
217]; immune evasion and bradyzoite differentiation [147-151]; and promotion of 
asexual cell cycle progression [218-220]. 
While ApiAP2 proteins vary in size (~70-9000 amino acids) across the entire 
apicomplexan phylum, one thing they all have in common is the presence of at least 
one 60 aa AP2 DNA-binding domain consisting of 3 β-strands and 1 stabilizing α-helix 
[214, 221]. Other domains that may found in an ApiAP2 TF include: zinc fingers, AT-
hooks, ACDC (AP2-coincident domain mainly at the C-terminus), and pentapeptide 
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repeat-like domains [222]. These other domains likely aid the ApiAP2 TF in binding of 
specific DNA loci. Some ApiAP2 proteins are known to dimerize once bound to DNA. 
For example, X-ray crystallography of a P. falciparum ApiAP2 (PF14_0633) identified a 
domain-swapping mechanism in which the α-helix of one dimer stabilizes the 3 β-
strands of its partnering dimer [221]. It is thought that dimerization of ApiAP2’s could be 
influencing gene expression, as is the case with other eukaryotic TFs [221].  
Growing evidence indicates that protein-protein interactions with ApiAP2’s play 
key roles in regulating T. gondii gene expression [215, 216]. For example, immuno-
precipitation (IP) of TgAP2XI-5 followed by mass spectrometry (MS) identified TgAP2X-5 
as a sole binding partner. Genetic knockout (KO) of TgAP2X-5 decreased binding of 
TgAP2XI-5 to specific promoter regions, many of which being ROP gene promoters, 
which led to decreased invasion efficiency and a complete loss of virulence in mice [216]. 
Thus, a number of virulence-related genes in T. gondii are dependent on the cooperative 
binding of TgAP2XI-5 and TgAP2X-5. In a different study with similar proteomic 
approaches, TgGCN5b, a lysine acetyltransferase, was found to associate with four 
ApiAP2’s: TgAP2IX-7, TgAP2X-8, TgAP2XI-2, and TgAP2XII-4 [216]. Interestingly, only 
one of these ApiAP2’s, TgAP2X-8, has an acetylation site, indicating that the other 
TgAP2’s may be responsible for recruiting TgGCN5b to specific DNA loci, thereby 
allowing for histone H3K9/K14 acetylation and resulting gene upregulation [223]. 
TgGCN5b is essential for T. gondii and an inducible knockdown (iKD) results in a 
reversible arrest in cell replication, likely due to the misregulation of gene expression 
[216]. Genetic manipulation of TgGCN5b’s four interacting AP2 partners has not been 
evaluated, but will likely also prove essential for the parasite given their low fitness scores 
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(< -2.3) [224]. Taken together, AP2 TF’s, and their potential cofactors, are emerging as 
prominent expression regulatory factors controlling many aspects of parasite biology. 
 
1.8 Evolve and Resequence (E&R)  
 Evolve and Resequencing (E&R) is a recent technique that expands upon an old 
approach commonly known as experimental evolution. Experimental evolution, is a 
research approach designed to observe evolution under a controlled experimental 
condition, generally by altering an organism’s environment (e.g. nutrient availability). 
While experimental evolution can be applied to multicellular organisms [225-228], it is 
often performed with unicellular organisms because of their ease to culture and 
manipulate, as well as their relatively fast reproductive and mutation rate [229]. Typically, 
in experimental evolution, microbes (bacteria, yeast, virus, etc.) are cultured in well-
defined growth conditions and monitored over time (e.g. passages, generations) for 
changes in phenotypes (e.g. plaque size) or overall fitness (e.g. growth rate) [229].  
Experimental evolution dates as far back as the late 19th century, with pioneers 
such as William Dallinger and Charlton Batisian who observed gradual adaptation and 
ultimate survival of bacteria under superheated conditions [230, 231]. Experimental 
evolution’s popularity as a research approach began skyrocketing at the beginning of the 
21st century due to the emergence of high-throughput Next Generation Sequencing 
(NGS) technology, which now allowed researchers to investigate, in real time, the genetic 
factors underlying evolution. This synergistic coupling of experimental evolution and NGS 
sparked the term Evolve and Resequence (E&R) by Turner et al in 2011, although 
experimental evolution and E&R are still often used interchangeably [226].  
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The most famous and longstanding experimental evolution study is Dr. Lenski’s 
Long-Term Experimental Evolution (LTEE) experiment. Starting in 1988, the Lenski lab 
has monitored the adaptation of Escherichia coli under low glucose conditions for over 
66,000 generations (as of 2016) [232]. With the coming age of E&R, the Lenski lab 
performed NGS and expression profiling on several parallel evolving lines resulting in the 
identification adaptive alleles, expression profiles, and mechanisms behind E. coli’s 
adaptation to low glucose [233-237]. Moreover, their findings have provided tremendous 
insight into factors behind microbial population structure, adaptations rates, and genome 
evolution [235, 236, 238-240]. Across a variety of organisms, other E&R studies have 
examined adaptation to extreme temperature [241], unbalanced nutrition [228, 242], 
hypoxia [225], pathogen resistance [227, 243], drug resistance [244, 245], competition 
[246, 247], aging [248], and multicellularity [249, 250]. Although never applied to T. gondii, 
experimental evolution/E&R (in vivo and in vitro) has been successfully applied to other 
Apicomplexa in order to understand parasite virulence [251, 252] and the genetic basis 
for drug resistance [244, 245]. For example, the apicomplexan parasite Plasmodium 
chabaudi evolved enhanced virulence when serially passaged in immunized mice, 
suggesting that strong in-host selection pressures can select for higher virulence. 
Interestingly, in a separate study, P. chabaudi was found to evolve into a more virulent 
strain when serially passaged in immune-suppressed mice, suggesting that immune-
suppressed hosts can too provide an environment that promotes the evolution of 
virulence factors [252]. Thus, these E&R studies in Plasmodium reveal important insights 
into the evolution of apicomplexan virulence in vivo. A list of the above and other 




1.9. Open questions and synopsis of dissertation 
The two type I genotype T. gondii stains, RH, a lab-adapted strain, and GT1, a 
non-lab-adapted strain, have a genetic difference of only 0.002%, but show remarkable 
phenotypic differences in vitro. For example, it has long been known that RH’s plaquing 
capacity and extracellular survival is far superior to that of GT1, likely due to prolonged 
lab-adaptation. The genetic basis of these phenotypes, however, remains largely 
unknown despite previous efforts interrogating the functionality of individual SNPs. The 
emerging hypothesis of previous investigations deliberate epistatic interactions as the 
genetic basis of differential type I phenotypes. Uncovering such epistasis, such as in the 
polymorphic ROP18/5 example, will support our growing understanding of T. gondii 
virulence. Furthermore, doing so in vitro will enable the discovery of more universal 
virulence factors that can be targeted for therapeutics. To answer this question, E&R is 
applied on non-lab-adapted GT1 through the in vitro lab-adaptation process for roughly 
1500 generations (~ 2 years) (Figure 1.4). In short, lab-adaptation results in GT1’s 
augmented in vitro virulence; resequencing of genomic DNA at various timepoints 
identified one candidate polymorphic gene associated with lab-adaptation, suggesting 
that epistatic interactions are not driving adaptation; resequencing of mRNA identified 
several hundred candidate genes that are differentially expressed (DE) and functional 
analysis suggests that epigenetic regulation of many genes are more likely driving GT1’s 
adaptation; furthermore, fatty acid biosynthesis and lipid homeostasis are suggested as 




Figure 1.1. The life cycle of Toxoplasma gondii  
 
 
Esch et al., 2013
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Figure 1.1. The life cycle of Toxoplasma gondii 
Fecal oocysts shed from Felidaes (e.g. the cat) contaminate soil, water, grass, 
fruits and vegetables. The consumption of unwashed produce or grasslands 
contaminated with fecal oocysts infects intermediate hosts, such as humans, cows, mice, 
etc. Raw or undercooked consumption of infected intermediate hosts can transmit 
infection in the form of tissue cyst-containing bradyzoites. The consumption of 
bradyzoites or oocysts during pregnancy can transmit infection vertically to the fetus. 
Furthermore, organ transplant or blood transfusions from an infected host could transmit 
infection to recipients. A cat’s consumption of infected intermediates hosts, such as bird 
or mice, completes the parasites life cycle. Figure 1.1 reprinted by permission from 






















Figure 1.2. The acute lytic cycle of T. gondii 
 
 a. Highly motile extracellular tachyzoites attach to and orient their apical end 
toward the host cell before active invasion of the host. Successful invasion of the host 
cell results in the formation of a protective parasitophorous vacuole (PV) around the 
parasite. Intracellular parasites replicate by endodyogeny, until internal signals induce 
















parasite egress, thereby completing the lytic cycle. Figure 1.2a. reprinted by permission 
from Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (order 
4839040152222). b. Ultrastructure of T. gondii; being a member of the Apicomplexa, T. 
gondii contain unique structures such as the conoid and organelles, such as 













































Figure 1.3. Comparison of RH and GT1 isolates 
The RH strain was isolated in 1939 by Albert Sabin from a fatal human case of 
toxoplasmic encephalitis. The RH strain was propagated in mice until 1977 when Elmer 
Pfefferkorn cloned and propagated the strain into laboratory culture. Because it was the 
first available isolate, RH has been widely distributed and has undergone several decades 
of lab-adaptation, resulting in considerable in vitro virulence, as measured by plaque 
assay. The GT1 strain was isolated from a goat in 1979 and expanded briefly in vitro for 
the purpose of mass cryogenic freezing and depositing at BEI Resources Repository. The 
GT1 strain was thawed and cultured in our laboratory since 2015. Plaque assay analysis 
revealed significantly reduced in vitro virulence of GT1, relative to RH, even though both 
type I strains are genetically similar. Comparative genomic studies between RH and GT1 
identified 1,394 SNPs resulting in 133 nonsynonymous changes to a proteins CDS and 
54 CDS indels; however, identifying beneficial and/or epistatic mutations between the two 
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Figure 1.4. E&R timeline of GT1 populations 
One un-cloned (B0) and three monoclonal (B2, B4, and B6) starting GT1 
populations were introduced to standard in vitro culture conditions. Continued lab-
adaptation involved serial passaging (1:20) of parasites for up to ~1500 generations, or 
~220 passages (P). Evolving parasite populations were continually resequenced by DNA-
sequencing and/or mRNA-sequencing at the indicated timepoints. Figure is drawn to 




Table 1.1. List of key experimental evolution and E&R publications 
 
  
Author Year PMID Species Time Variable Notes
Jalvingh, K.M., et al. 2014 24500162 Asobara tabida 5 host generations Pathogen resistance
Strong selection likely acts on standing genetic variation within 
the population in a short time frame
Haas, J.W. 1887 11624308 Bacteria 500,000 generations Temperature Early example of evolved adaptation to stress
Bastian, H.C. 1907 20897082 Bacteria 3 months (est.) Temperature and salinity Early example of evolved adaptation to stress
Rechavi, O., G. 
Minevich, and O. Hobert
2011 22119442 Caenorhabditis elegans 10 generations Viral replication RNAi-dependent viral silencing is an epigenetic response
Kronholm, I., et al. 2017 28535256 Chlamydomonas 200 generations
salt stress, phosphate 
starvation, and high CO2
Genetic and epigenetic mechanisms (DNA methylation) 
promote adaptive evolution to various stresses
terHorst, C.P. 2011 20964780 Colpoda 100 generations Competition
Interspecific competition selected for populations drives 
phenotypes and increased fitness
Kolss, M., et al. 2009 19473389 Drosophila melanogaster 64 generations Malnutrition
Larval adaptations to malnutrition results in fitness trade-offs in 
adult flies, but not larva
Zhou, D., et al. 2011 21262834 Drosophila melanogaster 200 generations Hypoxia
Regulatory mutations increased regulon expression which 
confers tolerance to hypoxic conditions
Turner, T.L., et al. 2011 21437274 Drosophila melanogaster 100 generations Fly size Fly size is the result of polygenic inheritance
Remolina, S.C., et al. 2012 23106705 Drosophila melanogaster 50 generations Aging and fecundity
Mutations and gene expression patterns are associated with 
aging and fecundity
Stern, S., et al. 2012 22832276 Drosophila melanogaster 6 generations Developmental stress
Epigenetic adaption to developmental stress is indeed 
heritable, even when stress in removed
Bennett, A.F. and R.E. 
Lenski
1993 28568084 Escherichia coli 2,000 generations Temperature
Temperature adapation results in optimal fitness without any 
fitness tradeoffs at different temperatures (32-42oC)
Lenski, R.E. and M. 
Travisano
1994 8041701 Escherichia coli 10000 generations Limited glucose
Parallel-evolving populations display similar phenotypic 
changes that are initially rapid and then approach stasis
Cooper, T.F., D.E. 
Rozen, and R.E. Lenski
2003 16702438 Escherichia coli 20,000 generations Limited glucose
Regulatory mutations increased regulon expression resulting in 
similar fitness effects of parallel-evolving populations
Woods, R., et al. 2006 16751270 Escherichia coli 20,000 generations Limited glucose
The same candidate genes are mutated in parallel-evolving 
populations; observing the same mutations is rare
Cooper, T.F., et al. 2008 18282111 Escherichia coli 20,000 generations Limited glucose
Epstatic interactions between mutations contribute to adaptive 
evolution
Blount, Z.D., C.Z. 
Borland, and R.E. 
Lenski
2008 18524956 Escherichia coli 40,000 generations Limited glucose
Adaptation is dependent on the genetic background, 
suggesting epistatic interactions
Barrick, J.E., et al. 2009 19838166 Escherichia coli 40,000 generations Limited glucose
Mutations accumulate at a steady state while finess rapidly 
increase and approaches stasis
Cooper, T.F. and R.E. 
Lenski
2010 20070898 Escherichia coli 2,000 generations
Fluctuating sugar 
availability
Genetic diversity within a population increases under 
fluctuating environmental conditions
Woods, R.J., et al. 2011 21415350 Escherichia coli 883 generations Fitness competiton
Epistatic interactions between mutations affects fitness 
landscape and future evolability
Maddamsetti, R., et al. 2017 28379360 Escherichia coli 50,000 generations Limited glucose
The core genome of E. coli evolves faster under positive 
selection experiments than they would in nature
Kram, K.E., et al. 2017 28289732 Escherichia coli 300 generations Delayed serial passaging
Adaptation results in swift selection of genomic changes to the 
same genes in parallel-evolving populations
Mukherjee, K., et al. 2019 30733453 Galleria mellonella 6 generations Pathogen resistance
Epigenetic mechanisms (DNA methylation, histone 
modification, and miRNA) enable adaptive fitness
O'Driscoll, L., et al. 2006 17170223 MIN6 (pancreas) cell line 40 passages
Prolonged serial 
passaging
Long-term passaging results in phenotypic and gene 
expression changes
Zbinden, M., C.R. Haag, 
and D. Ebert
2008 18462312 Octosporea bayeri 15 host generations Pathogen resistance
Evolution of pathogen tolerance did not result in host fitness 
trade-offs under prevailing conditions
Mackinnon, M.J. and 
A.F. Read
2004 15221031 Plasmodium chabaudi 20 passages in host Immunization Host immunity promotes evolution of pathogen virulence
Hunt, P., et al. 2010 20846421 Plasmodium chabaudi N/A Drug resistance Drug resistance in Plasmodium is genetic
Martinelli, A., et al. 2011 20858498 Plasmodium chabaudi N/A Drug resistance Drug resistance in Plasmodium is genetic
Barclay, V.C., et al. 2014 25061677 Plasmodium chabaudi 3 passages in host Immune-suppression Immune-supression promotes evolution of pathogen virulence
Ariey, F., et al. 2014 24352242 Plasmodium falciparum 5 years Drug resistance Drug resistance in Plasmodium is genetic
Rogers, D.W. and D. 
Greig
2009 18842545 S. cerevisiae 13 mating cycles Sexual competition
Beneficial alleles are naturally selected for under strong 
selection pressures, but not weak selection pressures
Araya, C., et al. 2010 20128923 Saccharomyces cerevisiae 188 generations Sulfate limitation
SNPs and copy number variations are asscoiated with 
adaptation
Dhar, R., et al. 2011 21375649 Saccharomyces Cerevisiae 300 generations Salinity
Salt adaptation is associated with DNA ploidy and gene 
expression and not genomic mutations
Dhar, R., et al. 2013 23125229 Saccharomyces Cerevisiae 300 generations
Alternating salt & 
oxidative stress
Adaptation to cycling stress is associated with cross-protection 
and anticipatory gene regulation
Ratcliff, W.C., et al. 2015 25600558 Saccharomyces cerevisiae 227 days Settling time Multicellularity and evolvability of snowflake yeast is genetic
Rosenberg, A., et al. 2019 31806760 Toxoplasma gondii 1376 generations Drug resistance Drug resistance in Toxoplasma is genetic
Grubaugh, N.D., et al. 2015 25993022 West Nile Virus 5 passages in host Host species
Strong selection pressures result in less genetic diversity and 
repeat mutations in parallel experiments
Versace, E., et al. 2014 24387805 Wolbachia 57 host generations Temperature
The genotype of an endosymbiont reproducibly contributes to 
fly fitness in cold, but not hot, temperatures
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 Genetic analysis by multi-locus RFLP and DNA-sequencing have identified four 
clonal lineages of Toxoplasma gondii termed type I, type II, type III, and type 12 [25, 26]. 
Phenotypic characterization of type I, II, and III virulence traits are quite comprehensive, 
while type 12 is limited due to its more recent discovery. Nevertheless, type I genotypes 
display faster replication [119], enhanced transepithelial migration [173], and greater 
extracellular viability [167]. Such superior virulence traits enable type I parasites to have 
a faster lytic cycle and, consequently, greater virulence both in vitro and in vivo. 
Comparative genomics aimed at uncovering the genetic basis of these phenotypes have 
identified many polymorphic virulence factors that aid in parasite virulence in vivo, the 
mechanisms of which are designed to modulate the host’s immune response. 
Unfortunately, the genetic basis of type I in vitro virulence and its associated virulence 
traits (e.g. extracellular survival, invasion, replication, egress), have remained poorly 
understood.  
 Within the type I lineage, two particular strains of interest, RH (a lab-adapted strain) 
and GT1 (a non-lab-adapted strain), show remarkable phenotypic differences. The lab-
adapted RH strain displays an exceptionally enhanced in vitro virulence, as determined 
by plaque size, relative to GT1 and six other non-lab-adapted type I isolates [168]. 
Furthermore, RH’s replication rate and extracellular viability are superior to GT1, which 
likely contribute to the observed differences in in vitro virulence [168]. Interestingly, the 
most ancestral RH population, RH-JSR, that was passaged only in mice shows 
significantly smaller plaques, similar to that of GT1, indicating that in vitro lab-adaptation 
of RH had resulted in augmentation of its in vitro virulence [168].  
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 Interestingly, despite these phenotypic differences, RH and GT1, both of the type 
I genotype, are genetically similar. Previous comparative genomic studies by Yang et al. 
identified 1,394 single nucleotide polymorphisms (SNPs) between RH and GT1, of which 
133 caused nonsynonymous amino acid changes and 54 were insertions/deletions 
(indels) within predicted coding regions [183]. It was hypothesized that some of these 
SNPs are responsible for the phenotypic differences observed between RH and GT1. 
Unfortunately, efforts to uncover the genetic basis of these phenotypes have had limited 
success. In brief, the authors identified two mutually exclusive SNPs found in GRA2 and 
GRA15 that differentially modulate host IFNγ and NFκB immune response pathways, 
respectively; the degree these two polymorphisms have on in vitro virulence, however, 
appears insignificant [183]. The authors concluded that the genetic basis of RH’s superior 
in vitro virulence and associated virulence traits are likely a combination of alleles (i.e. 
epistasis) or gene expression patterns, rather than individual genes [183]. Uncovering 
epistatic interactions from a list containing 1,394 polymorphisms, however, would 
generate an unwieldy matrix (<106) of allele possibilities that will be difficult to 
experimentally untangle. To overcome this problem, we reasoned that lab-adaptation of 
the GT1 strain should result in enhanced in vitro virulence that coincides with the 
accumulation of mutations, and, by chronologically identifying emerging mutations during 
lab-adaptation, we would be able to establish genotype-phenotype correlations that can 
be experimentally validated. This particular approach to uncover the genetic basis of 
evolutionary traits is referred to as evolve and resequencing (E&R).  
To evolve GT1’s phenotypes, we first lab-adapted several GT1 populations by in 
vitro serial passaging and measured phenotypic changes during the first 2-years of lab-
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adaptation (~220 passages, ~1500 generations) (Figure 1.4). The RH strain was utilized 
as a proxy for GT1’s lab-adaptation. Indeed, we observe a significant increase in GT1’s 
in vitro virulence, albeit still significantly inferior to RH. Additionally, we observe a 
significant increase in GT1’s reinvasion efficiency and extracellular survival- both 
virulence traits within the extracellular milieu of the lytic cycle. Replication rate and egress, 





2.2.1. Phenotypic comparison of RH (lab-adapted) and GT1 (non-lab-adapted) 
parasites 
 To verify familiar, and identify novel differential phenotypes between lab-adapted 
and non-lab-adapted strains, we first measured the following phenotypes of the acute lytic 
cycle in both RH and low passage (≤P16) GT1: in vitro virulence (plaque size), 
extracellular survival, invasion, replication, and egress. Plaque size analysis confirmed 
the dramatic 4.32- to 5.94-fold difference (p-value ≤10-4) in in vitro virulence between RH 
and GT1, as previously reported [168] (Figure 2.1). Temporal extracellular survival assays 
also confirm the dramatic difference previously reported between RH and GT1 [168], with 
RH and GT1’s extracellular LT50 to be 5.5hrs and 2hrs, respectively (p-value ≤0.01) 
(Figure 2.2a). Measuring the area under these survival curves indicated that the overall 
viability of RH is 1.89-fold higher (p-value ≤0.01) than GT1 (Figure 2.2b). Reinvasion 
efficiency was assessed by measuring the number of plaques, relative to inoculum size, 
immediately following mechanical release from host cells, and reveals that RH parasites 
are 3.40- to 3.65-fold (p-value ≤0.001) more efficient at reinvading a host cell than GT1 
parasites (Figure 2.3). Replication assays confirm previous observations that RH has a 
faster replication cycle than GT1 [168], with RH having significantly fewer 1- and 4-
parasite vacuoles and more vacuoles containing 8 parasites than GT1 (p-value ≤0.05) at 
24hrs post invasion (Figure 2.4a-c). Lastly, egress assays with 30-hour intracellular 
parasites reveal that RH has similar egress capabilities to that of GT1 (Figure 2.4d). 
Taken together, these results reveal that both intracellular and extracellular virulence 
traits of the lytic cycle are phenotypically different between RH and GT1, which likely 
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explain in the overall in vitro virulence difference observed between these two type I 
strains. 
 
2.2.2. Lab-adaptation of GT1 results in enhanced in vitro virulence 
To ascertain a homogenous starting population, we first isolated several GT1 
clones from the cryopreserved strain originally used for establishing T. gondii’s reference 
genome [253]. Next, we propagated the original un-cloned GT1 strain (designated B0) as 
well as three monoclonal GT1 population (designated B2, B4, and B6) into culture for up 
to 223 serial passages (~2 years, ~1500 generations), with approximately 5% of the 
culture being serially passed every 2-3 days (Figure 1.4). Parasite populations at various 
time points along the adaptation process were cryogenically stored for downstream 
analysis and permit future studies to connect phenotype and genotype.  
We monitored lab-adaptation by measuring GT1’s in vitro virulence, as determined 
by plaque size, over time; indeed, all GT1 populations showed a steady increase in plaque 
size (Figure 2.1). The GT1 population B0 displayed a 2.30-fold increase (p-value ≤0.001) 
in plaque size by B0-P218, relative to B0-P15 (Figure 2.1a); the GT1 population B2 
displayed 2.19-fold increase (p-value ≤0.001) in plaque size by B2-P223, relative to B2-
P12 (Figure 2.1b); and the GT1 population B4 displayed 1.86-fold increase (p-value 
≤0.001) in plaque size by B4-P204, relative to B4-P11 (Figure 2.1c). These data support 
our initial hypothesis that phenotypic augmentation in T. gondii can be induced by lab-
adaptation. However, plaque size of RH remains 2.31- to 2.62-fold larger (p-value ≤10-4) 
than all >P200 GT1 populations, suggesting that GT1 is not as evolved as RH after 2-
years of lab-adaptation (Figure 2.1). 
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Because RH and GT1 strains were isolated from different species (human and 
goat, respectively) we next tested whether the difference in plaque forming capacity was 
associated with the host of origin. We therefore measured in vitro virulence of RH, B2-
P22 and B2-P177 in both human foreskin fibroblasts (HFF) and goat skeletal fibroblasts 
(GSF) as host cells. Plaque size of RH remained superior to GT1, regardless of host 
species (Figure 2.1d). Furthermore, plaque size of B2-P177 remained 2.5-fold bigger than 
B2-P22, regardless of host species (Figure 2.1d). Taken together, these results illustrate 
that lab-adaptation of T. gondii positively affects their in vitro virulence in a host-
independent manner.  
 
2.2.3. Lab-adaptation of GT1 results in enhanced extracellular survival capacity 
Because we observed augmented in vitro virulence, we next set out to determine 
which virulence traits of the acute lytic cycle had evolved. We focused these efforts 
primarily on GT1 population B2 while analyzing changes in B4 or polyclonal line B0 on an 
ad hoc basis. We first tested the extracellular viability of GT1 during the course of lab-
adaptation by subjecting B2 parasites to extracellular conditions for 0-10 hours and 
assessing viability hourly by plaque assay (Figure 2.2a). These temporal survival curves 
revealed a LT50 of only 2hrs for B2-P9 but a significant increase to 5.5hrs by B2-P211 (p-
value <0.05), which is identical to the lab-adapted RH strain (Figure 2.2a). Measuring the 
area under these survival curves indicated that GT1’s overall extracellular viability 
significantly increases 2.21-fold (p-value ≤0.01) by B2-P211, relative to B2-P13 (Figure 
2.2b). Thus, extracellular survival is a major selective pressure intrinsic to laboratory 
conditions and is thereby a lab-adaptive trait in GT1 parasites. 
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 Given this fast adaptation of extracellular survival capacity, we wondered when 
during lab-adaptation could such a strong selection pressure have been exerted onto the 
parasites. We hypothesized that while serial passaging from flask to flask, the inoculated 
parasites might spend significant time extracellularly while settling by gravity on the new 
host monolayer. To test this, we determined the kinetics of this settling process by plaque 
assay using RH parasites. Indeed, only ~50% of RH parasites settled onto a new T25 
host cell monolayer 8hrs after passing (Figure 2.2c). Moreover, even after 24 hrs not all 
parasites that have plaque forming capacity had settled yet (Figure 2.2c). Thus, standard 
laboratory cultivation instills a significant selection pressure on non-lab-adapted 
extracellular parasites, resulting in T. gondii’s evolved extracellular capabilities. 
 
2.2.4. Lab-adaptation of GT1 results in enhanced invasion efficiency 
The second virulence trait we tested for adaptability is invasion efficiency. We 
determined invasion efficiency by measuring the number of plaques, relative to inoculum 
size, immediately following mechanical release from host cells (as to avoid any bias of 
extracellular stress upon natural egress). All GT1 populations measured showed a steady 
increase in reinvasion efficiency over time (Figure 2.3). B0 displayed a 2.76-fold increase 
(p-value ≤0.05) in reinvasion efficiency by B0-P219, relative to B0-P15 (Figure 2.3a); B2 
displayed 2.24-fold increase (p-value ≤0.01) in reinvasion efficiency by B2-P223, relative 
to B2-P12 (Figure 2.3b); and B4 displayed 2.27-fold increase in reinvasion efficiency by 
B4-P204, relative to B4-P10 (Figure 2.3c; n=2 so statistics was not performed). 
Interestingly, reinvasion efficiency of RH remains 2.24- to 2.77-fold larger than all >P200 
GT1 populations, suggesting that longer adaptation is needed for GT1 to be comparable 
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to RH in this regard (Figure 2.3). Nevertheless, these data indicate that reinvasion 
efficiency is also a highly lab-adaptive virulence trait in T. gondii. 
 
2.2.5. Lab-adaptation of GT1 does not result in altered replication efficiency 
To test the contribution of enhanced replication rate during lab-adaptation, we 
enumerated the number of parasites per vacuole at 24hrs following synchronized invasion 
for 10 mins. During the course of lab-adaptation, GT1’s replication rate shows an 
extremely modest, at best, change in replication rate by having slightly fewer 4-parasite 
and slightly more 8-parasite-containing vacuoles at B2-P157, and more 8-parasite-
containing vacuoles at B2-P268, relative to B2-P16 (p-value ≤0.05) (Figure 2.4a). 
Expressed as the number of doubling events after 24hrs of replication revealed no 
significant changes in B2’s replication during the course of lab-adaptation (Figure 2.4b). 
Similar results were observed for GT1 population B4, with little changes in the number of 
parasites per vacuole after 24hrs of invasion, albeit a small yet significant decrease in the 
number of vacuoles containing 16 parasites at B4-P260 relative to B4-P16 (p-value ≤0.05) 
(Figure 2.4c). Overall, these data show little phenotypic enhancement, indicating 
intracellular replication as a very weak lab-adaptive trait in our GT1 study. 
 
2.2.6. Lab-adaptation of GT1 does not result in altered egress efficiency 
 Lastly, to complete the lytic cycle, we performed egress assays on 30-hour 
intracellular B2-P12, B2-P83, and B2-P211 parasites using the Ca2+ ionophore, A23187, 
or ethanol (EtOH) to stimulate egress for five minutes (Figure 2.4d). Counting the number 
of egressed vs non-egressed vacuoles by IFA reveals no significant differences in GT1’s 
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ability to egress during its two years of lab-adaptation (Figure 2.4d). Therefore, it appears 
that egress efficiency is another intracellular virulence trait that is not lab-adaptive under 





We utilized RH as the golden standard for lab-adaptation because it has been 
cultured the longest and, moreover, plaque assays of three cryogenically frozen RH 
populations over a 32-year period show no major change in RH’s in vitro virulence, 
indicating that RH has maximized its adaptation to an in vitro niche [168]. Indeed, after 2 
years of lab-adaptation (~1500 generations), GT1 displayed significant enhancement in 
various phenotypes. Overall, GT1’s in vitro virulence increased 1.86- to 2.3-fold, 
indicating that the parasite was capable of optimizing its lytic cycle to the cell culture 
conditions. Notably, this was observed in both human and goat cell fibroblasts, indicating 
that in vitro adaptation had proceeded in a host-independent manner and outside the 
context of an in vivo immune response. Paralleling our observations, increased in vivo 
virulence has been observed in Plasmodium when serially passaged in immune-
suppressed mice, suggesting that immune-deficient milieus can facilitate the evolution of 
virulence [252].  
Interestingly, it appears that extracellular virulence traits were the most affected 
while intracellular virulence traits were largely unaffected. Extracellular survival is 
probably the least studied trait of the lytic cycle, likely because it is still debated whether 
or not extracellular parasites can actually disseminate through the body via the 
bloodstream. Circulating extracellular tachyzoites have been found in the blood stream of 
infected mice, rats, and humans, suggesting the possibility of extracellular dissemination 
[254-256]. However, it is well known that tachyzoites disseminate to the peripheral tissues 
by invading and hijacking the driver’s seat of dendritic cells, macrophages, leukocytes, 
and monocytes (i.e. phagocytes) and induce hypermotility [15, 257-260]. This “trojan 
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horse” mode of dissemination appears to be preferential for type II and III parasites, as 
type I (e.g. RH) do not invade as many phagocytes or induce as robust of a hypermotility 
phenotype [261]. Furthermore, ex vivo experiments reveal that extracellular RH 
tachyzoites have a superior migratory capacity compared to type II and III parasites, with 
demonstrated abilities to transmigrate across mouse intestines and penetrate the 
vascular endothelium [173]. Additionally, in vitro microfluidic analysis shows that shear 
forces, which mimic blood flow, enhance the ability of extracellular RH tachyzoites to glide 
across and invade endothelial cells [72]. Lastly, following i.p. injection in mice, RH exhibits 
a more dramatic expansion of parasite biomass in more distant organs compared to type 
II tachyzoites [262]. Taken together, it would appear that extracellular dissemination via 
the bloodstream for RH is possible. Our studies have revealed that extracellular viability 
is a lab-adaptive trait in T. gondii which leads us to hypothesize that lab-adaptation of RH 
has resulted in prolonged extracellular viability, thereby supporting RH’s presumed 
extracellular dissemination to peripheral tissue via the bloodstream. This hypothesis is 
supported by the fact that type II tachyzoites, which have severely reduced extracellular 
viability, disseminate to the peripheral tissues of mice almost exclusively through 
intracellular modes [70]. While further experiments with non-lab-adapted type I parasites 
are needed to support this hypothesis, it would surely indicate that this overlooked 
phenotype is a major influence of parasite virulence both in vitro and in vivo. 
 Reinvasion efficiency was GT1’s fastest lab-adaptive trait, with GT1 being 
statistically similar to RH by B0-P219 and B2-P163, and, although there is a slight 
reduction in the phenotype at B2 >P200, the phenotype remains more than 2.2-fold higher 
than its non-lab-adapted ancestor. It is likely that slightly longer lab-adaptation will result 
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in phenotypically stable population akin to that of RH. We aimed to reduce the effects of 
extracellular stress during our reinvasion assays by synchronously needle lysing 
parasites from their hosts rather than letting parasites egress in a naturally asynchronous 
way. We also tried to centrifuge parasites onto monolayers, however, this resulted in 
uneven distribution of parasite settling and resulting plaque formation. Therefore, we let 
parasites settle by gravity, as performed with serial passaging, albeit in less depth of 
media than during serial passaging as to reduce the settling time. 
Interestingly, intracellular virulence traits of the lytic cycle were relatively static 
during lab-adaptation. Since egress efficiency was no different between RH and non-lab-
adapted GT1, it was expected to see no evolution of GT1’s egress efficiency during lab-
adaptation. However, considering RH has a faster replication rate than non-lab-adaptive 
GT1, we were surprised to observe no major shift in GT1’s replication rate during lab-
adaptation. This suggests that the selection pressure for faster replication is limited under 
our laboratory conditions possibly due to competition with other phenotypically enhanced 
populations or to purge selection during the selective extracellular milieu that is intrinsic 
to serial passaging. As the population adapts to extracellular selection, the purge would 
be mitigated and natural selection will favor the evolution of other directional phenotypes 
like replication rate. Thus we hypothesize that replication rate of GT1 will eventually 
evolve toward RH now that extracellular viability of GT1 has evolved. 
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Figure 2.1. Lab-adaptation of GT1 results in enhanced in vitro virulence in a host-
independent manner 
Plaque size was quantified after 11-day plaque assays in order to assess the in 
vitro virulence of RH and of parallel-evolving a.) B0, b.) B2, and c.) B4 GT1 populations 
over the course of lab-adaptation. Black asterisks (*) indicate the p-value of the indicated 
GT1 passages relative to RH; colored asterisks (*, *, *) indicates the p-value of the 
indicated GT1 passage relative to the respective population’s earliest passage. * = p 
≤0.05, ** = p ≤0.01, *** = p ≤0.001. Error bars indicate standard deviation of biological 
replicates. Colored block indicates mean of biological replicates. Number of biological 
replicates are indicated in the plot by symbols. One biological replicate is the mean 
quantification of ≥25 plaques. d.) Plaque size was quantified after 11-day plaque assays 
in order to assess the in vitro virulence of RH and B2 in the context human foreskin 
fibroblasts (HFF) or goat skeletal fibroblast (GSF) host cells. Error bars indicate standard 














































































































Figure 2.2. Lab-adaptation of GT1 results in enhanced extracellular survival 
Parasites mechanically released from their host cells were incubated without a 
host for 0-10hrs following an 11-day plaque assay to determine parasite viability. a.) The 
number of plaques quantified at the given hour, relative to 0hr, determined the percent 
survival. b.) The area under the survival curves in a. was quantified to determine the 
overall relative viability of parasites during the entire 10hr assay. a.u. = arbitrary units. c.) 
Mechanically egressed parasites were immediately inoculated into T25 flasks containing 
host cell monolayers and allowed to settle onto monolayers for the given times, upon 
which flasks were vigorously washed to remove unsettled parasites and incubated for 11-
day plaque assays. The number of plaques, relative to the unwashed “input”, determined 
the number of parasites that strongly attached and/or invaded the host cell monolayer. 
Error bars indicate standard deviation of ≥3 biological replicates, containing ≥2 technical 
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Figure 2.3. Lab-adaptation of GT1 results in enhanced reinvasion efficiency 
 A known number (input) of mechanically released RH and parallel-evolving a.) B0, 
b.) B2, and c.) B4 GT1 parasites were immediately inoculated onto host cell monolayers 
for reinvasion followed by 11-day plaque assay. The number of formed plaques, relative 
to input, was quantified in order to yield the parasite’s reinvasion efficiency. Black 
asterisks (*) indicate the p-value of the indicated GT1 passage relative to RH; colored 
asterisks (*, *, *) indicates the p-value of the indicated GT1 passage relative to the 
respective population’s earliest passage; * = p≤0.05, ** = p≤0.01, *** = p≤0.001; error bars 
indicate standard deviation of ≥3 biological replicates; number of biological replicates are 

























































































































































Figure 2.4. Intracellular virulence traits are not enhanced during lab-adaptation 
 a.) RH and GT1-B2 parasites mechanically released from their host cells were 
allowed to invade host cells for 10 mins following 24hrs of incubation. The number of 
parasites per vacuole were observed by IFA and quantified in 100 vacuoles at random 
fields. b.) From the same dataset as a., the average number of duplication events was 
calculated for RH and GT1-B2. Biological replicates are indicated by symbols. c.) 
Mechanically egressed RH and GT1-B4 parasites were allowed to invade host cells for 
10 mins following 24hrs of incubation. The number of parasites per vacuole were 
observed by IFA and quantified in 100 vacuoles at random fields. d.) 30-hr intracellular 
parasites were treated for five minutes with either DMSO (control), calcium ionophore 
(A23187), or Ethanol (EtOH). The number of egressed and non-egressed vacuoles was 
enumerated by IFA; error bars indicate standard deviation of ≥3 biological replicates, each 




Chapter 3: Whole genome resequencing of GT1 during lab-adaptation identified 





3.1. Introduction  
To identify the genetic basis underlying GT1’s observed phenotypic changes 
during lab-adaptation (Chapter 2), we performed 150bp paired-end WGS on RH and 
several GT1 lines (designated B0, B2, and B4) over time (i.e. passages). Previous WGS 
studies identified 1,394 SNPs/indels between RH and GT1 using reference-guided 
sequence alignment and analysis [183]. However, these short-read sequencing data rely 
heavily on an accurately assembled reference genome, for which the GT1 reference 
genome, comprising 14 chromosomes, is incomplete and assembled into 302 contigs. 
Therefore, to circumvent the limitations of an incomplete reference genome, we utilized 
a reference-free variant discovery tool, RUFUS, developed by the Marth lab 
(https://github.com/jandrewrfarrell/RUFUS) [263]. RUFUS directly compares the k-mer 
reads from two samples without the need to align reads to a reference genome, thereby 
eliminating reference biases such as misaligned k-mers, poor reference coverage, poor 
scaffold assembly, and false positive variants, all without sacrificing sensitivity [263]. 
Surprisingly, we identified little accumulation of fixed genomic mutations in the 
evolving populations. This suggests that the basis of phenotypic changes, in contrast to 
our hypothesis, is not buttressed by changes in CDS or epistatic interactions. Sequencing 
individual clones from a population half way through the lab-adaptation experiment 
uncovered several genomic mutations, indicating that random genomic evolution does 
occur, but they did not fix in the population within 1000 generations. Only a single gene 
(TGGT1_245510), a P4 phospholipid-translocating P-type ATPase (P4-flippase), 
independently accumulated two different non-synonymous SNPs that fixed in the 
population: an L270R in the B2 evolving line and A477D in the B6 evolving line. In both 
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populations the mutations became fixed in the population before P33 (~200 generations), 
suggesting they provided a key benefit in the early stages of lab-adaptation. Attempts to 
directly test the impact of this mutation on GT1 fitness using CRISPR/Cas9-mediated 
genetic engineering were unable to generate recombinant parasites with the desired 
SNP, hampering our ability to verify its effect on lab-adaptation. However, we did recover 
a P4-flippase frameshift mutant resulting in a premature stop codon. This frameshift 
mutant (∆P4-Flippase) displayed a dramatic reduction in in vitro virulence, suggesting that 
this gene is critical to the parasite and that the observed mutations are likely beneficial to 






3.2.1. Genetic comparison of RH (lab-adapted) and GT1 (non-lab-adapted) parasites 
First, we compared WGS data of all low passaged (≤P15) GT1 samples to RH 
using RUFUS in order to establish the baseline of population complexity and clone-to-
clone variation. In total, 207 SNPs/indels were identified, with 69 causing changes to a 
genes CDS (Table 3.1). Of those mutations that caused protein coding changes, 55 were 
non-synonymous and 14 were synonymous. Furthermore, several of these mutations are 
in common with previous analysis, including the polymorphic virulence factor GRA2 that 
is associated with immune evasion [183]. Additionally, 15 previously identified mutations 
were confirmed in our strains by PCR-sequencing (Table 3.2) [183]. Taken together, 
these results refine previous comparative analyses and identify significantly fewer, higher 
confidence mutations that may explain the phenotypic differences observed between the 
RH (lab-adapted) and GT1 (non-lab-adapted) strains. 
 
3.2.2. Parallel resequencing identified two mutations within a P4-flippase 
 Resequencing was performed with Illumina’s Next Generation Sequencing (NGS) 
platform at several time points amongst three parallel-evolving GT1 populations (B0, B2, 
and B4), next to RH as control (Figure 1.4). RUFUS-based WGS analysis across the 
evolving GT1 populations provided the identity and allele frequency of high-quality 
polymorphisms within the entire genome. To asses clonality of our starting GT1 
populations, we first compared the starting population (B0-P4) and three clonal 
populations (B2-P15, B4-P15, and B6-P10) by RUFUS. Remarkably, no mutational 
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differences were identified between any these samples, indicating strong clonality within 
all of our GT1 populations at the beginning of the experiment (data not shown).  
The evolving B4 population was sequenced at four passages, P15, P32, P79, and 
P105 (~802 generations), for which we observed two mutations fixing in the population 
(Figure 3.1a). The first mutation mapped to the 13th intron of TGGT1_203135 (annotated 
as a dynein heavy chain) and fixed within the population by P32. The second mutation is 
in the same intron and also fixed by P32. Interestingly, one of these intronic mutations 
displayed a dynamic evolution by disappearing at B4-P79 and remerging by B4-P105 
(Figure 3.1a).  
 The evolving GT1 B2 population was sequenced at passages P15, P52, P86, 
P120, and P135, spanning about 1000 generations. Surprisingly, only one non-
synonymous mutation, L270R, emerged within the 2nd exon of TGGT1_245510, a 
phospholipid-translocating P-type ATPase (P4-flippase) gene, and remained fixed within 
the entire population by B2-P52 (Figure 3.1b).  
The evolving GT1 B6 population was sequenced at only two passages, P10 and 
P33, spanning ~305 generations, for which one non-synonymous mutation, A477D, 
emerged within the same P4-flippase gene and fixed within the population by B6-P33 
(Figure 3.1c). Interestingly, the A477D mutation identified in population B6 was just 620bp 
downstream of the L270R mutation identified in population B2. To finer map when and 
how fast these mutations occurred in the population, we PCR amplified the L270R and 
A477D genomic regions by PCR and Sanger sequenced the amplicons at additional 
passages recovered from cryopreserved samples. The chromatogram revealed that the 
L270R mutation emerged as early as B2-P20, when we observe a 50:50 distribution, and 
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fixed within the population by B2-P32 (Figure 3.2a). Similar resolution of the A477D 
mutation was confirmed by B6-P33 (Figure 3.2b), revealing that both mutations emerged 
within ~200 generations of lab-adaptation.  
 In order to identify additional mutations, estimate the mutation rate for GT1, and 
gauge the genetic complexity of GT1 during lab-adaptation, we performed WGS with five 
clones derived from B2-P86 (Figure 3.1b). As expected, the L270R P4-flippase mutation 
was found in all sequenced clones (Figure 3.1b). Additionally, 17 mutations were 
identified amongst the five clones, illustrating the presence of a complex population 
structure during lab-adaptation and supporting genomic evolution in GT1; however, none 
of these additional mutations fixed within the population by P135 (Figure 3.1b). Taken 
together, as expected, we see evidence of random mutations occurring in individual 
parasites and generating a complex population, however, only one mutation fixed in the 
B2 or B6 population suggesting that, germane to fitness, most mutations are near neutral 
or deleterious or hindered by genetic drift. 
 
3.2.3. ∆P4-flippase significantly reduced in vitro virulence 
Discovering two different non-synonymous mutations in the same gene around the 
same time across two parallel evolving lines strongly suggest that these mutations confer 
critical fitness benefits for GT1 during lab-adaptation [237, 264]. In addition, it highlights 
this gene’s candidacy as a novel polymorphic in vitro virulence factor. To test whether this 
gene is a driver of lab-adaptation, we aimed to revert the L270R mutation back to its wild 
type allele (270L) in GT1 population B2-P86 clone 1 using CRISPR/Cas9-mediated 
genetic engineering. Briefly, two plasmids containing a Cas9-mNeonGreen fusion 
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targeting either the upstream or downstream regions of the SNP were co-transfected 
along with a 2,258bp synthesized cDNA repair template (spanning 4 exons) containing 
the wild type allele and approximately 600bp arms complementary to the site of double 
stranded breaks (DSB) in order to allow for homologous recombination (Figure 3.3a). 
FACS sorting was utilized to enrich mNeonGreen+ (transfected) and mNeonGreen- 
(untransfected) parasites (Figure 3.3b). Unfortunately, subsequent single cell cloning and 
screening by PCR-sequencing identified no recombinant parasites with the allele of 
interest. We did, however, inadvertently generate a clonal frameshift mutant resulting in 
two 5’ premature stop codons (∆P4-flippase) (Figure 3.4). Serendipitously, we observed 
severe growth defects in ∆P4-flippase, resulting in a 0.12-fold decrease in GT1’s in vitro 
virulence (Figure 3.4). While we were unsuccessful in characterizing the functionality of 
our candidate SNPs, our ∆P4-flippase frameshift mutant suggests, at the very least, that 
our candidate mutations do not result in a complete loss-of-function of the gene, thereby 
supporting our hypothesis that R270L and A477D are beneficial mutations for low 
passage GT1. Future experiments will be needed to validate this hypothesis (see Chapter 
5.2.1.). 
 
3.2.4 Estimating GT1’s mutation rate 
By sequencing five clonal populations at two timepoints 520 generations (71 
passages) apart (B2-P15 and B2-P86) (Figure 32.b), we determined the mutation rate 
of GT1 to vary between 6.01 x10-11 and 2.71 x10-10, with an average mutation rate of 
1.14 x10-10 mutations/bp/generation. Recently, estimations of RH’s average mutation 
rate has been estimated to be ~5.8 x10-11 mutations/bp/generation, which is within the 
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range of our observed mutation rate with GT1 [265]. To put RH and GT1’s average 
mutation rate into context, this is similar to observing roughly 2-4% of a T. gondii 
population accumulating a single mutation within a single passage (2-3 days) under 
standard laboratory conditions (assuming a 64 Mb genome and our calculated of 5.8 
generations per passage).   
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3.3. Discussion  
Our data on the P4-flippase gene suggest its expression is critical for in vitro 
parasite fitness. Typically, P4-flippase proteins are membrane transporters of cations, 
heavy metals, and particularly, phospholipids across lipid bilayer leaflets in order to 
maintain lipid homeostasis [266]. Phospholipid flipping activity is of great biological 
importance for the biogenesis of vesicles [267, 268], creating a fusion-competent bilayer 
[269], maintaining membrane stability [270, 271], and generating signaling cues [272-
274]. These typical functions indicate that the changes in phospholipid flippase activity 
could contribute access to exogenous phospholipids that confer a competitive edge 
over parasites missing this mutation. Predictive structural analysis 
(http://www.sbg.bio.ic.ac.uk/~phyre2/html/page.cgi?id=index) suggests that the L270R 
mutation is located within a loop that connects two transduction domains and the mutant 
allele results in a 72 Å decrease in local cavity space. Similar analysis with the A477D 
mutation predicts its location to be within the alpha helix of an ATPase transmembrane 
domain. The significant reduction in plaque size of our frameshift mutant suggest that 
loss-of-function of P4-flippase will severely reduce parasite fitness; previous KO of P4-
flippase in a genome-wide CRISPR study suggests the same essentiality [224]. With 
this in mind, and because we observe an early fixation of both mutations (~200 
generations), these mutations could possibly bestow beneficial functional changes to 
the flippase activity, likely as an adaptation in response to some limited factor in the in 
vitro environment (e.g. lipids). 
Additional functional information can be gained from the subcellular localization of 
the P4-flippase. Several attempts to tag this protein by insertion of a C-terminal tag in the 
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genomic locus were unsuccessful (data not shown). However, localization insights can 
be gleaned from a recent Hyperplexed Localization of Organelle Proteins by Isotope 
Tagging (hyper-LOPIT) study, which assigned P4-flippase to the Golgi apparatus and 
plasma membrane fractions [275], suggesting that access to environmental lipids is a 
putative mechanism on how the mutations could confer competitive advantage. 
Resequencing of GT1 population B4 also identified 1 gene of interest that evolved 
two mutations that are 15 bp away from each other within the 13th intron of a dynein heavy 
chain family protein (TGGT1_203135). While these intronic mutations might indicate 
splice variants, we decided not to investigate them due to the extremely low expression 
(FPKM <0.60) of this gene in all of our samples, and the more than >30-fold increased 
expression of this gene observed during late merogony in the cat [276], which taken 
together indicate this gene is likely biologically irrelevant during the tachyzoite stage. 
Moreover, the high 87% A-T-richness surrounding this mutation make its identification 
and allele frequency calling unreliable (Figure 3.1b).  
Sequencing of clonal B2-P15, B4-P15, and B6-P10 GT1 populations reveals no 
genetic differences between these three strains (data not shown), indicating strong 
clonality when we started our lab-adaptation experiment. Roughly mid-way through our 
study, we resequenced five clones derived from B2-P86 in order to assess genetic 
complexity of the evolving B2 population. Interestingly, we identify several low-level 
mutations that are found within clones 3, 4, and 5, but not detected in the polyclonal 
population, consistent with the notion that mutation accumulation leads to an array of very 
low-level sub-populations that must overcome genetic drift and clonal interference in 
order to emerge from natural selection and fix within the entire population [229]. In the 
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case of clones 3, 4, and 5, they remain largely undetected in the population by B2-P135, 
indicating these mutations as non-beneficial or were lost to genetic drift. Clone 1 appears 
to have emerged as the dominant population, with clone 2 making up ~20% of the 
population by B2-P135, indicating some of these mutations as potentially beneficial. 
Considering that the B2-P86 clones evolved anywhere from one to nine mutations during 
71 passages (~520 generations), relative to the starting clone (B2-P15), we estimated T. 
gondii’s mutation rate to be between 6.01 x10-11 and 2.71 x10-10, with an average mutation 
rate of 1.14 x10-10 mutations/bp/generation. This mutation rate is similar to that of other 
single-celled organisms [277], such as S. cerevisiae (3.3 x10-10) [278] and S. pombe (2.0 
x10-10) [279] and E. coli (1.6 x10-10) [235]. Interestingly, this mutation rate is about 15- to 
30-fold lower than what has been calculated for P. falciparum (1.7 x10-9) [280], suggesting 
that there is likely a range of in vitro selection pressures and adaptive mechanisms for 
various apicomplexan parasites in culture. 
Although E&R has been successfully applied to a variety of organisms, including 
Plasmodium and Toxoplasma, to identify the genetic basis of drug resistance [244, 245, 
265], our experiments shows that gradual and relatively fast changes in phenotype do 
not completely correlate with the fixation of genomic mutations in parasites. Hence, the 
molecular basis of the lab-adaptive phenotypes identified in our experiments must stem 














TGGT1_245510 XII 2276797 GCC -> GAT A477D 0.00 0.00 1.00 phospholipid-translocating P-type ATPase
GT1 B6
Gene ID Chrom. Position Codon/NT Amino Acid RH Product Description
~305 generations
P15 P52 P86 Clone 1 Clone 2 Clone 3 Clone 4 Clone 5 P120 P135
TGGT1_245510 XII 2277419 CTG -> CGG L270R 0.00 0.00 1.00 0.97 0.99 1.00 1.00 0.99 1.00 1.00 0.99 phospholipid-translocating P-type ATPase
TGGT1_234250 X 4144128 TCC -> TCT S813S 0.00 0.00 0.00 0.02 0.00 1.00 0.00 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_265870A IX 1218247 GGG -> GAG G441E 0.00 0.00 0.00 0.47 0.39 1.00 0.00 0.00 0.00 0.12 0.27 pantoate-beta-alanine ligase
TGGT1_321410 Ib 1842756 TCT -> TGT S442C 0.00 0.00 0.00 0.38 0.00 0.99 0.00 0.00 0.00 0.15 0.25 hypothetical protein
TGGT1_410050 V 1970981 G -> C N/A 0.00 0.00 0.00 0.45 0.00 1.00 0.00 0.00 0.00 0.14 0.18 tRNA-Pro
TGGT1_253615 III 1043595 A -> G Intronic 0.00 0.00 0.00 0.40 0.02 1.00 0.00 0.00 0.00 0.17 0.16 hypothetical protein
TGGT1_320000 IV 549609 G -> A Intronic 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 SCY kinase (incomplete catalytic triad)
Intergenic Ib 661732 G -> C Intergenic 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 N/A
Intergenic V 1825065 C -> T Intergenic 0.00 0.00 0.00 0.40 0.36 1.00 0.00 0.00 0.00 0.15 0.29 N/A
TGGT1_215700 X 7003044 GTA -> GCA V1134A 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 phosphatidylinositol 3- and 4-kinase
TGGT1_228070 X 528213 ACG -> ATG T1220M 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_206550 VIIa 863356 C -> G Intronic 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_237890 IV 2493525 T -> C Intronic 0.01 0.00 0.06 0.02 0.03 0.00 0.99 0.03 0.00 0.00 0.04 calcium-dependent protein kinase CDPK4
Intergenic XII 2972581 A -> C Intergenic 0.00 0.00 0.00 0.00 0.00 0.00 0.99 0.00 0.00 0.00 0.00 N/A
TGGT1_309760 XI 754634 CAG -> TAG Q169* 0.00 0.00 0.04 0.33 0.00 0.00 0.00 1.00 0.00 0.35 0.04 hypothetical protein
Intergenic XII 1269841 G -> G Intergenic 0.00 0.00 0.00 0.00 0.00 0.02 0.00 1.00 0.00 0.00 0.00 N/A
Intergenic V 2426180 A -> G Intergenic 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 N/A
Intergenic XII 4886211 G -> C Intergenic 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 N/A
Product DescriptionGene ID Chrom. Position Codon/NT Amino Acid
GT1 B2 GT1 B2
RH




P15 P32 P79 P105
TGGT1_203135 VIIa 2687693 CAG -> TTT Intronic 1.00 0.00 1.00 1.00 1.00 dynein heavy chain family protein
TGGT1_203135 VIIa 2687677 G -> A Intronic 1.00 0.00 1.00 0.00 1.00 dynein heavy chain family protein
RH
GT1 B4




Figure 3.1. WGS identifies few genomic mutations in GT1 during lab-adaptation 
 WGS was performed on RH and GT1 populations a.) B4, b.) B2, and c.) B6, 
alongside with five clones derived from B2-P86, at the various timepoints indicated. Low 
genetic complexity of the both B4 intronic mutations is shown in panel a. Allele 
frequencies, the percentage of reads with the indicated allele, are represented by the 


































Figure 3.2. Validation of P4-flippase mutations in GT1 
 PCR-sequencing confirms the presence of the a.) L270R mutation in B2 GT1 
population. The emergence of two alleles in the evolving population can be observed by 
P20, zoomed in panel. b.) PCR-sequencing confirms the presence of the A477D mutation 












Figure 3.3. P4-flippase allele swap strategy 
 a.) Transfection of two Cas9-mNeonGreen plasmids encoding two different 
protospacers and a synthesized cDNA repair template containing the WT allele of the P4-
flippase. Successful homologous recombination of the repair template will result in an 
allele swap in the recombinant parasites. Colored boxes represent exons; black line 
represents introns. b.) FACS-sorting of untransfected and transfected parasites in order 





Figure 3.4. P4-flippase frameshift mutant results in reduced in vitro virulence 
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Figure 3.4. P4-flippase frameshift mutant results in reduced in vitro virulence 
a.) Untransfected and b.) transfected B2-P86 parasites were screened for 
homologous recombination of the repair template but only resulted in the identification of 
a frameshift mutant containing two premature stop codons. c.) Quantification of plaque 
size reveals a dramatic reduction of in vitro virulence in the frameshift mutant. 
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Chapter 4: GT1 lab-adaptation results in modified transcriptional programs during 






 Since genomic changes do not fully track with the phenotypic changes seen during 
GT1’s lab-adaptation, we reasoned that the mechanistic basis might be due changes in 
the expression level of particular genes, which has been previously suggested [168]. 
Similar mechanisms have been observed in yeast adapting to salt stress [281, 282], E. 
coli adapting to limited glucose [236], and mammalian cells lab-adapting to culture 
conditions [283]. Interestingly, previous microarray analysis of RH, RH-JSR, and GT1 
have identified many differences in gene expression, suggesting differential expression 
(DE) of genes (DEGs) as a molecular basis for phenotypic differences within T. gondii’s 
type I lineage [168, 183].  
 To test this hypothesis, we performed mRNA-sequencing (RNA-seq) across 
several time points of the GT1 populations (Figure 1.4). Since the lytic cycle consists of 
intracellular and extracellular milieus, we sampled both intracellular and 6-hour 
extracellular parasites. Complementary to our phenotypic data (Chapter 2), most changes 
in gene expression occurred in extracellular parasites. Advanced analysis of these data 
identified 988 DEGs that trend up or down during 1500 generations of lab-adaptation, of 
which 319 strongly correlate in time with our phenotype data. Interestingly, the dataset 
largely reflects a pro-tachyzoite transcriptomic profile as many tachyzoite-related genes 
are upregulated and other zoite-related genes are down-regulated. We selected five 
upregulated DEGs for experimental validation, of which four DEGs demonstrated a 
significant impact on GT1’s in vitro virulence. Furthermore, we utilized gene set 
enrichment analysis (GSEA), gene ontology enrichment analysis (GOEA), and metabolic 
pathway enrichment analysis (MPEA) to gather insights into some of the biological 
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processes that may be affected by lab-adaptation. The biological pathways displaying the 
most dramatic changes in gene expression pointed toward acetyl-CoA and de novo fatty 
acid (FA) biosynthesis within the apicoplast as key biological processes upregulated 
during lab-adaptation. Based on these data, we conclude that lab-adaptation of GT1 is 
likely anchored in epigenetic changes that promote tachyzoite virulence likely by 






4.2.1. Transcriptomic comparison of RH (lab-adapted) and GT1 (non-lab-adapted) 
parasites  
To discern the differences in gene expression between lab-adapted and non-lab-
adapted parasites, RNA-seq was first performed on asynchronously replicating, 30-hour 
intracellular and 6-hour extracellular RH and cloned B2-P11 and B4-P11 GT1 
populations. Differential expression analysis (DEA) was used to identify DEGs between 
RH and low passage (<P12) GT1 populations. Genes were considered to be DE if the 
fold change (FC) was ≥2 and if the q-value was ≤0.05. DEA of intracellular parasites 
identified 545 DEGs between RH and B2-P11, of which 331 DEGs were upregulated and 
214 DEGs were downregulated, relative to RH (Table 4.1). Similarly, DEA of intracellular 
parasites identified 764 DEGs between RH and B4-P11, of which 526 DEGs were 
upregulated and 238 DEGs were downregulated (Table 4.1). With both GT1 populations 
combined, intracellular B2-P11 and B4-P11 share 498/811 (~62%) DEGs with similar 
expression, relative to RH (Table 4.1).  
DEA of extracellular parasites identified 927 DEGs between RH and B2-P11, of 
which 476 DEGs were upregulated and 451 DEGs were downregulated (Table 4.2). 
Similarly, DEA of extracellular parasites identified 955 DEGs between RH and B4-P11, 
of which 380 DEGs were upregulated and 575 DEGs were downregulated (Table 4.2). 
With both GT1 populations combined, extracellular B2-P11 and B4-P11 share 692/1190 
(~58%) DEGs with similar expression, relative to RH (Table 4.2).  
With a vast number of DEGs observed across the two type I strains, RH and GT1, 
we also aimed to assess the clonality of gene expression within the GT1 strain. Similar to 
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our DNA-seq analysis of clones, RNA-seq analysis indicates our starting GT1 population 
was highly clonal in its gene expression patterns because no significant DEGs were 
identified amongst B0-P7, B2-P11, and B4-P11 GT1 populations in neither intracellular 
nor extracellular samples (data not shown). Taken together, the above comparative data 
reveal that RH and GT1 are very different in terms of their gene expression patterns, both 
intracellularly and extracellularly, dramatically expanding upon our current knowledge of 
the transcriptomic differences previously characterized between the two isolates [168, 
183], and supporting a hypothesis for differential gene expression as a molecular basis 
for phenotypic differences observed across T. gondii’s type I lineage. 
 
4.2.2. Few transcriptomic changes are observed in intracellular parasites during 
GT1’s lab-adaptation 
To uncover changes in gene expression that could be responsible for lab-adaptive 
changes to GT1’s phenotypes, RNA-seq was first performed on asynchronously 
replicating intracellular GT1-B2 parasites at three passages: P11, P84, and P148. DEA 
relative to B2-P11 only identified 12 DEGs, with many (9/12) being annotated as 
hypothetical (Table 4.3). These data indicate that the intracellular state of GT1 is likely 
not affected by lab-adaptation, or that major differences are within cell-cycle genes, of 
which the noise of an asynchronized population would obscure. Given that we did not 
observe any major differences in intracellular virulence traits (Figure 2.4), but did observe 
major difference in extracellular virulence traits (Figure 2.2 & 2.3), we next hypothesized 
that the extracellular transcriptomic state of GT1 likely changes during lab-adaptation. 
Indeed, we observed >80-fold more DEGs in our extracellular data set, and because we 
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largely observed augmentation of extracellular virulence traits (Chapter 2), we pursued 
further RNA-seq analysis with only our extracellular transcriptomic data sets. 
 
4.2.3. Time course sequencing analysis of extracellular GT1 identified 988 DEGs 
that trend toward a tachyzoite-like profile during lab-adaptation 
To uncover changes in gene expression that could be responsible for changes in 
GT1’s phenotypes, RNA-seq was performed on extracellular GT1-B2 at several 
passages: P11, P35, P55, P85, P148, and P210. Because a vast number of DEGs were 
identified across several passages, we applied a novel RNA-seq analysis pipeline to 
process and interpret the temporal data (Figure 4.1, see methods). Following DEA, two 
subsequent analyses, 1) time course sequencing data analysis (TC-seq) and 2) 
regression analysis (RA), were utilized to interpret the expression data and identify 
candidate DE virulence factors (Figure 4.1). TC-seq identified 988 DEGs whose gene 
regulation showed a directional trend (Figure 4.2), with 437 DEGs trending up and 551 
DEGs trending down over time (Table 4.4). Of those trending, nearly 55% are genes of 
unknown function, limiting our ability to characterize the biology of the entire data set. 
However, other comparative RNA-seq analyses of T. gondii at different life stages have 
dramatically expanded our repertoire of expression data, and allowed us to characterize 
gene sets in the context of life cycle stages (i.e. tachyzoite, bradyzoite, merozoite, and 
sporozoite) regardless if those genes are annotated or not. In other words, we can, for 
example, quantify, or score, how bradyzoite-like a particular list of genes are based off 
how these genes are differentially expressed in bradyzoites, relative to the three other life 
stages (Figure 4.3a). This novel method (see methods) of “stage scoring” data sets was 
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first validated by scoring previously published tachyzoite-, bradyzoite-, and sporozoite-
associated lists of genes. Indeed, each list only scored significantly (p-value ≤0.05, 
bootstrap analysis) to their respective life stage, validating our scoring approach (Figure 
4.3b-d). Stage scoring was applied to the 988 trending DEGs found during lab-adaptation 
in 6-hour extracellular GT1 parasites. Of the 437 DEGs that trend up, a significant number 
were found to be more tachyzoite- and bradyzoite-like (p-value ≤0.05, bootstrap 
analysis); and of the 551 DEGs that trend down, a significant number were found to be 
bradyzoite-, merozoite-, and sporozoite-like (Figure 4.4) (p-value ≤0.05, bootstrap 
analysis). These data suggest that lab-adaptation results in increased expression of 
tachyzoite-associated genes and repression of genes associated with other life stages 
during the extracellular milieu.  
 
4.2.4. Enrichment analysis identified FA synthesis as a lab-adaptive biological 
process 
With so many DEGs to interpret, and with 50% of our DEGs annotated as having 
an unknown function, we employed three types of statistical enrichment analyses (GSEA, 
GOEA, MPEA) in order to uncover biological insights into GT1’s lab-adaptation. GSEA 
utilizes previously established lists of T. gondii genes that are associated with a particular 
biological state (G1, bradyzoites, etc.), process (e.g. invasion, metabolism, etc.) or 
organelle localization (ER, nucleus, etc.); GOEA utilizes a hierarchal classification system 
of genes (or gene products) that are organized into terms that describe the gene’s 
molecular function (ribosome, Ca2+ binding, etc.) biological process (phosphorylation, 
translation, etc.), and cellular component (proteasome complex, nucleus, etc.); and 
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MPEA utilizes established molecular interaction/reaction/relation networks (glycolysis, 
TCA cycle, etc.) in order to contextualize a researcher’s dataset. 
GSEA identified the upregulation of genes associated with: the apicoplast, 
saturated FA biosynthesis, bradyzoites, GRA proteins, and more. GOEA identified the 
upregulation of genes associated with: the apicoplast, FA biosynthesis, oxidoreductase 
activity, ribosomal structure, FA biosynthesis, metabolic process, and many more. MPEA 
identified the upregulation of genes associated with: glycolysis, FA biosynthesis, pyruvate 
to acetyl-CoA biosynthesis, and many more (Figure 4.6).   
Even though ~55% of our DEGs are annotated as hypothetical genes with 
unknown functions, one biological insight was distinct: FA biosynthesis. All three 
enrichment analyses of our upregulated RNA-seq data set highlight FA biosynthesis as 
an upregulated biological process in extracellular GT1 parasites during lab-adaptation; 
moreover, down regulation of FA degradation is also observed (Figure 4.7), supporting 
FA acquisition as a lab-adaptive biological process. Upon examining the genes involved 
in the fatty acid synthesis II (FASII) pathway, which is responsible for de novo FA 
synthesis in the apicoplast, we observed the upregulation of many genes over time 
(Figure 4.8a). Interestingly, many of these upregulated genes are involved with 
transporting and converting phosphoenolpyruvate (PEP), a product of glycolysis, all the 
way into FAs (Figure 4.8b). The carbon chains of FA’s can be further elongated in the 
ER, for which we observe a modest upregulation of the FA elongation pathway as well 
(4.8c-d). Taken together, these data suggest that increased de novo FA synthesis was 
selected for during the extracellular milieu of GT1’s lab-adaptation. 
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4.2.5. Enhanced phenotypes during lab-adaptation are a multifactorial effect of 
gene expression 
The upregulation of genes involved in FA metabolism represent just a small subset 
of all the DEGs, leaving the functional role of many other genes for T. gondii virulence in 
question. To choose the strongest candidates for functional analysis we performed 
regression analysis (RA) on our 988 DEGs in order to determine the strongest 
correlations between gene expression and phenotypic changes over time. RA identified 
319 DEGs (at least one time point = FC ≥2, q-value ≤0.05) that are highly expressed 
(CPM ≥50%) and strongly correlated (R2 ≥0.70) with at least one phenotype (plaque size, 
reinvasion efficiency, extracellular survival) (Table 4.5). Of those, 153 were upregulated, 
166 were downregulated, 192 correlated with plaque size, 275 correlated with reinvasion 
efficiency, and 52 correlated with extracellular survival (Figure 4.9a).  
Of course, correlation does not equal causation, so we sought validation by 
knocking out five upregulated genes of interest using a CRISPR/Cas9-mediated genetic 
engineering approach (Figure 4.9b). We generated KO’s with B2-P239 as this population 
had higher fitness and, therefore, likelihood of generating a recombinant parasite (which 
is already difficult given Toxoplasma’s efficient NHEJ DNA-repair pathway). The five 
candidate genes that were chosen to be validated as DE in vitro virulence factors were 
based off several variables: Log2FC, R2 value, phenotype score on ToxoDB (i.e. a modest 
fitness score to avoid picking genes essential for the lytic cycle [224]), and biological 
interests. We chose the following three genes from the 90th percentile for Log2FC and had 
the strongest R2 value for plaque size, extracellular survival and/or reinvasion efficiency: 
TGGT1_262590 and TGGT1_264240 are both hypotheticals genes of unknown function 
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with the highest R2 values for extracellular survival and reinvasion efficiency/plaque size, 
respectively (Figure 4.10a); and TGGT1_315885, a putative glycosyltransferase (Gnt1) 
also with the highest R2 value for reinvasion efficiency and plaque size (Figure 4.10a). 
We also chose the two following genes based on biological interest: TGGT1_230980, a 
myosin gene (MyoI), and TGGT1_260190, a microneme gene (MIC13). MyoI resides in 
the RB and ensures synchronicity of division between intravacuolar parasites [116], a 
process not intuitively associated with the extracellular milieu, whereas MIC13 was 
recently connected with oxidative stress survival through an unknown mechanism [284], 
which therefore serves as our positive control. 
Diagnostic PCR of pyrimethamine resistant clones confirmed homologous 
recombination of the DHFR selection cassette into the 5’ and/or 3’ locus of our gene of 
interest (Figure 4.9c); while DHFR did not undergo 5’ integration in two genes of interest 
(TGGT1_264240 & TGGT1_230980), 3’ integration of DHFR in all genes was confirmed 
and, moreover, qPCR of clonal populations confirmed ablation of mRNA expression in all 
transgenic lines (Figure 4.9d). Next, 11-day plaque assays were performed with our five 
KO’s, along with the parental GT1 line, B2-P239, and B2-P18 (Figure 4.10a-b). As 
previously observed, plaque size and reinvasion efficiency of high passage parasites (B2-
P239) is 3.14- and 3.82-fold superior to that of low passage parasites (B2-P18), 
respectively (Figure 4.10b-d). Relative to B2-P239, four KO lines show a significant (p-
value ≤0.01) 0.51- to 0.76-fold reduction in plaque size while three lines show a significant 
(p-value ≤0.05) 0.65- to 0.77-fold reduced reinvasion efficiency (Figure 4.10b-d).  
Interestingly, 4/5 of our candidate gene KO parasites display phenotypic characteristics 
that were predicted by the genes calculated R2 value, indicating a high degree of accuracy 
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in phenotype prediction from our RA. Moreover, these results indicate that our list of 
candidate genes likely contains many DE in vitro virulence factors that aid in GT1’s lab-







As observed with our phenotypic data (Chapter 2), our transcriptomic data reveals 
that most lab-adaptive changes occur with extracellular parasites. With so many DEGs 
and, moreover, many of unknown function, it is difficult to untangle biological insights 
associated with GT1’s lab-adaptation; therefore, we employed multiple enrichment 
analysis in order to gain biological insights. GSEA, GOEA, and MPEA analysis of GT1’s 
extracellular transcriptomic data revealed the expected downregulation of several related 
processes such as organelle fission, reproductive process, and cell cycle, which only 
occur intracellularly, thereby validating this approach. As for upregulated DEGs, MPEA 
identified glycolysis, acetyl-CoA biosynthesis, and pyruvate metabolism, all of which are 
intersecting pathways feeding into FA biosynthesis. Interestingly, FA biosynthesis was 
the only biological insight in common between MPEA, GSEA, and GOEA. Moreover, FA 
degradation was found to be downregulated by MPEA, supporting FA procurement as a 
biological mechanism for GT1’s lab-adaptation.  
Within the cytosol of the parasite, glycolysis converts glucose into 
phosphoenolpyruvate (PEP), which is then translocated into the apicoplast by apicoplast 
triosephosphate translocator 1 (APT1) [285]. Within the apicoplast, PEP is converted into 
pyruvate by pyruvate kinase 2 (PYK2) [286, 287]. The pyruvate dehydrogenase (PDH) 
complex is activated by lipoylation and then converts pyruvate into acetyl-CoA, the 
metabolite precursor for the fatty acid synthase II (FASII) pathway [288-290]. The FASII 
pathway begins with the conversion of acetyl-CoA to malonyl-CoA by acetyl-CoA 
carboxylase 1 (ACCase1) [291]. Next, malonyl-CoA and acyl-carrier-protein (ACP) are 
processed by FabD and FabH to form β-ketoacyl-ACP (i.e. FASII initiation), which is then 
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processed through a repeated series of reduction and dehydration reactions by FabG, 
FabZ, and ENR, (i.e. FASII elongation) to elongate the FA chain up to C:16 in length 
(Figure 4.8b) [292]. Further elongation or saturation of apicoplast-derived FAs can occur 
in the ER (Figure 4.8d) [293]. Additionally, glycerol 3-phosphate acetyltransferase 1 
(ATS1) can convert FAs into lysophosphatidic acid (LPA) [294], while ATS2 can convert 
LPA into phosphatidic acid (PA) [295], a central precursor for the de novo synthesis of all 
phospholipids (PL). Interestingly, many of these enzymes that feed into the production of 
short chain FAs are significantly upregulated in extracellular GT1 during lab-adaptation 
(Figure 4.8). Recent lipidomic studies reveal metabolic plasticity in T. gondii’s ability to 
not only scavenge lipids from host cells but create lipids de novo via the FasII pathway, 
supporting our observation of a shifted FASII expression profile [295]. Even under 0% 
FBS (lipid-starved conditions), lipidomic analysis reveals that RH is able to maintain its 
superior in vitro virulence by upregulating its de novo FA/lipid synthesis up by 15% [295]. 
In our study, we cultured GT1 in 1% FBS, which likely explains the observed natural 
selection of GT1 parasites with increased FASII expression and thus greater in vitro 
virulence; however future lipidomic experiments are needed to connect the upregulation 
of this pathway to augmented in vitro virulence and associated virulence traits in GT1 
(see Chapter 5.2.2.).  
Further biological insights were gained from our life-stage analysis, which 
characterized our trending up- and down-regulated DEGs as tachy-, brady-, mero and/or 
sporozoite. This transcriptomic analysis revealed that extracellular tachyzoites are 
becoming more tachyzoite-like during lab-adaptation, which is not surprising given RH is 
very lab-adapted and exclusively exhibits pro-tachyzoite tendencies. For example, RH 
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has the fastest asexual lytic of all T. gondii strains and no longer readily differentiates into 
other life stages. Similarly, in P. falciparum, it has been known that gametocyte (sexual 
life stage) production is lost upon prolonged asexual lab-adaptation [296]; interestingly, 
this is due to loss-of-function mutations in the ApiAP2-G TF that normally controls the 
expression of several associated gametocyte genes [297]. In RH, however, the genetic 
basis responsible for the loss of cell differentiation remains unknown. While we cannot 
rule out a mutation-based mechanism for RH, our study in GT1 suggest that the evolution 
of pro-tachyzoite tendencies could be, at least in part, due to epigenetic control. 
Supporting this notion, ApiAP2-G is suggested to be epigenetically controlled in P. 
falciparum [297-299] and its ablation provides an in vitro growth advantage [297]. Thus, 
we hypothesize that epigenetic control of TFs (e.g. AP2 or Myb-domain containing 
proteins) could be promoting GT1’s pro-tachyzoite transcriptomic shift and resulting in 
augmented in vitro virulence during lab-adaptation. Several potential TF’s of interest are 
listed in Table 4.6, of which two have been shown to be bradyzoite activators (AP2IV-3 & 
AP2Ib-1) [147] and one has been shown to be a bradyzoite repressor (AP2IX-9) [147, 
151]- others remain enigmatic. 
One mitigating factor in interpreting RNA-seq data is that the differential expression 
of mRNA does not always correlate with expression at the protein level due to post-
transcriptional regulatory mechanisms. In mammalian cells, many mRNAs associated 
with development and stress response are post-transcriptionally regulated [300]. In 
apicomplexans, translational control of mRNA transcripts is emerging as a significant 
regulator, especially of parasitic latency (e.g. bradyzoites, sporozoites), which can often 
be stress induced [301-303]. Recently, comparative RNA-seq and ribosome/polysome 
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profiling (Ribo-seq) identified little translational control amongst intracellular T. gondii 
tachyzoites [304]; however, upon extracellular conditions (<1hr estimated) 834 genes 
(~12% of T. gondii's detected translatome) are differentially controlled at the translational 
level [303], likely as a mechanism of stress response [301]. Of those translationally 
controlled genes, 93 overlap with our TC-seq-derived (trending) DEG’s, and 37 overlap 
with our RA-derived (phenotypically-correlated) DEGs. Thus, roughly 10% of our list of 
DE in vitro virulence factors are likely to be translationally controlled and may not present 
a phenotype when manipulated transcriptionally.  
To validate our list of DEGs, gene KO lines for five candidate genes trending 
strongly with phenotypic features were used to functionally validate their association with 
in vitro virulence and virulence traits. To our success, the correlation coefficient, R2, of 
phenotypes was highly accurate with 4/5 of our KO lines displaying the expected 
phenotype. For example, gene expression of MyoI and Gnt1 strongly correlated with 
plaque size and reinvasion efficiency during lab-adaptation, and KO of these genes 
validated their influence on those phenotypes. Alternatively, gene expression of 
TGGT1_262590 did not show strong correlation with plaque size and reinvasion efficiency 
during lab-adaptation, and phenotypic evaluation of this KO validated that relationship 
too. However, two unexpected outcomes were observed: TGGT1_264240 displayed 
reduced reinvasion efficiency of ~17% as expected by RA (R2 = 1.0), but this did not reach 
statistical significance (p-value = 0.24) due to the sizable standard deviation in our 
biological replicates; and MIC13 displayed a significant ~35% reduction in plaque size, 
which was much more dramatic than we expected given its R2 value of only 0.49. Overall, 
the majority of our predictions made by RA were accurate in identifying DE genes that 
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have significant influence on GT1’s phenotypes. Notably, no single gene KO was able to 
reduce the in vitro virulence of GT1-P239 down to the level of GT1-P18, indicating that in 
vitro virulence is a polygenic trait. 
Exactly how and why some of these genes aid in GT1’s lab-adaptation is unknown, 
but with the three annotated genes we functionally investigated, MIC13, Gnt1, and MyoI, 
some speculations can be made. First, it is possible that upregulation of MIC13 is part of 
a stress response to the extracellular environment as recent studies have identified 
MIC13 as an important factor of RH growth under stressed conditions [284]. In our GT1 
study, however, MIC13 appears significant for growth under standard “unstressed” 
laboratory conditions (Figure 4.10b-c), suggesting that our laboratory conditions are 
actually perceived as stressful in GT1 parasites or that MIC13 functions differently in RH 
and GT1. Second, in the case of Gnt1, previous studies have shown this 
glycosyltransferase to incorporate GlcNAc onto Skp1, an adaptor protein, which then 
promotes the formation of the Skp1/Cullin-1/F-box protein (SCF) complex, an E3-ubiquitin 
ligase [87, 305]. The SCF complex will polyubiquitinate specific regulatory and non-
regulatory proteins, marking them for degradation by the 26S proteasome. Moreover, the 
SCF complex was found to be O2 regulated in Dictyostelium [83], indicating its role in 
maintaining redox homeostasis in the cell. Interestingly, during GT1’s lab-adaptation, six 
genes of the proteasome core complex were upregulated over time, suggesting that lab-
adaptation, results in increased protein turnover within extracellular parasites. Exactly 
how this might aid in GT1’s enhanced reinvasion efficiency or in vitro virulence requires 
further investigation but it possible to be a starvation response mechanism aimed at 
recycling amino acids for new proteins [306] or to combat damage induced by reactive 
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oxygen species (ROS). After all, lab-adaptation involves the parasite’s frequent exposure 
to atmospheric O2 levels (21%) which is dramatically higher than what is experienced in 
vivo. Lastly, the identification of MyoI is quite peculiar as it is a class XXIV motor protein 
that is known to localize to the RB of intracellular parasites [116]. Functional analysis has 
shown that MyoI is required to establish the basal RB connection that maintains parasite-
to-parasite communication and cell synchronicity of dividing parasites [116]. In our study, 
there is an increased expression of MyoI in extracellular parasites, indicating perhaps a 
novel extracellular function of MyoI. Indeed, the basal complex of the parasites display 
several features of an import/export port, and, in intracellular parasites, have been shown 
to be a likely site of host vesicle uptake (reviewed in [307]). Thus, we hypothesize that 
the basal complex might serve as lipid uptake port in extracellular parasites. 
In conclusion, 8/10 phenotype predictions across 4/5 gene KO’s we examined 
were confirmed in our phenotypic validation experiments, indicating our list of candidate 
DEGs as likely containing many genes responsible for in vitro virulence in our adapted 
GT1 strain. This gene set therefore provides a rich resource for discovering and assigning 
new gene-function associations. Furthermore, our DNA- and RNA-seq results, taken 
together, suggest that epigenetic mechanisms are likely responsible for much of GT1’s 
evolved in vitro virulence during lab-adaptation rather than an accumulation of mutations. 
Future work characterizing the dynamics of chromatin accessibility during lab-adaptation, 
coupled with our transcriptomic data, will evaluate our hypothesis of epigenetically 





















Figure 4.1. Experimental workflow and RNA-seq analysis pipeline 
 Following lab-adaptation of GT1, mRNA-sequencing (RNA-seq) was performed at 
several evolutionary time points (i.e. passages) and data was analyzed by differential 
expression analysis (DEA). To identify expression patterns within the data set, time-
course sequencing (TC-seq) was utilized and identified 988 differentially expressed 
genes (DEGs) that trend up or down over time. Life stage analysis, gene set enrichment 
analysis (GSEA), gene ontology enrichment analysis (GOEA), and metabolic pathway 
enrichment analysis (MPEA) were utilized on TC-seq data set to identify biological 
insights into lab-adaptation. The TC-seq data set was further filtered by regression 
analysis (RA) to identify 319 DEGs that strongly correlated with lab-adaptive phenotypes. 
Functional analysis of several DEGs was then performed by CRISPR/Cas9-mediated 






Figure 4.2. Time-course sequencing analysis identified 8 expression profiles that 







Figure 4.2. Time-course sequencing analysis identified 8 expression profiles that 
largely trend upward or downward during lab-adaptation 
 Following RNA-seq of 6-hour extracellular GT1 parasites, TC-seq analysis 
identified eight prominent expression patterns amongst significant DEGs. DEGs were 
considered significant if the absolute FC ≥2 and q-value ≤0.05 in at least one time point 
(i.e. passage). Five expression patterns show a general downward trend while three 
expression patterns show a general upward trend in expression during lab-adaptation. 
The number of genes within each trend is indicated in each plot. Expression at each 












































































































Figure 4.3. Developing and validating T. gondii’s life stage score analysis 
 a.) Available tachyzoite, bradyzoite, merozoite, and sporozoite RNA-seq data sets 
(ToxoDB.org, see methods) were utilized for differential expression analysis (DEA). Each 
stage was compared to the 3 other stages (e.g. tachyzoite vs. bradyzoite; tachyzoite vs. 
sporozoite; tachyzoite vs. merozoite). The number of times each gene was significantly 
upregulated in this 3-way DEA was enumerated to yield a max score of 3 or min score of 
0 for each gene. The average enumeration of previously published lists of genes was 
calculated for b.) tachyzoite-, c.) bradyzoite-, and d.) sporozoite-associated genes. Color-
coded asterisks (*) indicate p-value ≤0.05, as determined by an independent bootstrap 




Figure 4.4. Life stage scoring identified pro-tachyzoite gene expression in lab-




















































































































Figure 4.4. Life stage scoring identified pro-tachyzoite gene expression in lab-
adapting GT1 parasites 
 a.) Life stage scoring was performed on 437 DEGs identified by TC-seq as trending 
upward or b.) 551 DEGs identified by TC-seq as trending downward during lab-
adaptation. Color-coded asterisks (*) indicate p-value ≤0.05, as determined by an 
independent bootstrap analysis (n= 1000 random sampling) for each individual life stage. 
c.) The downregulated stage score is subtracted from the upregulated stage score to 





































































































Figure 4.5. Gene set enrichment analysis (GSEA) of trending genes 
 Up- and down-regulated DEGs identified by TC-seq were subject to GSEA, which 
utilizes previously published gene sets that describe organelle-associated genes, 
metabolic genes, life stage genes, and genes involved with different biological processes. 
The significance of overlap between our set of genes with these previously published 
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Figure 4.6. Gene ontology enrichment analysis (GOEA) of trending genes 
a.) Up- and b.) down-regulated DEGs identified by TC-seq were subject to GOEA 
on ToxoDB.org to identify GO-terms associated with biological processes, molecular 
functions, and cellular components. Redundant GO terms were removed by REVIGO 




Figure 4.7. Metabolic pathway enrichment analysis (MPEA) of trending genes 
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Figure 4.7. Metabolic pathway enrichment analysis (MPEA) of trending genes 
a.) Up- and b.) down-regulated DEGs identified by TC-seq were subject to MPEA 
on ToxoDB.org to identify associated metabolic pathways. Several identified terms have 





Figure 4.8. Evolution of the FASII pathway and elongation pathway in extracellular 













































RH P11 P35 P55 P85 P148 P210
TGGT1_261070 -0.01 0.00 -0.07 -0.12 1.28 1.23 0.75 APT1
TGGT1_299070 -0.72 0.00 -0.18 0.05 0.19 0.26 0.44 PyKII
TGGT1_245670 -0.11 0.00 -0.49 -0.08 2.33 1.55 1.50 PDH-E1⍺
TGGT1_272290 -0.23 0.00 -0.01 -0.18 0.45 -0.02 -0.02 PDH-E1β
TGGT1_206610 -0.17 0.00 0.45 -0.16 1.14 0.54 0.42 PDH-E2
TGGT1_305980 0.19 0.00 0.31 0.90 1.88 1.47 1.65 PDH-E3I
TGGT1_221320 -2.01 0.00 0.11 0.22 0.69 0.92 0.95 ACC1
TGGT1_264080 -0.48 0.00 0.08 0.40 1.50 1.30 1.21 ACP
TGGT1_225990 -0.16 0.00 0.06 -0.26 1.09 0.51 0.40 FabD
TGGT1_231890 -0.08 0.00 0.18 0.66 1.34 1.41 1.16 FabH
TGGT1_321570 0.55 0.00 0.46 0.66 0.94 1.10 0.73 FabZ
TGGT1_251930 0.36 0.00 -0.23 -0.16 2.05 1.52 0.95 ENR
TGGT1_226400 -0.29 0.00 -0.22 -0.14 -0.21 -0.10 -0.09 LipA
TGGT1_315640 0.67 0.00 0.07 0.42 0.29 0.40 0.53 LipB
TGGT1_270910 -0.78 0.00 0.50 0.15 -0.48 -0.48 -0.21 ATS1
TGGT1_297640 -0.29 0.00 0.26 0.06 -0.25 -0.41 -0.07 ATS2
Log2 FC (relative to GT1 B2-P11)Gene ID Name
Log2 FC
-1 10
RH P11 P35 P55 P85 P148 P210
TGGT1_243880 N/A N/A N/A N/A N/A N/A N/A ELO-A
TGGT1_242380 0.56 0.00 0.20 0.40 0.34 0.28 0.48 ELO-B
TGGT1_205350 0.31 0.00 0.22 0.35 0.09 0.01 0.47 ELO-C
TGGT1_271888 0.05 0.00 -0.30 -0.48 -0.04 -0.03 -0.71 KCR
TGGT1_311290 0.43 0.00 0.04 0.29 0.72 0.66 0.62 DEH
TGGT1_285240 0.58 0.00 0.03 0.08 0.52 0.50 0.30 ECR
Log2 FC (relative to GT1-B2-P11Gene ID Name
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Figure 4.8. Evolution of the FASII pathway and elongation pathway in extracellular 
GT1 during lab-adaptation 
a.) Expression of several genes involved in the multi-step process of de novo fatty 
acid synthesis within the apicoplast. b.) Glycolysis produces PEP, which is transported 
into the apicoplast by APT1 and converted into pyruvate by PyKII. Once lipoylated by 
LipA/B, the PDH complex converts pyruvate into acetyl-CoA, which is then metabolized 
to generate malonyl-CoA, the precursor metabolite required for the FASII pathway and 
FA synthesis. c.) Expression of several genes involved in fatty acid elongation within the 
ER. d.) Medium chain FA are translocated from the apicoplast to the ER for repeated 




























































































































Figure 4.9. Generating genetic knockouts of regression analysis candidates by 
CRISPR/Cas9 
a.) Venn diagram of the 319 differentially expressed genes (DEGS) that strongly 
correlate (R2 ≥0.70) with changes in plaque size, reinvasion efficiency, and/or 
extracellular survival during lab-adaptation. b.) Strategy for generating KO of candidate 
DEGs. Transfection of one or two CRISPR plasmids generates a DSB, allowing for 
recombination of a co-transfected DHFR selection cassette with short homologous 
flanks, into the genetic locus and disrupting the gene of interest. Note, sites of 
recombination are not drawn to scale; relative regions for diagnostic PCR to confirm 
integration and qPCR to confirm ablation of mRNA expression are shown. c.) 
Diagnostic PCR of clonal KO parasites confirms integration of the DHFR cassette into 
the gene of interest. d.) qPCR of clonal KO parasites confirms ablation of mRNA 




Figure 4.10. Functional analysis of candidate knockouts identified several 
differentially expressed genes important for optimal in vitro virulence, suggesting 
acquired in vitro virulence is a polygenic trait 
 




















































































































23918 ∆262590 ∆264240 ∆230980 ∆260190 ∆315885
125 
B2 Passage (P)
RH P11 P35 P55 P85 P148 P210 Plaque Size Reinv. Effic. EC Survival
TGGT1_262590 2.90 0.00 2.06 2.98 2.66 2.58 3.45 0.56 0.56 0.94 hypothetical protein
TGGT1_264240 4.35 0.00 -0.04 0.36 1.04 3.44 3.22 0.85 1.00 0.05 hypothetical protein
TGGT1_230980 0.97 0.00 0.62 0.67 0.69 1.33 1.33 0.85 1.00 0.05 myosin I
TGGT1_260190 0.24 0.00 0.06 0.49 0.77 1.30 0.51 0.49 0.74 0.05 microneme protein MIC13
TGGT1_315885 -0.09 0.00 0.79 1.23 1.04 1.49 1.94 0.85 1.00 0.05 putative glycosyltransferase
Log2 FC (Relative to GT1 B2-P11) Correlation Coefficient (R2)






Figure 4.10. Functional analysis of candidate knockouts identified several 
differentially expressed genes important for optimal in vitro virulence, suggesting 
acquired in vitro virulence is a polygenic trait 
 a.) Expression profiles and phenotype correlation coefficients (R2) of five candidate 
DEGs chosen for phenotypic evaluation by CRISPR KO. Upon successful KO, b.) 11-day 
























5.1. Conclusions  
Most E&R experiments utilize lab-adapted organisms in order to identify genomic 
mutations that bestow adaptation to a single experimental variable, such as limited 
glucose or presence of a drug. Our E&R experiment differs from more traditional studies 
as we are utilizing a non-lab-adapted organism with the aim of identifying the genetic 
basis for augmented phenotypes observed during in vitro lab-adaptation. Notably, lab-
adaptation does not contain a single variable either; rather it is a combination of variables, 
such as nutrient availability (glucose, lipids, etc.), oxygen tension, and immune response, 
which are all altered in vitro when compared to natural in vivo conditions. Furthermore, 
with obligate intracellular parasites, such as Toxoplasma and Plasmodium, in vitro serial 
passaging is cyclically exposing microorganisms to differing nutrient, ionic, pH, oxygen, 
and axenic environments due to the parasite’s lytic cycle. Thus, in vitro lab-adaptation, 
especially for lytic parasites, is actually a complex set of ever-changing variables. While 
more environmentally dynamic and complex E&R studies are limited, one relatable study 
in yeast adapting to alternating salt and oxidative stress cycles were found to adapt by 
increasing their DNA content and gene expression profiles (one mutation was also 
identified but it increased fitness in control populations as well) [282]. Another study in 
bacteria found that adaptation to delayed serial passaging, which exposes bacteria to 
several different environments (lag, log, stationary, and death), is controlled by genetic 
mutations [264]. Thus, mechanisms of adaptation in microorganisms can range from the 
accumulation of mutations to mechanisms altering gene expression patterns. In our E&R 
study, we lab-adapted a strain of T. gondii in order to identify the genomic mutations, 
epistatic interactions, or transcriptomic profiles that are associated with altered 
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phenotypes during lab-adaptation. In doing so, we could identify polymorphic virulence 
factors, novel epistatic interactions, or gene expression profiles that contribute to parasite 
fitness. 
A recently published mutation rate of RH closely resembles our calculated 
mutation rate of GT1, corroborating our analysis, yet both mutations rates are dramatically 
lower than that of the related apicomplexan species P. falciparum [280]. Having such a 
relatively low mutation rate, T. gondii’s population complexity is likely to be impacted upon 
serial passaging due to genetic drift, resulting in the loss of potentially beneficial mutations 
[229]. By performing WGS on clonal GT1 populations, we were able to capture some of 
this genetic diversity within the bulk population and observe that many mutations continue 
to remain at low frequency or are completely lost following continued lab-adaptation. 
Maintaining an appropriate population size can reduce the effects of genetic drift, as 
observed in yeast and bacterial studies [229]. Therefore, our observations agree with 
many others that it is important to take genetic drift, mutation rate, and population size 
into account when performing E&R experiments, especially if genomic mutations are of 
particular interest [229]. Notably, our E&R experiment was designed to identify the basis 
of phenotypic changes during standard laboratory conditions [8], thus we did not aim to 
alter the mutation rate (e.g. mutagenesis) or increase the population size of our GT1 
cultures (e.g. 1:5 serial transfers as opposed to standard 1:20).  
While mutation accumulation or epistatic interactions do not appear to play a 
significant role in GT1’s lab-adaptation, gene expression appeared far more malleable 
and conducive, suggesting epigenetic mechanisms are at play. While the vast number of 
E&R studies have revealed genomic mutations as a fundamental basis of evolutionary 
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adaptations, there is growing evidence for epigenetic control of evolutionary adaptations 
as well [208-210, 212]. Interestingly, our characterization of GT1’s adapting transcriptome 
illustrates a significant trend toward a more tachyzoite-like transcriptome. Such a 
transcriptomic trend parallels the behavioral essence of a tachyzoite’s tendencies and, 
therefore, are likely a genetic basis for GT1’s evolved virulence in vitro. Indeed, our 
genetic KO’s support this hypothesis and, therefore, passage history is an important 
variable to consider when interpreting plaque assays or cell differentiation. Anecdotally, 
it has been advised to periodically passage parasites in vivo (e.g. mice) in order to 
maintain the “vigor and biologic characteristics of the strain” [8]. Furthermore, it has been 
suggested that prolonged cultivation of the RH strain is likely the reason why it does not 
readily differentiate into bradyzoites anymore [168]. Our data is the first to demonstrate 
the potential expression changes that likely underlies previous anecdotal observations of 
pro-tachyzoite tendencies during prolonged serial passaging. Furthermore, in the 
absence of mutation accumulation, our data indicates that epigenetic control of pro-
tachyzoite genes is likely the dominant mechanism of GT1’s lab-adaptation. 
Aside from passage history, another variable to strongly consider with E&R is the 
amount of fetal bovine serum (FBS) used in culture media. FBS is a rich source of FAs, 
lipids, and many other components, and the amount of FBS utilized in T. gondii research 
differs between laboratories, commonly either 1% or 10% FBS. Knowing that RH fitness 
is unaffected by either concentration, we and many others utilize 1% FBS for economic 
purposes [8]. However, in the context of other strains, it is becoming clear that the amount 
of FBS is a significant variable in T. gondii, likely due to the availability of exogenous FA 
and lipids that are scavenged. In a recent study, the avirulent ME49 and Prugniaud strains 
 
  116
(both of type II) were shown to have roughly 2-fold increase in in vitro virulence when 
cultured in 10% FBS, relative to 1% FBS [295]. RH, however, is unaffected by the 
concentration of FBS, even with 0% FBS, because it is able to rapidly upregulate its de 
novo FASII pathway [295]. Notably, the FASII pathway is not essential for parasite 
survival due to lipid scavenging capabilities; however, FASII disruption can significantly 
reduce in vitro virulence >50% unless the culture media is supplemented with extra FAs 
(e.g. C:14-C:18) [289, 295, 308, 309]. Therefore, in vitro virulence is likely dependent on 
T. gondii’s ability to both scavenge and synthesize lipids. In our study, we culture GT1 in 
1% FBS and observed an overall increase in the expression of several FASII-related 
genes over time. This suggests that non-lab-adapted parasites are starved in 1% FBS 
conditions and they can adapt to this niche by upregulating genes of the FASII pathway, 
although future lipidomic work is needed to confirm the de novo synthesis of FAs and 
lipids (see Chapter 5.2.2.). The genomic mutations observed in the P4-flippase gene likely 
also cater to increase FA access, which will require further validation in the future. In 
short, FBS concentration is likely an overlooked variable that should be considered when 
working with non-lab-adapted strains as mechanisms for FA and lipid procurement 
appears to be naturally selected for during lab-adaptation. 
Regulation of the FASII pathway represents only a small fraction of the 988 DEGs 
identified in this study, suggesting that other adaptive biological processes are at play. 
First, antioxidant activity was enriched in GOEA, suggesting that the parasite is likely 
adapting to the 21% pO2 experienced during the extracellular milieus of lab-adaptation. 
Secondly, an increase in bradyzoite-associated genes was identified by life-stage 
analysis and GSEA, likely stemming from an unknown stress signal that is sensed by 
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extracellular parasites. It is well known that intracellular-stressed parasites will 
differentiate into bradyzoites and, although less publicized, 12-hour extracellular 
parasites are >50% more likely to differentiate into bradyzoite upon re-inoculation. 
Whether or not this quasi-bradyzoite-like state of extracellular parasites confers any 
adaptive advantage is a topic of future work. Lastly, our functional validation of 4/5 
candidate differentially expressed genes identified known and novel factors that can 
contribute to in vitro virulence: MIC13, MyoI, Gnt, and TGGT1_264240. MIC13, which is 
largely expressed in bradyzoites, was recently shown to be important for optimal growth 
under stressed-induced conditions [284] and, in our study, was important for GT1’s lab-
adaptation, further suggesting that non-lab-adapted strains introduced into culture will 
experience novel stress conditions, for example, prolonged extracellular survival during 
serial passaging. The discovery of MyoI, Gnt, and a TGGT1_264240 do not point to any 
obvious mechanisms of in vitro virulence, thus novel roles of these proteins are yet to be 
discovered. For example, MyoI residing at the basal complex could be accommodating 
enhanced lipid scavenging efficiency. 
In conclusion, these results indicate that lab-adaptation of GT1 results in 
augmented phenotypes largely influenced by the natural selection of extracellular 
parasites during serial passaging. Furthermore, our work demonstrates the phenotypic 
and transcriptomic pliability of low passage strains under the most basic laboratory 
conditions commonly practiced in the T. gondii field [8]. These results also indicate that 
lab-adaptive in vitro virulence is a complex and polygenic phenotype, at least in our 
experiment, likely stemming from epigenetic control. Future directions of this study will 
aim to understand some of the cis- and trans-regulatory factors that control the expression 
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of these differentially expressed virulence factors (see Chapter 5.2.3.) to decipher the 





5.2. Future Directions 
5.2.1. Functional analysis of P4-flippase mutations 
Contrary to our original hypothesis, we only identified one gene, P4-flippase, 
whose CDS evolved during GT1’s lab-adaptation. Interestingly, two different mutations 
(L270R and A477D) emerged within the same exon and around the same time in two 
parallel evolving populations. Unfortunately, our attempts to functionally characterize 
these mutations were unsuccessful, likely due to the parasite’s NHEJ repair mechanism 
that is favored over homologous recombination, with the latter necessary to integrate our 
allele-containing repair template. Therefore, to pursue functional characterization of 
L270R and A477D, future allele swapping experiments should be performed in novel 
GT1∆Ku80 parasites, which will ablate NHEJ [310]. Generating GT1∆Ku80 will be 
performed with two CRISPR/Cas9-mediated DSBs flanking the Ku80 CDS followed by 
homologous recombination of a DHFR selection cassette (repair template) into the Ku80 
locus. Proper DHFR integration into the genome will confer pyrimethamine-resistant 
parasites and diagnostic PCR can confirm Ku80’s removal from the genome. Our 
CRISPR KO experiments with GT1 invoked this very same KO approach (Figure 4.9b) 
which was relatively successful. Upon generation of GT1∆Ku80, allele swapping 
experiments can be repeated as before, this time with >300-fold greater chances of 
homologous recombination of the allele-containing repair template [310]. 
 
5.2.2. Investigating de novo FA biosynthesis as a regulator of GT1’s lab-adaptive 
in vitro virulence 
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 Enrichment analysis of our extracellular RNA-seq data identified the upregulation 
of many genes involved in de novo synthesis of FAs within the apicoplast, suggesting that 
FA synthesis is vital to GT1’s lab-adaptive virulence. To confirm the relative output of FA 
between high and low passage GT1 parasites, metabolic radio labeling experiments will 
be performed. Briefly, exogenous [13C6]-glucose will supplement the media for 48 hours 
to allow the incorporation of sugar-derived carbon (13C) into FA. Subsequently, gas 
chromatography-mass spectrometry (GC-MS) will analyze the relative abundance of 
isotopologues in high vs low passage GT1, specifically C:14 (myristic acid) and C:16 
(palmitic acid) FA’s which are primarily produced by the apicoplast (Figure 4.8). Should 
we confirm a significant difference in 13C incorporation into FAs, functional analysis will 
be performed by FA supplementation experiments. Briefly, in vitro virulence will be 
assessed in high and low passage GT1 parasites by plaque assays supplemented with 
or without myristic (C:140 and palmitic acid (C:16). We expect supplementation to result 
in enhanced in vitro virulence in low passage GT1 parasites, which would confirm the 
FASII pathway as an important factor in GT1’s lab-adapted virulence.  
 
5.2.3. Determine chromatin dynamics and identify trans-regulatory factors and cis-
regulatory motifs controlling GT1’s lab-adaptive in vitro virulence 
In our study, we identify differential gene expression as a vital process for the 
evolution of in vitro virulence, thus we hypothesize that evolution of GT1 is mediated by 
trans- and cis-regulatory elements. Trans-regulatory elements, such as ApiAP2 TF’s, 
have been show to control several aspects of T. gondii biology including asexual 
replication and bradyzoite differentiation [147-150, 216, 218-220]. ApiAP2 TF’s bind to 
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regulatory elements, typically within gene promoter regions, in a sequence-specific 
manner to drive gene expression. In T. gondii, for example, AP2XI-5 has been shown to 
recognize the motif GCTAGC and regulate the expression of over 300 genes, many 
involved in virulence, such as ROP18 [217]. However, it is well known that TF binding 
and gene regulation is contingent on chromatin accessibility (e.g. heterochromatin and 
euchromatin) [311]. In Plasmodium, for example, chromatin state has been shown to 
influence antigenic variation and virulence gene expression [206, 207]. Furthermore, an 
Assay for Transposase-Accessible Chromatin by sequencing (ATAC-seq) confirms the 
association between the dynamics in accessible chromatin and temporal gene expression 
profiles in Plasmodium [312]. Such experiments assessing chromatin dynamics, 
however, are lacking in T. gondii.  
To better understand the underlying expressionmechanisms of our lab-adaptation 
study, we will utilize ATAC-seq to identify genome-wide regulatory regions that played an 
essential role in GT1’s evolved in vitro virulence. Briefly, using the same GT1 cell lines 
and timepoints utilized in this study, we will use ATAC-seq to determine the dynamics of 
chromatin accessibility and co-regulated genes during lab-adaptation; extensive 
computational analysis will also be employed to define candidate cis-regulatory motifs 
within these co-regulated genes; and DNA-pulls down and mass spectrometry 
experiments will be utilized to identify interacting proteins, which can consist of chromatin 
remodeling complexes, AP2 TF’s, and other putative TFs (e.g. Myb-domain containing 
proteins). With the future work proposed here, we expect to identify cis- and trans-
regulatory factors that regulated GT1’s lab-adaptive in vitro virulence. Not only will this 
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enhance our understanding of apicomplexan biology, but provide a unique opportunity to 









6.1. Cell culture 
 The GT1 strain of Toxoplasma gondii was obtained through BEI Resources 
(catalog NR-20728) and propagated into culture using ED1 media supplemented with 
HEPES buffer: 1% heat-inactivated fetal bovine serum (FBS), 10 mM HEPES pH 7.6, 2 
mM L-glutamine, 1% penicillin/streptomycin, Dulbecco’s Modified Eagle Medium 
(DMEM), pH 7.2. After inoculation onto a host monolayer consisting of confluent human 
telomerase reverse transcriptase (hTERT) cells, parasites are incubated at 37ºC in 5% 
CO2. Typically, early passage (P) GT1 parasites require 3-4 days to lyse a T25 (25 cm2) 
flask of host cells while later passage GT1 parasites (>P80) require 2-3 days. Passing 
was performed serially by transferring 500 µl (~5%) of the lysed host cell flask into a new 
T25 flask of hTERT host cells containing 9 ml of warm ED1+HEPES media. Importantly, 
1 ml serological pipettes were used for transferring in order to reduce cross-contamination 
of separate T. gondii populations. Serial passaging of GT1 populations occurred in this 
fashion for up to >P220. Parasite populations were periodically frozen down for future 
analysis. 
 
6.2. Plaque assay 
 Plaque assays were performed with 3-6 week old monolayers of human foreskin 
fibroblasts (HFF) or goat skin fibroblasts cells (GSF) in 6-well plates. GSF cells are 
courtesy of Dr. Singh from Fort Valley State University [313]. Upon mechanical lysis (27G 
needle) of parasite vacuoles, 50 RH parasites or 125 GT1 parasites were inoculated onto 
host cell monolayers and allowed to form plaques undisturbed for 11 days. Plates were 
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then fixed in 100% ethanol and stained with crystal violet. Plaque size was quantified 
using FIJI [314].  
 
6.3. Extracellular survival assay 
 Infected host cell monolayers containing large vacuoles were washed 3x in warm 
PBS, cell scraped in ED1+HEPES buffer, passed through a 27G needle, and filtered 
through a 2 µm filter. The resulting cell suspension was then normalized to a final 
concentration 10,000 cells/ml in ED1+HEPES buffer. Next, 3 ml of the parasite cell 
suspension was incubated at 37ºC (5% CO2) in non-tissue-culture-treated 6-well plates. 
Plaque assays were performed hourly and quantified as mentioned above. Plaque 
numbers at each timepoint were then normalized to the 0-hour timepoint to yield percent 
survival. 
 
6.4. Reinvasion assay 
Infected host cell monolayers containing large vacuoles were washed 3x in warm 
PBS, cell scraped in ED1+HEPES buffer, passed through a 27G needle, and filtered 
through a 2 µm filter. After counting the number of suspended cells, either 50 RH 
parasites or 125 GT1 parasites were inoculated onto 6-well host cell monolayers and 
allowed to form plaques undisturbed for 11 days. Plates were then fixed in 100% ethanol 
and stained with crystal violet. The number of resulting plaques were quantified using FIJI 





6.5. Replication assay 
 Mechanically egressed parasites (27G needle) were inoculated onto confluent 
HFF monolayers grown on coverslips, centrifuged at 1000*g for 5 minutes, allowed to 
invade at 37ºC (floating in a water bath) for 10 minutes, and subsequently washed 3x with 
PBS. Intracellular parasites were then allowed to replicate for exactly 24 hours followed 
by methanol fixation and immunofluorescence assay (IFA) with αTgIMC3 and DAPI. The 
number of parasites per vacuole was enumerated for 100 vacuoles. 
 
6.6. Egress assay 
 Mechanically egressed RH and GT1 parasite populations were inoculated onto 6-
well HFF plates containing glass coverslips and allowed to replicate for 30-hours. Next 
fresh media containing either 1mM of A23187, 5% EtoH, or DMSO was added for exactly 
five minutes before fixation of infected monolayers with 4% PFA and IFA with αTgIMC3 
and DAPI. The number of egressed vacuoles was enumerated for a total of 50 vacuoles 
per conditions. 
 
6.7. DNA-sequencing and analysis 
Parasite gDNA was isolated using Qiagen DNAeasy Blood and Tissue kit (catalog 
69504) according to manufacturer’s protocol. Illumina’s Library Prep kit (FC-121-1030) 
was used to generate ~361bp DNA fragments, on average, which were quantified using 
Quibit Flex Fluorometer (catalog Q32851) and quality checked using Agilent’s 
TapeStation (catalog 5067-5584, 5067-5585). Next, 150bp paired-end sequencing was 
performed on Illumina’s NextSeq500 platform using their high output flow cell kit (FC-
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404-2004) according to manufacturer’s protocol. FASTQ reads were then analyzed by 
RUFUS analysis to call sequence variants between two samples 
(https://github.com/jandrewrfarrell/RUFUS) [263]. High frequency variants were called if 
the emerging mutation reached ≥75% allele frequency in at least one evolving 
population. 
 
6.8. RNA-sequencing and analysis 
T. gondii infected (24-36 hours) hTERT monolayers were washed 3x with PBS and 
immediately lysed and processed on ice for RNA isolation using Qiagen RNAeasy kit 
(catalog 74104) according to manufacturer’s protocol. RNA quality was confirmed by 
measuring the RNA integrity Number (RIN) using Agilent’s TapeStation (kit catalog 5067-
5579, 5067-5580). Illumina’s Library Prep kit (RS-122-2102) was used to generate 
~281bp cDNA fragments, on average, which were quantified using Quibit Flex 
Fluorometer (catalog Q32852) and quality checked using Agilent’s TapeStation (catalog 
5067-5584, 5067-5585). Next, 75bp paired-end sequencing was performed on Illumina’s 
NextSeq500 platform using their high-output (150 cycles) flow cell kit (FC-404-2002) 
according to manufacturer’s protocol. FASTQ reads were mapped to the Toxoplasma 
gondii GT1 genome (ToxoDB.org) using HISAT2 (Version 2.0.5). Normalized gene 
expression expressed as counts per million (CPM) and DEA were calculated using the 
edgeR R package (Version 3.24.3). Time-course sequencing analysis was performed by 





6.9. Plasmids and parasite strain generation 
 Synthesized and annealed forward and reverse oligos (Table 6.2), serving as 
sgRNAs, were cloned into BsaI digested pU6-Universal plasmid (Addgene #52694) to 
generate our final CRISPR/Cas9 plasmids. A DHFR selection cassette was amplified with 
a 60bp primers (Table 6.3) to yield a 2700bp repair template containing the entire 5’UTR, 
3’UTR, and CDS of DHFR, along with 39bp arms complementary to the site of Cas9-
mediated DSBs within the gene of interest (GOI). To KO a GOI, 20µg of each 
CRISPR/Cas9 plasmid were co-transfected with 20µg of the DHFR selection cassette to 
enabled DSB and homology-directed repair at the locus. Successful homologous 
recombination of the DHFR selection cassette into the GOI locus was confirmed with 
diagnostic PCR primer sets (Table 6.4). Successful ablation of mRNA expression was 
confirmed by qPCR (Tables 6.5).  
 
6.10. Life stage score analysis 
Tachyzoite, merozoite, and bradyzoite (tissue cyst) RNA-seq datasets that were 
used to generate stage-scores were published by Ramakrishnan et al. [276]; Sporozoite 
RNA-seq datasets that were used to generate stage scores were published by Fritz et al. 
[315]; all RNA-seq datasets were obtained from ToxoDB.org and downloaded as 
TGME49 gene IDs, which were then converted into TGGT1 gene IDs using the “syntenic 
orthologs” tool on ToxoDB.org. This process excluded 496 TGGT1 gene ID’s from the 
analysis. Four singular timepoints from these available datasets were chosen for DE 
analysis (“tachyzoites”, “tissue cysts”, “Mero 3”, and “Sporozoite day 4”). For each gene, 
all three possible differential expression scenarios between these four datasets were 
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calculated. For each gene, the number of >2-fold upregulated scenarios were 
enumerated and is considered the “stage-score” (score = 0 to 3). To validate the 
established stage scores, three previously published gene sets were examined for 
significant enrichment in their indicated life stage [316]. For analysis of our RNA-seq data 
sets, the DE-score of our upregulated and down-regulated gene sets were calculated. 
Bootstrap analysis (n = 1000 random sampling) was performed on each individual life 
stage in order to assign significance to the dataset’s sample distribution. 
 
6.11. Enrichment analysis 
 Previously published gene sets were utilized for GSEA [316] and statistical 
analysis was run using Fisher’s exact test to calculate the significance of enrichment 
between published datasets and our generated datasets. GOEA and MPEA was 
performed using the “Analyze results” feature on ToxoDB.org 
(https://toxodb.org/toxo/analysisTools.jsp). Redundant GO terms were removed from 
GOEA analysis using the REVIGO analysis feature on ToxoDB (http://revigo.irb.hr/) with 
0.4 similarity (“tiny”) allowed between GO terms. 
  
6.12. Statistical analysis 
 A student’s two-tailed equal variance t test was used to determine the 
significance (p-value) of evolved samples compared to the lowest passage (P) sample. 





Table 6.1. Primers used for PCR-sequencing of SNPs 
List of 15 primers names and sequences (5’ to 3’) used to validate SNPs 
identified by RUFUS sequence analysis. M13 tail sequences (red) were added to the 5’ 




Table 6.1. Primers used for PCR-sequencing of SNPs 
 
  
Chromosome Gene ID Codon Change Mutation PCR size Forward Primer (M13 Forward) Reverse Primer
TGGT1_chrVIIa TGGT1_016250 ATT to AAT Ile to Asn 585 TGTAAAACGACGGCCAGTTGTTGACGAATCCCCCAAAG CTTTTGCTTTGTGCTGCATG
TGGT1_chrX TGGT1_081400 GCT to GAT Ala to Asp 582 TGTAAAACGACGGCCAGTAGAGCAACAAGCCGATACTG CGACTTTTCTCCCTAGAAGC
TGGT1_chrVIIb TGGT1_011730 AAT to CAT Asn to His 576 TGTAAAACGACGGCCAGTTCTTTGCCCTTCTTCTGAAG GAGCAAGAGGATGTAAATCC
TGGT1_chrII TGGT1_065060 TGT to TCT Cys to Ser 557 TGTAAAACGACGGCCAGTCTTTCTAAAGGAACTATCCC TCTGGCGTTTTCGTTACCTC
TGGT1_chrVIIb TGGT1_007550 CTC to CGC Leu to Arg 550 TGTAAAACGACGGCCAGTAAAACTCGTTCTCTGTGTAG AGAACCAAGGGCGTTTCAAG
TGGT1_chrIV TGGT1_122460 GTG to GGG Val to Gly 493 TGTAAAACGACGGCCAGTCACAAGGAACAGACAAATTC AGTGGCACCTACCGAATATC
TGGT1_chrVIII TGGT1_116720 GGG to GCG Gly to Ala 495 TGTAAAACGACGGCCAGTTAGACTGGCGTGAGTTTGAC ATATACATGGACACCTGTAG
TGGT1_chrXI TGGT1_098520 GTT to TTT Val to Phe 490 TGTAAAACGACGGCCAGTGTTCGCACCTGAAACTTATG TACGGACAATGCGCATTTGG
TGGT1_chrVI TGGT1_051830 GAG to AAG Glu to Lys 459 TGTAAAACGACGGCCAGTCATGTGACTTCTGTGTCTTG ATCTGGCGTTGGAAATCCAC
TGGT1_chrVIII TGGT1_113990 TCC to TTC Ser to Phe 526 TGTAAAACGACGGCCAGTTCAGCAAGTGGTTTTTTGGC TTCTGTGGAGCACATACGTG
TGGT1_chrVIII TGGT1_060660 TTT to TCT Phe to Ser 536 TGTAAAACGACGGCCAGTTCCTCTCTCTCGTCACATTC GCATTTCCAGTTTTCTCTTG
TGGT1_chrIX TGGT1_041270 CAG to AAG Gln to Lys 526 TGTAAAACGACGGCCAGTTTCGGAAAAAGACCAAGCAC GTTCAGAGCATCTCTCAGAG
TGGT1_chrX TGGT1_071670 GAG to AAG Glu to Lys 514 TGTAAAACGACGGCCAGTCATTCCTGTTCACATGGTTG GTTGCATGCGCTAAATCGAC
TGGT1_chrXI TGGT1_088340 GAC to GCC Asp to Ala 533 TGTAAAACGACGGCCAGTTTGGACGTTGTTGATCGAAG ACTTGGAGCTCCAAAGGAAC
TGGT1_chrXII TGGT1_103920 AGT to ACT Ser to Thr 512 TGTAAAACGACGGCCAGTCATGCAGGAGGTTCCTTATC CTTGTTCGCCGTCACTTTTG
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Table 6.2. Protospacers for cloning into pU6-Universal plasmid 
List of primer sequences (5’ to 3’) used for cloning into the pU6-Universal 
plasmid (Addgene plasmid # 52694). sgRNA sequences are red and cloning flanks into 




Table 6.2. Protospacers for cloning into pU6-Universal plasmid 
 
  























Table 6.3. PCR primers used to generate a DHFR cassette 
 Long PCR primers sequences (5’ to 3’) used for amplifying the DHFR selection 
cassette. Sequences that recognize the 5’ UTR (Fwd) or 3’UTR (Rev) of the DHFR 
gene are in red. Primer tails consist of 38-39bp homologous arms (black) which allow 




Table 6.3. PCR primers used to generate a DHFR cassette 
 
  























Table 6.4. Diagnostic PCR primers for confirming homologous recombination 
List of primer sequences (5’ to 3’) used for confirming the integration of the 
DHFR selection cassette into the proper genomic locations. Primers in black are 








PCR 1 PCR 2
























Table 6.5. qPCR primers for confirming mRNA ablation 
List of primer sequences (5’ to 3’) used for confirming ablation of mRNA 






















We originally performed RNA-seq on both 30-hour intracellular and 6-hour 
extracellular parasites across several in vitro passages in order to identify DE virulence 
factors within both milieus of the parasites lytic cycle; however, this data was also 
analyzed in absence of a temporal context in order to analyze the transcriptomic profiles 
of intracellular vs extracellular parasites. Previous studies have indicated that the 
transcriptome of extracellular tachyzoites represent a transcriptomic state similar to that 
of bradyzoites [316]. Conversely, the transcriptome of extracellular mutant tachyzoites 
incapable of converting into bradyzoites more closely resemble intracellular parasites, 
supporting a link between bradyzoite development and the extracellular transcriptome 
[317]. Moreover, extracellular parasites are also enriched in G1-related transcripts of the 
cell cycle [316, 318], and G1-blockage of the cell cycle in intracellular parasites inhibits 
bradyzoite conversion [319]. Taken together, there appears to be an association between 
the process of bradyzoite conversion and genes found in the extracellular and G1 state.  
Being obligate intracellular parasites, T. gondii cannot fully convert into bradyzoites 
while in their extracellular milieu, thus begging the question: why express bradyzoite 
genes during a period of extracellular survival. Current insights suggest bradyzoites 
expression is part of a stress response mechanism as the expression of canonical 
bradyzoite markers are observed in conditions of nutrient deprivation, alkaline pH, and 
heat shock of intracellular parasites [142, 143]. Interestingly, tachyzoites exposed to 
stress of 12-hour extracellular conditions can also induce bradyzoite differentiation upon 
their subsequent reinvasion of host cells [320]. Because bradyzoite differentiation is a 
critical biological process to ensure T. gondii’s survival and continued transmission in 
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vivo, these responses to exogenous stress suggest that the parasite is capable of sensing 
danger in its environment both intracellularly and extracellularly [321]. Such anecdotal 
suggestions, however, have yet to be confirmed empirically and to understand why 
extracellular tachyzoites respond this way we must first better understand what the 
response is at the molecular level. Therefore, we sought to better characterize the 
molecular response to the extracellular milieu. To do so, we compared our previously 
generated intracellular and extracellular RNA-seq data sets and applied our RNA-seq 
analysis pipeline to perform DEA followed by stage scoring, GSEA, GOEA, and MPEA in 
order to uncover biological insights invoked during extracellular milieus, relative to the 
intracellular milieu. In summary, our data indicate a unique and mostly metabolically 
inactive transcriptomic state for extracellular parasites that can be described as anti-
tachyzoite, G1a-like, and quasi-bradyzoite. We discuss these profiles in the context of our 
lab-adaptation experiments (Chapter 4). Furthermore, we also identify many AP2 and 
Myb-domain containing TF that are DE upon extracellular survival, suggesting these as 






A.2.1. Extracellular tachyzoites represent a unique transcriptomic state resembling 
an anti-tachyzoite state halted at an early G1a-like state 
In this study, we performed RNA-seq on 30-hour intracellular and 6-hour 
extracellular RH and GT1 (B2-P11) in order to identify the molecular factors and biological 
processes involved in extracellular parasites (Figure A.1.a). DEA identified 1597 and 
1500 downregulated DEGs, relative to intracellular RH and GT1, respectively, of which 
1204 (~75-80%) were in common (Figure A.1.b); also, DEA identified 1584 and 1555 
upregulated DEGs in RH and GT1, respectively, of which 1189 (~76%) were in common 
(Figure A.1.b). Taken together, DEA across these two type I strains reveals a high degree 
of similarity to the response to extracellular conditions (Figure A.1.b).  
Life stage scoring of these DEGs show a significant upregulation on bradyzoite-, 
merozoite-, and sporozoite-associated genes while there is a significant downregulation 
of tachyzoite- and bradyzoite-associated genes (Figure A.2). While bradyzoite genes are 
both upregulated and downregulated, these data strongly indicate an anti-tachyzoite-like 
transcriptomic state in extracellular parasites. Interestingly, a master regulator of 
bradyzoite differentiation, BFD1, is significantly upregulated, along with an array of 
bradyzoite activators and repressors that are both up- and downregulated upon 
extracellular survival (Table A.1). Such misregulation indicates a complex network of 
bradyzoite differentiation that is finely balanced to bring about the quasi-bradyzoite state 
observed in extracellular parasites. 
Because extracellular parasites cannot continue their cell cycle, we next 
investigated the cell cycle state of extracellular parasites with GSEA [130, 316]. As 
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previously reported [316], both RH and GT1 extracellular tachyzoites are enriched in G1-
related genes (Figure A.3). More specifically, we were able to identify a restriction relative 
to G1a-related genes as there is an abrupt halt before predicted G1b progression [322], 
indicating that extracellular parasites are being halted at a G1a-to-G1b checkpoint (Figure 
A.3). 
 
A.2.2. Upon extracellular survival, parasites turn off many metabolic pathways and 
turn on regulatory genes 
 Of the DEGs downregulated upon extracellular survival, GSEA identified the 
downregulation of many genes associated with: metabolism, biosynthesis, DNA 
replication and repair, protein processing in the ER, bradyzoites, and many more (Figure 
A.4). GOEA identified the downregulation of many genes associated with: metabolism, 
Golgi vesicle transport, DNA replication, protein folding, glycosylation, and many more 
(Figure A.5). MPEA identified the downregulation of genes associated with: tRNA 
charging, glycolysis, pyruvate metabolism, TCA cycle, and many more (Figure A.6).  
Of the DEGs upregulated upon extracellular survival, GSEA identified the 
upregulation of far fewer genes, which were associated with: micronemes, bradyzoites, 
and sporogenesis (Figure A.4). GOEA identified the upregulation of genes associated 
with: protein kinase/phosphorylation activity, microtubule motor activity, TF activity, and a 
few others (Figure A.5). MPEA identified the upregulation of genes associated with: FA 
degradation, lipoxygenase, and a few others (Figure A.6). Taken together, these data 
suggest that, along with the cell cycle, cell metabolism is largely turned off in extracellular 
parasites when compared to intracellular. Instead, regulatory processes such as protein 
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phosphorylation and DNA-binding TFs are upregulated. In fact, >50% of T. gondii’s AP2 
TFs are DE upon extracellular survival (Table A.1). Interestingly, lipid peroxidation 
appears upregulated due to increase lipoxygenase activity, suggesting lipids may serve 





 In our analysis of the extra- vs intracellular transcriptome, we find that tachyzoite-
associated genes are largely downregulated in the extracellular state of RH and GT1 B2-
P11 parasites, suggesting that extracellular conditions largely promote an anti-tachyzoite 
transcriptome. Interestingly, temporal analysis of GT1 during lab-adaptation (Chapter 4) 
indicates a pro-tachyzoite transcriptome in extracellular parasites- when compared to B2-
P11 extracellular GT1 parasites (Figure 4.4). Taken together, DEA across conditions and 
over time suggest that the extracellular milieu of the lytic cycle induces an anti-tachyzoite 
response in the cell that can be slowly shifted in a pro-tachyzoite direction with prolonged 
lab-adaptation. Such a transcriptomic profile is associated with tachyzoite tendencies and 
in vitro virulence (Figure 2.1 & Figure 4.4). Understanding the transcriptional regulators 
(e.g. AP2 TFs) and biological mechanisms (e.g. lipid peroxidation, lipid biosynthesis) 
behind this response would aid in our understanding of the understudied extracellular 
milieu of T. gondii’s lytic cycle. 
In our analysis of the extra- vs intracellular transcriptome, we find that bradyzoite-
associated genes are largely misregulated during the extracellular state of RH and GT1 
B2-P11 parasites (Figure A.3 & Figure A.4). Temporal analysis of GT1 during lab-
adaptation (Chapter 4) also reveals up- and downregulation of many bradyzoite 
associated genes- relative to B2-P11 extracellular GT1 parasites (Figure 4.4). We 
hypothesize this may be due to a stress response pathway of extracellular parasites, 
perhaps through oxygen sensing mechanisms as extracellular parasites in vitro  are 
exposed to near 21% pO2, as compared to 1-10% pO2 intracellularly [79]. Interestingly, 
parasites are more likely to undergo spontaneous differentiation into bradyzoites when 
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left extracellular for several hours before inoculation [320]; in the context of our analysis, 
this suggests that the extracellular environment is transcriptionally priming parasites for 
bradyzoite differentiation in response to stress. Whether or not this response aids in 
GT1’s in vitro virulence or extracellular virulence traits still needs to be explored but could 




Figure A.1. Examining differentially expressed genes (DEGs) between intracellular 



























Figure A.1. Examining differentially expressed genes (DEGs) between intracellular 
and extracellular type I parasites 
a.) Roughly 30-hour intracellular and 6-hour extracellular parasites were harvested 
for mRNA-sequencing (RNA-seq) and data was analyzed by differential expression 
analysis (DEA), followed by life stage analysis, gene set enrichment analysis (GSEA), 
gene ontology enrichment analysis (GOEA), and metabolic pathway enrichment analysis 
(MPEA) in order to identify biological insights into lab-adaptation. b.) Venn diagram of 
DEGs identified across RH and B2-P11 GT1 populations.  
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Figure A.2. Life stage scoring identified anti-tachyzoite gene expression in 
















































































































































Figure A.2. Life stage scoring identified anti-tachyzoite gene expression in 
extracellular type I parasites 
 
Life stage scoring was performed on a.) upregulated and b.) down-regulated DEGs 
identified by DEA of extracellular parasites, relative to intracellular parasites. Color-coded 
asterisks (*) indicate p-value ≤0.05, as determined by an independent bootstrap analysis 
(n=1000 random sampling) for each individual life stage.  
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Figure A.3. The cell cycle of extracellular parasites is halted at a G1a state 
GSEA analysis of DEGs identified in extracellular parasites, relative to intracellular 
parasites (left y-axis), in the context of time-coursed cell-cycle data that was compiled 
and curated by Crocken et al. into published GSEA gene lists (x-axis) [316]. The number 
of S/M or G1 genes expressed at each timepoint is indicated by the right y-axis. Genes 
we identified as upregulated during extracellular conditions are in yellow, while 
downregulated genes are in blue. The statistical significance of the overlap between our 
dataset and published cell cycle gene lists are indicated by the size of the circles. Xue et 
al. recently published, at better resolution, the relative amount of time each step of the 
cell cycle is [322]; this abundance is aligned to scale with our data set.  
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Figure A.4. Gene set enrichment analysis (GSEA) of differentially expressed genes 





























































































































































































































Figure A.4. Gene set enrichment analysis (GSEA) of differentially expressed genes 
(DEGs) identified in extracellular type I parasites 
Up- and down-regulated DEGs identified by DEA of RH and B2-P11 GT1 
populations were subject to GSEA, which utilizes previously published gene sets that 
describe organelle-associated genes, metabolic genes, life stage genes, and genes 
involved with different biological processes. Genes we identified as upregulated during 
extracellular conditions are in yellow, while down-regulated genes are in blue. The 
statistical significance of overlap between our set of genes with these previously 
published gene sets are indicated by the size of the circle.  
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Figure A.5. Gene ontology enrichment analysis (GOEA) of differentially expressed 
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Figure A.5. Gene ontology enrichment analysis (GOEA) of differentially expressed 
genes (DEGs) identified in extracellular type I parasites 
Up- and down-regulated DEGs identified by DEA of B2-P11 GT1 populations were 
subject to GOEA on ToxoDB.org to identify GO-terms associated with biological 
processes, molecular functions, and cellular components. Redundant GO terms were 




Figure A.6. Metabolic pathway enrichment analysis (MPEA) of differentially 
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Figure A.6. Metabolic pathway enrichment analysis (MPEA) of differentially 
expressed genes (DEGs) identified in extracellular type I par8asites 
Up- and down-regulated DEGs identified by DEA of B2-P11 GT1 populations were 
subject to MPEA on ToxoDB.org to identify associated metabolic pathway. Several 




Table A.1. DE of many trans-regulatory elements upon prolonged extracellular 
survival 
List of AP2 TFs and Myb-domain containing proteins that are differentially 
expressed in B2-P11 GT1 populations upon extracellular conditions, relative to 
intracellular conditions.  
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Table 3.1. Whole genome sequencing (WGS) of RH and low passage GT1 
 WGS of RH and low passage GT1 populations B0-P4, B2-P15, B4-15, and B6-
P10 followed by RUFUS analysis identified 207 SNPs/indels between RH and GT1 and 
0 SNPs/indels between low passage GT1 populations. Allele frequencies, the percentage 





Table 3.1. Whole genome sequencing (WGS) of RH and low passage GT1 
 
B0-P4 B2-P15 B4-P15 B6-P10
TGGT1_202540 VIIa 3138655 C1462R 0.98 0.00 0.03 0.00 0.00 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_219320 XII 910066 I111N 1.00 0.00 0.04 0.00 0.00 acid phosphatase GAP50
TGGT1_246170 XII 2641576 P1839P 0.99 0.00 0.02 0.00 0.00 ARID/BRIGHT DNA binding domain-containing protein
TGGT1_247390 XII 3244849 G1304S 1.00 0.00 0.05 0.00 0.00 ATPase, AAA family protein
TGGT1_269390 VIII 5844479 A720A 1.00 0.00 0.04 0.00 0.00 CRAL/TRIO domain-containing protein
TGGT1_315770 XI 4916642 G296D 1.00 0.00 0.04 0.00 0.00 cytochrome p450 superfamily protein
TGGT1_313600 XI 3477327 D45E 1.00 0.00 0.03 0.00 0.00 DDHD domain-containing protein
TGGT1_236650 X 5362932 I372N 1.00 0.00 0.00 0.00 0.00 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17
TGGT1_226250 X 1669605 R478C 1.00 0.00 0.06 0.00 0.00 DEAD (Asp-Glu-Ala-Asp) box polypeptide DDX3X
TGGT1_260450 VIIb 2235939 S592L 1.00 0.00 0.00 0.00 0.00 DEAD/DEAH box helicase domain-containing protein
TGGT1_227620 X 780003 G138S 1.00 0.00 0.07 0.00 0.00 dense granule protein GRA2
TGGT1_285540 V 2196073 E1216E 1.00 0.00 0.03 0.00 0.00 DNA-directed DNA polymerase
TGGT1_249560 XII 4577955 F467L 1.00 0.00 0.00 0.00 0.00 DNA-directed RNA polymerase alpha chain rpoA
TGGT1_315920 XI 5020559 C147G 1.00 0.00 0.05 0.00 0.00 DNA-directed RNA polymerase II RPB11A
TGGT1_287980 IX 2089054 S1094L 1.00 0.00 0.00 0.00 0.00 FHA domain-containing protein
TGGT1_287980 IX 2095268 T479M 1.00 0.00 0.01 0.00 0.00 FHA domain-containing protein
TGGT1_265780 IX 1283013 E1022D 1.00 0.00 0.03 0.00 0.00 flagellar/basal body protein
TGGT1_207480 Ib 153771 F4871L 1.00 0.00 0.06 0.00 0.00 GCC2 and GCC3 domain-containing protein
TGGT1_315670 XI 4833635 V193V 1.00 0.00 0.03 0.00 0.00 HEAT repeat-containing protein
TGGT1_285490 V 2242699 H54H 1.00 0.00 0.02 0.00 0.00 helix-hairpin-helix motif domain-containing protein
TGGT1_257750 VIIb 3788597 I218I 1.00 0.00 0.05 0.00 0.00 homocysteine s-methyltransferase domain-containing protein
TGGT1_240330 VI 1158522 A228T 1.00 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_213255 V 745145 A3158P 1.00 0.01 0.06 0.04 0.08 hypothetical protein
TGGT1_218370 XII 1496007 C50R 1.00 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_299250 III 2074849 D162A 1.00 0.05 0.05 0.00 0.00 hypothetical protein
TGGT1_228120 X 475481 E1397D 1.00 0.00 0.03 0.00 0.00 hypothetical protein
TGGT1_234220 X 4096287 E393K 1.00 0.00 0.03 0.00 0.00 hypothetical protein
TGGT1_258970 VIIb 3033240 F1047I 1.00 0.00 0.02 0.00 0.00 hypothetical protein
TGGT1_259720 VIIb 2669294 F733V 1.00 0.06 0.07 0.00 0.00 hypothetical protein
TGGT1_305790 IX 5372425 F92S 1.00 0.00 0.04 0.00 0.00 hypothetical protein
TGGT1_258450 VIIb 3382360 F983F 1.00 0.00 0.06 0.00 0.00 hypothetical protein
TGGT1_248610 XII 3964466 Frameshift 1.00 0.00 0.07 0.00 0.00 hypothetical protein
TGGT1_218215 XII 1624033 K272R 1.00 0.00 0.04 0.00 0.00 hypothetical protein
TGGT1_462961 VIII 5161927 K4859R 1.00 0.00 0.04 0.00 0.00 hypothetical protein
TGGT1_312840 XI 2910414 L1007H 1.00 0.00 0.06 0.00 0.00 hypothetical protein
TGGT1_289290 IX 2960787 L138F 1.00 0.00 0.04 0.00 0.00 hypothetical protein
TGGT1_312580 XI 2763015 L369V 1.00 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_258480 VIIb 3365929 N238H 1.00 0.00 0.12 0.00 0.00 hypothetical protein
TGGT1_245530 XII 2294646 P1680S 1.00 0.00 0.06 0.00 0.00 hypothetical protein
TGGT1_312240 XI 2498041 R1551K 1.00 0.00 0.03 0.00 0.00 hypothetical protein
TGGT1_220920 II 48162 R324S 1.00 0.00 0.04 0.00 0.00 hypothetical protein
TGGT1_308060 XII 490727 R927R 1.00 0.00 0.01 0.00 0.00 hypothetical protein
TGGT1_225860 X 1900464 S297F 1.00 0.00 0.04 0.00 0.00 hypothetical protein
TGGT1_235380 X 4707788 S470R 1.00 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_313270 XI 3187357 S472P 1.00 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_213010 V 657224 S97C 1.00 0.00 0.05 0.00 0.00 hypothetical protein
TGGT1_285650 V 2177352 T1797R 1.00 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_408920 VIIb 3707401 T413A 1.00 0.00 0.07 0.00 0.00 hypothetical protein
TGGT1_301400 IV 2338233 V144X 0.99 0.00 0.05 0.00 0.00 hypothetical protein
TGGT1_280500 VIIa 325741 S932S 1.00 0.00 0.03 0.00 0.00 inorganic anion transporter, sulfate permease (SulP) family protein
TGGT1_311650 XI 2143476 A1093A 1.00 0.00 0.00 0.00 0.00 leucine rich repeat-containing protein
TGGT1_267550 IX 416884 S242R 1.00 0.00 0.00 0.00 0.00 leucine-rich repeat protein LRR1
TGGT1_213890 V 1277457 L528V 1.00 0.00 0.04 0.00 0.00 Myb family DNA-binding domain-containing protein
TGGT1_216440 XI 6065904 F64I 1.00 0.00 0.07 0.00 0.00 OTU family cysteine protease
TGGT1_253750 III 1148147 G1681G 1.00 0.00 0.08 0.00 0.00 PLU-1 family protein
TGGT1_272540 VIII 3908501 A396A 1.00 0.00 0.00 0.00 0.00 protein kinase (incomplete catalytic triad)
TGGT1_246800 XII 2944146 W824* 1.00 0.00 0.04 0.00 0.00 putative acylaminoacyl-peptidase
TGGT1_216790 XI 5800498 P588L 1.00 0.00 0.00 0.00 0.00 putative ATP-binding cassette sub-family E member 1
TGGT1_247560 XII 3348945 A2V 1.00 0.00 0.06 0.00 0.00 putative dynein light chain protein
TGGT1_310010 XI 969734 D166G 1.00 0.00 0.03 0.00 0.00 rhoptry neck protein RON1
TGGT1_207440 Ib 78769 V91A 1.00 0.00 0.06 0.00 0.00 ribosomal protein RPS4
TGGT1_202720 VIIa 2979839 E2279V 1.00 0.00 0.05 0.00 0.00 RNB family domain-containing protein
TGGT1_233460 VIII 2660973 T173T 1.00 0.00 0.04 0.00 0.00 SAG-related sequence SRS29B
TGGT1_231000 VIII 1182181 G351A 1.00 0.00 0.03 0.00 0.00 START domain-containing protein
TGGT1_225960 X 1802390 T3935A 1.00 0.00 0.06 0.00 0.00 STE kinase
TGGT1_213325 V 811115 A2467A 1.00 0.01 0.03 0.00 0.00 TBC domain-containing protein
TGGT1_226940 X 1125867 T47A 1.00 0.00 0.02 0.00 0.00 ubiquitin carboxyl-terminal hydrolase
TGGT1_254480 III 1747687 R300P 0.99 0.00 0.02 0.00 0.00 WD domain, G-beta repeat-containing protein
TGGT1_293300 Ia 227230 N34H 0.99 0.00 0.04 0.00 0.00 Yip1 domain-containing protein
TGGT1_263710 VIIb 351093 Intronic 0.99 0.00 0.02 0.00 0.00 acyl-CoA:cholesterol acyltransferase alpha ACAT1-alpha
TGGT1_265220 IX 1509271 Intronic 0.99 0.00 0.06 0.00 0.00 co-chaperone GrpE protein
TGGT1_219070 XII 1094139 Intronic 1.00 0.00 0.00 0.00 0.00 cyclic nucleotide-binding domain-containing protein
TGGT1_239820 VI 935257 Intronic 1.00 0.00 0.05 0.00 0.00 D-3-phosphoglycerate dehydrogenase
TGGT1_316750 XI 5513225 Intronic 1.00 0.00 0.09 0.00 0.00 DEAD/DEAH box helicase domain-containing protein
TGGT1_297530 II 1852611 Intronic 1.00 0.00 0.00 0.00 0.00 DNA-directed RNA polymerase I RPA2
TGGT1_219630 XII 750964 Intronic 1.00 0.00 0.04 0.00 0.00 flavodoxin domain-containing protein
TGGT1_292020 IX 4287104 Intronic 1.00 0.00 0.04 0.00 0.00 GCC2 and GCC3 domain-containing protein
TGGT1_257770 VIIb 3766328 Intronic 1.00 0.00 0.05 0.00 0.00 histone lysine methyltransferase SET2
TGGT1_202120 VIIa 3505266 Intronic 1.00 0.00 0.11 0.00 0.00 hypothetical protein
TGGT1_205730 VIIa 1108782 Intronic 1.00 0.04 0.13 0.00 0.00 hypothetical protein
TGGT1_205740 VIIa 1099615 Intronic 1.00 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_207100 X 7258697 Intronic 1.00 0.00 0.14 0.00 0.00 hypothetical protein
TGGT1_212940 V 584364 Intronic 1.00 0.00 0.04 0.00 0.00 hypothetical protein






TGGT1_214990 X 6562102 Intronic 1.00 0.00 0.03 0.00 0.00 hypothetical protein
TGGT1_219370 XII 902233 Intronic 1.00 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_221220 II 138708 Intronic 1.00 0.02 0.09 0.00 0.00 hypothetical protein
TGGT1_225000 X 2512702 Intronic 0.99 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_230220 VIII 694859 Intronic 1.00 0.00 0.05 0.00 0.00 hypothetical protein
TGGT1_240910 VI 1545511 Intronic 1.00 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_242260 VI 1840852 Intronic 1.00 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_250220 XII 4967308 Intronic 1.00 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_250220 XII 4974498 Intronic 1.00 0.00 0.05 0.00 0.00 hypothetical protein
TGGT1_251730 XII 5466327 Intronic 1.00 0.00 0.06 0.00 0.00 hypothetical protein
TGGT1_253615 III 1042206 Intronic 1.00 0.00 0.05 0.00 0.00 hypothetical protein
TGGT1_255635 VIIb 4670127 Intronic 1.00 0.00 0.04 0.00 0.00 hypothetical protein
TGGT1_263810 VIIb 291127 Intronic 1.00 0.00 0.07 0.00 0.00 hypothetical protein
TGGT1_270930 VIII 4856292 Intronic 1.00 0.00 0.07 0.00 0.00 hypothetical protein
TGGT1_272590 VIII 3860171 Intronic 0.99 0.00 0.03 0.00 0.00 hypothetical protein
TGGT1_273885 VIII 3193286 Intronic 1.00 0.00 0.06 0.00 0.00 hypothetical protein
TGGT1_274150 VIII 2980074 Intronic 1.00 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_277810 XII 6415386 Intronic 1.00 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_285800 V 2072298 Intronic 1.00 0.00 0.04 0.00 0.00 hypothetical protein
TGGT1_294400 Ia 869056 Intronic 1.00 0.00 0.03 0.00 0.00 hypothetical protein
TGGT1_294940 Ia 1270195 Intronic 0.99 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_313130 XI 3089958 Intronic 0.99 0.00 0.00 0.00 0.00 hypothetical protein
TGGT1_252270 III 438794 Intronic 1.00 0.00 0.00 0.00 0.00 L1P family of ribosomal protein
TGGT1_314900 XI 4342756 Intronic 0.99 0.00 0.00 0.00 0.00 LisH protein
TGGT1_308580 XI 228169 Intronic 1.00 0.00 0.00 0.00 0.00 Lon protease family protein
TGGT1_293180 Ia 126347 Intronic 1.00 0.00 0.00 0.00 0.00 NADP-specific glutamate dehydrogenase
TGGT1_309265 XI 562836 Intronic 1.00 0.00 0.06 0.00 0.00 oxidoreductase, short chain dehydrogenase/reductase family protein
TGGT1_209430 Ib 1227412 Intronic 1.00 0.00 0.00 0.00 0.00 putative 40S ribosomal protein S4
TGGT1_249810 XII 4765687 Intronic 1.00 0.00 0.08 0.00 0.00 putative activating signal cointegrator 1 complex subunit 3
TGGT1_216790 XI 5805722 Intronic 1.00 0.00 0.00 0.00 0.00 putative ATP-binding cassette sub-family E member 1
TGGT1_235020 X 4507941 Intronic 1.00 0.00 0.08 0.00 0.00 putative COPI protein
TGGT1_226700 X 1335364 Intronic 1.00 0.00 0.07 0.00 0.00 putative nuclease
TGGT1_201830 VIIa 3577355 Intronic 1.00 0.00 0.04 0.00 0.00 ribosomal protein L37
TGGT1_259230 VIIb 2814653 Intronic 1.00 0.00 0.00 0.00 0.00 site-specific recombinase, phage integrase family protein
TGGT1_310530 XI 1386907 Intronic 1.00 0.00 0.02 0.00 0.00 SNF2 family N-terminal domain-containing protein
TGGT1_273870 VIII 3202256 Intronic 1.00 0.00 0.08 0.00 0.00 SWI2/SNF2 ISWI-like (AT hook)
TGGT1_291090 IX 3926254 Intronic 1.00 0.00 0.00 0.00 0.00 SWI2/SNF2-containing protein
TGGT1_270070 VIII 5433586 Intronic 1.00 0.00 0.08 0.00 0.00 synaptobrevin family protein
TGGT1_297500 II 1809275 Intronic 1.00 0.02 0.08 0.00 0.00 T-complex protein 1 eta subunit
TGGT1_250920 XII 5249921 Intronic 1.00 0.00 0.03 0.00 0.00 tetratricopeptide repeat-containing protein
TGGT1_234410 X 4255009 Intronic 1.00 0.00 0.08 0.00 0.00 small conductance mechanosensitive ion channel (MscS) family protein
TGGT1_312520 XI 2724670 Intronic 1.00 0.00 0.07 0.00 0.00 tRNA dimethylallyltransferase
Intergenic Ia 470420 Intergenic 0.99 0.00 0.04 0.00 0.00 N/A
Intergenic Ib 880169 Intergenic 1.00 0.00 0.07 0.00 0.00 N/A
Intergenic Ib 1442011 Intergenic 1.00 0.00 0.03 0.00 0.00 N/A
Intergenic II 537627 Intergenic 1.00 0.00 0.05 0.00 0.00 N/A
Intergenic III 1536907 Intergenic 1.00 0.00 0.03 0.00 0.00 N/A
Intergenic III 439992 Intergenic 1.00 0.00 0.00 0.00 0.00 N/A
Intergenic III 2045363 Intergenic 1.00 0.00 0.04 0.00 0.00 N/A
Intergenic IV 1825960 Intergenic 1.00 0.00 0.04 0.00 0.00 N/A
Intergenic IV 1942258 Intergenic 1.00 0.00 0.04 0.00 0.00 N/A
Intergenic IX 2954953 Intergenic 1.00 0.00 0.06 0.00 0.00 N/A
Intergenic IX 5597650 Intergenic 1.00 0.00 0.05 0.00 0.00 N/A
Intergenic IX 1057959 Intergenic 1.00 0.00 0.09 0.00 0.00 N/A
Intergenic IX 2730252 Intergenic 1.00 0.00 0.07 0.00 0.00 N/A
Intergenic IX 5140738 Intergenic 1.00 0.00 0.06 0.00 0.00 N/A
Intergenic IX 900168 Intergenic 1.00 0.00 0.09 0.00 0.00 N/A
Intergenic IX 4603155 Intergenic 1.00 0.00 0.03 0.00 0.00 N/A
Intergenic IX 3685652 Intergenic 0.98 0.00 0.08 0.00 0.00 N/A
Intergenic IX 591204 Intergenic 0.82 0.00 0.05 0.00 0.00 N/A
Intergenic IX 5807494 Intergenic 1.00 0.00 0.03 0.00 0.00 N/A
Intergenic V 1099737 Intergenic 1.00 0.00 0.06 0.00 0.00 N/A
Intergenic V 2987554 Intergenic 1.00 0.00 0.04 0.00 0.00 N/A
Intergenic VI 492205 Intergenic 1.00 0.00 0.04 0.00 0.00 N/A
Intergenic VI 713008 Intergenic 1.00 0.00 0.02 0.00 0.00 N/A
Intergenic VIIa 358021 Intergenic 1.00 0.00 0.03 0.00 0.00 N/A
Intergenic VIIa 585218 Intergenic 1.00 0.00 0.04 0.00 0.00 N/A
Intergenic VIIa 1745855 Intergenic 1.00 0.00 0.05 0.00 0.00 N/A
Intergenic VIIa 2294095 Intergenic 1.00 0.00 0.06 0.00 0.00 N/A
Intergenic VIIa 2305275 Intergenic 1.00 0.00 0.04 0.00 0.00 N/A
Intergenic VIIa 3319699 Intergenic 1.00 0.00 0.00 0.00 0.00 N/A
Intergenic VIIa 3657742 Intergenic 1.00 0.00 0.00 0.00 0.00 N/A
Intergenic VIIa 424565 Intergenic 1.00 0.00 0.03 0.00 0.00 N/A
Intergenic VIIa 3278484 Intergenic 1.00 0.00 0.06 0.00 0.00 N/A
Intergenic VIIb 61563 Intergenic 1.00 0.00 0.06 0.00 0.00 N/A
Intergenic VIIb 2126748 Intergenic 1.00 0.00 0.02 0.00 0.00 N/A
Intergenic VIIb 2831303 Intergenic 1.00 0.00 0.00 0.00 0.00 N/A
Intergenic VIIb 4119445 Intergenic 1.00 0.00 0.06 0.00 0.00 N/A
Intergenic VIIb 4783554 Intergenic 1.00 0.00 0.04 0.00 0.00 N/A
Intergenic VIIb 4606259 Intergenic 1.00 0.00 0.05 0.00 0.00 N/A
Intergenic VIIb 2656622 Intergenic 0.99 0.00 0.03 0.00 0.00 N/A
Intergenic VIII 98117 Intergenic 1.00 0.00 0.04 0.00 0.00 N/A
Intergenic VIII 607622 Intergenic 1.00 0.00 0.06 0.00 0.00 N/A
Intergenic VIII 898273 Intergenic 1.00 0.00 0.04 0.00 0.00 N/A
Intergenic VIII 903926 Intergenic 1.00 0.00 0.00 0.00 0.00 N/A








Intergenic VIII 3168227 Intergenic 1.00 0.00 0.05 0.00 0.00 N/A
Intergenic VIII 4792051 Intergenic 1.00 0.00 0.00 0.00 0.00 N/A
Intergenic VIII 5589730 Intergenic 1.00 0.00 0.02 0.00 0.00 N/A
Intergenic VIII 2493242 Intergenic 0.98 0.00 0.05 0.00 0.00 N/A
Intergenic VIII 1618200 Intergenic 0.98 0.00 0.07 0.00 0.00 N/A
Intergenic VIII 5476330 Intergenic 0.97 0.00 0.00 0.00 0.00 N/A
Intergenic X 19316 Intergenic 1.00 0.00 0.00 0.00 0.00 N/A
Intergenic X 50233 Intergenic 1.00 0.00 0.02 0.00 0.00 N/A
Intergenic X 2928546 Intergenic 1.00 0.00 0.09 0.00 0.00 N/A
Intergenic X 3762836 Intergenic 1.00 0.00 0.00 0.00 0.00 N/A
Intergenic X 6663623 Intergenic 1.00 0.00 0.04 0.00 0.00 N/A
Intergenic X 6285025 Intergenic 0.99 0.00 0.00 0.00 0.00 N/A
Intergenic X 7232649 Intergenic 0.98 0.00 0.03 0.00 0.00 N/A
Intergenic XI 3281365 Intergenic 1.00 0.00 0.08 0.00 0.00 N/A
Intergenic XI 4072004 Intergenic 1.00 0.00 0.03 0.00 0.00 N/A
Intergenic XI 5156138 Intergenic 1.00 0.00 0.02 0.00 0.00 N/A
Intergenic XI 6172343 Intergenic 1.00 0.00 0.06 0.00 0.00 N/A
Intergenic XI 1420899 Intergenic 1.00 0.00 0.06 0.00 0.00 N/A
Intergenic XI 1688696 Intergenic 1.00 0.00 0.09 0.00 0.00 N/A
Intergenic XI 5465613 Intergenic 1.00 0.00 0.05 0.00 0.00 N/A
Intergenic XI 1255287 Intergenic 1.00 0.02 0.06 0.00 0.00 N/A
Intergenic XI 2245313 Intergenic 1.00 0.00 0.03 0.00 0.00 N/A
Intergenic XI 5357331 Intergenic 0.99 0.00 0.00 0.00 0.00 N/A
Intergenic XI 1354223 Intergenic 0.99 0.00 0.06 0.00 0.00 N/A
Intergenic XII 3338865 Intergenic 1.00 0.00 0.05 0.00 0.00 N/A
Intergenic XII 3677401 Intergenic 1.00 0.00 0.06 0.00 0.00 N/A
Intergenic XII 4273612 Intergenic 1.00 0.00 0.07 0.00 0.00 N/A
Intergenic XII 5000288 Intergenic 1.00 0.00 0.06 0.00 0.00 N/A
Intergenic XII 3585773 Intergenic 1.00 0.00 0.05 0.00 0.00 N/A
Intergenic XII 2813301 Intergenic 1.00 0.00 0.05 0.00 0.00 N/A
Intergenic XII 1678844 Intergenic 1.00 0.05 0.00 0.00 0.00 N/A
Intergenic XII 3583729 Intergenic 1.00 0.04 0.00 0.08 0.00 N/A
Intergenic XII 1489806 Intergenic 1.00 0.00 0.07 0.00 0.00 N/A
Intergenic XII 2239394 Intergenic 1.00 0.00 0.04 0.00 0.00 N/A
Intergenic XII 944795 Intergenic 1.00 0.00 0.05 0.00 0.00 N/A
Intergenic XII 682963 Intergenic 0.99 0.00 0.00 0.00 0.00 N/A
Intergenic XII 2697201 Intergenic 0.99 0.00 0.03 0.00 0.00 N/A
Intergenic XII 6505010 Intergenic 0.99 0.00 0.05 0.00 0.00 N/A
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Chromosome Gene ID Codon Change Mutation PCR size Forward Primer (M13 Forward) Reverse Primer
TGGT1_chrVIIa TGGT1_016250 ATT to AAT Ile to Asn 585 TGTAAAACGACGGCCAGTTGTTGACGAATCCCCCAAAG CTTTTGCTTTGTGCTGCATG
TGGT1_chrX TGGT1_081400 GCT to GAT Ala to Asp 582 TGTAAAACGACGGCCAGTAGAGCAACAAGCCGATACTG CGACTTTTCTCCCTAGAAGC
TGGT1_chrVIIb TGGT1_011730 AAT to CAT Asn to His 576 TGTAAAACGACGGCCAGTTCTTTGCCCTTCTTCTGAAG GAGCAAGAGGATGTAAATCC
TGGT1_chrII TGGT1_065060 TGT to TCT Cys to Ser 557 TGTAAAACGACGGCCAGTCTTTCTAAAGGAACTATCCC TCTGGCGTTTTCGTTACCTC
TGGT1_chrVIIb TGGT1_007550 CTC to CGC Leu to Arg 550 TGTAAAACGACGGCCAGTAAAACTCGTTCTCTGTGTAG AGAACCAAGGGCGTTTCAAG
TGGT1_chrIV TGGT1_122460 GTG to GGG Val to Gly 493 TGTAAAACGACGGCCAGTCACAAGGAACAGACAAATTC AGTGGCACCTACCGAATATC
TGGT1_chrVIII TGGT1_116720 GGG to GCG Gly to Ala 495 TGTAAAACGACGGCCAGTTAGACTGGCGTGAGTTTGAC ATATACATGGACACCTGTAG
TGGT1_chrXI TGGT1_098520 GTT to TTT Val to Phe 490 TGTAAAACGACGGCCAGTGTTCGCACCTGAAACTTATG TACGGACAATGCGCATTTGG
TGGT1_chrVI TGGT1_051830 GAG to AAG Glu to Lys 459 TGTAAAACGACGGCCAGTCATGTGACTTCTGTGTCTTG ATCTGGCGTTGGAAATCCAC
TGGT1_chrVIII TGGT1_113990 TCC to TTC Ser to Phe 526 TGTAAAACGACGGCCAGTTCAGCAAGTGGTTTTTTGGC TTCTGTGGAGCACATACGTG
TGGT1_chrVIII TGGT1_060660 TTT to TCT Phe to Ser 536 TGTAAAACGACGGCCAGTTCCTCTCTCTCGTCACATTC GCATTTCCAGTTTTCTCTTG
TGGT1_chrIX TGGT1_041270 CAG to AAG Gln to Lys 526 TGTAAAACGACGGCCAGTTTCGGAAAAAGACCAAGCAC GTTCAGAGCATCTCTCAGAG
TGGT1_chrX TGGT1_071670 GAG to AAG Glu to Lys 514 TGTAAAACGACGGCCAGTCATTCCTGTTCACATGGTTG GTTGCATGCGCTAAATCGAC
TGGT1_chrXI TGGT1_088340 GAC to GCC Asp to Ala 533 TGTAAAACGACGGCCAGTTTGGACGTTGTTGATCGAAG ACTTGGAGCTCCAAAGGAAC
TGGT1_chrXII TGGT1_103920 AGT to ACT Ser to Thr 512 TGTAAAACGACGGCCAGTCATGCAGGAGGTTCCTTATC CTTGTTCGCCGTCACTTTTG
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Table 4.1. Differential expression analysis identified many differentially expressed 
gene amongst intracellular RH and non-lab-adapted GT1 populations 
 Following RNA-seq of 30-hour intracellular parasites, DEA identified 545 DEGs in 
GT1 population B2-P11 and 764 DEGS in GT1 population B4-P11, both relative to RH. 
In union, 498 DEGs were found to have similar expression across the two GT1 
populations. All genes with Log2 FC values shown are considered significant (FC ≥2; q-
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TGGT1_278365 8.16 8.42 Toxoplasma gondii family A protein
TGGT1_301150 6.83 5.06 SAG-related sequence SRS19B
TGGT1_320190 6.82 7.46 SAG-related sequence SRS16B
TGGT1_242760 6.58 6.35 hypothetical protein
TGGT1_217420 6.07 6.25 hypothetical protein
TGGT1_300980 6.05 6.86 hypothetical protein
TGGT1_285470 5.86 5.65 patched family protein
TGGT1_320105 5.79 7.23 hypothetical protein
TGGT1_265030 5.76 5.95 hypothetical protein
TGGT1_300990 5.72 5.33 Toxoplasma gondii family C protein
TGGT1_410080 5.69 9.87 hypothetical protein
TGGT1_278370 5.67 4.98 Toxoplasma gondii family A protein
TGGT1_301180 5.58 5.03 SAG-related sequence SRS19F
TGGT1_207150 5.51 6.71 SAG-related sequence SRS49C
TGGT1_290970 5.48 6.04 8-amino-7-oxononanoate synthase
TGGT1_201690 5.25 7.04 BT1 family protein
TGGT1_202025 5.18 4.76 hypothetical protein
TGGT1_278400 5.15 4.33 Toxoplasma gondii family A protein
TGGT1_293840 5.07 4.89 hypothetical protein
TGGT1_284310 5.02 5.34 hypothetical protein
TGGT1_278110 4.94 5.19 1,3-beta-glucan synthase component protein
TGGT1_284420 4.87 5.29 hypothetical protein
TGGT1_301370 4.82 4.55 DHHC zinc finger domain-containing protein
TGGT1_305790 4.75 4.94 hypothetical protein
TGGT1_292375 4.72 5.37 KRUF family protein
TGGT1_301170 4.59 4.74 SAG-related sequence SRS19D
TGGT1_278120 4.53 3.03 SCP family extracellular subfamily protein
TGGT1_410090 4.51 5.01 hypothetical protein
TGGT1_306480 4.48 5.09 CAM kinase, CDPK family
TGGT1_411820 4.46 3.45 toxoplasma gondii family C protein
TGGT1_301690 4.36 4.74 hypothetical protein
TGGT1_323310 4.32 4.90 hypothetical protein
TGGT1_225290 4.32 4.10 GDA1/CD39 (nucleoside phosphatase) family protein
TGGT1_462968 4.31 4.40 putative ATPase family protein
TGGT1_292280 4.25 3.74 SAG-related sequence SRS36D
TGGT1_216140 4.23 5.57 tetratricopeptide repeat-containing protein
TGGT1_270655 4.18 4.44 hypothetical protein
TGGT1_255210 4.00 4.30 ATPase, AAA family protein
TGGT1_264660 3.98 3.71 SAG-related sequence SRS44
TGGT1_278380 3.91 3.35 Toxoplasma gondii family A protein
TGGT1_318120 3.91 3.84 hypothetical protein
TGGT1_411360 3.90 3.40 rhoptry kinase family protein
TGGT1_293500 3.89 3.65 hypothetical protein
TGGT1_217400 3.86 3.23 hypothetical protein
TGGT1_278090 3.80 2.74 Toxoplasma gondii family A protein
TGGT1_323320 3.79 4.13 hypothetical protein
TGGT1_255200 3.79 4.09 putative Radial spoke head protein 9
Gene ID





TGGT1_313890 3.77 4.13 hypothetical protein
TGGT1_358470 3.74 3.99 hypothetical protein
TGGT1_356400 3.74 3.94 cAMP-dependent protein kinase
TGGT1_408620 3.70 3.53 hypothetical protein
TGGT1_410720 3.69 6.69 putative protein kinase
TGGT1_200130 3.58 4.09 Toxoplasma gondii family C protein
TGGT1_245530 3.56 4.47 hypothetical protein
TGGT1_307480 3.56 3.26 Toxoplasma gondii family B protein
TGGT1_283450 3.48 3.44 Toxoplasma gondii family B protein
TGGT1_220720 3.47 3.10 hypothetical protein
TGGT1_226450 3.46 2.41 hypothetical protein
TGGT1_255215 3.45 3.93 hypothetical protein
TGGT1_280580 3.44 3.07 SAG-related sequence SRS35B
TGGT1_209985 3.42 3.29 cAMP-dependent protein kinase
TGGT1_293780 3.41 3.48 hypothetical protein
TGGT1_273110 3.40 2.70 SAG-related sequence SRS30D
TGGT1_210450 3.40 3.70 hypothetical protein
TGGT1_363340 3.31 4.07 hypothetical protein
TGGT1_301210 3.30 2.77 putative NAD(P) transhydrogenase subunit beta
TGGT1_239910 3.29 3.65 cyclin-dependent kinase
TGGT1_222080 3.28 5.27 hypothetical protein
TGGT1_244710 3.26 3.68 hypothetical protein
TGGT1_320180 3.22 3.33 SAG-related sequence SRS16C
TGGT1_410610 3.18 4.72 hypothetical protein
TGGT1_306338B 3.18 2.97 putative dynein gamma chain, flagellar outer arm
TGGT1_298820 3.14 4.50 hypothetical protein
TGGT1_410730 3.13 3.90 PT repeat protein
TGGT1_214545 3.10 1.99 hypothetical protein
TGGT1_266105 3.08 3.31 EF hand family protein
TGGT1_318130A 3.07 2.87 Toxoplasma gondii family E protein
TGGT1_307070 3.07 4.19 hypothetical protein
TGGT1_278882 3.06 3.41 GDA1/CD39 (nucleoside phosphatase) family protein
TGGT1_257945 3.03 2.90 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_258230 3.00 3.13 rhoptry kinase family protein ROP20
TGGT1_244700 2.98 3.13 NAD(+)/NADH kinase domain-containing protein
TGGT1_222370 2.98 2.89 SAG-related sequence SRS13
TGGT1_219218 2.98 2.71 hypothetical protein
TGGT1_271015 2.94 3.32 hypothetical protein
TGGT1_411310 2.94 3.09 hypothetical protein
TGGT1_253770 2.91 3.71 hypothetical protein
TGGT1_359770 2.89 3.21 SAG-related sequence protein SRS22E
TGGT1_232770 2.88 2.68 hypothetical protein
TGGT1_311335 2.87 3.52 dual specificity phosphatase, catalytic domain-containing protein
TGGT1_278580 2.87 3.15 hypothetical protein
TGGT1_243360 2.85 1.77 hypothetical protein
TGGT1_206290 2.81 2.25 hypothetical protein
TGGT1_301160 2.80 2.75 SAG-related sequence SRS19C
TGGT1_217724 2.80 2.86 hypothetical protein
TGGT1_207865 2.79 2.42 GCC2 and GCC3 domain-containing protein
TGGT1_315802 2.78 2.52 hypothetical protein
TGGT1_411390 2.77 2.92 hypothetical protein
TGGT1_304920 2.77 4.47 hypothetical protein
TGGT1_215340 2.75 3.72 AP2 domain transcription factor AP2X-10
TGGT1_278390 2.75 2.32 Toxoplasma gondii family A protein
TGGT1_411800 2.74 2.09 hypothetical protein
TGGT1_411270 2.72 3.11 hypothetical protein
TGGT1_210235 2.71 2.26 hypothetical protein
TGGT1_215775 2.71 2.58 rhoptry protein ROP8
TGGT1_293810 2.69 2.96 carboxyvinyl-carboxyphosphonate phosphorylmutase




TGGT1_409990 2.67 2.81 hypothetical protein
TGGT1_204360 2.64 3.26 subtilisin SUB4
TGGT1_231470 2.61 2.28 hypothetical protein
TGGT1_218400 2.61 2.11 NEK kinase
TGGT1_208730 2.61 3.09 putative microneme protein
TGGT1_215180 2.61 3.23 hypothetical protein
TGGT1_276920 2.60 2.38 protein phosphatase 2C domain-containing protein
TGGT1_247540 2.60 3.48 ATP-binding cassette G family transporter ABCG107
TGGT1_287460 2.58 2.86 hypothetical protein
TGGT1_276980 2.58 3.19 hypothetical protein
TGGT1_356030 2.58 2.03 hypothetical protein
TGGT1_306455 2.54 1.87 hypothetical protein
TGGT1_263750 2.54 2.67 hypothetical protein
TGGT1_409850 2.53 1.66 SAG-related sequence protein SRS47A
TGGT1_411400 2.50 3.04 hypothetical protein
TGGT1_257000 2.49 2.02 hypothetical protein
TGGT1_408770 2.49 1.65 putative transmembrane protein
TGGT1_240470 2.48 2.30 hypothetical protein
TGGT1_313650 2.48 3.43 hypothetical protein
TGGT1_411730 2.48 2.57 hypothetical protein
TGGT1_218390 2.46 2.45 hypothetical protein
TGGT1_306500 2.46 4.03 hypothetical protein
TGGT1_239880 2.45 3.18 hypothetical protein
TGGT1_202020 2.44 3.64 DnAK-TPR
TGGT1_356970 2.44 1.49 hypothetical protein
TGGT1_306450 2.42 3.59 putative short chain dehydrogenase family protein
TGGT1_207140 2.42 2.48 SAG-related sequence SRS49B
TGGT1_225280 2.42 2.97 hypothetical protein
TGGT1_262590 2.40 2.19 hypothetical protein
TGGT1_264240 2.39 2.91 hypothetical protein
TGGT1_409590 2.37 2.15 putative transmembrane protein
TGGT1_254060 2.35 1.82 SAG-related sequence SRS14A
TGGT1_207700 2.35 1.89 rhoptry kinase family protein ROP22 (incomplete catalytic triad)
TGGT1_264260 2.34 2.62 hypothetical protein
TGGT1_219660 2.34 3.63 hypothetical protein
TGGT1_217915 2.33 2.74 hypothetical protein
TGGT1_208760 2.33 2.11 hypothetical protein
TGGT1_253790 2.30 1.70 zinc finger (CCCH type) motif-containing protein
TGGT1_217920 2.28 2.72 hypothetical protein
TGGT1_309405 2.27 2.42 hypothetical protein
TGGT1_202910 2.27 2.09 zinc carboxypeptidase superfamily protein
TGGT1_248140 2.27 2.36 hypothetical protein
TGGT1_249810 2.26 2.36 putative activating signal cointegrator 1 complex subunit 3
TGGT1_210095 2.26 2.96 hypothetical protein
TGGT1_365020 2.25 1.95 cytochrome C family oxidase subunit III subfamily protein
TGGT1_241165 2.24 1.80 hypothetical protein
TGGT1_296231 2.24 2.77 hypothetical protein
TGGT1_243615 2.24 3.00 hypothetical protein
TGGT1_207875 2.24 2.48 GCC2 and GCC3 domain-containing protein
TGGT1_257568 2.23 2.20 hypothetical protein
TGGT1_257572 2.23 2.14 hypothetical protein
TGGT1_266670 2.23 2.02 hypothetical protein
TGGT1_215970 2.21 2.55 hypothetical protein
TGGT1_322110 2.21 2.24 hypothetical protein
TGGT1_321480 2.20 2.68 SAG-related sequence SRS12B
TGGT1_241130 2.20 2.18 hypothetical protein
TGGT1_411000 2.19 2.07 hypothetical protein
TGGT1_215343 2.19 1.97 hypothetical protein
TGGT1_363480 2.18 3.01 hypothetical protein




TGGT1_220060 2.18 1.92 hypothetical protein
TGGT1_239510 2.17 1.85 hypothetical protein
TGGT1_320230 2.14 2.51 SAG-related sequence SRS15C
TGGT1_410930 2.13 2.28 hypothetical protein
TGGT1_217410 2.13 3.51 hypothetical protein
TGGT1_295720 2.11 2.47 putative sulfite oxidase
TGGT1_266950 2.11 2.31 putative protein kinase
TGGT1_216290A 2.10 2.35 hypothetical protein
TGGT1_283882 2.10 1.61 hypothetical protein
TGGT1_257610 2.09 2.26 hypothetical protein
TGGT1_252070 2.09 2.66 KRUF family protein
TGGT1_259670 2.09 1.98 von Willebrand factor type A domain-containing protein
TGGT1_260480 2.09 2.22 leucine rich repeat-containing protein
TGGT1_269600 2.08 2.12 biotin-requiring enzyme domain-containing protein
TGGT1_315740 2.07 1.85 SAG-related sequence SRS54
TGGT1_285860 2.07 1.61 SAG-related sequence SRS20C
TGGT1_411410 2.06 2.73 putative transmembrane protein
TGGT1_300780 2.04 1.83 hypothetical protein
TGGT1_309930 2.03 2.13 melibiase subfamily protein
TGGT1_219742 2.02 1.64 hypothetical protein
TGGT1_277930 2.02 1.68 hypothetical protein
TGGT1_272680 2.00 2.80 hypothetical protein
TGGT1_286660 2.00 2.63 putative kinesin
TGGT1_254890 1.99 1.57 hypothetical protein
TGGT1_244515 1.98 2.68 hypothetical protein
TGGT1_307030 1.98 2.19 Purine nucleoside phosphorylase
TGGT1_201840 1.98 2.40 aspartyl protease ASP1
TGGT1_214760 1.94 1.63 erythronate-4-phosphate dehydrogenase domain-containing protein
TGGT1_243635 1.93 2.15 hypothetical protein
TGGT1_272440 1.93 2.03 RNA recognition motif-containing protein
TGGT1_248425 1.92 1.73 hypothetical protein
TGGT1_235183 1.90 2.37 PAN domain-containing protein
TGGT1_229405 1.90 2.18 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_314250 1.88 1.79 bradyzoite rhoptry protein BRP1
TGGT1_315260 1.88 1.99 alanine dehydrogenase
TGGT1_215195 1.88 1.75 tetratricopeptide repeat-containing protein
TGGT1_223430 1.87 1.85 hypothetical protein
TGGT1_216290B 1.87 1.85 hypothetical protein
TGGT1_268300 1.84 1.45 hypothetical protein
TGGT1_227430 1.84 2.01 transmembrane amino acid transporter protein
TGGT1_289350 1.84 1.71 ATP-binding cassette G family transporter ABCG84
TGGT1_224810 1.84 1.24 hypothetical protein
TGGT1_269300 1.84 1.93 lipase
TGGT1_271174 1.82 1.60 hypothetical protein
TGGT1_315900 1.82 1.62 hypothetical protein
TGGT1_304930 1.81 1.47 hypothetical protein
TGGT1_223560 1.80 1.58 hypothetical protein
TGGT1_206570 1.79 1.35 putative kinesin
TGGT1_310177 1.78 1.74 hypothetical protein
TGGT1_223060 1.78 1.81 MORN repeat-containing protein
TGGT1_409050 1.77 2.00 hypothetical protein
TGGT1_295960 1.76 1.59 hypothetical protein
TGGT1_216335 1.75 2.05 hypothetical protein
TGGT1_291860 1.74 1.64 HORMA domain-containing protein
TGGT1_265810 1.74 1.73 hypothetical protein
TGGT1_258225 1.73 1.90 hypothetical protein
TGGT1_294225 1.73 1.31 hypothetical protein
TGGT1_313840 1.72 1.06 hypothetical protein
TGGT1_295950 1.72 1.63 KRUF family protein




TGGT1_411020 1.71 2.22 hypothetical protein
TGGT1_249290 1.71 2.49 hypothetical protein
TGGT1_411150 1.71 2.39 hypothetical protein
TGGT1_224845 1.70 1.87 hypothetical protein
TGGT1_217722 1.70 3.06 hypothetical protein
TGGT1_235680 1.70 1.68 peptidase M16 inactive domain-containing protein
TGGT1_294595 1.69 2.41 hypothetical protein
TGGT1_273065 1.69 1.24 hypothetical protein
TGGT1_205090 1.67 1.27 Toxoplasma gondii family D protein
TGGT1_328800 1.66 1.77 hypothetical protein
TGGT1_411120 1.66 1.59 putative transmembrane protein
TGGT1_277810 1.65 2.51 hypothetical protein
TGGT1_411520 1.63 2.04 hypothetical protein
TGGT1_288945 1.62 2.05 hypothetical protein
TGGT1_262600 1.61 1.57 hypothetical protein
TGGT1_292260 1.61 1.11 SAG-related sequence SRS36B
TGGT1_244180 1.59 1.53 microneme-like protein
TGGT1_287490 1.59 1.19 hypothetical protein
TGGT1_219240 1.59 1.64 Peptidyl-tRNA hydrolase PTH2 domain-containing protein
TGGT1_205210 1.58 1.65 hypothetical protein
TGGT1_222188 1.57 1.17 hypothetical protein
TGGT1_239020 1.57 1.40 ABC transporter transmembrane region domain-containing protein
TGGT1_217660 1.56 2.22 Tctex-1 family protein
TGGT1_261022 1.56 1.90 dynein heavy chain family protein
TGGT1_252255 1.54 1.11 hypothetical protein
TGGT1_295945 1.54 1.53 hypothetical protein
TGGT1_204500 1.54 2.01 hypothetical protein
TGGT1_243740 1.53 1.85 WD domain, G-beta repeat-containing protein
TGGT1_309860 1.53 1.27 hypothetical protein
TGGT1_271335 1.51 1.49 hypothetical protein
TGGT1_228410 1.51 1.28 Tubulin-tyrosine ligase family protein
TGGT1_234930 1.51 1.28 SAG-related sequence SRS43
TGGT1_316670 1.51 2.01 Toxoplasma gondii family D protein
TGGT1_271310 1.50 1.47 hypothetical protein
TGGT1_321800 1.49 2.50 EGF family domain-containing protein
TGGT1_217020 1.49 1.81 ATPase, AFG1 family protein
TGGT1_207750 1.49 1.52 hypothetical protein
TGGT1_305000 1.49 1.09 hypothetical protein
TGGT1_217728 1.49 1.43 hypothetical protein
TGGT1_411190 1.47 1.97 hypothetical protein
TGGT1_315410 1.47 1.26 SAG-related sequence SRS53F
TGGT1_213820 1.46 1.48 hypothetical protein
TGGT1_244940 1.46 1.64 hypothetical protein
TGGT1_213560 1.45 1.18 hypothetical protein
TGGT1_248430 1.43 1.91 hypothetical protein
TGGT1_263100 1.42 1.76 hypothetical protein
TGGT1_266910 1.41 1.21 putative cell-cycle-associated protein kinase GSK
TGGT1_285865 1.41 1.43 hypothetical protein
TGGT1_236990 1.40 1.32 beta-ketoacyl synthase, N-terminal domain-containing protein
TGGT1_301350 1.40 1.34 SNARE associated protein
TGGT1_308075 1.39 1.49 hypothetical protein
TGGT1_273120 1.39 1.55 SAG-related sequence SRS30C
TGGT1_237270 1.37 1.08 hypothetical protein
TGGT1_242590 1.37 2.08 hypothetical protein
TGGT1_293258 1.34 1.84 hypothetical protein
TGGT1_408760 1.33 1.05 toxoplasma gondii family A protein
TGGT1_268765 1.33 1.43 hypothetical protein
TGGT1_269417 1.32 1.41 hypothetical protein
TGGT1_216680 1.32 1.26 ankyrin repeat-containing protein




TGGT1_232950 1.30 1.68 hypothetical protein
TGGT1_253930 1.29 1.41 GCC2 and GCC3 domain-containing protein
TGGT1_202255 1.29 1.28 hypothetical protein
TGGT1_222160 1.28 1.18 aldehyde dehydrogenase
TGGT1_238960 1.27 1.24 EF hand domain-containing protein
TGGT1_254340 1.26 1.99 hypothetical protein
TGGT1_301355 1.22 1.00 hypothetical protein
TGGT1_248470 1.22 1.66 subtilisin SUB6
TGGT1_309410 1.17 1.23 AP2 domain transcription factor AP2XI-1
TGGT1_310520 1.17 1.40 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_223725 1.16 1.36 hypothetical protein
TGGT1_316290 1.15 1.72 hypothetical protein
TGGT1_215347 1.14 1.05 hypothetical protein
TGGT1_316510 1.10 1.12 hypothetical protein
TGGT1_254635 1.06 1.30 hypothetical protein
TGGT1_281400 1.06 1.55 phosphofructokinase domain-containing protein
TGGT1_305040 1.06 1.12 HEAT repeat-containing protein
TGGT1_359210 1.05 1.07 hypothetical protein
TGGT1_238140 1.05 1.22 hypothetical protein
TGGT1_280810 1.04 1.24 hypothetical protein
TGGT1_226420 1.02 1.13 peptidase family M3 protein
TGGT1_278060 1.02 1.08 Mre11 DNA-binding domain-containing protein
TGGT1_271025 1.02 1.25 hypothetical protein
TGGT1_306680 1.01 1.30 hypothetical protein
TGGT1_264760 -1.02 -1.05 Oxysterol-binding protein
TGGT1_246210 -1.03 -1.06 hypothetical protein
TGGT1_267560 -1.03 -1.04 folate-binding protein YgfZ protein
TGGT1_267570 -1.05 -1.05 hypothetical protein
TGGT1_267790 -1.05 -1.05 hypothetical protein
TGGT1_240580 -1.05 -1.33 hypothetical protein
TGGT1_288045 -1.06 -1.05 hypothetical protein
TGGT1_255280 -1.07 -1.21 hypothetical protein
TGGT1_267440 -1.08 -1.00 RING zinc finger protein
TGGT1_279400 -1.08 -1.03 putative glutaredoxin
TGGT1_267580 -1.08 -1.10 cyclin2 related protein
TGGT1_313852 -1.09 -1.37 hypothetical protein
TGGT1_267610 -1.09 -1.22 hypothetical protein
TGGT1_264680 -1.10 -1.04 hypothetical protein
TGGT1_216970 -1.10 -1.19 putative coronin
TGGT1_205250 -1.10 -1.25 rhoptry protein ROP18
TGGT1_279360 -1.11 -1.09 hypothetical protein
TGGT1_267840 -1.11 -1.03 tetratricopeptide repeat-containing protein
TGGT1_267650 -1.12 -1.08 hypothetical protein
TGGT1_266410 -1.12 -1.14 hypothetical protein
TGGT1_279370 -1.13 -1.23 SNARE associated Golgi protein
TGGT1_264730 -1.13 -1.04 hypothetical protein
TGGT1_242625 -1.13 -1.01 TPase family associated with various cellular activities (AAA) subfamily protei
TGGT1_264900 -1.13 -1.09 hypothetical protein
TGGT1_288040 -1.14 -1.07 hypothetical protein
TGGT1_297488 -1.14 -1.01 hypothetical protein
TGGT1_264820 -1.14 -1.07 RbAp48
TGGT1_267740 -1.15 -1.06 hypothetical protein
TGGT1_267450 -1.15 -1.15 alpha-tubulin suppressor protein
TGGT1_267855 -1.16 -1.19 hypothetical protein
TGGT1_267620 -1.18 -1.18 multi-pass transmembrane protein
TGGT1_207470 -1.20 -1.06 hypothetical protein
TGGT1_231990 -1.21 -1.39 hypothetical protein
TGGT1_264790 -1.21 -1.18 hypothetical protein
TGGT1_308965 -1.22 -1.24 hypothetical protein




TGGT1_299010 -1.22 -1.27 hypothetical protein
TGGT1_267430 -1.22 -1.17 DnaJ domain-containing protein
TGGT1_266390 -1.22 -1.25 DNA mismatch repair protein, C-terminal domain-containing protein
TGGT1_264890 -1.23 -1.16 hypothetical protein
TGGT1_295110 -1.23 -1.37 rhoptry protein ROP7
TGGT1_267680 -1.23 -1.42 microneme protein MIC12
TGGT1_264752 -1.24 -1.19 HEAT repeat-containing protein
TGGT1_323020 -1.25 -1.19 KRUF family protein
TGGT1_256650 -1.27 -1.04 hypothetical protein
TGGT1_410770 -1.27 -1.20 histone deacetylase SIR2-like protein
TGGT1_264745 -1.27 -1.04 hypothetical protein
TGGT1_264870 -1.28 -1.07 Sodium:neurotransmitter symporter family protein
TGGT1_288020 -1.29 -1.35 hypothetical protein
TGGT1_267370 -1.29 -1.29 kinesin motor domain-containing protein
TGGT1_229220 -1.30 -1.09 hypothetical protein
TGGT1_264670 -1.30 -1.23 DNA polymerase family B protein
TGGT1_255290 -1.31 -1.39 hypothetical protein
TGGT1_266360 -1.31 -1.08 hypothetical protein
TGGT1_250220 -1.32 -1.04 hypothetical protein
TGGT1_366480 -1.36 -1.37 phosphofructokinase
TGGT1_267630 -1.36 -1.15 hypothetical protein
TGGT1_226100 -1.39 -1.52 haloacid dehalogenase family hydrolase domain-containing protein
TGGT1_294651 -1.39 -1.41 hypothetical protein
TGGT1_409260 -1.40 -1.30 hypothetical protein
TGGT1_244280 -1.40 -1.43 hypothetical protein
TGGT1_267380 -1.40 -1.47 UDP-galactose transporter subfamily protein
TGGT1_224840 -1.41 -1.44 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_267720 -1.44 -1.18 transporter, cation channel family protein
TGGT1_264748 -1.45 -1.21 hypothetical protein
TGGT1_216610 -1.46 -1.54 ribosomal RNA large subunit methyltransferase J protein
TGGT1_226310 -1.46 -1.65 zinc finger (CCCH type) motif-containing protein
TGGT1_270580 -1.46 -1.83 HECT-domain (ubiquitin-transferase) domain-containing protein
TGGT1_279100 -1.47 -1.63 hypothetical protein
TGGT1_221220 -1.47 -1.17 hypothetical protein
TGGT1_287980 -1.48 -1.40 FHA domain-containing protein
TGGT1_306730 -1.49 -1.35 hypothetical protein
TGGT1_230905 -1.51 -1.26 hydrolase, alpha/beta fold family protein
TGGT1_264720 -1.52 -1.46 hypothetical protein
TGGT1_237450 -1.53 -1.27 hypothetical protein
TGGT1_287990 -1.54 -1.22 hypothetical protein
TGGT1_235700 -1.55 -1.44 sedoheptulose-1,7-bisphosphatase
TGGT1_264225 -1.56 -1.86 Toxoplasma gondii family B protein
TGGT1_222420 -1.57 -1.56 hypothetical protein
TGGT1_264940 -1.58 -1.62 kelch repeat-containing protein
TGGT1_310160 -1.59 -1.64 argonaute AGO
TGGT1_202580 -1.62 -1.36 ATPase, AAA family protein
TGGT1_462961 -1.62 -2.13 hypothetical protein
TGGT1_266035 -1.66 -1.37 hypothetical protein
TGGT1_319308 -1.66 -1.59 hypothetical protein
TGGT1_315123 -1.67 -1.64 hypothetical protein
TGGT1_267820 -1.68 -1.62 putative electron transfer flavoprotein subunit beta
TGGT1_410390 -1.68 -1.63 hypothetical protein
TGGT1_217860 -1.69 -1.72 hypothetical protein
TGGT1_272730 -1.69 -1.31 hypothetical protein
TGGT1_233960 -1.69 -1.65 hypothetical protein
TGGT1_254840 -1.74 -1.78 tetratricopeptide repeat-containing protein
TGGT1_297910 -1.75 -1.97 hypothetical protein
TGGT1_266380 -1.80 -1.71 hypothetical protein
TGGT1_263030 -1.81 -1.79 dynein light chain 8 family E protein




TGGT1_322100 -1.84 -1.62 myosin-light-chain kinase
TGGT1_319890 -1.85 -1.94 hypothetical protein
TGGT1_312435 -1.85 -1.58 hypothetical protein
TGGT1_227350 -1.89 -1.81 hypothetical protein
TGGT1_312240 -1.91 -1.38 hypothetical protein
TGGT1_410660 -1.94 -2.16 hypothetical protein
TGGT1_270670 -1.94 -2.05 hypothetical protein
TGGT1_233370 -1.96 -1.99 hypothetical protein
TGGT1_363030 -1.96 -2.00 rhoptry protein ROP8
TGGT1_295125 -1.97 -2.26 rhoptry protein ROP4
TGGT1_264950 -1.98 -2.01 hypothetical protein
TGGT1_274290 -2.01 -2.03 Toxoplasma gondii family B protein
TGGT1_279350 -2.05 -1.64 hypothetical protein
TGGT1_230830 -2.07 -1.93 se family associated with various cellular activities (AAA) domain-containing p
TGGT1_267585 -2.07 -1.71 hypothetical protein
TGGT1_239475 -2.07 -1.53 hypothetical protein
TGGT1_207880 -2.15 -1.57 hypothetical protein
TGGT1_270680 -2.15 -2.21 hypothetical protein
TGGT1_286250 -2.16 -2.03 hypothetical protein
TGGT1_291075 -2.16 -2.42 hypothetical protein
TGGT1_212810 -2.17 -2.11 hypothetical protein
TGGT1_237170 -2.17 -2.31 hypothetical protein
TGGT1_222340 -2.18 -2.21 NOL1/NOP2/sun family protein
TGGT1_411240 -2.18 -2.44 toxoplasma gondii family B protein
TGGT1_254850 -2.24 -2.23 putative myosin heavy chain
TGGT1_279345 -2.27 -1.87 hypothetical protein
TGGT1_283840 -2.29 -2.49 GATA zinc finger domain-containing protein
TGGT1_230900 -2.30 -2.34 hypothetical protein
TGGT1_411560 -2.35 -2.12 hypothetical protein
TGGT1_204010 -2.36 -2.42 hypothetical protein
TGGT1_231125 -2.36 -2.17 hypothetical protein
TGGT1_205265 -2.37 -2.31 transporter, cation channel family protein
TGGT1_277230 -2.38 -1.33 hypothetical protein
TGGT1_238210 -2.39 -2.07 EGF family domain-containing protein
TGGT1_244950 -2.40 -2.37 hypothetical protein
TGGT1_204000 -2.43 -1.91 hypothetical protein
TGGT1_320000 -2.58 -2.49 SCY kinase (incomplete catalytic triad)
TGGT1_233210 -2.60 -2.27 hypothetical protein
TGGT1_202280 -2.62 -2.75 WD domain, G-beta repeat-containing protein
TGGT1_314362 -2.65 -2.48 hypothetical protein
TGGT1_211270 -2.68 -2.44 sushi domain (scr repeat) domain-containing protein
TGGT1_264485 -2.69 -2.69 AP2 domain transcription factor AP2IX-3
TGGT1_222060 -2.70 -2.63 hypothetical protein
TGGT1_259155 -2.74 -2.74 hypothetical protein
TGGT1_268220 -2.74 -2.60 hypothetical protein
TGGT1_267030 -2.75 -2.90 ribonuclease type III Dicer
TGGT1_294650 -2.77 -2.50 hypothetical protein
TGGT1_306700 -2.78 -2.83 hypothetical protein
TGGT1_294400 -2.78 -2.19 hypothetical protein
TGGT1_295440 -2.85 -2.83 hypothetical protein
TGGT1_213255 -2.87 -1.80 hypothetical protein
TGGT1_329600 -2.91 -2.75 hypothetical protein
TGGT1_289218 -2.92 -3.02 hypothetical protein
TGGT1_233770A -2.95 -2.09 calcium-translocating P-type ATPase, PMCA-type protein
TGGT1_267435 -2.97 -2.37 hypothetical protein
TGGT1_244412 -3.01 -2.63 hypothetical protein
TGGT1_200320 -3.02 -3.18 hypoxanthine-xanthine-guanine phosphoribosyl transferase HXGPRT
TGGT1_289222 -3.02 -3.12 hypothetical protein
TGGT1_289060 -3.09 -2.84 hypothetical protein




TGGT1_245746B -3.33 -3.20 hypothetical protein
TGGT1_301890 -3.41 -3.55 Toxoplasma gondii family B protein
TGGT1_244408 -3.43 -3.41 hypothetical protein
TGGT1_244406 -3.45 -3.45 cysteine dioxygenase type i protein
TGGT1_289216 -3.47 -3.53 hypothetical protein
TGGT1_215540 -3.61 -3.74 hypothetical protein
TGGT1_312245 -3.61 -3.22 hypothetical protein
TGGT1_233770B -3.65 -2.67 calcium-translocating P-type ATPase, PMCA-type protein
TGGT1_361030 -3.65 -3.60 hypothetical protein
TGGT1_293420 -3.79 -3.98 transporter, major facilitator family protein
TGGT1_223480 -3.85 -3.87 sushi domain (scr repeat) domain-containing protein
TGGT1_319992 -3.95 -3.87 hypothetical protein
TGGT1_266500 -4.04 -4.24 hypothetical protein
TGGT1_245746A -4.13 -3.80 hypothetical protein
TGGT1_411650 -4.23 -4.63 hypothetical protein
TGGT1_314340 -4.28 -4.19 Sodium:neurotransmitter symporter family protein
TGGT1_287240 -4.44 -3.99 hypothetical protein
TGGT1_287235 -4.47 -4.26 hypothetical protein
TGGT1_203685 -4.51 -3.78 hypothetical protein
TGGT1_203682 -4.53 -3.71 hypothetical protein
TGGT1_245748 -4.57 -4.22 hypothetical protein
TGGT1_274280 -4.65 -4.93 hypothetical protein
TGGT1_462973 -4.67 -4.16 hypothetical protein
TGGT1_411750 -4.69 -4.81 hypothetical protein
TGGT1_411680 -4.73 -5.05 hypothetical protein
TGGT1_245752 -4.77 -4.48 WD domain, G-beta repeat-containing protein
TGGT1_200595 -4.81 -4.57 hypothetical protein
TGGT1_280500 -4.99 -4.84 inorganic anion transporter, sulfate permease (SulP) family protein
TGGT1_408600 -5.10 -4.74 hypothetical protein
TGGT1_203688 -5.45 -4.81 hypothetical protein
TGGT1_304450 -11.20 -11.41 cation-transporting ATPase
TGGT1_306334 3.61 N.S. hypothetical protein
TGGT1_311485 2.80 N.S. hypothetical protein
TGGT1_294320 2.10 N.S. Oxysterol-binding protein
TGGT1_282000 1.50 N.S. hypothetical protein
TGGT1_218910 1.43 N.S. hypothetical protein
TGGT1_246760 1.41 N.S. hypothetical protein
TGGT1_254603 1.36 N.S. hypothetical protein
TGGT1_235860 1.26 N.S. subtilisin SUB11
TGGT1_218540 1.23 N.S. putative peptidase S15
TGGT1_200700 1.19 N.S. Toxoplasma gondii family C protein
TGGT1_306070 1.19 N.S. hypothetical protein
TGGT1_411430 1.19 N.S. rhoptry protein ROP5
TGGT1_244400 1.17 N.S. hypothetical protein
TGGT1_200250 1.12 N.S. microneme protein MIC17A
TGGT1_212970 1.08 N.S. protein kinase (incomplete catalytic triad)
TGGT1_202010 1.06 N.S. hypothetical protein
TGGT1_269930 1.05 N.S. calcium binding egf domain-containing protein
TGGT1_255860 1.03 N.S. hypothetical protein
TGGT1_258670 1.01 N.S. hypothetical protein
TGGT1_293650 1.00 N.S. hypothetical protein
TGGT1_208820 -1.00 N.S. 1-deoxy-D-xylulose-5-phosphate synthase
TGGT1_310650 -1.00 N.S. hypothetical protein
TGGT1_267725 -1.01 N.S. hypothetical protein
TGGT1_267530 -1.01 N.S. hypothetical protein
TGGT1_269050 -1.01 N.S. hypothetical protein
TGGT1_266366 -1.02 N.S. BT1 family protein
TGGT1_288030 -1.03 N.S. hypothetical protein
TGGT1_267700 -1.03 N.S. hypothetical protein




TGGT1_365840 -1.04 N.S. hypothetical protein
TGGT1_267775 -1.04 N.S. hypothetical protein
TGGT1_299000 -1.04 N.S. hypothetical protein
TGGT1_267800 -1.05 N.S. dynamin-related protein DRPA
TGGT1_264830 -1.07 N.S. hypothetical protein
TGGT1_411300 -1.08 N.S. hypothetical protein
TGGT1_288000 -1.09 N.S. hypothetical protein
TGGT1_205680 -1.11 N.S. hypothetical protein
TGGT1_268660 -1.11 N.S. hypothetical protein
TGGT1_279310 -1.12 N.S. hypothetical protein
TGGT1_268035 -1.15 N.S. hypothetical protein
TGGT1_314550 -1.22 N.S. hypothetical protein
TGGT1_306692 -1.22 N.S. hypothetical protein
TGGT1_258550 -1.28 N.S. SAG-related sequence SRS28
TGGT1_221880 -1.29 N.S. hypothetical protein
TGGT1_410860 -1.38 N.S. hypothetical protein
TGGT1_294240 -1.77 N.S. hypothetical protein
TGGT1_306860 -2.27 N.S. hypothetical protein
TGGT1_207160 N.S. 6.27 SAG-related sequence SRS49D
TGGT1_318130B N.S. 5.63 Toxoplasma gondii family E protein
TGGT1_252080 N.S. 5.46 hypothetical protein
TGGT1_214550 N.S. 5.16 hypothetical protein
TGGT1_263135 N.S. 4.90 hypothetical protein
TGGT1_278710 N.S. 4.75 hypothetical protein
TGGT1_278080 N.S. 4.29 Toxoplasma gondii family A protein
TGGT1_204870 N.S. 4.06 hypothetical protein
TGGT1_225102 N.S. 3.89 hypothetical protein
TGGT1_245770B N.S. 3.73 hypothetical protein
TGGT1_218470 N.S. 3.56 putative protein disulfide-isomerase
TGGT1_269315 N.S. 3.54 hypothetical protein
TGGT1_305890 N.S. 3.33 hypothetical protein
TGGT1_205420 N.S. 3.30 aspartate-semialdehyde dehydrogenase
TGGT1_245770A N.S. 3.28 hypothetical protein
TGGT1_242350 N.S. 3.27 tetratricopeptide repeat-containing protein
TGGT1_220080 N.S. 3.21 Toxoplasma gondii family C protein
TGGT1_215900 N.S. 3.18 hypothetical protein
TGGT1_236900 N.S. 3.18 hypothetical protein
TGGT1_249520 N.S. 3.18 hypothetical protein
TGGT1_311370 N.S. 3.17 putative methylmalonate-semialdehyde dehydrogenase [acylating]
TGGT1_243382 N.S. 3.08 hypothetical protein
TGGT1_356590 N.S. 3.07 hypothetical protein
TGGT1_215185 N.S. 2.94 hypothetical protein
TGGT1_411080 N.S. 2.94 hypothetical protein
TGGT1_293800 N.S. 2.91 putative transmembrane protein 65
TGGT1_300070 N.S. 2.86 hypothetical protein
TGGT1_223045 N.S. 2.78 hypothetical protein
TGGT1_268800 N.S. 2.77 hypothetical protein
TGGT1_270280 N.S. 2.73 hypothetical protein
TGGT1_307045 N.S. 2.69 Toxoplasma gondii family B protein
TGGT1_257010 N.S. 2.68 sporozoite developmental protein
TGGT1_280570 N.S. 2.67 SAG-related sequence SRS35A
TGGT1_221840 N.S. 2.64 hypothetical protein
TGGT1_358440 N.S. 2.59 KRUF family protein
TGGT1_216875 N.S. 2.57 cpw-wpc domain-containing protein
TGGT1_410970 N.S. 2.57 hypothetical protein
TGGT1_224760 N.S. 2.47 SAG-related sequence SRS40E
TGGT1_307050 N.S. 2.47 hypothetical protein
TGGT1_209755B N.S. 2.47 hypothetical protein
TGGT1_273468 N.S. 2.45 hypothetical protein




TGGT1_267980 N.S. 2.43 hypothetical protein
TGGT1_286782 N.S. 2.43 MAM domain-containing protein
TGGT1_259270 N.S. 2.43 SAG-related sequence SRS26E
TGGT1_204560 N.S. 2.42 putative type I fatty acid synthase
TGGT1_305100 N.S. 2.41 hypothetical protein
TGGT1_262160 N.S. 2.40 hypothetical protein
TGGT1_260460 N.S. 2.38 putative oxidoreductase
TGGT1_291040 N.S. 2.38 lactate dehydrogenase LDH2
TGGT1_253760 N.S. 2.37 hypothetical protein
TGGT1_235950 N.S. 2.36 subtilisin SUB8
TGGT1_258200 N.S. 2.33 hypothetical protein
TGGT1_239855 N.S. 2.32 Ras-associated protein Rap1 isoform 1 family protein
TGGT1_238980 N.S. 2.31 hypothetical protein
TGGT1_306688 N.S. 2.31 hypothetical protein
TGGT1_301140 N.S. 2.30 SAG-related sequence SRS19A
TGGT1_299020 N.S. 2.30 AP2 domain transcription factor AP2III-4
TGGT1_273980 N.S. 2.30 hypothetical protein
TGGT1_315520 N.S. 2.29 calcium binding egf domain-containing protein
TGGT1_266785 N.S. 2.28 zinc finger (CCCH type) motif-containing protein
TGGT1_408550 N.S. 2.27 hypothetical protein
TGGT1_225140 N.S. 2.24 BT1 family protein
TGGT1_309840 N.S. 2.24 hypothetical protein
TGGT1_243700 N.S. 2.21 hypothetical protein
TGGT1_240930 N.S. 2.21 MoaC family protein
TGGT1_235010 N.S. 2.19 hypothetical protein
TGGT1_235187A N.S. 2.18 hypothetical protein
TGGT1_285665 N.S. 2.16 hypothetical protein
TGGT1_271980 N.S. 2.14 SAG-related sequence SRS32
TGGT1_297660 N.S. 2.13 hypothetical protein
TGGT1_268860 N.S. 2.13 enolase 1
TGGT1_252640 N.S. 2.11 P-type ATPase PMA1
TGGT1_411050 N.S. 2.11 KRUF family protein
TGGT1_210950 N.S. 2.08 oocyst wall protein
TGGT1_209755A N.S. 2.07 hypothetical protein
TGGT1_227090 N.S. 2.06 aspartokinase
TGGT1_225070 N.S. 2.05 hypothetical protein
TGGT1_231900 N.S. 2.05 acyl-CoA dehydrogenase domain-containing protein
TGGT1_227070 N.S. 2.04 hypothetical protein
TGGT1_222935 N.S. 2.03 hypothetical protein
TGGT1_245980 N.S. 2.02 hypothetical protein
TGGT1_320090 N.S. 2.00 hypothetical protein
TGGT1_275380 N.S. 2.00 SAG-related sequence SRS47D
TGGT1_261560 N.S. 2.00 Tat binding protein 1(TBP-1)-interacting protein TBPIP
TGGT1_220585 N.S. 1.99 hypothetical protein
TGGT1_213290 N.S. 1.94 hypothetical protein
TGGT1_269640 N.S. 1.92 hypothetical protein
TGGT1_224080 N.S. 1.91 Kazal-type serine protease inhibitor domain-containing protein
TGGT1_320250 N.S. 1.91 SAG-related sequence SRS15A
TGGT1_286540 N.S. 1.91 hypothetical protein
TGGT1_411490 N.S. 1.90 putative toxoplasma gondii family E protein
TGGT1_291830 N.S. 1.89 putative DNA double-strand break repair rad50 ATPase
TGGT1_237585 N.S. 1.89 hypothetical protein
TGGT1_285825 N.S. 1.88 hypothetical protein
TGGT1_297670 N.S. 1.86 hypothetical protein
TGGT1_299260 N.S. 1.85 hypothetical protein
TGGT1_211050 N.S. 1.83 ATPase, AAA family protein
TGGT1_293250 N.S. 1.82 hypothetical protein
TGGT1_410790 N.S. 1.82 hypothetical protein
TGGT1_225028 N.S. 1.81 putative myosin heavy chain




TGGT1_260000 N.S. 1.80 hypothetical protein
TGGT1_273750 N.S. 1.80 hypothetical protein
TGGT1_218510 N.S. 1.77 hypothetical protein
TGGT1_316320 N.S. 1.77 ABC transporter transmembrane region domain-containing protein
TGGT1_293252 N.S. 1.76 hypothetical protein
TGGT1_254335 N.S. 1.75 hypothetical protein
TGGT1_233792 N.S. 1.75 hypothetical protein
TGGT1_270273 N.S. 1.75 hypothetical protein
TGGT1_215895 N.S. 1.73 AP2 domain-containing protein
TGGT1_257720 N.S. 1.73 putative proton ATPase
TGGT1_286570 N.S. 1.73 hypothetical protein
TGGT1_200230 N.S. 1.72 microneme protein MIC17C
TGGT1_212275 N.S. 1.72 hypothetical protein
TGGT1_282030 N.S. 1.70 hypothetical protein
TGGT1_312930 N.S. 1.70 putative cystathione gamma lyase
TGGT1_253755 N.S. 1.69 hypothetical protein
TGGT1_319390 N.S. 1.69 hypothetical protein
TGGT1_356120 N.S. 1.68 putative kelch repeat protein
TGGT1_217961 N.S. 1.66 hypothetical protein
TGGT1_366630 N.S. 1.65 hypothetical protein
TGGT1_201650 N.S. 1.65 hypothetical protein
TGGT1_201180A N.S. 1.64 hypothetical protein
TGGT1_204325 N.S. 1.64 hypothetical protein
TGGT1_358240 N.S. 1.64 hypothetical protein
TGGT1_255175 N.S. 1.63 hypothetical protein
TGGT1_285300 N.S. 1.62 hypothetical protein
TGGT1_411070 N.S. 1.62 tRNA-Ala
TGGT1_225098 N.S. 1.62 hypothetical protein
TGGT1_224680 N.S. 1.61 hypothetical protein
TGGT1_258520 N.S. 1.60 WD domain, G-beta repeat-containing protein
TGGT1_319360 N.S. 1.59 SAG-related sequence SRS17A
TGGT1_243655 N.S. 1.58 GMC oxidoreductase
TGGT1_265320 N.S. 1.58 hypothetical protein
TGGT1_210320 N.S. 1.57 SAG-related sequence SRS37A
TGGT1_254330 N.S. 1.56 lipase
TGGT1_281660 N.S. 1.54 hypothetical protein
TGGT1_203200 N.S. 1.54 hypothetical protein
TGGT1_293280 N.S. 1.53 cyclin protein
TGGT1_289740 N.S. 1.53 hypothetical protein
TGGT1_269310 N.S. 1.53 hypothetical protein
TGGT1_276200 N.S. 1.52 hypothetical protein
TGGT1_409760 N.S. 1.51 putative transmembrane protein
TGGT1_281675 N.S. 1.50 putative protein kinase
TGGT1_207130 N.S. 1.49 SAG-related sequence SRS49A
TGGT1_357130 N.S. 1.48 WD domain, G-beta repeat protein
TGGT1_212180 N.S. 1.47 hypothetical protein
TGGT1_203230 N.S. 1.46 hypothetical protein
TGGT1_242750 N.S. 1.46 hypothetical protein
TGGT1_203590 N.S. 1.45 hypothetical protein
TGGT1_237510 N.S. 1.44 hypothetical protein
TGGT1_226610 N.S. 1.44 hypothetical protein
TGGT1_408250 N.S. 1.43 hypothetical protein
TGGT1_254790 N.S. 1.42 hypothetical protein
TGGT1_275360 N.S. 1.41 SAG-related sequence SRS47B
TGGT1_247310 N.S. 1.40 cpw-wpc domain-containing protein
TGGT1_316380 N.S. 1.39 hypothetical protein
TGGT1_200350 N.S. 1.37 subtilisin SUB3
TGGT1_209705 N.S. 1.37 hypothetical protein
TGGT1_305150 N.S. 1.37 tetratricopeptide repeat-containing protein




TGGT1_408330 N.S. 1.35 toxoplasma gondii family D protein
TGGT1_217940 N.S. 1.35 hypothetical protein
TGGT1_251857 N.S. 1.34 hypothetical protein
TGGT1_237800 N.S. 1.33 dense granule protein GRA11
TGGT1_252370 N.S. 1.32 AP2 domain transcription factor AP2III-1
TGGT1_313220 N.S. 1.32 hypothetical protein
TGGT1_215680 N.S. 1.32 SAG-related sequence SRS18
TGGT1_240200 N.S. 1.32 hypothetical protein
TGGT1_235315 N.S. 1.31 PAN domain-containing protein
TGGT1_223520 N.S. 1.30 EF hand domain-containing protein
TGGT1_280465 N.S. 1.29 hypothetical protein
TGGT1_230640 N.S. 1.28 hypothetical protein
TGGT1_232170 N.S. 1.27 hypothetical protein
TGGT1_212410 N.S. 1.27 dense granule protein GRA11
TGGT1_304730 N.S. 1.27 Mob1/phocein family protein
TGGT1_287430 N.S. 1.27 hypothetical protein
TGGT1_260375 N.S. 1.26 hypothetical protein
TGGT1_274170 N.S. 1.25 protein kinase (incomplete catalytic triad)
TGGT1_311815 N.S. 1.24 hypothetical protein
TGGT1_247570 N.S. 1.23 hypothetical protein
TGGT1_211280 N.S. 1.22 hypothetical protein
TGGT1_212420 N.S. 1.21 hypothetical protein
TGGT1_251855 N.S. 1.21 hypothetical protein
TGGT1_273740 N.S. 1.21 putative acetyl-CoA acyltransferase B
TGGT1_305610 N.S. 1.20 hypothetical protein
TGGT1_253120 N.S. 1.19 putative mandelonitrile lyase
TGGT1_286740 N.S. 1.19 microneme-like protein
TGGT1_240390 N.S. 1.18 calcium-dependent protein kinase
TGGT1_209040 N.S. 1.18 hypothetical protein
TGGT1_233040 N.S. 1.17 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_276810 N.S. 1.16 hypothetical protein
TGGT1_232270 N.S. 1.15 histidine acid phosphatase superfamily protein
TGGT1_318742 N.S. 1.15 hypothetical protein
TGGT1_233153 N.S. 1.14 hypothetical protein
TGGT1_268970 N.S. 1.14 hypothetical protein
TGGT1_311490 N.S. 1.14 hypothetical protein
TGGT1_271010 N.S. 1.14 hypothetical protein
TGGT1_258870B N.S. 1.13 hypothetical protein
TGGT1_286460 N.S. 1.11 hypothetical protein
TGGT1_201180B N.S. 1.10 hypothetical protein
TGGT1_220060B N.S. 1.10 hypothetical protein
TGGT1_293520 N.S. 1.09 hypothetical protein
TGGT1_245428 N.S. 1.08 hypothetical protein
TGGT1_220420 N.S. 1.08 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_200240 N.S. 1.06 microneme protein MIC17B
TGGT1_239600 N.S. 1.06 rhoptry kinase family protein ROP23 (incomplete catalytic triad)
TGGT1_315962 N.S. 1.06 hypothetical protein
TGGT1_310090 N.S. 1.05 hypothetical protein
TGGT1_299790 N.S. 1.05 hypothetical protein
TGGT1_275870 N.S. 1.04 tubulin/FtsZ family, GTPase domain-containing protein
TGGT1_219640 N.S. 1.03 hypothetical protein
TGGT1_248280 N.S. 1.03 hypothetical protein
TGGT1_256020 N.S. 1.02 putative EFHC1
TGGT1_267660 N.S. -1.01 hypothetical protein
TGGT1_306720 N.S. -1.01 hypothetical protein
TGGT1_264710 N.S. -1.02 bucentaur or craniofacial development domain-containing protein
TGGT1_264770 N.S. -1.02 hypothetical protein
TGGT1_267710 N.S. -1.03 CPSF A subunit region protein
TGGT1_264472 N.S. -1.03 hypothetical protein
















TGGT1_276155 N.S. -1.06 hypothetical protein
TGGT1_264875 N.S. -1.06 hypothetical protein
TGGT1_202970 N.S. -1.06 hypothetical protein
TGGT1_267500 N.S. -1.08 hypothetical protein
TGGT1_285445 N.S. -1.09 hypothetical protein
TGGT1_226985 N.S. -1.09 hypothetical protein
TGGT1_236670B N.S. -1.10 hypothetical protein
TGGT1_279380 N.S. -1.11 hypothetical protein
TGGT1_205520 N.S. -1.11 hypothetical protein
TGGT1_266270 N.S. -1.13 short-chain-acyl-CoA dehydrogenase
TGGT1_237560 N.S. -1.13 iron-sulfur cluster protein ISCU
TGGT1_226110 N.S. -1.16 Copper-exporting ATPase
TGGT1_264420 N.S. -1.23 putative lipoprotein
TGGT1_366510 N.S. -1.26 hypothetical protein
TGGT1_294660 N.S. -1.28 hypothetical protein
TGGT1_259150 N.S. -1.29 hypothetical protein
TGGT1_462971 N.S. -1.30 hypothetical protein
TGGT1_310830 N.S. -1.30 enoyl-CoA hydratase/isomerase family protein
TGGT1_411590 N.S. -1.31 nucleoside-triphosphatase
TGGT1_267642 N.S. -1.34 hypothetical protein
TGGT1_280680 N.S. -1.35 hypothetical protein
TGGT1_285400 N.S. -1.38 hypothetical protein
TGGT1_218750 N.S. -1.39 hypothetical protein
TGGT1_220280 N.S. -1.40 mucin family glycoprotein
TGGT1_216710 N.S. -1.42 transporter, major facilitator family protein
TGGT1_411760 N.S. -1.48 actin
TGGT1_236290 N.S. -1.51 hypothetical protein
TGGT1_205050 N.S. -1.56 hypothetical protein
TGGT1_242100 N.S. -1.66 hypothetical protein
TGGT1_363220 N.S. -1.67 hypothetical protein
TGGT1_234400 N.S. -1.68 hypothetical protein
TGGT1_289280 N.S. -1.70 hypothetical protein
TGGT1_295662 N.S. -1.72 hypothetical protein
TGGT1_268360 N.S. -1.73 hypothetical protein
TGGT1_316550 N.S. -1.83 hypothetical protein
TGGT1_304480 N.S. -1.89 3-oxo-5-alpha-steroid 4-dehydrogenase
TGGT1_252890 N.S. -2.09 hypothetical protein
TGGT1_266740 N.S. -2.31 RNA recognition motif-containing protein
TGGT1_411210 N.S. -2.57 hypothetical protein
TGGT1_287250 N.S. -2.58 hypothetical protein
TGGT1_410520 N.S. -2.58 putative OTU family cysteine protease
TGGT1_275760 N.S. -2.99 hypothetical protein
TGGT1_242900 N.S. -3.10 Toxoplasma gondii family A protein
TGGT1_358120 N.S. -6.82 hypothetical protein
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Table 4.2. Differential expression analysis identified many differentially expressed 
gene amongst extracellular RH and non-lab-adapted GT1 populations 
Following RNA-seq of 6-hour extracellular parasites, DEA identified 927 DEGs in 
GT1 population B2-P11 and 955 DEGS in GT1 population B4-P11, both relative to RH. 
In union, 692 DEGs were found to have similar expression across the two GT1 
populations. All genes with Log2 FC values shown are considered significant (absolute 
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TGGT1_292375 7.64 8.65 KRUF family protein
TGGT1_300980 7.56 7.38 hypothetical protein
TGGT1_242760 7.02 6.92 hypothetical protein
TGGT1_410080 6.93 6.53 hypothetical protein
TGGT1_298820 6.68 6.49 hypothetical protein
TGGT1_363340 6.62 6.37 hypothetical protein
TGGT1_220720 6.62 5.96 hypothetical protein
TGGT1_285470 6.35 5.89 patched family protein
TGGT1_220080 6.11 5.66 Toxoplasma gondii family C protein
TGGT1_278365 6.02 5.62 Toxoplasma gondii family A protein
TGGT1_300990 5.84 5.55 Toxoplasma gondii family C protein
TGGT1_411310 5.78 5.47 hypothetical protein
TGGT1_301180 5.65 5.33 SAG-related sequence SRS19F
TGGT1_411800 5.49 5.20 hypothetical protein
TGGT1_411520 5.49 5.12 hypothetical protein
TGGT1_293840 5.49 5.06 hypothetical protein
TGGT1_216680 5.19 5.06 ankyrin repeat-containing protein
TGGT1_411000 5.14 5.00 hypothetical protein
TGGT1_307050 5.08 4.97 hypothetical protein
TGGT1_200130 5.01 4.90 Toxoplasma gondii family C protein
TGGT1_265030 4.94 4.83 hypothetical protein
TGGT1_284310 4.91 4.78 hypothetical protein
TGGT1_264260 4.80 4.75 hypothetical protein
TGGT1_300780 4.70 4.65 hypothetical protein
TGGT1_249800 4.70 4.49 hypothetical protein
TGGT1_219218 4.70 4.47 hypothetical protein
TGGT1_278120 4.68 4.36 SCP family extracellular subfamily protein
TGGT1_278110 4.66 4.31 1,3-beta-glucan synthase component protein
TGGT1_411020 4.63 4.31 hypothetical protein
TGGT1_289350 4.60 4.27 ATP-binding cassette G family transporter ABCG84
TGGT1_216290B 4.40 4.27 hypothetical protein
TGGT1_264240 4.35 4.25 hypothetical protein
TGGT1_409050 4.35 4.24 hypothetical protein
TGGT1_216290A 4.17 4.21 hypothetical protein
TGGT1_201690 4.10 4.18 BT1 family protein
TGGT1_255210 4.09 4.09 ATPase, AAA family protein
TGGT1_217724 4.09 3.96 hypothetical protein
TGGT1_293780 4.05 3.91 hypothetical protein
TGGT1_278400 4.03 3.91 Toxoplasma gondii family A protein
TGGT1_210235 4.01 3.88 hypothetical protein
TGGT1_358470 3.99 3.81 hypothetical protein
TGGT1_301170 3.99 3.76 SAG-related sequence SRS19D
TGGT1_210245 3.96 3.75 hypothetical protein
TGGT1_462968 3.96 3.73 putative ATPase family protein
TGGT1_278380 3.94 3.71 Toxoplasma gondii family A protein
TGGT1_311335 3.79 3.70 dual specificity phosphatase, catalytic domain-containing protein
Gene ID





TGGT1_283450 3.79 3.65 Toxoplasma gondii family B protein
TGGT1_202025 3.76 3.63 hypothetical protein
TGGT1_410890 3.70 3.62 hypothetical protein
TGGT1_323320 3.59 3.57 hypothetical protein
TGGT1_411150 3.52 3.51 hypothetical protein
TGGT1_305790 3.50 3.48 hypothetical protein
TGGT1_217020 3.48 3.46 ATPase, AFG1 family protein
TGGT1_323310 3.48 3.42 hypothetical protein
TGGT1_220060 3.48 3.41 hypothetical protein
TGGT1_307480 3.48 3.40 Toxoplasma gondii family B protein
TGGT1_307070 3.45 3.40 hypothetical protein
TGGT1_284420 3.44 3.39 hypothetical protein
TGGT1_278370 3.38 3.26 Toxoplasma gondii family A protein
TGGT1_257945 3.38 3.26 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_216140 3.36 3.24 tetratricopeptide repeat-containing protein
TGGT1_210450 3.36 3.21 hypothetical protein
TGGT1_249810 3.35 3.21 putative activating signal cointegrator 1 complex subunit 3
TGGT1_301210 3.35 3.21 putative NAD(P) transhydrogenase subunit beta
TGGT1_244700 3.33 3.20 NAD(+)/NADH kinase domain-containing protein
TGGT1_410730 3.32 3.20 PT repeat protein
TGGT1_320190 3.32 3.17 SAG-related sequence SRS16B
TGGT1_253770 3.29 3.16 hypothetical protein
TGGT1_410930 3.26 3.07 hypothetical protein
TGGT1_244710 3.25 3.05 hypothetical protein
TGGT1_217728 3.24 3.04 hypothetical protein
TGGT1_287460 3.20 2.99 hypothetical protein
TGGT1_328800 3.20 2.98 hypothetical protein
TGGT1_271015 3.19 2.96 hypothetical protein
TGGT1_306688 3.18 2.95 hypothetical protein
TGGT1_411420 3.17 2.89 hypothetical protein
TGGT1_255215 3.14 2.89 hypothetical protein
TGGT1_276810 3.13 2.89 hypothetical protein
TGGT1_410090 3.06 2.88 hypothetical protein
TGGT1_409590 3.03 2.87 putative transmembrane protein
TGGT1_263730 3.02 2.87 FAD-dependent glycerol-3-phosphate dehydrogenase
TGGT1_411820 2.97 2.87 toxoplasma gondii family C protein
TGGT1_305890 2.96 2.87 hypothetical protein
TGGT1_322110 2.95 2.85 hypothetical protein
TGGT1_281400 2.95 2.83 phosphofructokinase domain-containing protein
TGGT1_410970 2.94 2.83 hypothetical protein
TGGT1_262590 2.90 2.81 hypothetical protein
TGGT1_278410 2.90 2.81 Toxoplasma gondii family A protein
TGGT1_217420 2.90 2.80 hypothetical protein
TGGT1_410790 2.84 2.80 hypothetical protein
TGGT1_216335 2.82 2.79 hypothetical protein
TGGT1_263740 2.79 2.72 ABC transporter transmembrane region domain-containing protein
TGGT1_411390 2.69 2.71 hypothetical protein
TGGT1_262600 2.68 2.69 hypothetical protein
TGGT1_301370 2.66 2.67 DHHC zinc finger domain-containing protein
TGGT1_411730 2.62 2.67 hypothetical protein
TGGT1_245530 2.61 2.65 hypothetical protein
TGGT1_411270 2.60 2.65 hypothetical protein
TGGT1_251857 2.60 2.65 hypothetical protein
TGGT1_252255 2.58 2.65 hypothetical protein
TGGT1_290970 2.58 2.63 8-amino-7-oxononanoate synthase
TGGT1_409990 2.57 2.63 hypothetical protein
TGGT1_260530 2.56 2.62 Sel1 repeat-containing protein
TGGT1_204870 2.56 2.54 hypothetical protein
TGGT1_411400 2.55 2.54 hypothetical protein




TGGT1_365020 2.52 2.46 cytochrome C family oxidase subunit III subfamily protein
TGGT1_217722 2.52 2.46 hypothetical protein
TGGT1_235680 2.49 2.45 peptidase M16 inactive domain-containing protein
TGGT1_217400 2.48 2.45 hypothetical protein
TGGT1_215180 2.47 2.44 hypothetical protein
TGGT1_220650 2.46 2.43 hypothetical protein
TGGT1_278060 2.45 2.43 Mre11 DNA-binding domain-containing protein
TGGT1_306680 2.44 2.41 hypothetical protein
TGGT1_215343 2.42 2.37 hypothetical protein
TGGT1_231470 2.41 2.37 hypothetical protein
TGGT1_270655 2.39 2.36 hypothetical protein
TGGT1_213635 2.38 2.34 hypothetical protein
TGGT1_207750 2.34 2.32 hypothetical protein
TGGT1_267980 2.34 2.32 hypothetical protein
TGGT1_283855 2.33 2.28 hypothetical protein
TGGT1_304670 2.30 2.25 leucine rich repeat-containing protein
TGGT1_320740 2.30 2.22 hypothetical protein
TGGT1_411120 2.27 2.22 putative transmembrane protein
TGGT1_320105 2.27 2.20 hypothetical protein
TGGT1_306338B 2.25 2.20 putative dynein gamma chain, flagellar outer arm
TGGT1_293500 2.23 2.19 hypothetical protein
TGGT1_231992 2.21 2.18 hypothetical protein
TGGT1_258230 2.20 2.17 rhoptry kinase family protein ROP20
TGGT1_242590 2.19 2.16 hypothetical protein
TGGT1_269600 2.17 2.15 biotin-requiring enzyme domain-containing protein
TGGT1_266105 2.14 2.15 EF hand family protein
TGGT1_217630 2.14 2.13 hypothetical protein
TGGT1_261022 2.13 2.13 dynein heavy chain family protein
TGGT1_244715 2.13 2.10 hypothetical protein
TGGT1_206290 2.11 2.07 hypothetical protein
TGGT1_296231 2.09 2.07 hypothetical protein
TGGT1_287430 2.07 2.07 hypothetical protein
TGGT1_411110 2.07 2.06 hypothetical protein
TGGT1_307640 2.06 2.05 CMGC kinase, CK2 family
TGGT1_216965 2.06 2.02 leucine rich repeat-containing protein
TGGT1_202255 2.04 2.01 hypothetical protein
TGGT1_223060 2.03 2.01 MORN repeat-containing protein
TGGT1_293790 2.02 2.00 hypothetical protein
TGGT1_217660 2.01 1.99 Tctex-1 family protein
TGGT1_285920 2.00 1.96 hypothetical protein
TGGT1_276920 1.99 1.93 protein phosphatase 2C domain-containing protein
TGGT1_301690 1.97 1.93 hypothetical protein
TGGT1_259670 1.96 1.92 von Willebrand factor type A domain-containing protein
TGGT1_217030 1.95 1.91 hypothetical protein
TGGT1_223045 1.89 1.90 hypothetical protein
TGGT1_286770 1.89 1.90 hypothetical protein
TGGT1_359210 1.88 1.89 hypothetical protein
TGGT1_240800 1.88 1.85 MORN repeat-containing protein
TGGT1_408560 1.87 1.84 hypothetical protein
TGGT1_247540 1.87 1.84 ATP-binding cassette G family transporter ABCG107
TGGT1_305030 1.86 1.83 kinase, pfkB family protein
TGGT1_273110 1.86 1.83 SAG-related sequence SRS30D
TGGT1_215185 1.85 1.83 hypothetical protein
TGGT1_239020 1.85 1.83 ABC transporter transmembrane region domain-containing protein
TGGT1_291860 1.81 1.81 HORMA domain-containing protein
TGGT1_243378 1.81 1.80 hypothetical protein
TGGT1_411190 1.81 1.79 hypothetical protein
TGGT1_266785 1.79 1.78 zinc finger (CCCH type) motif-containing protein
TGGT1_222080 1.78 1.78 hypothetical protein




TGGT1_236990 1.78 1.77 beta-ketoacyl synthase, N-terminal domain-containing protein
TGGT1_258030 1.77 1.77 DNA polymerase
TGGT1_255200 1.77 1.76 putative Radial spoke head protein 9
TGGT1_217040 1.77 1.75 hypothetical protein
TGGT1_200700 1.75 1.74 Toxoplasma gondii family C protein
TGGT1_243635 1.75 1.72 hypothetical protein
TGGT1_316290 1.74 1.72 hypothetical protein
TGGT1_277685 1.74 1.72 hypothetical protein
TGGT1_256020 1.74 1.71 putative EFHC1
TGGT1_313840 1.74 1.68 hypothetical protein
TGGT1_231991 1.73 1.68 hypothetical protein
TGGT1_243600 1.73 1.68 acetyltransferase, GNAT family protein
TGGT1_224130 1.72 1.68 hypothetical protein
TGGT1_253930 1.72 1.68 GCC2 and GCC3 domain-containing protein
TGGT1_263750 1.70 1.67 hypothetical protein
TGGT1_279355 1.68 1.66 hypothetical protein
TGGT1_220060B 1.66 1.66 hypothetical protein
TGGT1_269417 1.66 1.65 hypothetical protein
TGGT1_247310 1.64 1.64 cpw-wpc domain-containing protein
TGGT1_234370 1.64 1.63 SAG-related sequence SRS42
TGGT1_215970 1.64 1.62 hypothetical protein
TGGT1_220420 1.64 1.62 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_243740 1.63 1.61 WD domain, G-beta repeat-containing protein
TGGT1_244590 1.63 1.61 katanin-like family protein
TGGT1_253760 1.63 1.60 hypothetical protein
TGGT1_203070 1.62 1.59 hypothetical protein
TGGT1_248430 1.60 1.59 hypothetical protein
TGGT1_265320 1.59 1.55 hypothetical protein
TGGT1_408550 1.58 1.54 hypothetical protein
TGGT1_411430 1.58 1.52 rhoptry protein ROP5
TGGT1_204360 1.57 1.51 subtilisin SUB4
TGGT1_217726 1.57 1.51 hypothetical protein
TGGT1_222370 1.56 1.51 SAG-related sequence SRS13
TGGT1_235183 1.54 1.51 PAN domain-containing protein
TGGT1_236980 1.54 1.49 AMP-binding enzyme domain-containing protein
TGGT1_320180 1.53 1.49 SAG-related sequence SRS16C
TGGT1_258870B 1.50 1.48 hypothetical protein
TGGT1_202910 1.50 1.48 zinc carboxypeptidase superfamily protein
TGGT1_410160 1.50 1.47 hypothetical protein
TGGT1_306470 1.49 1.47 isoprenylcysteine carboxyl methyltransferase (icmt) family protein
TGGT1_270280 1.49 1.46 hypothetical protein
TGGT1_214850 1.47 1.46 putative 1-deoxy-D-xylulose 5-phosphate reductoisomerase
TGGT1_220060A 1.47 1.45 hypothetical protein
TGGT1_212160 1.46 1.45 hypothetical protein
TGGT1_285410 1.45 1.45 putative calmodulin-binding carboxy-terminal kinesin-like family protein
TGGT1_218910 1.45 1.45 hypothetical protein
TGGT1_217961 1.45 1.44 hypothetical protein
TGGT1_295950 1.44 1.44 KRUF family protein
TGGT1_315900 1.44 1.43 hypothetical protein
TGGT1_203990 1.44 1.43 rhoptry protein ROP12
TGGT1_211860 1.44 1.43 hypothetical protein
TGGT1_307270 1.43 1.43 hypothetical protein
TGGT1_217915 1.43 1.42 hypothetical protein
TGGT1_266950 1.41 1.42 putative protein kinase
TGGT1_257010 1.41 1.42 sporozoite developmental protein
TGGT1_226532 1.41 1.42 hypothetical protein
TGGT1_243700 1.40 1.41 hypothetical protein
TGGT1_297940 1.40 1.41 single-strand binding protein
TGGT1_263100 1.39 1.41 hypothetical protein




TGGT1_317705 1.39 1.40 enoyl-CoA hydratase/isomerase family protein
TGGT1_286660 1.39 1.40 putative kinesin
TGGT1_298060 1.38 1.40 Toxoplasma gondii family C protein
TGGT1_245770A 1.38 1.39 hypothetical protein
TGGT1_329400 1.38 1.39 Toxoplasma gondii family C protein
TGGT1_257040 1.37 1.39 TB2/DP1, HVA22 family protein
TGGT1_207950 1.37 1.39 hypothetical protein
TGGT1_293200 1.36 1.38 hypothetical protein
TGGT1_252385 1.36 1.38 hypothetical protein
TGGT1_207240 1.36 1.38 hypothetical protein
TGGT1_232770 1.35 1.37 hypothetical protein
TGGT1_277810 1.35 1.37 hypothetical protein
TGGT1_293650 1.35 1.36 hypothetical protein
TGGT1_363480 1.35 1.35 hypothetical protein
TGGT1_238490 1.34 1.35 SAG-related sequence SRS22E
TGGT1_239770 1.34 1.35 alveolin domain containing intermediate filament IMC11
TGGT1_209600 1.33 1.35 hypothetical protein
TGGT1_266910 1.33 1.33 putative cell-cycle-associated protein kinase GSK
TGGT1_257568 1.32 1.33 hypothetical protein
TGGT1_297660 1.32 1.33 hypothetical protein
TGGT1_247350 1.32 1.32 thioredoxin domain-containing protein
TGGT1_276940 1.32 1.32 putative ribosome associated membrane protein RAMP4
TGGT1_313890 1.31 1.30 hypothetical protein
TGGT1_295920 1.30 1.30 hypothetical protein
TGGT1_281470 1.30 1.30 hypothetical protein
TGGT1_215360 1.29 1.29 hypothetical protein
TGGT1_211675 1.29 1.29 hypothetical protein
TGGT1_278580 1.28 1.28 hypothetical protein
TGGT1_297670 1.28 1.27 hypothetical protein
TGGT1_245428 1.27 1.26 hypothetical protein
TGGT1_201840 1.27 1.26 aspartyl protease ASP1
TGGT1_294225 1.27 1.26 hypothetical protein
TGGT1_295960 1.26 1.25 hypothetical protein
TGGT1_239910 1.26 1.24 cyclin-dependent kinase
TGGT1_226420 1.26 1.24 peptidase family M3 protein
TGGT1_223520 1.26 1.24 EF hand domain-containing protein
TGGT1_244180 1.25 1.24 microneme-like protein
TGGT1_271335 1.24 1.23 hypothetical protein
TGGT1_211280 1.24 1.22 hypothetical protein
TGGT1_230610 1.22 1.21 transmembrane protein TMEM222
TGGT1_235515 1.22 1.21 MORN repeat-containing protein
TGGT1_201170 1.22 1.19 hypothetical protein
TGGT1_270040 1.22 1.19 hypothetical protein
TGGT1_228780 1.20 1.18 Toxoplasma gondii family C protein
TGGT1_299570 1.20 1.17 Toxoplasma gondii family B protein
TGGT1_313750 1.19 1.17 hypothetical protein
TGGT1_253755 1.19 1.17 hypothetical protein
TGGT1_292600 1.19 1.16 hypothetical protein
TGGT1_314690 1.19 1.16 hypothetical protein
TGGT1_268610 1.18 1.15 hypothetical protein
TGGT1_215895 1.18 1.14 AP2 domain-containing protein
TGGT1_275860 1.17 1.14 hypothetical protein
TGGT1_287160 1.17 1.13 internal kinesin motor domain protein
TGGT1_279540 1.17 1.13 hypothetical protein
TGGT1_222975 1.17 1.12 hypothetical protein
TGGT1_253180 1.16 1.11 hypothetical protein
TGGT1_258870A 1.16 1.10 hypothetical protein
TGGT1_227900 1.15 1.10 AP2 domain transcription factor AP2X-1
TGGT1_313690 1.14 1.09 Sel1 repeat-containing protein




TGGT1_232640 1.13 1.09 RNA 2'-phosphotransferase, Tpt1/KptA family protein
TGGT1_219470 1.12 1.08 hypothetical protein
TGGT1_249780 1.12 1.08 hypothetical protein
TGGT1_316600 1.12 1.07 hypothetical protein
TGGT1_411580 1.11 1.07 TPRX1
TGGT1_286130 1.10 1.06 hypothetical protein
TGGT1_307260 1.10 1.06 Toxoplasma gondii family C protein
TGGT1_300052 1.10 1.06 hypothetical protein
TGGT1_256025 1.09 1.06 SPEF1 family protein
TGGT1_208010 1.09 1.05 hypothetical protein
TGGT1_202500 1.08 1.05 GAPM1a
TGGT1_227840 1.08 1.04 Memo family protein
TGGT1_273300 1.07 1.04 hypothetical protein
TGGT1_319690 1.07 1.04 hypothetical protein
TGGT1_299015 1.07 1.04 hypothetical protein
TGGT1_228410 1.07 1.04 Tubulin-tyrosine ligase family protein
TGGT1_275755 1.06 1.03 hypothetical protein
TGGT1_224520 1.04 1.03 alveolin domain containing intermediate filament IMC8
TGGT1_356060 1.04 1.02 hypothetical protein
TGGT1_300055 1.04 1.02 hypothetical protein
TGGT1_245440 1.03 1.02 hypothetical protein
TGGT1_223070 1.02 1.01 hypothetical protein
TGGT1_315750 1.02 1.01 hypothetical protein
TGGT1_223140 1.01 1.00 tRNA binding domain-containing protein
TGGT1_271250 1.01 1.00 hypothetical protein
TGGT1_250940 1.01 1.00 hypothetical protein
TGGT1_211020 1.00 1.00 RNA recognition motif-containing protein
TGGT1_246210 -1.00 -1.00 hypothetical protein
TGGT1_224160 -1.01 -1.00 hypothetical protein
TGGT1_215270 -1.01 -1.01 hypothetical protein
TGGT1_273500 -1.01 -1.01 O-linked N-acetylglucosamine transferase
TGGT1_214800 -1.02 -1.01 hypothetical protein
TGGT1_259200A -1.02 -1.01 Na+/H+ exchanger NHE1
TGGT1_236970 -1.02 -1.01 SWI2/SNF2-containing PHD finger protein
TGGT1_226700 -1.03 -1.02 putative nuclease
TGGT1_231220 -1.03 -1.02 hypothetical protein
TGGT1_226460 -1.03 -1.03 hypothetical protein
TGGT1_279360 -1.03 -1.03 hypothetical protein
TGGT1_247970 -1.03 -1.03 hypothetical protein
TGGT1_256700 -1.03 -1.04 hypothetical protein
TGGT1_277070 -1.04 -1.05 SWI2/SNF2-containing protein
TGGT1_254625 -1.04 -1.05 hypothetical protein
TGGT1_215960 -1.04 -1.05 hypothetical protein
TGGT1_255380 -1.04 -1.05 hypothetical protein
TGGT1_257580 -1.04 -1.06 hypothetical protein
TGGT1_219660 -1.04 -1.06 hypothetical protein
TGGT1_203800 -1.05 -1.06 hypothetical protein
TGGT1_319320 -1.05 -1.06 hypothetical protein
TGGT1_281675 -1.05 -1.06 putative protein kinase
TGGT1_313630 -1.05 -1.07 hypothetical protein
TGGT1_270670 -1.05 -1.08 hypothetical protein
TGGT1_244450 -1.05 -1.09 protein phosphatase 2C domain-containing protein
TGGT1_295390 -1.05 -1.09 hypothetical protein
TGGT1_304720 -1.05 -1.09 hypothetical protein
TGGT1_271115 -1.05 -1.09 hypothetical protein
TGGT1_214540 -1.06 -1.09 hypothetical protein
TGGT1_244335 -1.06 -1.10 hypothetical protein
TGGT1_217500 -1.06 -1.10 HMG (high mobility group) box domain-containing protein
TGGT1_244910 -1.06 -1.10 MIZ/SP-RING zinc finger domain-containing protein




TGGT1_236400 -1.07 -1.11 hypothetical protein
TGGT1_209650B -1.07 -1.11 RNA-directed DNA polymerase
TGGT1_267710 -1.07 -1.11 CPSF A subunit region protein
TGGT1_278660 -1.07 -1.11 putative P-type ATPase4
TGGT1_266035 -1.07 -1.11 hypothetical protein
TGGT1_277940 -1.07 -1.12 hypothetical protein
TGGT1_257490 -1.07 -1.12 prefoldin subunit superfamily protein
TGGT1_267875 -1.08 -1.12 putative NBP2b protein
TGGT1_249170 -1.08 -1.13 Ras family protein
TGGT1_286250 -1.08 -1.14 hypothetical protein
TGGT1_214920 -1.09 -1.14 putative GPI-anchored wall transfer protein GWT1
TGGT1_245570 -1.09 -1.14 origin recognition complex subunit 2 protein
TGGT1_213710 -1.09 -1.14 WD domain, G-beta repeat-containing protein
TGGT1_225430 -1.09 -1.14 Ras-related GTP binding A family protein
TGGT1_409310 -1.09 -1.15 tRNA-Met
TGGT1_229350 -1.09 -1.15 HEAT repeat-containing protein
TGGT1_297920 -1.09 -1.15 hypothetical protein
TGGT1_202010 -1.09 -1.15 hypothetical protein
TGGT1_221895 -1.10 -1.15 hypothetical protein
TGGT1_203350 -1.10 -1.15 hypothetical protein
TGGT1_310730 -1.10 -1.16 hypothetical protein
TGGT1_261730 -1.10 -1.16 hypothetical protein
TGGT1_312075 -1.10 -1.16 hypothetical protein
TGGT1_287970 -1.10 -1.16 hypothetical protein
TGGT1_295970 -1.10 -1.16 hypothetical protein
TGGT1_314370 -1.11 -1.16 hypothetical protein
TGGT1_259250 -1.11 -1.17 ATP-dependent DNA helicase, RecQ family protein
TGGT1_214870 -1.11 -1.17 ribosomal protein L9, N-terminal domain-containing protein
TGGT1_267470 -1.11 -1.17 cold-shock DNA-binding domain-containing protein
TGGT1_267642 -1.11 -1.19 hypothetical protein
TGGT1_288940 -1.11 -1.19 hypothetical protein
TGGT1_261260B -1.11 -1.19 histone lysine demethylase JMJD6a
TGGT1_206660 -1.12 -1.20 hypothetical protein
TGGT1_264780 -1.12 -1.20 UTP-glucose-1-phosphate uridylyltransferase subfamily protein
TGGT1_226310 -1.12 -1.20 zinc finger (CCCH type) motif-containing protein
TGGT1_264640 -1.12 -1.20 bromodomain-containing protein
TGGT1_255960 -1.13 -1.20 hypothetical protein
TGGT1_271780 -1.13 -1.21 Filamin/ABP280 repeat-containing protein
TGGT1_209650A -1.13 -1.21 RNA-directed DNA polymerase
TGGT1_312500 -1.13 -1.22 hypothetical protein
TGGT1_262610 -1.13 -1.23 hypothetical protein
TGGT1_206430 -1.13 -1.23 formin FRM1
TGGT1_240730 -1.13 -1.23 hypothetical protein
TGGT1_247485 -1.13 -1.23 zinc finger, C3HC4 type (RING finger) domain-containing protein
TGGT1_231400B -1.13 -1.23 tubulin/FtsZ family, GTPase domain-containing protein
TGGT1_279330 -1.14 -1.24 DEAD/DEAH box helicase family protein
TGGT1_295980 -1.14 -1.24 hypothetical protein
TGGT1_312480 -1.15 -1.25 putative uracil phosphoribosyltransferase FUR1
TGGT1_220340 -1.15 -1.25 hypothetical protein
TGGT1_202050 -1.15 -1.26 hypothetical protein
TGGT1_215955 -1.15 -1.27 hypothetical protein
TGGT1_231215 -1.16 -1.27 hypothetical protein
TGGT1_281575 -1.17 -1.27 hypothetical protein
TGGT1_290860 -1.17 -1.27 putative amino acid transporter
TGGT1_277550 -1.17 -1.27 UvrD/REP helicase domain-containing protein
TGGT1_267440 -1.17 -1.28 RING zinc finger protein
TGGT1_264760 -1.17 -1.28 Oxysterol-binding protein
TGGT1_295110 -1.17 -1.29 rhoptry protein ROP7
TGGT1_221170 -1.17 -1.29 CAAX metallo endopeptidase




TGGT1_214270 -1.18 -1.29 putative translation initiation factor IF-2
TGGT1_247390 -1.18 -1.30 ATPase, AAA family protein
TGGT1_214510 -1.19 -1.30 hypothetical protein
TGGT1_250010 -1.19 -1.31 Sad1 / UNC family protein
TGGT1_289216 -1.19 -1.31 hypothetical protein
TGGT1_277050 -1.19 -1.31 hypothetical protein
TGGT1_276110 -1.20 -1.32 cytochrome b5 family heme/steroid binding domain-containing protein
TGGT1_318430 -1.20 -1.32 malate dehydrogenase MDH
TGGT1_267370 -1.20 -1.32 kinesin motor domain-containing protein
TGGT1_223025 -1.20 -1.33 hypothetical protein
TGGT1_240325 -1.20 -1.33 Toxoplasma gondii family E protein
TGGT1_277950 -1.20 -1.33 lipase
TGGT1_285990 -1.21 -1.33 Filamin/ABP280 repeat-containing protein
TGGT1_208710 -1.21 -1.33 DNA/RNA non-specific endonuclease
TGGT1_249880 -1.21 -1.34 hypothetical protein
TGGT1_297210 -1.21 -1.34 hypothetical protein
TGGT1_287960 -1.22 -1.34 hypothetical protein
TGGT1_270090 -1.22 -1.34 hypothetical protein
TGGT1_312065 -1.22 -1.34 hypothetical protein
TGGT1_208340 -1.22 -1.34 hypothetical protein
TGGT1_411770 -1.22 -1.35 putative IgA-specific serine endopeptidase
TGGT1_264710 -1.23 -1.35 bucentaur or craniofacial development domain-containing protein
TGGT1_201700 -1.24 -1.35 WD domain, G-beta repeat-containing protein
TGGT1_233870 -1.24 -1.35 hypothetical protein
TGGT1_259230 -1.24 -1.36 site-specific recombinase, phage integrase family protein
TGGT1_270680 -1.24 -1.36 hypothetical protein
TGGT1_239270 -1.24 -1.36 hypothetical protein
TGGT1_267570 -1.24 -1.37 hypothetical protein
TGGT1_214545 -1.25 -1.38 hypothetical protein
TGGT1_266380 -1.25 -1.38 hypothetical protein
TGGT1_246800 -1.25 -1.39 putative acylaminoacyl-peptidase
TGGT1_315345 -1.25 -1.40 SAG-related sequence SRS52F
TGGT1_246070 -1.25 -1.40 SAG-related sequence SRS56
TGGT1_285220 -1.26 -1.40 CAP-Gly domain-containing protein
TGGT1_262800 -1.26 -1.40 hypothetical protein
TGGT1_260680 -1.27 -1.40 putative small subunit DNA primase
TGGT1_202580 -1.27 -1.40 ATPase, AAA family protein
TGGT1_316580 -1.27 -1.40 hypothetical protein
TGGT1_264790 -1.27 -1.41 hypothetical protein
TGGT1_279320 -1.27 -1.41 hypothetical protein
TGGT1_256920 -1.27 -1.41 phosphatidylinositol-4-phosphate 5-Kinase
TGGT1_318770 -1.27 -1.41 aurora kinase(incomplete catalytic triad)
TGGT1_295030 -1.28 -1.41 hypothetical protein
TGGT1_202650 -1.29 -1.41 hypothetical protein
TGGT1_240930 -1.29 -1.41 MoaC family protein
TGGT1_281900 -1.29 -1.42 SET domain containing lysine methyltransferase KMTox
TGGT1_312240 -1.29 -1.42 hypothetical protein
TGGT1_242320 -1.29 -1.43 B-box zinc finger domain-containing protein
TGGT1_311640 -1.29 -1.43 hypothetical protein
TGGT1_264748 -1.29 -1.44 hypothetical protein
TGGT1_289222 -1.29 -1.44 hypothetical protein
TGGT1_248590 -1.29 -1.44 hypothetical protein
TGGT1_266390 -1.30 -1.44 DNA mismatch repair protein, C-terminal domain-containing protein
TGGT1_203135 -1.30 -1.45 dynein heavy chain family protein
TGGT1_282200 -1.30 -1.45 ATPase, AAA family protein
TGGT1_288450 -1.31 -1.46 aldehyde dehydrogenase (NAD) family protein
TGGT1_203330 -1.31 -1.46 hypothetical protein
TGGT1_263120 -1.31 -1.47 hypothetical protein
TGGT1_233180 -1.32 -1.47 hypothetical protein




TGGT1_209730 -1.32 -1.48 hypothetical protein
TGGT1_271892 -1.32 -1.49 hypothetical protein
TGGT1_208020 -1.32 -1.49 AP2 domain transcription factor AP2Ib-1
TGGT1_291930 -1.32 -1.50 RNA recognition motif-containing protein
TGGT1_305950 -1.32 -1.51 tetratricopeptide repeat-containing protein
TGGT1_267600 -1.32 -1.51 FHA domain-containing protein
TGGT1_208580 -1.33 -1.52 putative DNA ligase 1
TGGT1_410630 -1.33 -1.52 tRNA-Sec
TGGT1_264610 -1.33 -1.52 RNA recognition motif-containing protein
TGGT1_291900 -1.33 -1.53 Ydr279p family (RNase H2 complex component) protein
TGGT1_279100 -1.33 -1.53 hypothetical protein
TGGT1_263110 -1.34 -1.54 hypothetical protein
TGGT1_211480 -1.34 -1.54 putative GTP-binding protein engA
TGGT1_239810 -1.35 -1.55 hypothetical protein
TGGT1_200430 -1.35 -1.55 ine and deoxycytidylate deaminase zinc-binding region domain-containing pr
TGGT1_263510 -1.36 -1.55 Spc97 / Spc98 family protein
TGGT1_208842 -1.36 -1.56 DEAD/DEAH box helicase domain-containing protein
TGGT1_231200 -1.37 -1.56 hypothetical protein
TGGT1_323020 -1.37 -1.56 KRUF family protein
TGGT1_308945 -1.37 -1.57 hypothetical protein
TGGT1_410770 -1.38 -1.58 histone deacetylase SIR2-like protein
TGGT1_264752 -1.38 -1.58 HEAT repeat-containing protein
TGGT1_288455 -1.38 -1.58 hypothetical protein
TGGT1_236290 -1.38 -1.58 hypothetical protein
TGGT1_254890 -1.38 -1.58 hypothetical protein
TGGT1_214230 -1.39 -1.58 Dopey, N-terminal domain-containing protein
TGGT1_278878 -1.39 -1.58 GDA1/CD39 (nucleoside phosphatase) family protein
TGGT1_232240 -1.39 -1.58 hypothetical protein
TGGT1_218560 -1.40 -1.58 acetyl-coA carboxylase ACC2
TGGT1_267610 -1.40 -1.59 hypothetical protein
TGGT1_300150 -1.40 -1.59 hypothetical protein
TGGT1_267620 -1.40 -1.59 multi-pass transmembrane protein
TGGT1_323200 -1.40 -1.59 OTU family cysteine protease
TGGT1_267480 -1.40 -1.59 putative tRNA (guanine(26)-N(2))-dimethyltransferase
TGGT1_279405 -1.40 -1.59 hypothetical protein
TGGT1_319312 -1.40 -1.60 hypothetical protein
TGGT1_230830 -1.41 -1.60 se family associated with various cellular activities (AAA) domain-containing p
TGGT1_259155 -1.41 -1.60 hypothetical protein
TGGT1_462965 -1.43 -1.60 formin domain-containing protein
TGGT1_287240 -1.43 -1.61 hypothetical protein
TGGT1_224170 -1.43 -1.61 SAG-related sequence SRS60A
TGGT1_203665 -1.43 -1.61 hypothetical protein
TGGT1_215940 -1.43 -1.61 putative Acetyl-coenzyme A transporter
TGGT1_279410 -1.43 -1.61 hypothetical protein
TGGT1_244130 -1.44 -1.62 hypothetical protein
TGGT1_203705 -1.44 -1.62 hypothetical protein
TGGT1_204395 -1.45 -1.62 hypothetical protein
TGGT1_267775 -1.45 -1.62 hypothetical protein
TGGT1_254160 -1.46 -1.64 hypothetical protein
TGGT1_319580 -1.46 -1.64 hypothetical protein
TGGT1_201230 -1.47 -1.64 kinesin motor domain-containing protein
TGGT1_308940 -1.47 -1.66 hypothetical protein
TGGT1_249890 -1.48 -1.66 hypothetical protein
TGGT1_314362 -1.49 -1.66 hypothetical protein
TGGT1_264430 -1.49 -1.68 hypothetical protein
TGGT1_276155 -1.49 -1.68 hypothetical protein
TGGT1_262655 -1.49 -1.69 hypothetical protein
TGGT1_267670 -1.50 -1.69 hypothetical protein
TGGT1_205670 -1.50 -1.69 SF-assemblin/beta giardin protein




TGGT1_322100 -1.51 -1.70 myosin-light-chain kinase
TGGT1_221310 -1.51 -1.71 aminopeptidase N protein
TGGT1_278518 -1.51 -1.72 N-acetylgalactosaminyl transferase
TGGT1_275430 -1.52 -1.72 hypothetical protein
TGGT1_313940 -1.52 -1.72 hypothetical protein
TGGT1_222340 -1.52 -1.72 NOL1/NOP2/sun family protein
TGGT1_267585 -1.53 -1.72 hypothetical protein
TGGT1_203740 -1.53 -1.73 hypothetical protein
TGGT1_237220 -1.53 -1.74 putative DNA replication licensing factor Mcm7
TGGT1_246010 -1.54 -1.75 hypothetical protein
TGGT1_244550 -1.54 -1.75 hypothetical protein
TGGT1_214190 -1.54 -1.75 SAG-related sequence SRS46
TGGT1_410390 -1.54 -1.75 hypothetical protein
TGGT1_227370 -1.54 -1.77 hydrolase CocE/NonD family protein
TGGT1_269630 -1.54 -1.77 hypothetical protein
TGGT1_233540 -1.55 -1.77 transporter, major facilitator family protein
TGGT1_233210 -1.55 -1.78 hypothetical protein
TGGT1_267490 -1.55 -1.78 putative preprocathepsin c precursor
TGGT1_233360 -1.55 -1.78 hypothetical protein
TGGT1_271860 -1.55 -1.79 tRNA (Uracil-5-)-methyltransferase
TGGT1_249380 -1.56 -1.79 DHHC zinc finger domain-containing protein
TGGT1_311710 -1.56 -1.80 hypothetical protein
TGGT1_213700 -1.56 -1.80 hypothetical protein
TGGT1_267810 -1.56 -1.80 Rab 5
TGGT1_269380 -1.56 -1.81 hypothetical protein
TGGT1_256650 -1.56 -1.81 hypothetical protein
TGGT1_312175 -1.56 -1.81 hypothetical protein
TGGT1_362090 -1.57 -1.82 hypothetical protein
TGGT1_231780 -1.58 -1.83 hypothetical protein
TGGT1_267800 -1.58 -1.84 dynamin-related protein DRPA
TGGT1_224570 -1.58 -1.85 hypothetical protein
TGGT1_267380 -1.59 -1.86 UDP-galactose transporter subfamily protein
TGGT1_238940 -1.59 -1.86 putative GDP mannose 4,6-dehydratase
TGGT1_304480 -1.59 -1.86 3-oxo-5-alpha-steroid 4-dehydrogenase
TGGT1_295440 -1.59 -1.87 hypothetical protein
TGGT1_264805 -1.61 -1.87 hypothetical protein
TGGT1_229230 -1.61 -1.89 hypothetical protein
TGGT1_264420 -1.62 -1.89 putative lipoprotein
TGGT1_363030 -1.62 -1.90 rhoptry protein ROP8
TGGT1_221675B -1.63 -1.91 hypothetical protein
TGGT1_229220 -1.63 -1.93 hypothetical protein
TGGT1_287235 -1.64 -1.93 hypothetical protein
TGGT1_243920 -1.64 -1.93 putative DNA replication licensing factor MCM5
TGGT1_256950 -1.66 -1.94 hypothetical protein
TGGT1_228160 -1.68 -1.94 acid phosphatase
TGGT1_267540 -1.69 -1.95 AGC kinase
TGGT1_265770 -1.69 -1.95 hypothetical protein
TGGT1_255280 -1.69 -1.96 hypothetical protein
TGGT1_267790 -1.70 -1.97 hypothetical protein
TGGT1_248170 -1.70 -1.97 hypothetical protein
TGGT1_266366 -1.70 -1.97 BT1 family protein
TGGT1_278910 -1.72 -1.98 putative O-acetylserine (thiol) lyase 2
TGGT1_219370 -1.72 -1.98 hypothetical protein
TGGT1_282130 -1.73 -2.00 hypothetical protein
TGGT1_294240 -1.74 -2.00 hypothetical protein
TGGT1_244280 -1.76 -2.00 hypothetical protein
TGGT1_237450 -1.76 -2.00 hypothetical protein
TGGT1_274160 -1.77 -2.01 hypothetical protein
TGGT1_410900 -1.78 -2.02 toxoplasma gondii family A protein




TGGT1_280690 -1.83 -2.03 DNA polymerase epsilon subunit B protein
TGGT1_233370 -1.83 -2.03 hypothetical protein
TGGT1_273940 -1.84 -2.05 hypothetical protein
TGGT1_218810 -1.84 -2.06 histidyl-tRNA synthetase
TGGT1_203710 -1.86 -2.06 AP2 domain transcription factor AP2VIIa-4
TGGT1_255290 -1.86 -2.08 hypothetical protein
TGGT1_254840 -1.87 -2.08 tetratricopeptide repeat-containing protein
TGGT1_200320 -1.89 -2.10 hypoxanthine-xanthine-guanine phosphoribosyl transferase HXGPRT
TGGT1_261610 -1.89 -2.11 hypothetical protein
TGGT1_221220 -1.90 -2.11 hypothetical protein
TGGT1_232320 -1.90 -2.11 hypothetical protein
TGGT1_208850 -1.92 -2.11 SAG-related sequence SRS11
TGGT1_311700 -1.92 -2.12 hypothetical protein
TGGT1_289218 -1.92 -2.13 hypothetical protein
TGGT1_264840 -1.93 -2.14 ATP-dependent DNA helicase, RecQ family protein
TGGT1_295130 -1.93 -2.14 hypothetical protein
TGGT1_267435 -1.94 -2.15 hypothetical protein
TGGT1_221675A -1.94 -2.18 hypothetical protein
TGGT1_319370 -1.96 -2.18 hypothetical protein
TGGT1_202445 -2.00 -2.20 hypothetical protein
TGGT1_267820 -2.00 -2.23 putative electron transfer flavoprotein subunit beta
TGGT1_409410 -2.00 -2.23 tRNA-Leu
TGGT1_221320 -2.01 -2.24 acetyl-CoA carboxylase ACC1
TGGT1_237045 -2.02 -2.27 hypothetical protein
TGGT1_411550 -2.03 -2.27 toxoplasma gondii family A protein
TGGT1_204010 -2.04 -2.29 hypothetical protein
TGGT1_244950 -2.05 -2.31 hypothetical protein
TGGT1_267410 -2.05 -2.31 scavenger receptor protein SR1 precursor
TGGT1_321470 -2.05 -2.32 SAG-related sequence SRS12D
TGGT1_267855 -2.06 -2.34 hypothetical protein
TGGT1_245746B -2.06 -2.34 hypothetical protein
TGGT1_410520 -2.07 -2.35 putative OTU family cysteine protease
TGGT1_211730 -2.07 -2.36 histone lysine methyltransferase SET8
TGGT1_295125 -2.09 -2.36 rhoptry protein ROP4
TGGT1_203770 -2.09 -2.37 hypothetical protein
TGGT1_222420 -2.10 -2.38 hypothetical protein
TGGT1_213340 -2.10 -2.38 GMC oxidoreductase
TGGT1_205050 -2.10 -2.39 hypothetical protein
TGGT1_315127 -2.11 -2.40 hypothetical protein
TGGT1_205520 -2.11 -2.44 hypothetical protein
TGGT1_205658 -2.11 -2.44 F5/8 type C domain-containing protein
TGGT1_269075 -2.13 -2.49 hypothetical protein
TGGT1_233770A -2.13 -2.50 calcium-translocating P-type ATPase, PMCA-type protein
TGGT1_221890 -2.15 -2.50 WD domain, G-beta repeat-containing protein
TGGT1_312245 -2.15 -2.50 hypothetical protein
TGGT1_238210 -2.18 -2.50 EGF family domain-containing protein
TGGT1_236670B -2.18 -2.52 hypothetical protein
TGGT1_363220 -2.18 -2.54 hypothetical protein
TGGT1_308965 -2.18 -2.57 hypothetical protein
TGGT1_280500 -2.19 -2.58 inorganic anion transporter, sulfate permease (SulP) family protein
TGGT1_267030 -2.19 -2.58 ribonuclease type III Dicer
TGGT1_239290 -2.20 -2.58 hypothetical protein
TGGT1_411750 -2.21 -2.61 hypothetical protein
TGGT1_245752 -2.24 -2.61 WD domain, G-beta repeat-containing protein
TGGT1_237170 -2.25 -2.62 hypothetical protein
TGGT1_203688 -2.30 -2.65 hypothetical protein
TGGT1_252890 -2.31 -2.66 hypothetical protein
TGGT1_256960 -2.32 -2.68 FYVE zinc finger domain-containing protein
TGGT1_272730 -2.33 -2.68 hypothetical protein




TGGT1_244406 -2.34 -2.69 cysteine dioxygenase type i protein
TGGT1_223480 -2.35 -2.70 sushi domain (scr repeat) domain-containing protein
TGGT1_221880 -2.39 -2.70 hypothetical protein
TGGT1_203685 -2.40 -2.71 hypothetical protein
TGGT1_221830 -2.40 -2.74 subtilisin SUB12
TGGT1_265255 -2.43 -2.74 hypothetical protein
TGGT1_205662 -2.48 -2.75 LCCL domain-containing protein
TGGT1_410860 -2.51 -2.78 hypothetical protein
TGGT1_203682 -2.51 -2.78 hypothetical protein
TGGT1_305630 -2.52 -2.80 hypothetical protein
TGGT1_269085 -2.53 -2.81 hypothetical protein
TGGT1_319992 -2.54 -2.82 hypothetical protein
TGGT1_274280 -2.54 -2.83 hypothetical protein
TGGT1_296020 -2.55 -2.84 hypothetical protein
TGGT1_211270 -2.56 -2.84 sushi domain (scr repeat) domain-containing protein
TGGT1_289060 -2.56 -2.89 hypothetical protein
TGGT1_411680 -2.60 -2.90 hypothetical protein
TGGT1_319860 -2.69 -2.90 DNA polymerase family B protein
TGGT1_218192 -2.72 -2.96 hypothetical protein
TGGT1_319308 -2.73 -2.99 hypothetical protein
TGGT1_409630 -2.74 -3.01 toxoplasma gondii family E protein
TGGT1_279460 -2.75 -3.05 Toxoplasma gondii family B protein
TGGT1_222060 -2.75 -3.07 hypothetical protein
TGGT1_227100 -2.77 -3.12 hypothetical protein
TGGT1_295430 -2.78 -3.14 hypothetical protein
TGGT1_293420 -2.80 -3.17 transporter, major facilitator family protein
TGGT1_291910 -2.80 -3.17 hypothetical protein
TGGT1_410480 -2.80 -3.17 hypothetical protein
TGGT1_320000 -2.83 -3.18 SCY kinase (incomplete catalytic triad)
TGGT1_240370 -2.83 -3.24 Toxoplasma gondii family E protein
TGGT1_322210 -2.83 -3.42 putative apocytochrome b
TGGT1_240365 -2.83 -3.42 hypothetical protein
TGGT1_264950 -2.88 -3.48 hypothetical protein
TGGT1_291920 -2.90 -3.50 hypothetical protein
TGGT1_233770B -2.93 -3.54 calcium-translocating P-type ATPase, PMCA-type protein
TGGT1_244408 -3.04 -3.56 hypothetical protein
TGGT1_200595 -3.05 -3.61 hypothetical protein
TGGT1_207880 -3.14 -3.61 hypothetical protein
TGGT1_212810 -3.23 -3.65 hypothetical protein
TGGT1_215540 -3.31 -3.74 hypothetical protein
TGGT1_239475 -3.49 -3.80 hypothetical protein
TGGT1_314340 -3.62 -3.82 Sodium:neurotransmitter symporter family protein
TGGT1_244412 -3.72 -3.91 hypothetical protein
TGGT1_227350 -4.06 -3.98 hypothetical protein
TGGT1_266500 -4.85 -5.04 hypothetical protein
TGGT1_304450 -5.42 -5.97 cation-transporting ATPase
TGGT1_361230 5.12 N.S. toxoplasma gondii family B protein
TGGT1_207150 3.72 N.S. SAG-related sequence SRS49C
TGGT1_277930 3.40 N.S. hypothetical protein
TGGT1_202020 3.24 N.S. DnAK-TPR
TGGT1_301150 3.05 N.S. SAG-related sequence SRS19B
TGGT1_305040 3.05 N.S. HEAT repeat-containing protein
TGGT1_292280 3.04 N.S. SAG-related sequence SRS36D
TGGT1_207865 2.61 N.S. GCC2 and GCC3 domain-containing protein
TGGT1_207140 2.61 N.S. SAG-related sequence SRS49B
TGGT1_356400 2.60 N.S. cAMP-dependent protein kinase
TGGT1_209985 2.40 N.S. cAMP-dependent protein kinase
TGGT1_293254 2.11 N.S. hypothetical protein
TGGT1_244515 2.11 N.S. hypothetical protein




TGGT1_315740 2.06 N.S. SAG-related sequence SRS54
TGGT1_304920 2.03 N.S. hypothetical protein
TGGT1_211370 2.01 N.S. tetratricopeptide repeat-containing protein
TGGT1_213480 1.99 N.S. hypothetical protein
TGGT1_225950 1.96 N.S. hypothetical protein
TGGT1_285860 1.93 N.S. SAG-related sequence SRS20C
TGGT1_239880 1.93 N.S. hypothetical protein
TGGT1_225290 1.89 N.S. GDA1/CD39 (nucleoside phosphatase) family protein
TGGT1_293800 1.89 N.S. putative transmembrane protein 65
TGGT1_283882 1.87 N.S. hypothetical protein
TGGT1_408760 1.87 N.S. toxoplasma gondii family A protein
TGGT1_205420 1.82 N.S. aspartate-semialdehyde dehydrogenase
TGGT1_205410 1.80 N.S. RNA pseudouridine synthase superfamily protein
TGGT1_285790 1.71 N.S. hypothetical protein
TGGT1_230663 1.70 N.S. hypothetical protein
TGGT1_235187A 1.70 N.S. hypothetical protein
TGGT1_207665 1.67 N.S. kinesin motor domain-containing protein
TGGT1_356030 1.66 N.S. hypothetical protein
TGGT1_293256 1.65 N.S. hypothetical protein
TGGT1_253500 1.65 N.S. hypothetical protein
TGGT1_269300 1.64 N.S. lipase
TGGT1_212275 1.64 N.S. hypothetical protein
TGGT1_268300 1.60 N.S. hypothetical protein
TGGT1_310173 1.58 N.S. hypothetical protein
TGGT1_210478 1.57 N.S. hypothetical protein
TGGT1_286782 1.55 N.S. MAM domain-containing protein
TGGT1_230598 1.55 N.S. hypothetical protein
TGGT1_307090 1.54 N.S. hypothetical protein
TGGT1_211030 1.52 N.S. hypothetical protein
TGGT1_207740 1.52 N.S. hypothetical protein
TGGT1_288945 1.51 N.S. hypothetical protein
TGGT1_280580 1.49 N.S. SAG-related sequence SRS35B
TGGT1_241130 1.49 N.S. hypothetical protein
TGGT1_301160 1.49 N.S. SAG-related sequence SRS19C
TGGT1_242360 1.49 N.S. tetratricopeptide repeat-containing protein
TGGT1_359770 1.48 N.S. SAG-related sequence protein SRS22E
TGGT1_315962 1.48 N.S. hypothetical protein
TGGT1_248445 1.48 N.S. hypothetical protein
TGGT1_253020 1.48 N.S. hypothetical protein
TGGT1_309990 1.47 N.S. hypothetical protein
TGGT1_298050 1.46 N.S. hypothetical protein
TGGT1_217920 1.45 N.S. hypothetical protein
TGGT1_241165 1.45 N.S. hypothetical protein
TGGT1_314310 1.45 N.S. hypothetical protein
TGGT1_308090 1.45 N.S. rhoptry protein ROP5
TGGT1_203720 1.42 N.S. vitamin k epoxide reductase family protein
TGGT1_260480 1.42 N.S. leucine rich repeat-containing protein
TGGT1_307045 1.42 N.S. Toxoplasma gondii family B protein
TGGT1_221840 1.40 N.S. hypothetical protein
TGGT1_286040 1.39 N.S. hypothetical protein
TGGT1_282000 1.37 N.S. hypothetical protein
TGGT1_272490 1.37 N.S. protoporphyrinogen oxidase
TGGT1_214350 1.36 N.S. putative GTP-binding protein
TGGT1_222160 1.33 N.S. aldehyde dehydrogenase
TGGT1_228370 1.33 N.S. hypothetical protein
TGGT1_308075 1.33 N.S. hypothetical protein
TGGT1_278090 1.32 N.S. Toxoplasma gondii family A protein
TGGT1_295035 1.31 N.S. hypothetical protein
TGGT1_319560 1.31 N.S. microneme protein MIC3




TGGT1_214760 1.29 N.S. erythronate-4-phosphate dehydrogenase domain-containing protein
TGGT1_230200 1.28 N.S. hypothetical protein
TGGT1_217940 1.28 N.S. hypothetical protein
TGGT1_249290 1.26 N.S. hypothetical protein
TGGT1_320730 1.26 N.S. putative homoserine O-acetyltransferase
TGGT1_233460 1.26 N.S. SAG-related sequence SRS29B
TGGT1_233040 1.25 N.S. 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_217890 1.25 N.S. putative alkyl hydroperoxide reductase/ Thiol specific antioxidant/ Mal allergen
TGGT1_306310 1.25 N.S. RecF/RecN/SMC N terminal domain-containing protein
TGGT1_254855 1.24 N.S. hypothetical protein
TGGT1_285700 1.23 N.S. ubiquitin fusion degradation protein UFD1AP
TGGT1_278390 1.22 N.S. Toxoplasma gondii family A protein
TGGT1_271310 1.22 N.S. hypothetical protein
TGGT1_257000 1.22 N.S. hypothetical protein
TGGT1_409850 1.21 N.S. SAG-related sequence protein SRS47A
TGGT1_257330 1.21 N.S. hypothetical protein
TGGT1_310940 1.20 N.S. hypothetical protein
TGGT1_230602 1.20 N.S. hypothetical protein
TGGT1_217800 1.20 N.S. hypothetical protein
TGGT1_224760 1.19 N.S. SAG-related sequence SRS40E
TGGT1_264660 1.18 N.S. SAG-related sequence SRS44
TGGT1_278882 1.18 N.S. GDA1/CD39 (nucleoside phosphatase) family protein
TGGT1_230970 1.17 N.S. hypothetical protein
TGGT1_244940 1.16 N.S. hypothetical protein
TGGT1_322400 1.15 N.S. hypothetical protein
TGGT1_240290 1.15 N.S. hypothetical protein
TGGT1_270840 1.15 N.S. poly(ADP-ribose) polymerase catalytic domain-containing protein
TGGT1_293680 1.14 N.S. hypothetical protein
TGGT1_215195 1.13 N.S. tetratricopeptide repeat-containing protein
TGGT1_214080 1.13 N.S. toxofilin
TGGT1_252070 1.13 N.S. KRUF family protein
TGGT1_202550 1.13 N.S. NLI interacting factor family phosphatase
TGGT1_238110 1.13 N.S. replication factor a protein 3 protein
TGGT1_360000 1.12 N.S. hypothetical protein
TGGT1_203090 1.12 N.S. hypothetical protein
TGGT1_227280 1.12 N.S. dense granule protein GRA3
TGGT1_286150 1.12 N.S. PAN/Apple domain-containing protein
TGGT1_307570 1.11 N.S. putative glycerol-3-phosphate dehydrogenase (gpdh)
TGGT1_217930 1.11 N.S. hypothetical protein
TGGT1_320030 1.11 N.S. hypothetical protein
TGGT1_307780 1.11 N.S. hypothetical protein
TGGT1_408250 1.11 N.S. hypothetical protein
TGGT1_215900 1.10 N.S. hypothetical protein
TGGT1_222410 1.10 N.S. hypothetical protein
TGGT1_289900 1.10 N.S. n-acetyltransferase family protein
TGGT1_213780 1.09 N.S. radical SAM domain-containing protein
TGGT1_293810 1.09 N.S. carboxyvinyl-carboxyphosphonate phosphorylmutase
TGGT1_315520 1.09 N.S. calcium binding egf domain-containing protein
TGGT1_312380 1.09 N.S. tetratricopeptide repeat-containing protein
TGGT1_315110 1.09 N.S. prefoldin, alpha subunit protein
TGGT1_230205 1.09 N.S. hypothetical protein
TGGT1_311740 1.08 N.S. hypothetical protein
TGGT1_286720 1.08 N.S. heat shock protein HSP28
TGGT1_306570 1.08 N.S. hypothetical protein
TGGT1_269170 1.08 N.S. hypothetical protein
TGGT1_290300 1.07 N.S. hypothetical protein
TGGT1_209180 1.07 N.S. PAN domain-containing protein
TGGT1_212930 1.07 N.S. NifU family domain-containing protein
TGGT1_357130 1.07 N.S. WD domain, G-beta repeat protein




TGGT1_300030 1.06 N.S. hypothetical protein
TGGT1_227430 1.05 N.S. transmembrane amino acid transporter protein
TGGT1_211330 1.05 N.S. methionine aminopeptidase
TGGT1_227030 1.05 N.S. hypothetical protein
TGGT1_219140 1.05 N.S. EF-1 guanine nucleotide exchange domain-containing protein
TGGT1_275310 1.05 N.S. hypothetical protein
TGGT1_253300 1.04 N.S. hypothetical protein
TGGT1_310270 1.04 N.S. hypothetical protein
TGGT1_301420 1.03 N.S. hypothetical protein
TGGT1_254820 1.03 N.S. hypothetical protein
TGGT1_266300 1.03 N.S. hypothetical protein
TGGT1_224810 1.03 N.S. hypothetical protein
TGGT1_219170 1.03 N.S. hypothetical protein
TGGT1_315330 1.03 N.S. SAG-related sequence SRS52D
TGGT1_286750 1.03 N.S. MA3 domain-containing protein
TGGT1_313380 1.03 N.S. hypothetical protein
TGGT1_240840 1.03 N.S. histone lysine demethylase JmjC NO66
TGGT1_362290 1.02 N.S. hypothetical protein
TGGT1_321170 1.02 N.S. Toxoplasma gondii family C protein
TGGT1_219175 1.02 N.S. hypothetical protein
TGGT1_224210 1.02 N.S. hypothetical protein
TGGT1_211390 1.01 N.S. hypothetical protein
TGGT1_239795 1.01 N.S. hypothetical protein
TGGT1_203120 1.01 N.S. hypothetical protein
TGGT1_235370 1.01 N.S. hypothetical protein
TGGT1_271080 1.01 N.S. hypothetical protein
TGGT1_230070 1.00 N.S. BolA family protein
TGGT1_293510 1.00 N.S. DP-ribose) polymerase and DNA-Ligase Zn-finger region domain-containing 
TGGT1_247260 1.00 N.S. hypothetical protein
TGGT1_215160 -1.00 N.S. hypothetical protein
TGGT1_214910 -1.00 N.S. hypothetical protein
TGGT1_203780 -1.00 N.S. hypothetical protein
TGGT1_408850 -1.01 N.S. hypothetical protein
TGGT1_310055 -1.01 N.S. hypothetical protein
TGGT1_266290 -1.01 N.S. hypothetical protein
TGGT1_255510 -1.01 N.S. ankyrin repeat-containing protein
TGGT1_211470 -1.02 N.S. Fcf2 pre-rRNA processing protein
TGGT1_286470 -1.02 N.S. AGC kinase
TGGT1_287990 -1.02 N.S. hypothetical protein
TGGT1_268380 -1.03 N.S. RNA recognition motif-containing protein
TGGT1_305080 -1.03 N.S. hypothetical protein
TGGT1_264940 -1.03 N.S. kelch repeat-containing protein
TGGT1_223020 -1.04 N.S. coproporphyrinogen III oxidase
TGGT1_239365 -1.04 N.S. hypothetical protein
TGGT1_318130A -1.04 N.S. Toxoplasma gondii family E protein
TGGT1_269620 -1.05 N.S. hypothetical protein
TGGT1_235390 -1.06 N.S. PAN domain-containing protein
TGGT1_313900 -1.06 N.S. non-specific serine/threonine protein kinase
TGGT1_205160 -1.07 N.S. hypothetical protein
TGGT1_309060 -1.07 N.S. ubiquitin carboxyl-terminal hydrolase
TGGT1_245560 -1.08 N.S. hypothetical protein
TGGT1_261260A -1.08 N.S. histone lysine demethylase JMJD6a
TGGT1_321340 -1.08 N.S. putative membrane protein
TGGT1_264720 -1.08 N.S. hypothetical protein
TGGT1_209510 -1.09 N.S. hypothetical protein
TGGT1_306700 -1.09 N.S. hypothetical protein
TGGT1_258910 -1.12 N.S. hypothetical protein
TGGT1_268220 -1.13 N.S. hypothetical protein
TGGT1_214420 -1.13 N.S. hypothetical protein




TGGT1_329800 -1.14 N.S. hypothetical protein
TGGT1_237100 -1.15 N.S. RAP domain-containing protein
TGGT1_267560 -1.15 N.S. folate-binding protein YgfZ protein
TGGT1_266065 -1.16 N.S. hypothetical protein
TGGT1_287980 -1.17 N.S. FHA domain-containing protein
TGGT1_277055 -1.17 N.S. hypothetical protein
TGGT1_294400 -1.17 N.S. hypothetical protein
TGGT1_264740 -1.17 N.S. hypothetical protein
TGGT1_267720 -1.19 N.S. transporter, cation channel family protein
TGGT1_267725 -1.20 N.S. hypothetical protein
TGGT1_224840 -1.21 N.S. 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_264890 -1.22 N.S. hypothetical protein
TGGT1_268360 -1.22 N.S. hypothetical protein
TGGT1_262620 -1.23 N.S. RNA recognition motif-containing protein
TGGT1_408750 -1.25 N.S. hypothetical protein
TGGT1_268340 -1.25 N.S. glycosyltransferase family 28 C-terminal domain-containing protein
TGGT1_264860 -1.25 N.S. zinc finger, C3HC4 type (RING finger) domain-containing protein
TGGT1_214430 -1.25 N.S. hypothetical protein
TGGT1_228500 -1.28 N.S. 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_279310 -1.30 N.S. hypothetical protein
TGGT1_242625 -1.30 N.S. TPase family associated with various cellular activities (AAA) subfamily protei
TGGT1_213880 -1.32 N.S. hypothetical protein
TGGT1_205140 -1.32 N.S. hypothetical protein
TGGT1_366510 -1.33 N.S. hypothetical protein
TGGT1_261240 -1.33 N.S. histone H3
TGGT1_316690 -1.35 N.S. hypothetical protein
TGGT1_279315 -1.35 N.S. hypothetical protein
TGGT1_280680 -1.35 N.S. hypothetical protein
TGGT1_268350 -1.38 N.S. hypothetical protein
TGGT1_270970 -1.40 N.S. hypothetical protein
TGGT1_239430 -1.42 N.S. EF hand domain-containing protein
TGGT1_410820 -1.43 N.S. tRNA-Ser
TGGT1_410870 -1.49 N.S. tRNA-Pro
TGGT1_204290 -1.58 N.S. hypothetical protein
TGGT1_237894 -1.63 N.S. OTU family cysteine protease
TGGT1_366530 -1.65 N.S. KRUF family protein
TGGT1_361030 -1.74 N.S. hypothetical protein
TGGT1_226880 -1.77 N.S. hypothetical protein
TGGT1_264620 -1.81 N.S. hypothetical protein
TGGT1_236670A -1.83 N.S. hypothetical protein
TGGT1_408600 -2.23 N.S. hypothetical protein
TGGT1_364790 N.S. 2.27 putative transmembrane protein
TGGT1_258520 N.S. 1.89 WD domain, G-beta repeat-containing protein
TGGT1_408770 N.S. 1.83 putative transmembrane protein
TGGT1_409300 N.S. 1.60 tRNA-Gly
TGGT1_203375 N.S. 1.55 cpw-wpc domain-containing protein
TGGT1_320500 N.S. 1.55 patched family protein
TGGT1_208730 N.S. 1.43 putative microneme protein
TGGT1_261530 N.S. 1.40 eukaryotic aspartyl protease superfamily protein
TGGT1_225110 N.S. 1.40 AP2 domain transcription factor AP2X-2
TGGT1_305530 N.S. 1.35 hypothetical protein
TGGT1_315130 N.S. 1.34 L-isoaspartyl protein carboxyl methyltransferase family protein
TGGT1_200340 N.S. 1.33 hypothetical protein
TGGT1_216830 N.S. 1.32 DTW domain-containing protein
TGGT1_217720 N.S. 1.28 hypothetical protein
TGGT1_309930 N.S. 1.25 melibiase subfamily protein
TGGT1_409780 N.S. 1.24 tRNA-Ile
TGGT1_310020 N.S. 1.24 hypothetical protein
TGGT1_270320 N.S. 1.24 protein phosphatase 2C domain-containing protein




TGGT1_289590 N.S. 1.23 hypothetical protein
TGGT1_294990 N.S. 1.20 hypothetical protein
TGGT1_314680 N.S. 1.19 hypothetical protein
TGGT1_297647 N.S. 1.17 hypothetical protein
TGGT1_256100 N.S. 1.15 tetratricopeptide repeat-containing protein
TGGT1_233490 N.S. 1.15 hypothetical protein
TGGT1_411080 N.S. 1.15 hypothetical protein
TGGT1_217000 N.S. 1.14 hypothetical protein
TGGT1_316660 N.S. 1.14 cullin family protein
TGGT1_316340 N.S. 1.14 hypothetical protein
TGGT1_248130 N.S. 1.13 hypothetical protein
TGGT1_237270 N.S. 1.12 hypothetical protein
TGGT1_271790 N.S. 1.11 hypothetical protein
TGGT1_219460 N.S. 1.11 hypothetical protein
TGGT1_297410 N.S. 1.11 hypothetical protein
TGGT1_305450 N.S. 1.10 acetyltransferase, GNAT family protein
TGGT1_253100 N.S. 1.10 hypothetical protein
TGGT1_257470 N.S. 1.09 myosin J
TGGT1_310290 N.S. 1.09 regulator of chromosome condensation (RCC1) repeat-containing protein
TGGT1_219240 N.S. 1.08 Peptidyl-tRNA hydrolase PTH2 domain-containing protein
TGGT1_304730 N.S. 1.08 Mob1/phocein family protein
TGGT1_261970 N.S. 1.08 hypothetical protein
TGGT1_307030 N.S. 1.08 Purine nucleoside phosphorylase
TGGT1_314900 N.S. 1.08 LisH protein
TGGT1_230340 N.S. 1.07 hypothetical protein
TGGT1_257300 N.S. 1.07 hypothetical protein
TGGT1_200350 N.S. 1.06 subtilisin SUB3
TGGT1_215910 N.S. 1.06 hypothetical protein
TGGT1_253570 N.S. 1.06 hypothetical protein
TGGT1_306720 N.S. 1.05 hypothetical protein
TGGT1_258050 N.S. 1.05 actin like protein ALP2a
TGGT1_250000 N.S. 1.05 hypothetical protein
TGGT1_251470 N.S. 1.05 hypothetical protein
TGGT1_306300 N.S. 1.05 hypothetical protein
TGGT1_311760 N.S. 1.05 hypothetical protein
TGGT1_222240 N.S. 1.05 hypothetical protein
TGGT1_216090 N.S. 1.03 hypothetical protein
TGGT1_258105 N.S. 1.02 hypothetical protein
TGGT1_289620 N.S. 1.01 cathepsin CPC1
TGGT1_254700 N.S. 1.01 hypothetical protein
TGGT1_218510 N.S. 1.01 hypothetical protein
TGGT1_309960B N.S. 1.00 hypothetical protein
TGGT1_247220 N.S. 1.00 nudix -type motif 9 isoform a family protein
TGGT1_311110 N.S. 1.00 putative Ubiquitin-fold modifier 1 precursor family protein
TGGT1_294340 N.S. 1.00 hypothetical protein
TGGT1_217050 N.S. 1.00 ADA2-A transcriptional co-activator SAGA component
TGGT1_225680 N.S. 1.00 hypothetical protein
TGGT1_215650 N.S. 1.00 hypothetical protein
TGGT1_206440 N.S. -1.00 cpw-wpc domain-containing protein
TGGT1_234970 N.S. -1.01 Tyrosine kinase-like (TKL) protein
TGGT1_225270 N.S. -1.01 hypothetical protein
TGGT1_226220 N.S. -1.01 alveolin domain containing intermediate filament IMC9
TGGT1_225410 N.S. -1.01 histone H3 centromeric CENH3
TGGT1_240450 N.S. -1.02 Maf family protein
TGGT1_239340 N.S. -1.02 hypothetical protein
TGGT1_218840 N.S. -1.02 mutS domain protein
TGGT1_237160 N.S. -1.03 hypothetical protein
TGGT1_258480 N.S. -1.03 hypothetical protein
TGGT1_221280 N.S. -1.03 hypothetical protein




TGGT1_292170 N.S. -1.04 putative histone lysine methyltransferase, SET
TGGT1_239320 N.S. -1.04 BolA family protein
TGGT1_281560 N.S. -1.04 hypothetical protein
TGGT1_320110 N.S. -1.04 proliferating cell nuclear antigen PCNA2
TGGT1_217620 N.S. -1.04 hypothetical protein
TGGT1_255890 N.S. -1.05 pyridine nucleotide-disulfide oxidoreductase domain-containing protein
TGGT1_233920 N.S. -1.05 zinc finger, C3HC4 type (RING finger) domain-containing protein
TGGT1_202290 N.S. -1.05 putative membrane protein
TGGT1_321660 N.S. -1.05 putative mannosyltransferase
TGGT1_211220 N.S. -1.05 hypothetical protein
TGGT1_280540 N.S. -1.05 HEAT repeat-containing protein
TGGT1_310350 N.S. -1.05 PGAP1 family protein
TGGT1_257595 N.S. -1.05 hypothetical protein
TGGT1_306080 N.S. -1.06 ATP-dependent DNA helicase, RecQ family protein
TGGT1_209930 N.S. -1.06 hypothetical protein
TGGT1_251550 N.S. -1.06 acyl-coa-binding protein
TGGT1_240950 N.S. -1.07 hypothetical protein
TGGT1_264770 N.S. -1.07 hypothetical protein
TGGT1_279390 N.S. -1.07 putative proliferation-associated protein 2G4
TGGT1_286140 N.S. -1.07 hypothetical protein
TGGT1_309265 N.S. -1.07 oxidoreductase, short chain dehydrogenase/reductase family protein
TGGT1_253370 N.S. -1.07 hypothetical protein
TGGT1_284645 N.S. -1.07 hypothetical protein
TGGT1_236950 N.S. -1.08 hypothetical protein
TGGT1_301480 N.S. -1.08 hypothetical protein
TGGT1_227650 N.S. -1.08 putative microtubule-associated protein RP/EB family
TGGT1_279430 N.S. -1.09 cwf18 pre-mRNA splicing factor protein
TGGT1_293380 N.S. -1.09 histone lysine acetyltransferase HAT1
TGGT1_226985 N.S. -1.09 hypothetical protein
TGGT1_207100 N.S. -1.10 hypothetical protein
TGGT1_279440 N.S. -1.10 PA14 domain-containing protein
TGGT1_307850 N.S. -1.10 6-phosphogluconate dehydrogenase
TGGT1_223000 N.S. -1.11 dynein light chain DLC
TGGT1_289710 N.S. -1.11 AP2 domain transcription factor AP2IX-5
TGGT1_312520 N.S. -1.11 tRNA dimethylallyltransferase
TGGT1_289720 N.S. -1.11 hypothetical protein
TGGT1_258710 N.S. -1.11 T-complex protein 10 domain-containing protein
TGGT1_249840 N.S. -1.11 putative dynein heavy chain 2
TGGT1_320750 N.S. -1.11 hypothetical protein
TGGT1_238040B N.S. -1.12 protein disulfide-isomerase domain-containing protein
TGGT1_225090 N.S. -1.12 hypothetical protein
TGGT1_270910 N.S. -1.13 acyltransferase domain-containing protein
TGGT1_365080 N.S. -1.13 rhoptry protein ROP7
TGGT1_247370 N.S. -1.13 hypothetical protein
TGGT1_228180 N.S. -1.13 putative cytochrome C oxidase assembly factor COX15
TGGT1_267390 N.S. -1.13 DNA-directed RNA polymerase I RPAC1
TGGT1_258380 N.S. -1.14 elongation factor p (ef-p) kow family domain-containing protein
TGGT1_243940 N.S. -1.14 hypothetical protein
TGGT1_250360 N.S. -1.14 alpha/beta hydrolase fold domain-containing protein
TGGT1_240580 N.S. -1.15 hypothetical protein
TGGT1_273330 N.S. -1.15 hypothetical protein
TGGT1_206650 N.S. -1.15 zinc finger, c2h2 type domain-containing protein
TGGT1_273530 N.S. -1.15 flagellar associated protein
TGGT1_288700 N.S. -1.16 RecF/RecN/SMC N terminal domain-containing protein
TGGT1_203830 N.S. -1.16 FHA domain-containing protein
TGGT1_274170 N.S. -1.16 protein kinase (incomplete catalytic triad)
TGGT1_237425 N.S. -1.16 AP2 domain transcription factor AP2X-6
TGGT1_312230 N.S. -1.17 putative DNA topoisomerase 2
TGGT1_224910 N.S. -1.18 divalent cation tolerance protein, CutA1 family protein




TGGT1_222030 N.S. -1.18 hypothetical protein
TGGT1_215010 N.S. -1.18 hypothetical protein
TGGT1_202040 N.S. -1.18 hypothetical protein
TGGT1_206700 N.S. -1.18 hypothetical protein
TGGT1_310130 N.S. -1.19 Spc97 / Spc98 family protein
TGGT1_359590 N.S. -1.19 hypothetical protein
TGGT1_294640 N.S. -1.19 ribonucleoside-diphosphate reductase large chain
TGGT1_264080 N.S. -1.19 acyl carrier protein ACP
TGGT1_203340 N.S. -1.20 metallo-beta-lactamase domain-containing protein
TGGT1_311625 N.S. -1.20 WD domain, G-beta repeat-containing protein
TGGT1_276220 N.S. -1.20 hypothetical protein
TGGT1_232550 N.S. -1.21 hypothetical protein
TGGT1_281930 N.S. -1.21 SAG-related sequence SRS39
TGGT1_280810 N.S. -1.22 hypothetical protein
TGGT1_232450 N.S. -1.22 SWI2/SNF2-containing protein RAD54
TGGT1_273540 N.S. -1.22 putative phosphatidylserine synthase
TGGT1_203700 N.S. -1.23 SFT2 family protein
TGGT1_227640 N.S. -1.23 hypothetical protein
TGGT1_254110 N.S. -1.23 tryptophanyl-tRNA synthetase (TrpRS1)
TGGT1_268990 N.S. -1.23 hypothetical protein
TGGT1_267430 N.S. -1.23 DnaJ domain-containing protein
TGGT1_246200 N.S. -1.23 zinc finger (CCCH type) motif-containing protein
TGGT1_220560 N.S. -1.24 hypothetical protein
TGGT1_247680 N.S. -1.24 hypothetical protein
TGGT1_246190 N.S. -1.25 hypothetical protein
TGGT1_222270 N.S. -1.26 hypothetical protein
TGGT1_300270 N.S. -1.26 hypothetical protein
TGGT1_205640 N.S. -1.26 hypothetical protein
TGGT1_254580 N.S. -1.26 UDP-galactose transporter family protein
TGGT1_210280 N.S. -1.27 PEK kinase
TGGT1_216200 N.S. -1.27 hypothetical protein
TGGT1_218362 N.S. -1.27 zinc finger protein ZFP1
TGGT1_266150 N.S. -1.27 hypothetical protein
TGGT1_267460 N.S. -1.27 AP2 domain transcription factor AP2IX-1
TGGT1_319590 N.S. -1.29 hypothetical protein
TGGT1_202510 N.S. -1.29 multi-pass transmembrane protein
TGGT1_218530 N.S. -1.29 proteasome-interacting thioredoxin domain-containing protein
TGGT1_253780 N.S. -1.29 putative GTP cyclohydrolase I
TGGT1_202120 N.S. -1.31 hypothetical protein
TGGT1_279420 N.S. -1.31 hypothetical protein
TGGT1_267400 N.S. -1.32 ribosomal protein RPL32
TGGT1_229370 N.S. -1.32 AP2 domain transcription factor AP2VIII-1
TGGT1_203170 N.S. -1.33 OB-fold nucleic acid binding domain-containing protein
TGGT1_262470 N.S. -1.34 putative C protein immunoglobulin-A-binding beta antigen
TGGT1_202065 N.S. -1.35 hypothetical protein
TGGT1_231360 N.S. -1.35 hypothetical protein
TGGT1_208560 N.S. -1.37 carrier superfamily protein
TGGT1_212940 N.S. -1.37 hypothetical protein
TGGT1_268010 N.S. -1.38 hypothetical protein
TGGT1_257770 N.S. -1.38 histone lysine methyltransferase SET2
TGGT1_311485 N.S. -1.39 hypothetical protein
TGGT1_257540 N.S. -1.39 hypothetical protein
TGGT1_289070 N.S. -1.41 E1-E2 ATPase subfamily protein
TGGT1_217900 N.S. -1.42 hypothetical protein
TGGT1_209060 N.S. -1.43 thrombospondin type 1 domain-containing protein
TGGT1_249160 N.S. -1.44 UAA transporter family protein
TGGT1_240380 N.S. -1.44 hypothetical protein
TGGT1_301460 N.S. -1.45 hypothetical protein
TGGT1_247580 N.S. -1.45 glutaredoxin domain-containing protein




TGGT1_251410 N.S. -1.46 tetratricopeptide repeat-containing protein
TGGT1_294651 N.S. -1.46 hypothetical protein
TGGT1_253870 N.S. -1.47 hypothetical protein
TGGT1_266270 N.S. -1.47 short-chain-acyl-CoA dehydrogenase
TGGT1_267070 N.S. -1.47 aquaporin 2
TGGT1_249020 N.S. -1.47 kinesin motor domain-containing protein
TGGT1_271200 N.S. -1.47 AP2 domain transcription factor AP2VIII-5
TGGT1_289890 N.S. -1.48 hypothetical protein
TGGT1_260490 N.S. -1.48 hypothetical protein
TGGT1_205265 N.S. -1.48 transporter, cation channel family protein
TGGT1_320620 N.S. -1.49 queuine tRNA ribosyl transferase
TGGT1_231890 N.S. -1.49 putative beta-ketoacyl-acyl carrier protein synthase III
TGGT1_278740 N.S. -1.49 diaminopimelate decarboxylase
TGGT1_275370 N.S. -1.49 SAG-related sequence SRS47C
TGGT1_232500 N.S. -1.50 hypothetical protein
TGGT1_311490 N.S. -1.52 hypothetical protein
TGGT1_237140 N.S. -1.55 putative ethylene inducible protein
TGGT1_288730 N.S. -1.57 hypothetical protein
TGGT1_272383 N.S. -1.57 hypothetical protein
TGGT1_262660 N.S. -1.60 hypothetical protein
TGGT1_295662 N.S. -1.60 hypothetical protein
TGGT1_223258 N.S. -1.61 hypothetical protein
TGGT1_294650 N.S. -1.65 hypothetical protein
TGGT1_272285 N.S. -1.66 tetratricopeptide repeat-containing protein
TGGT1_237880 N.S. -1.68 hypothetical protein
TGGT1_260270 N.S. -1.68 HEAT repeat-containing protein
TGGT1_233960 N.S. -1.71 hypothetical protein
TGGT1_219100 N.S. -1.72 cyclin-dependent kinase regulatory subunit protein
TGGT1_269015 N.S. -1.72 hypothetical protein
TGGT1_286050 N.S. -1.73 hypothetical protein
TGGT1_225370 N.S. -1.73 hypothetical protein
TGGT1_231815 N.S. -1.74 hypothetical protein
TGGT1_264650 N.S. -1.74 phosphoacetylglucosamine mutase
TGGT1_216700 N.S. -1.75 hypothetical protein
TGGT1_269020 N.S. -1.78 hypothetical protein
TGGT1_204505 N.S. -1.80 hypothetical protein
TGGT1_410660 N.S. -1.80 hypothetical protein
TGGT1_249660 N.S. -1.81 hypothetical protein
TGGT1_315560 N.S. -1.82 ATP-binding cassette G family transporter ABCG77
TGGT1_260410 N.S. -1.83 hypothetical protein
TGGT1_284010 N.S. -1.84 5'-3' exonuclease, N-terminal resolvase family domain-containing protein
TGGT1_238060 N.S. -1.92 EF hand domain-containing protein
TGGT1_273130 N.S. -1.96 SAG-related sequence SRS30A
TGGT1_266335 N.S. -2.09 Toxoplasma gondii family A protein
TGGT1_217855 N.S. -2.09 hypothetical protein
TGGT1_411350 N.S. -2.13 rhoptry kinase family (incomplete catalytic triad) protein
TGGT1_231170 N.S. -2.17 RecF/RecN/SMC N terminal domain-containing protein
TGGT1_206415 N.S. -2.19 myosin K
TGGT1_236595 N.S. -2.20 ankyrin repeat-containing protein
TGGT1_308093 N.S. -2.32 rhoptry kinase family protein (incomplete catalytic triad)
TGGT1_358120 N.S. -2.50 hypothetical protein
TGGT1_218340 N.S. -2.51 hypothetical protein
TGGT1_258085 N.S. -2.61 hypothetical protein
TGGT1_266330 N.S. -2.61 Toxoplasma gondii family A protein
TGGT1_312690 N.S. -2.71 hypothetical protein
TGGT1_367020 N.S. -2.90 hypothetical protein
TGGT1_207650 N.S. -3.08 OTU family cysteine protease
TGGT1_237070 N.S. -3.26 hypothetical protein
TGGT1_275660 N.S. -3.27 hypothetical protein








TGGT1_254060 N.S. -3.31 SAG-related sequence SRS14A
TGGT1_243302 N.S. -3.49 hypothetical protein
TGGT1_266340 N.S. -3.92 Toxoplasma gondii family A protein
TGGT1_240360 N.S. -5.66 Toxoplasma gondii family E protein
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Table 4.3. Differential expression analysis identified few intracellular differentially 
expressed gene during GT1’s lab-adaptation 
Following RNA-seq of 30-hour intracellular parasites, DEA identified 12 
significantly DEGs amongst the lab-adapting B2 GT1 population, relative to the starting 
B2-P11 clonal population. DEGs were considered significant if the absolute FC ≥2 and q-











Table 4.3. Differential expression analysis identified few intracellular differentially 







RH P11 P85 P148
TGGT1_411800 2.74 0.00 0.88 2.55 hypothetical protein
TGGT1_262590 2.40 0.00 2.75 2.82 hypothetical protein
TGGT1_264240 2.39 0.00 0.29 2.43 hypothetical protein
TGGT1_264260 2.34 0.00 0.31 2.35 hypothetical protein
TGGT1_216290B 1.87 0.00 2.18 0.42 hypothetical protein
TGGT1_409050 1.77 0.00 0.14 2.27 hypothetical protein
TGGT1_262600 1.61 0.00 1.56 1.62 hypothetical protein
TGGT1_213620 0.39 0.00 1.60 1.55 ABC1 family protein
TGGT1_213635 0.23 0.00 3.09 3.34 hypothetical protein
TGGT1_280400 0.14 0.00 1.01 1.50 hypothetical protein
TGGT1_254840 -1.74 0.00 1.95 1.90 tetratricopeptide repeat-containing protein
TGGT1_280500 -4.99 0.00 1.71 1.04 inorganic anion transporter, sulfate permease (SulP) family protein
Gene ID




Table 4.4. Differential expression analysis followed by time-course sequencing 
analysis identified many extracellular differentially expressed genes that trend 
during GT1’s lab-adaptation 
Following RNA-seq and DEA of 6-hour extracellular GT1 parasites, TC-seq 
identified 988 significant DEGs that generally trend up (yellow) or down (blue) over time 
(i.e. passages). DEGs were considered significant if the absolute FC ≥2 and q-value ≤0.05 
(red text) in at least one time point (i.e. passage). All DEGs shown here fit one of the 







Table 4.4. Differential expression analysis followed by time-course sequencing 
analysis identified many extracellular differentially expressed genes that trend 




RH P11 P35 P55 P85 P148 P210
TGGT1_411800 5.49 0.00 1.90 1.89 1.22 3.95 5.06 hypothetical protein
TGGT1_409050 4.35 0.00 1.87 1.82 1.05 3.68 4.74 hypothetical protein
TGGT1_264260 4.80 0.00 1.21 1.19 1.01 3.54 4.07 hypothetical protein
TGGT1_249800 4.70 0.00 -0.30 0.17 0.60 3.17 3.98 hypothetical protein
TGGT1_213635 2.38 0.00 1.94 2.67 3.41 3.71 3.73 hypothetical protein
TGGT1_361230 5.12 0.00 1.22 1.48 2.96 4.20 3.49 toxoplasma gondii family B protein
TGGT1_262590 2.90 0.00 2.06 2.98 2.66 2.58 3.45 hypothetical protein
TGGT1_264240 4.35 0.00 -0.04 0.36 1.04 3.44 3.22 hypothetical protein
TGGT1_280400 0.81 0.00 3.08 3.23 2.03 2.91 3.11 hypothetical protein
TGGT1_253330 0.10 0.00 0.91 0.62 1.84 3.04 2.73 Rhoptry kinase family protein
TGGT1_216290B 4.40 0.00 1.04 1.98 3.06 1.15 2.63 hypothetical protein
TGGT1_249810 3.35 0.00 0.14 0.24 0.10 1.68 2.60 putative activating signal cointegrator 1 complex subunit 3
TGGT1_301180 5.65 0.00 1.05 1.76 2.39 4.41 2.51 SAG-related sequence SRS19F
TGGT1_301890 -1.38 0.00 0.95 1.17 1.87 2.85 2.49 Toxoplasma gondii family B protein
TGGT1_262600 2.68 0.00 1.36 2.10 2.10 2.18 2.48 hypothetical protein
TGGT1_306688 3.18 0.00 1.01 1.32 0.87 1.63 2.47 hypothetical protein
TGGT1_266760 0.94 0.00 0.67 1.50 2.53 2.46 2.31 isocitrate dehydrogenase
TGGT1_216290A 4.17 0.00 1.22 1.80 2.69 0.99 2.30 hypothetical protein
TGGT1_276810 3.13 0.00 1.58 1.70 2.55 2.70 2.29 hypothetical protein
TGGT1_309930 0.98 0.00 1.18 1.01 1.79 2.37 2.21 melibiase subfamily protein
TGGT1_216680 5.19 0.00 0.29 0.76 1.22 1.64 2.17 ankyrin repeat-containing protein
TGGT1_358470 3.99 0.00 1.81 0.71 0.88 1.14 2.06 hypothetical protein
TGGT1_306692 0.20 0.00 1.14 0.92 1.33 1.71 2.02 hypothetical protein
TGGT1_304670 2.30 0.00 1.64 1.74 1.16 1.37 2.01 leucine rich repeat-containing protein
TGGT1_301210 3.35 0.00 0.34 0.87 0.93 2.93 2.01 putative NAD(P) transhydrogenase subunit beta
TGGT1_222020 0.92 0.00 -0.28 0.60 3.19 2.46 1.99 phosphoglycerate kinase PGKII
TGGT1_323310 3.48 0.00 0.36 0.79 0.56 1.51 1.97 hypothetical protein
TGGT1_216335 2.82 0.00 0.78 1.44 1.85 0.58 1.95 hypothetical protein
TGGT1_207140 2.61 0.00 0.07 0.46 3.46 2.88 1.95 SAG-related sequence SRS49B
TGGT1_240820 0.97 0.00 1.35 1.62 1.61 1.65 1.95 hypothetical protein
TGGT1_315885 -0.09 0.00 0.79 1.23 1.04 1.49 1.94 putative glycosyltransferase
TGGT1_410970 2.94 0.00 1.32 0.80 0.17 1.34 1.93 hypothetical protein
TGGT1_411240 -0.78 0.00 0.65 1.00 1.25 1.98 1.92 toxoplasma gondii family B protein
TGGT1_236670B -2.18 0.00 1.04 1.25 -0.35 0.14 1.91 hypothetical protein
TGGT1_286420A 0.44 0.00 1.09 1.41 1.06 1.33 1.89 putative elongation factor 1-alpha (EF-1-ALPHA)
TGGT1_313640 0.89 0.00 0.42 0.92 1.61 1.87 1.87 hypothetical protein
TGGT1_277685 1.74 0.00 1.43 1.60 1.36 1.79 1.82 hypothetical protein
TGGT1_231992 2.21 0.00 1.32 1.35 1.02 1.00 1.80 hypothetical protein
TGGT1_289170 0.82 0.00 1.10 1.38 1.04 1.31 1.80 adenylate and guanylate cyclase catalytic domain-containing protein
TGGT1_203990 1.44 0.00 1.45 1.55 1.00 0.92 1.77 rhoptry protein ROP12
TGGT1_220060B 1.66 0.00 0.75 0.89 0.33 0.99 1.77 hypothetical protein
TGGT1_243520 0.33 0.00 0.82 1.34 1.35 1.18 1.76 hypothetical protein
TGGT1_230705 0.31 0.00 1.11 1.42 0.87 1.45 1.75 hypothetical protein
TGGT1_263520 0.68 0.00 1.72 1.72 0.56 0.51 1.74 microtubule associated protein SPM1
TGGT1_285700 1.23 0.00 0.87 1.24 2.08 2.02 1.73 ubiquitin fusion degradation protein UFD1AP
TGGT1_316700 0.04 0.00 0.80 0.80 1.19 2.00 1.72 uridine kinase
TGGT1_306860 -1.68 0.00 0.75 0.39 -0.03 0.74 1.71 hypothetical protein
TGGT1_410930 3.26 0.00 0.47 0.28 0.66 1.92 1.70 hypothetical protein
TGGT1_285865 1.14 0.00 1.04 1.36 1.46 1.86 1.70 hypothetical protein
TGGT1_220420 1.64 0.00 1.03 1.09 0.99 1.74 1.68 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_260480 1.42 0.00 1.01 1.09 1.96 2.49 1.68 leucine rich repeat-containing protein
TGGT1_254840 -1.87 0.00 0.38 0.95 1.67 1.48 1.68 tetratricopeptide repeat-containing protein
TGGT1_206320 0.60 0.00 0.90 1.23 1.47 1.39 1.67 hypothetical protein
TGGT1_224130 1.72 0.00 1.15 1.20 1.40 1.88 1.67 hypothetical protein
TGGT1_262655 -1.49 0.00 1.28 1.43 0.47 0.52 1.67 hypothetical protein
TGGT1_287270 0.52 0.00 0.63 0.52 1.55 1.60 1.66 hypothetical protein
TGGT1_270840 1.15 0.00 1.13 1.34 1.80 2.42 1.66 poly(ADP-ribose) polymerase catalytic domain-containing protein
TGGT1_305980 0.19 0.00 0.31 0.90 1.88 1.47 1.65 pyruvate dehydrogenase complex subunit PDH-E3I
TGGT1_202970 -0.70 0.00 0.35 0.92 0.40 0.50 1.65 hypothetical protein
TGGT1_363250 -0.10 0.00 0.68 0.91 0.69 0.98 1.65 hypothetical protein
TGGT1_226330 -0.30 0.00 1.03 1.39 0.80 1.04 1.64 hypothetical protein
TGGT1_255330 0.78 0.00 0.66 1.37 1.33 1.72 1.64 hypothetical protein
TGGT1_258410 0.64 0.00 1.56 1.64 0.66 0.82 1.63 photosensitized INA-labeled protein PHIL1
TGGT1_207665 1.67 0.00 0.08 0.82 1.33 1.65 1.63 kinesin motor domain-containing protein
TGGT1_280500 -2.19 0.00 0.64 1.37 1.86 1.14 1.61 inorganic anion transporter, sulfate permease (SulP) family protein
TGGT1_360830 -0.12 0.00 1.00 1.06 0.50 0.81 1.60 nucleoside-triphosphatase
TGGT1_247350 1.32 0.00 0.94 0.82 1.39 1.37 1.60 thioredoxin domain-containing protein
TGGT1_296020 -2.55 0.00 1.64 1.12 1.24 1.54 1.60 hypothetical protein
TGGT1_269775 0.99 0.00 1.04 1.36 0.99 1.27 1.60 hypothetical protein
Log2 FC (relative to GT1 B2-P11)




TGGT1_254820 1.03 0.00 0.50 0.83 1.32 1.60 1.59 hypothetical protein
TGGT1_408600 -2.23 0.00 1.40 1.48 0.65 0.94 1.59 hypothetical protein
TGGT1_320740 2.30 0.00 1.07 1.21 1.71 1.80 1.58 hypothetical protein
TGGT1_252255 2.58 0.00 1.19 1.51 1.39 1.67 1.58 hypothetical protein
TGGT1_323320 3.59 0.00 0.13 0.26 0.80 1.79 1.57 hypothetical protein
TGGT1_222270 -0.24 0.00 0.80 1.15 1.48 1.61 1.57 hypothetical protein
TGGT1_318430 -1.20 0.00 0.56 0.76 1.16 1.23 1.56 malate dehydrogenase MDH
TGGT1_290300 1.07 0.00 1.30 1.14 0.59 0.97 1.55 hypothetical protein
TGGT1_240610 0.92 0.00 0.43 0.87 1.34 1.45 1.55 hypothetical protein
TGGT1_409590 3.03 0.00 0.09 0.58 0.72 1.19 1.55 putative transmembrane protein
TGGT1_220060 3.48 0.00 0.77 0.91 1.12 1.55 1.55 hypothetical protein
TGGT1_240410 -0.36 0.00 0.75 0.78 0.75 0.96 1.55 protein kinase (incomplete catalytic triad)
TGGT1_285170 -0.09 0.00 0.16 0.97 1.30 1.60 1.54 putative ribosomal RNA large subunit methyltransferase I
TGGT1_235515 1.22 0.00 0.69 1.19 1.47 1.73 1.54 MORN repeat-containing protein
TGGT1_289210 0.54 0.00 1.03 1.33 1.12 1.06 1.52 prefoldin subunit protein
TGGT1_297245 0.41 0.00 0.21 0.71 1.54 1.26 1.52 transporter, major facilitator family protein
TGGT1_257000 1.22 0.00 0.74 0.99 1.51 2.00 1.51 hypothetical protein
TGGT1_200700 1.75 0.00 0.73 0.86 0.96 1.50 1.51 Toxoplasma gondii family C protein
TGGT1_217020 3.48 0.00 0.09 0.88 1.36 0.46 1.51 ATPase, AFG1 family protein
TGGT1_265005 0.15 0.00 1.12 1.13 0.78 1.24 1.50 hypothetical protein
TGGT1_245670 -0.11 0.00 -0.49 -0.08 2.33 1.55 1.50 pyruvate dehydrogenase complex subunit PDH-E1Alpha
TGGT1_317720 0.24 0.00 0.71 0.98 0.73 0.92 1.49 putative eukaryotic translation initiation factor 3 subunit 7
TGGT1_220640 0.02 0.00 1.21 1.27 0.16 0.33 1.48 hypothetical protein
TGGT1_214540 -1.06 0.00 0.29 0.76 1.23 1.25 1.47 hypothetical protein
TGGT1_286580 0.76 0.00 1.15 1.20 0.74 0.81 1.47 hypothetical protein
TGGT1_213460 0.82 0.00 0.78 0.56 1.06 3.04 1.47 hypothetical protein
TGGT1_290580 0.55 0.00 0.27 0.84 1.67 1.93 1.46 ATP-binding cassette G family transporter ABCG89
TGGT1_265370 0.07 0.00 1.19 1.33 0.58 0.57 1.45 hypothetical protein
TGGT1_253540 -0.21 0.00 -1.02 -0.08 1.15 1.61 1.44 hypothetical protein
TGGT1_231990 -0.49 0.00 1.17 1.42 1.10 1.12 1.42 hypothetical protein
TGGT1_284310 4.91 0.00 0.70 1.07 1.01 1.22 1.42 hypothetical protein
TGGT1_212735 0.08 0.00 0.87 0.76 1.17 1.32 1.41 hypothetical protein
TGGT1_211030 1.52 0.00 0.83 0.95 1.76 1.74 1.41 hypothetical protein
TGGT1_223045 1.89 0.00 0.92 1.02 0.50 1.21 1.40 hypothetical protein
TGGT1_211060 0.21 0.00 1.01 1.36 0.66 0.53 1.40 hypothetical protein
TGGT1_309860 0.87 0.00 1.00 1.24 0.77 1.39 1.39 hypothetical protein
TGGT1_222410 1.10 0.00 1.02 1.28 1.14 1.07 1.39 hypothetical protein
TGGT1_298050 1.46 0.00 0.81 1.06 1.73 1.87 1.39 hypothetical protein
TGGT1_244700 3.33 0.00 0.27 0.43 0.20 0.50 1.39 NAD(+)/NADH kinase domain-containing protein
TGGT1_260860 0.24 0.00 0.60 0.97 0.45 0.59 1.39 hypothetical protein
TGGT1_306470 1.49 0.00 0.77 0.88 1.00 1.07 1.39 isoprenylcysteine carboxyl methyltransferase (icmt) family protein
TGGT1_253100 0.92 0.00 1.22 1.22 0.24 0.36 1.38 hypothetical protein
TGGT1_264990 1.00 0.00 1.37 1.43 0.55 0.49 1.37 hypothetical protein
TGGT1_268170 0.61 0.00 1.07 1.28 0.04 -0.08 1.37 hypothetical protein
TGGT1_240830 1.00 0.00 0.84 1.16 1.28 1.50 1.36 hydrolase, alpha/beta fold family protein
TGGT1_252210 0.07 0.00 0.15 0.21 0.32 1.35 1.36 pentatricopeptide repeat domain-containing protein
TGGT1_322110 2.95 0.00 -0.03 0.33 0.45 1.16 1.35 hypothetical protein
TGGT1_315900 1.44 0.00 0.76 0.75 0.46 0.90 1.35 hypothetical protein
TGGT1_315690 0.50 0.00 0.73 0.77 0.88 1.05 1.35 DnaJ domain-containing protein
TGGT1_410360 0.02 0.00 1.12 1.22 0.24 0.46 1.35 putative transmembrane protein
TGGT1_228990 -0.13 0.00 1.11 0.83 0.64 0.99 1.34 zinc finger (CCCH type) motif-containing protein
TGGT1_228370 1.33 0.00 1.16 1.13 1.17 1.20 1.34 hypothetical protein
TGGT1_264660 1.18 0.00 1.29 0.81 0.54 1.49 1.34 SAG-related sequence SRS44
TGGT1_278630 0.85 0.00 0.81 0.94 1.08 1.31 1.33 tetratricopeptide repeat-containing protein
TGGT1_217810 -0.70 0.00 0.59 0.94 0.15 0.14 1.33 hypothetical protein
TGGT1_230980 0.97 0.00 0.62 0.67 0.69 1.33 1.33 myosin I
TGGT1_229280 0.68 0.00 0.85 0.90 0.18 0.74 1.33 hypothetical protein
TGGT1_230520 0.35 0.00 0.22 0.53 1.62 1.89 1.32 putative cyclophilin 1
TGGT1_281500 0.62 0.00 0.66 0.81 0.81 0.82 1.32 hypothetical protein
TGGT1_248900 -0.51 0.00 0.90 0.87 0.53 1.16 1.32 hypothetical protein
TGGT1_247510 0.27 0.00 0.81 0.92 0.86 1.07 1.32 fructose-bisphospatase II
TGGT1_313290 0.63 0.00 0.99 1.05 0.45 0.62 1.31 MORN repeat-containing protein
TGGT1_286810 0.54 0.00 1.18 1.17 0.35 0.38 1.31 hypothetical protein
TGGT1_294990 0.88 0.00 0.83 1.02 0.60 0.90 1.31 hypothetical protein
TGGT1_361030 -1.74 0.00 0.91 0.98 0.91 1.16 1.30 hypothetical protein
TGGT1_252280 0.76 0.00 0.31 0.73 0.81 1.20 1.29 hypothetical protein
TGGT1_282150 0.27 0.00 0.99 0.84 1.30 1.53 1.29 hypothetical protein
TGGT1_240600 0.73 0.00 0.16 0.69 1.46 1.57 1.29 putative chaperonin cpn60
TGGT1_203450 0.64 0.00 0.62 0.96 0.97 0.87 1.29 DUF3228 domain-containing protein
TGGT1_217728 3.24 0.00 1.21 0.91 0.98 0.95 1.29 hypothetical protein
TGGT1_273800 -0.72 0.00 0.73 0.84 0.51 1.11 1.29 WD domain, G-beta repeat-containing protein
TGGT1_249935 -0.14 0.00 0.60 0.93 1.47 1.64 1.29 hypothetical protein
TGGT1_247520 0.24 0.00 1.10 1.17 0.67 0.66 1.28 hypothetical protein
TGGT1_292920 0.28 0.00 0.25 0.50 0.91 1.20 1.27 putative heat shock protein 75
TGGT1_219170 1.03 0.00 1.26 1.25 0.71 0.82 1.27 hypothetical protein
TGGT1_243545 0.48 0.00 1.17 1.22 0.60 0.65 1.27 hypothetical protein
TGGT1_411390 2.69 0.00 0.83 0.22 0.46 1.18 1.26 hypothetical protein
TGGT1_242820 0.29 0.00 1.08 1.18 0.72 0.81 1.26 hypothetical protein
TGGT1_241155 0.41 0.00 0.80 0.85 0.54 0.70 1.26 hypothetical protein
TGGT1_286720 1.08 0.00 0.72 1.07 1.09 1.22 1.26 heat shock protein HSP28
TGGT1_305050 0.84 0.00 1.06 1.17 1.06 0.93 1.25 putative calmodulin
TGGT1_231140 0.36 0.00 0.75 0.90 0.95 1.04 1.25 ribosomal protein RPS25
TGGT1_357130 1.07 0.00 2.22 1.33 -0.06 0.25 1.25 WD domain, G-beta repeat protein
TGGT1_235635 0.30 0.00 1.36 1.03 0.02 0.25 1.24 hypothetical protein
TGGT1_329600 0.01 0.00 0.16 -0.14 1.32 1.70 1.24 hypothetical protein
TGGT1_292120 0.63 0.00 0.96 0.91 0.45 0.59 1.24 membrane occupation and recognition nexus protein MORN2




TGGT1_316340 0.89 0.00 0.94 0.95 0.62 0.92 1.24 hypothetical protein
TGGT1_267500 -0.28 0.00 1.05 1.21 0.64 0.55 1.23 hypothetical protein
TGGT1_230830 -1.41 0.00 0.51 0.78 0.79 1.13 1.23 TPase family associated with various cellular activities (AAA) domain-containing prote
TGGT1_320030 1.11 0.00 1.30 1.20 0.38 0.25 1.23 hypothetical protein
TGGT1_275470 0.75 0.00 0.93 1.03 0.23 0.48 1.23 dense granule protein GRA15
TGGT1_268010 -0.54 0.00 0.01 0.06 0.46 0.67 1.23 hypothetical protein
TGGT1_221470 0.95 0.00 0.68 0.71 1.04 1.32 1.22 hypothetical protein
TGGT1_312380 1.09 0.00 1.03 0.93 1.31 1.37 1.22 tetratricopeptide repeat-containing protein
TGGT1_254720 0.15 0.00 0.81 0.97 0.00 0.23 1.22 dense granule protein GRA8
TGGT1_243600 1.73 0.00 0.85 1.11 0.78 1.01 1.22 acetyltransferase, GNAT family protein
TGGT1_410790 2.84 0.00 0.41 -0.05 0.45 1.63 1.22 hypothetical protein
TGGT1_411350 -1.43 0.00 0.24 1.01 0.98 2.69 1.21 rhoptry kinase family (incomplete catalytic triad) protein
TGGT1_215270 -1.01 0.00 0.63 0.91 0.02 0.43 1.21 hypothetical protein
TGGT1_219700 0.99 0.00 0.02 0.40 1.10 1.16 1.21 putative DNA replication licensing factor MCM4
TGGT1_260850 0.47 0.00 0.40 0.83 0.64 0.97 1.21 putative mitochondrial import inner membrane translocase subunit TIM10
TGGT1_264080 -0.48 0.00 0.08 0.40 1.50 1.30 1.21 acyl carrier protein ACP
TGGT1_265010 0.19 0.00 0.73 0.89 0.64 1.02 1.21 glutamate 5-kinase domain-containing protein
TGGT1_220060A 1.47 0.00 0.45 0.65 1.00 1.24 1.20 hypothetical protein
TGGT1_275770 0.26 0.00 0.99 1.16 0.68 0.66 1.20 hypothetical protein
TGGT1_283702 0.49 0.00 -0.50 -0.26 1.61 1.24 1.18 FATC domain-containing protein
TGGT1_293780 4.05 0.00 1.13 0.58 1.53 2.82 1.17 hypothetical protein
TGGT1_248445 1.48 0.00 1.44 1.21 0.94 0.98 1.17 hypothetical protein
TGGT1_262910 0.08 0.00 0.78 1.01 0.82 0.99 1.16 putative NADH-cytochrome b5 reductase 1
TGGT1_312075 -1.10 0.00 1.11 1.07 0.28 0.25 1.16 hypothetical protein
TGGT1_409300 0.89 0.00 0.96 1.15 0.41 0.65 1.16 tRNA-Gly
TGGT1_291010 0.21 0.00 0.91 0.97 0.85 0.94 1.16 hypothetical protein
TGGT1_213350 0.34 0.00 0.58 0.68 0.90 1.21 1.16 ribosomal protein RPS15
TGGT1_319695 0.41 0.00 0.60 1.07 0.88 1.03 1.16 hypothetical protein
TGGT1_231890 -0.08 0.00 0.18 0.66 1.34 1.41 1.16 putative beta-ketoacyl-acyl carrier protein synthase III
TGGT1_294980 0.72 0.00 0.60 0.78 0.42 0.73 1.15 hypothetical protein
TGGT1_292290 -0.09 0.00 1.01 0.92 0.68 1.13 1.15 hypothetical protein
TGGT1_233030 0.33 0.00 1.19 1.15 0.42 0.39 1.15 gliding-associated protein GAP70
TGGT1_226420 1.26 0.00 0.69 0.65 0.91 1.22 1.14 peptidase family M3 protein
TGGT1_245746A -1.84 0.00 0.80 0.84 0.49 0.68 1.14 hypothetical protein
TGGT1_216280 0.54 0.00 0.82 1.24 1.57 2.42 1.14 adenylate and guanylate cyclase catalytic domain-containing protein
TGGT1_258470 -0.12 0.00 0.83 0.79 0.61 1.17 1.13 hypothetical protein
TGGT1_293510 1.00 0.00 0.88 0.92 1.07 1.42 1.13 y(ADP-ribose) polymerase and DNA-Ligase Zn-finger region domain-containing prot
TGGT1_255370 0.73 0.00 0.32 0.74 1.08 1.31 1.13 TIC20 protein
TGGT1_294340 0.75 0.00 0.87 0.88 0.55 0.63 1.12 hypothetical protein
TGGT1_263850 0.53 0.00 0.82 0.92 0.73 0.69 1.12 hypothetical protein
TGGT1_270580 0.25 0.00 0.83 0.89 0.60 0.68 1.12 HECT-domain (ubiquitin-transferase) domain-containing protein
TGGT1_306310 1.25 0.00 0.53 0.79 1.28 1.43 1.12 RecF/RecN/SMC N terminal domain-containing protein
TGGT1_227840 1.08 0.00 0.34 0.52 0.73 0.61 1.12 Memo family protein
TGGT1_297940 1.40 0.00 0.33 0.38 0.75 1.15 1.12 single-strand binding protein
TGGT1_284010 -0.36 0.00 -0.32 -0.23 1.46 1.28 1.12 5'-3' exonuclease, N-terminal resolvase family domain-containing protein
TGGT1_409990 2.57 0.00 0.60 0.06 0.43 1.14 1.12 hypothetical protein
TGGT1_293460 0.67 0.00 0.62 0.99 0.74 1.06 1.11 ATP-dependent DNA ligase domain-containing protein
TGGT1_270250 0.74 0.00 1.03 1.04 0.64 0.85 1.11 dense granule protein GRA1
TGGT1_293590 0.01 0.00 0.49 0.77 1.21 0.99 1.11 putative 3-oxoacyl-acyl-carrier protein synthase I/II
TGGT1_224235 0.87 0.00 0.60 0.92 1.21 1.40 1.11 translation initiation factor IF-3 protein
TGGT1_265020 -0.13 0.00 0.98 1.10 0.10 0.12 1.11 putative arabinogalactan protein
TGGT1_286630 0.74 0.00 0.42 0.59 1.49 1.57 1.11 redoxin domain-containing protein
TGGT1_305030 1.86 0.00 0.71 0.68 1.16 1.45 1.10 kinase, pfkB family protein
TGGT1_266372 -0.22 0.00 0.72 0.89 0.50 0.52 1.10 hypothetical protein
TGGT1_263730 3.02 0.00 0.38 0.75 0.71 0.73 1.10 FAD-dependent glycerol-3-phosphate dehydrogenase
TGGT1_207760 0.40 0.00 0.24 0.50 0.61 0.71 1.10 DnaJ C terminal region domain-containing protein
TGGT1_261075 -0.06 0.00 0.40 0.46 1.11 0.99 1.10 hypothetical protein
TGGT1_291350 0.78 0.00 0.53 0.83 0.38 0.55 1.09 hypothetical protein
TGGT1_261690 0.84 0.00 0.67 0.81 1.00 1.02 1.09 hypothetical protein
TGGT1_237170 -2.25 0.00 0.14 0.48 0.99 1.02 1.09 hypothetical protein
TGGT1_310770 0.75 0.00 0.98 0.80 0.56 0.60 1.09 hypothetical protein
TGGT1_306320 0.75 0.00 0.35 0.89 1.01 1.13 1.08 Myb family DNA-binding domain-containing protein
TGGT1_411560 -0.66 0.00 0.68 0.82 0.43 0.59 1.08 hypothetical protein
TGGT1_200595 -3.05 0.00 0.48 0.42 0.84 1.24 1.08 hypothetical protein
TGGT1_261950 -0.06 0.00 0.41 0.70 0.72 0.76 1.08 ATP synthase beta subunit ATP-B
TGGT1_256990 0.61 0.00 0.47 0.64 0.75 0.91 1.08 glycyl-tRNA synthetase
TGGT1_202300 0.88 0.00 0.70 0.87 0.91 0.92 1.08 putative inosine triphosphate pyrophosphatase
TGGT1_226570 0.12 0.00 0.47 0.74 0.44 0.52 1.08 hypothetical protein
TGGT1_264040 0.72 0.00 0.68 0.89 1.08 0.96 1.08 hypothetical protein
TGGT1_228360 0.38 0.00 0.66 0.83 0.59 0.55 1.07 putative peptidyl-prolyl isomerase FKBP12
TGGT1_262935 -0.18 0.00 0.67 0.77 0.57 0.80 1.07 hypothetical protein
TGGT1_411400 2.55 0.00 0.57 0.07 0.34 1.09 1.07 hypothetical protein
TGGT1_204050 -0.37 0.00 0.97 1.04 0.00 0.09 1.07 subtilisin SUB1
TGGT1_286050 -0.03 0.00 -0.01 0.60 1.56 1.60 1.07 hypothetical protein
TGGT1_234340 0.75 0.00 0.95 0.86 0.56 0.61 1.07 hypothetical protein
TGGT1_285470 6.35 0.00 0.63 0.69 0.92 2.20 1.07 patched family protein
TGGT1_272460 0.15 0.00 0.54 0.58 0.51 0.83 1.07 hypothetical protein
TGGT1_202620 0.95 0.00 0.65 0.77 0.31 0.57 1.07 hypothetical protein
TGGT1_309590 0.96 0.00 0.99 1.00 0.38 0.46 1.07 rhoptry protein ROP1
TGGT1_314885 -0.09 0.00 0.86 0.85 -0.31 -0.22 1.07 hypothetical protein
TGGT1_230210 0.82 0.00 1.09 1.11 0.36 0.35 1.06 alveolin domain containing intermediate filament IMC10
TGGT1_225690 0.54 0.00 1.31 1.18 -0.01 0.00 1.06 hypothetical protein
TGGT1_282180 0.30 0.00 0.78 0.89 0.47 0.41 1.06 hypothetical protein
TGGT1_228110 0.67 0.00 0.93 1.13 0.60 0.50 1.06 hypothetical protein
TGGT1_234450 0.80 0.00 0.56 0.58 1.09 1.31 1.06 ribosomal protein RPS15A
TGGT1_225050 -0.35 0.00 0.07 0.38 1.06 1.40 1.06 putative adenosylhomocysteinase




TGGT1_259090 0.12 0.00 0.77 0.89 0.22 0.24 1.05 ubiquitin-conjugating enzyme subfamily protein
TGGT1_209710 0.55 0.00 0.35 0.65 1.16 1.13 1.05 ribosomal protein RPL28
TGGT1_307605 0.64 0.00 0.37 0.69 1.15 1.25 1.05 hypothetical protein
TGGT1_278160 0.41 0.00 0.55 0.83 1.20 1.46 1.05 vesicle transport v-snare protein
TGGT1_313710 0.39 0.00 0.38 0.58 1.08 1.55 1.05 hypothetical protein
TGGT1_293650 1.35 0.00 0.35 1.00 1.42 1.25 1.05 hypothetical protein
TGGT1_313690 1.14 0.00 0.62 0.73 0.92 1.07 1.05 Sel1 repeat-containing protein
TGGT1_410470 0.35 0.00 1.06 1.16 0.46 0.74 1.05 tRNA-Tyr
TGGT1_314415 0.12 0.00 0.91 1.13 0.42 0.43 1.05 hypothetical protein
TGGT1_245752 -2.24 0.00 0.98 0.93 0.44 0.66 1.05 WD domain, G-beta repeat-containing protein
TGGT1_306330 0.60 0.00 0.75 0.90 0.42 0.61 1.05 phospholipase
TGGT1_224210 1.02 0.00 0.61 0.90 0.72 0.81 1.04 hypothetical protein
TGGT1_285840 -0.55 0.00 0.18 0.66 0.29 0.42 1.04 RAP domain-containing protein
TGGT1_244670 0.78 0.00 0.10 0.52 0.64 0.88 1.03 hypothetical protein
TGGT1_260180 0.86 0.00 0.61 0.75 0.74 0.80 1.03 hypothetical protein
TGGT1_209820 -0.21 0.00 1.06 0.93 0.74 0.54 1.03 syntaxin protein
TGGT1_286450 0.66 0.00 0.71 0.78 0.74 1.02 1.03 dense granule protein GRA5
TGGT1_321590 -0.13 0.00 0.32 0.63 1.14 1.25 1.03 hypothetical protein
TGGT1_269438 0.16 0.00 1.13 1.10 0.22 0.17 1.03 hypothetical protein
TGGT1_206430 -1.13 0.00 0.73 0.75 -0.82 -0.38 1.02 formin FRM1
TGGT1_291940 0.63 0.00 0.66 0.64 1.08 1.29 1.02 hypothetical protein
TGGT1_275440 0.33 0.00 0.72 0.78 0.58 0.88 1.02 dense granule protein GRA6
TGGT1_227030 1.05 0.00 0.69 0.75 1.17 1.11 1.02 hypothetical protein
TGGT1_236990 1.78 0.00 0.80 0.64 0.55 1.06 1.02 beta-ketoacyl synthase, N-terminal domain-containing protein
TGGT1_311460 0.07 0.00 0.33 0.52 0.73 0.98 1.02 hypothetical protein
TGGT1_233470 0.52 0.00 0.95 0.23 0.46 0.68 1.02 hypothetical protein
TGGT1_257380 0.66 0.00 0.61 0.70 0.55 0.62 1.02 hypothetical protein
TGGT1_243570 0.29 0.00 0.68 0.78 0.72 0.87 1.02 ribosomal protein RPS26
TGGT1_263720 0.61 0.00 0.66 0.82 0.96 1.20 1.02 HMG (high mobility group) box domain-containing protein
TGGT1_216435 0.54 0.00 0.80 0.93 0.63 0.69 1.01 hypothetical protein
TGGT1_297060 0.46 0.00 0.50 0.73 1.04 1.07 1.01 phosphoglycerate mutase PGMII
TGGT1_211680 0.95 0.00 0.38 0.58 1.37 1.27 1.01 protein disulfide isomerase
TGGT1_214220 -0.08 0.00 0.68 0.46 0.61 1.24 1.01 hypothetical protein
TGGT1_263633 -0.31 0.00 0.97 0.97 -0.55 -0.29 1.01 hypothetical protein
TGGT1_242570 0.97 0.00 0.81 0.83 0.54 0.74 1.01 hypothetical protein
TGGT1_203790 0.00 0.00 0.69 0.84 0.27 0.69 1.00 hypothetical protein
TGGT1_230340 0.88 0.00 1.16 1.13 0.26 0.04 1.00 hypothetical protein
TGGT1_298040 0.89 0.00 0.65 0.63 0.90 1.02 1.00 hypothetical protein
TGGT1_240840 1.03 0.00 0.57 0.56 1.00 1.01 0.99 histone lysine demethylase JmjC NO66
TGGT1_263630 0.13 0.00 1.04 1.16 0.36 0.29 0.99 hypothetical protein
TGGT1_284040 0.23 0.00 0.32 0.48 0.79 1.03 0.98 hypothetical protein
TGGT1_231630 0.88 0.00 1.01 0.97 0.40 0.20 0.97 alveolin domain containing intermediate filament IMC4
TGGT1_201840 1.27 0.00 0.56 0.46 1.16 1.70 0.97 aspartyl protease ASP1
TGGT1_275330 0.10 0.00 1.04 0.97 0.34 0.42 0.97 ribosomal protein RPL29
TGGT1_239600 0.76 0.00 0.13 0.28 0.94 1.65 0.97 rhoptry kinase family protein ROP23 (incomplete catalytic triad)
TGGT1_313380 1.03 0.00 1.12 1.05 0.57 0.44 0.96 hypothetical protein
TGGT1_293680 1.14 0.00 0.64 0.78 1.10 1.22 0.96 hypothetical protein
TGGT1_233870 -1.24 0.00 -0.05 0.27 0.72 1.07 0.96 hypothetical protein
TGGT1_200340 0.98 0.00 0.96 1.09 0.55 0.36 0.96 hypothetical protein
TGGT1_216000 0.58 0.00 1.14 1.11 0.15 0.04 0.95 alveolin domain containing intermediate filament IMC3
TGGT1_299990 0.52 0.00 1.19 0.85 0.15 0.20 0.95 archease family protein
TGGT1_229140 0.31 0.00 0.88 1.04 0.41 0.26 0.95 MaoC family domain-containing protein
TGGT1_297880 -0.34 0.00 -0.01 0.10 0.87 1.19 0.95 dense granule protein DG32
TGGT1_251930 0.36 0.00 -0.23 -0.16 2.05 1.52 0.95 enoyl-acyl carrier reductase ENR
TGGT1_275690 0.26 0.00 0.06 0.40 1.03 1.36 0.94 putative ClpB
TGGT1_225250 -0.40 0.00 0.83 1.02 0.29 0.22 0.94 putative LSU ribosomal protein L14P
TGGT1_230510 -0.14 0.00 0.17 0.33 1.13 1.10 0.94 hypothetical protein
TGGT1_237880 -0.48 0.00 0.05 -0.07 1.12 1.26 0.93 hypothetical protein
TGGT1_314730 0.64 0.00 0.21 0.45 0.96 1.11 0.93 ALG6, ALG8 glycosyltransferase family protein
TGGT1_312500 -1.13 0.00 0.09 0.30 0.71 1.06 0.93 hypothetical protein
TGGT1_254620 0.69 0.00 0.62 0.59 1.07 1.35 0.93 ribosomal protein RPL39
TGGT1_220270 0.76 0.00 1.02 1.02 0.47 0.37 0.92 alveolin domain containing intermediate filament IMC6
TGGT1_266620 0.71 0.00 0.30 0.56 1.08 1.14 0.92 thioredoxin domain-containing protein
TGGT1_264220 0.56 0.00 0.35 0.38 1.03 1.14 0.92 hypothetical protein
TGGT1_213069 -0.49 0.00 1.03 1.12 0.18 0.11 0.92 hypothetical protein
TGGT1_266300 1.03 0.00 1.14 0.89 0.99 0.31 0.91 hypothetical protein
TGGT1_411270 2.60 0.00 0.47 -0.12 0.48 1.18 0.91 hypothetical protein
TGGT1_318750 0.24 0.00 0.57 0.67 1.07 1.39 0.91 deoxyribose-phosphate aldolase
TGGT1_248530 -0.12 0.00 -0.04 0.50 0.83 1.19 0.90 FATC domain-containing protein
TGGT1_315130 0.94 0.00 0.65 0.80 0.84 1.01 0.89 L-isoaspartyl protein carboxyl methyltransferase family protein
TGGT1_263300 0.95 0.00 0.42 0.59 1.16 1.16 0.88 eukaryotic porin protein
TGGT1_222340 -1.52 0.00 0.47 1.16 0.62 0.94 0.87 NOL1/NOP2/sun family protein
TGGT1_214350 1.36 0.00 0.07 0.34 1.47 1.40 0.87 putative GTP-binding protein
TGGT1_209060 -0.39 0.00 0.39 0.51 0.81 1.00 0.87 thrombospondin type 1 domain-containing protein
TGGT1_218780 0.97 0.00 0.26 0.54 1.00 0.90 0.87 putative phosphoserine aminotransferase
TGGT1_244300 0.03 0.00 -0.14 0.11 1.01 1.06 0.87 hypothetical protein
TGGT1_314310 1.45 0.00 0.45 0.71 1.04 1.16 0.87 hypothetical protein
TGGT1_240580 -0.84 0.00 0.27 0.46 1.15 1.16 0.87 hypothetical protein
TGGT1_204460 -0.07 0.00 1.58 0.68 -0.12 1.76 0.86 putative hydroxymethylglutaryl-CoA lyase
TGGT1_246995 0.23 0.00 0.32 0.68 0.95 1.65 0.86 hypothetical protein
TGGT1_285425 0.37 0.00 1.23 0.92 0.07 -0.02 0.86 hypothetical protein
TGGT1_243510 0.79 0.00 0.35 0.53 1.09 1.02 0.85 OTU family cysteine protease
TGGT1_246100 0.47 0.00 0.56 0.69 1.01 1.03 0.85 putative phosducin
TGGT1_297270 0.28 0.00 0.11 0.36 1.12 1.16 0.84 hypothetical protein
TGGT1_207865 2.61 0.00 0.62 1.12 1.57 3.17 0.84 GCC2 and GCC3 domain-containing protein
TGGT1_320620 -0.92 0.00 0.41 0.48 1.01 1.17 0.83 queuine tRNA ribosyl transferase




TGGT1_306895 0.52 0.00 1.05 0.97 0.19 0.00 0.83 hypothetical protein
TGGT1_208050 -0.27 0.00 -0.31 0.36 0.56 1.03 0.82 putative ABC transporter
TGGT1_409790 0.11 0.00 0.84 1.02 -0.10 -0.16 0.81 putative transmembrane protein
TGGT1_297910 0.95 0.00 1.05 0.56 0.35 0.99 0.81 hypothetical protein
TGGT1_220720 6.62 0.00 1.00 1.24 0.94 0.70 0.80 hypothetical protein
TGGT1_249590 0.78 0.00 0.36 0.50 1.05 0.94 0.80 putative proteasome subunit alpha type 5-2
TGGT1_261580 0.30 0.00 0.98 0.66 1.10 1.87 0.79 histone H2AX
TGGT1_202440 1.03 0.00 -0.11 0.69 1.40 1.61 0.78 hypothetical protein
TGGT1_259550 -0.06 0.00 -0.18 0.19 0.98 1.17 0.78 dihydropteroate synthase
TGGT1_409020 0.02 0.00 1.01 0.96 0.10 -0.14 0.76 hypothetical protein
TGGT1_309210 0.67 0.00 0.24 0.31 1.14 1.18 0.75 putative peroxiredoxin 6
TGGT1_261070 -0.01 0.00 -0.07 -0.12 1.28 1.23 0.75 apicoplast triosephosphate translocator APT1
TGGT1_321570 0.55 0.00 0.46 0.66 0.94 1.10 0.73 beta-hydroxyacyl-acyl carrier protein dehydratase (FABZ)
TGGT1_226515 0.62 0.00 1.18 0.96 -0.06 0.07 0.73 hypothetical protein
TGGT1_301420 1.03 0.00 1.00 0.91 0.54 0.27 0.72 hypothetical protein
TGGT1_232770 1.35 0.00 0.99 1.14 -0.30 -0.63 0.72 hypothetical protein
TGGT1_281470 1.30 0.00 1.73 1.32 -0.57 0.56 0.71 hypothetical protein
TGGT1_289740 0.97 0.00 0.08 0.15 0.89 1.38 0.70 hypothetical protein
TGGT1_304450 -5.42 0.00 0.31 0.33 0.89 1.22 0.70 cation-transporting ATPase
TGGT1_356950 1.21 0.00 2.10 0.78 -0.93 -0.11 0.69 hypothetical protein
TGGT1_300120 -0.32 0.00 -0.43 0.15 0.80 1.37 0.68 aminotransferase, class V superfamily protein
TGGT1_295730 0.62 0.00 -0.37 0.23 1.03 1.11 0.66 tetratricopeptide repeat-containing protein
TGGT1_205558 0.84 0.00 0.22 0.24 0.98 1.04 0.65 NAC domain-containing protein
TGGT1_226410 0.80 0.00 -0.14 0.16 1.11 1.01 0.65 EF-1 guanine nucleotide exchange domain-containing protein
TGGT1_319890 -0.04 0.00 0.24 1.01 1.43 3.87 0.64 hypothetical protein
TGGT1_249000 0.30 0.00 1.21 0.60 -0.11 -0.09 0.64 regulator of chromosome condensation (RCC1) repeat-containing protein
TGGT1_222160 1.33 0.00 -0.25 0.02 1.15 1.33 0.64 aldehyde dehydrogenase
TGGT1_245440 1.03 0.00 1.19 0.70 -0.09 -0.21 0.63 hypothetical protein
TGGT1_271320 -0.04 0.00 0.66 0.63 0.70 1.11 0.63 hypothetical protein
TGGT1_239770 1.34 0.00 0.36 0.51 0.99 1.02 0.62 alveolin domain containing intermediate filament IMC11
TGGT1_239100 0.29 0.00 0.23 0.29 0.86 1.02 0.61 ribosomal protein RPS7
TGGT1_261790 0.16 0.00 1.03 0.60 -0.07 0.06 0.61 hypothetical protein
TGGT1_255210 4.09 0.00 0.25 0.18 1.50 1.39 0.60 ATPase, AAA family protein
TGGT1_233153 0.45 0.00 0.35 0.45 0.91 1.33 0.60 hypothetical protein
TGGT1_218910 1.45 0.00 0.43 1.08 0.75 0.40 0.60 hypothetical protein
TGGT1_223258 -0.82 0.00 -0.04 0.37 0.67 1.16 0.60 hypothetical protein
TGGT1_269780 0.84 0.00 -0.03 0.24 0.82 1.05 0.60 putative ADP-ribosylation factor
TGGT1_310380 0.85 0.00 1.35 0.72 -0.06 -0.29 0.58 brix domain containing protein
TGGT1_212290 0.11 0.00 0.02 0.14 0.74 1.01 0.58 ribosomal protein RPS19
TGGT1_208560 -0.69 0.00 -0.26 -0.08 0.67 1.00 0.57 carrier superfamily protein
TGGT1_299570 1.20 0.00 1.18 0.68 -0.16 0.27 0.56 Toxoplasma gondii family B protein
TGGT1_209700 0.61 0.00 0.17 0.13 0.90 1.20 0.56 hypothetical protein
TGGT1_222220 0.38 0.00 0.02 0.19 0.82 1.04 0.56 alveolin domain containing intermediate filament IMC7
TGGT1_297960A 0.29 0.00 1.09 0.90 -0.24 -0.45 0.56 rhoptry neck protein RON6
TGGT1_221295 0.74 0.00 0.46 0.51 0.84 1.06 0.55 hypothetical protein
TGGT1_269588 0.16 0.00 1.08 0.68 -0.31 -0.47 0.54 hypothetical protein
TGGT1_317705 1.39 0.00 -0.25 0.07 1.05 1.13 0.54 enoyl-CoA hydratase/isomerase family protein
TGGT1_224540 -0.51 0.00 1.01 0.88 -0.61 -0.49 0.54 hypothetical protein
TGGT1_232300 0.36 0.00 0.12 0.17 0.82 1.05 0.52 ribosomal protein RPS3
TGGT1_295350 0.24 0.00 0.05 0.10 0.93 1.15 0.51 putative nucleoside diphosphate kinase
TGGT1_260190 0.24 0.00 0.06 0.49 0.77 1.30 0.51 microneme protein MIC13
TGGT1_236800 0.44 0.00 0.15 0.40 1.09 0.95 0.51 hypothetical protein
TGGT1_287460 3.20 0.00 -0.18 -0.74 0.32 1.20 0.50 hypothetical protein
TGGT1_411170 -0.73 0.00 1.03 0.86 -0.76 -0.77 0.48 hypothetical protein
TGGT1_305520 0.49 0.00 -0.10 0.05 0.88 1.09 0.48 ribosomal protein RPS2
TGGT1_260530 2.56 0.00 1.86 0.90 -0.05 0.48 0.47 Sel1 repeat-containing protein
TGGT1_218850 -0.50 0.00 -0.19 0.07 0.75 1.07 0.47 ribosomal protein RPS9
TGGT1_240310B 0.26 0.00 1.14 0.56 -0.39 0.58 0.46 Toxoplasma gondii family E protein
TGGT1_313780 -0.06 0.00 1.08 0.79 -0.72 -0.92 0.45 hypothetical protein
TGGT1_285870 0.33 0.00 0.33 0.33 0.89 1.04 0.42 SAG-related sequence SRS20A
TGGT1_269582 0.33 0.00 1.09 0.61 -0.31 -0.42 0.42 hypothetical protein
TGGT1_208850 -1.92 0.00 -0.27 -0.08 1.11 1.62 0.41 SAG-related sequence SRS11
TGGT1_286420B 0.72 0.00 -0.56 -0.20 1.16 1.43 0.41 putative elongation factor 1-alpha (EF-1-ALPHA)
TGGT1_289350 4.60 0.00 -0.09 0.13 0.54 2.04 0.41 ATP-binding cassette G family transporter ABCG84
TGGT1_234550 0.37 0.00 0.21 0.16 0.76 1.04 0.38 ribosomal protein RPL29
TGGT1_311335 3.79 0.00 0.27 1.14 1.86 0.10 0.36 dual specificity phosphatase, catalytic domain-containing protein
TGGT1_224310 0.53 0.00 -0.20 0.04 0.51 1.07 0.35 DHHC zinc finger domain-containing protein
TGGT1_216285 0.45 0.00 0.03 0.67 1.11 0.74 0.35 hypothetical protein
TGGT1_204325 0.61 0.00 1.19 0.97 -0.19 -0.62 0.34 hypothetical protein
TGGT1_312090 0.13 0.00 0.03 -0.01 0.80 1.02 0.33 ribosomal protein RPL23
TGGT1_307270 1.43 0.00 -0.34 0.02 1.00 1.30 0.32 hypothetical protein
TGGT1_286770 1.89 0.00 0.09 0.39 1.53 1.75 0.32 hypothetical protein
TGGT1_291850 0.49 0.00 0.01 -0.04 0.90 1.10 0.30 ribosomal protein RPS30
TGGT1_285400 -0.26 0.00 -0.11 0.41 1.19 1.27 0.30 hypothetical protein
TGGT1_308960 0.53 0.00 1.23 0.29 -0.83 -0.48 0.30 ATPase, AAA family protein
TGGT1_263530 0.00 0.00 -0.33 -0.11 0.85 1.02 0.29 putative chaperonin
TGGT1_248390 0.28 0.00 0.05 -0.01 0.82 1.08 0.28 ribosomal protein RPL26
TGGT1_307260 1.10 0.00 -0.10 0.08 0.81 1.01 0.27 Toxoplasma gondii family C protein
TGGT1_288860 0.74 0.00 -0.17 -0.06 1.63 0.76 0.27 RuvB family 2 protein
TGGT1_307030 0.92 0.00 0.04 -0.46 0.39 1.29 0.24 Purine nucleoside phosphorylase
TGGT1_305040 3.05 0.00 -0.38 0.15 0.89 2.37 0.24 HEAT repeat-containing protein
TGGT1_408550 1.58 0.00 1.20 0.46 -0.12 0.53 0.23 hypothetical protein
TGGT1_215343 2.42 0.00 1.51 0.62 0.19 0.78 0.20 hypothetical protein
TGGT1_410250 -0.56 0.00 1.35 0.65 -0.72 -0.36 0.16 hypothetical protein
TGGT1_252385 1.36 0.00 1.05 0.18 -0.11 -0.24 0.15 hypothetical protein
TGGT1_259060 0.93 0.00 1.09 0.38 0.21 -0.77 0.15 hypothetical protein




TGGT1_362290 1.02 0.00 0.25 0.70 1.13 0.38 0.12 hypothetical protein
TGGT1_233350 0.42 0.00 -0.39 -0.12 1.21 0.79 0.11 putative nuclear transport factor 2
TGGT1_307640 2.06 0.00 1.80 1.05 0.30 -0.63 0.10 CMGC kinase, CK2 family
TGGT1_233490 0.88 0.00 1.06 0.08 -0.56 -0.34 0.09 hypothetical protein
TGGT1_205430 -0.33 0.00 1.58 0.71 -0.57 1.21 0.09 isovaleryl-CoA dehydrogenase
TGGT1_207610 0.55 0.00 1.13 -0.01 -0.94 -0.67 0.09 rhoptry kinase family protein ROP36 (incomplete catalytic triad)
TGGT1_297680 0.96 0.00 1.49 0.59 -0.41 -0.80 0.05 putative calmodulin
TGGT1_269680 0.35 0.00 1.04 0.14 -0.65 -0.04 0.01 putative acyl-CoA carboxyltransferase beta chain
TGGT1_221818 -0.23 0.00 1.17 0.27 -0.40 -0.51 0.01 hypothetical protein
TGGT1_260260 0.70 0.00 -0.44 -0.44 0.99 1.17 -0.05 ribosomal protein RPP1
TGGT1_239730 0.69 0.00 1.41 0.39 -0.98 -1.16 -0.08 MORN repeat-containing protein
TGGT1_310480 -0.26 0.00 1.15 0.09 -1.14 -0.98 -0.10 flagellar/basal body protein, PACRG family protein
TGGT1_314460 0.49 0.00 1.62 0.37 0.35 -0.20 -0.15 hypothetical protein
TGGT1_266070 0.35 0.00 -0.53 -0.50 0.98 1.04 -0.17 ribosomal protein RPL31
TGGT1_255215 3.14 0.00 -0.57 -0.37 1.57 1.34 -0.18 hypothetical protein
TGGT1_210400 -0.06 0.00 1.54 0.36 -1.02 -0.04 -0.26 hypothetical protein
TGGT1_278110 4.66 0.00 -0.62 -0.16 1.19 1.46 -0.27 1,3-beta-glucan synthase component protein
TGGT1_410820 -1.43 0.00 1.05 0.05 -1.41 -1.78 -0.41 tRNA-Ser
TGGT1_208810 -0.13 0.00 1.13 0.46 -0.39 0.52 -0.42 hypothetical protein
TGGT1_314670 0.65 0.00 1.36 -0.06 -1.20 -0.67 -0.55 hypothetical protein
TGGT1_244500 0.03 0.00 0.51 0.13 -0.56 -1.00 -0.09 Tubulin-tyrosine ligase family protein
TGGT1_244050 -0.36 0.00 0.56 0.08 -0.86 -1.13 -0.29 hypothetical protein
TGGT1_251740 0.37 0.00 0.26 0.12 -0.95 -1.10 -0.35 AP2 domain transcription factor AP2XII-9
TGGT1_246190 -0.91 0.00 0.35 0.15 -1.02 -0.72 -0.35 hypothetical protein
TGGT1_248240 -0.07 0.00 0.97 0.20 -1.15 -0.48 -0.38 leucine rich repeat-containing protein
TGGT1_271070 0.67 0.00 -1.50 -0.30 0.63 0.88 -0.38 hypothetical protein
TGGT1_312430 -0.95 0.00 -0.17 -0.05 -0.67 -1.01 -0.40 hypothetical protein
TGGT1_291830 0.25 0.00 0.32 -0.50 -1.24 -0.39 -0.40 putative DNA double-strand break repair rad50 ATPase
TGGT1_276230 -0.17 0.00 -1.27 -0.53 0.43 0.12 -0.43 Toxoplasma gondii family B protein
TGGT1_261300 0.03 0.00 0.02 -0.09 -0.92 -1.15 -0.53 hypothetical protein
TGGT1_295620 -0.44 0.00 0.03 -0.32 -0.96 -1.00 -0.55 hypothetical protein
TGGT1_228680 -0.40 0.00 0.21 -0.36 -1.02 -1.02 -0.55 mitochondrial carrier superfamily protein
TGGT1_252370 -0.31 0.00 0.77 0.16 -1.32 0.22 -0.60 AP2 domain transcription factor AP2III-1
TGGT1_306020 -0.28 0.00 -0.03 -0.20 -1.01 -0.82 -0.61 hypothetical protein
TGGT1_245520 0.35 0.00 -1.10 -0.95 0.34 0.33 -0.68 hypothetical protein
TGGT1_271000 -0.19 0.00 0.22 -0.16 -0.81 -1.14 -0.68 hypothetical protein
TGGT1_205370 0.10 0.00 0.13 -0.16 -0.94 -1.15 -0.69 hypothetical protein
TGGT1_277050 -1.19 0.00 -0.05 -0.50 -0.97 -1.05 -0.71 hypothetical protein
TGGT1_304730 0.45 0.00 0.51 -0.30 -1.05 -1.29 -0.71 Mob1/phocein family protein
TGGT1_220930 -0.67 0.00 -0.09 -0.56 -0.80 -1.16 -0.72 hypothetical protein
TGGT1_280770 -0.62 0.00 -0.29 -0.67 -0.48 -1.15 -0.73 regulator of chromosome condensation (RCC1) repeat-containing protein
TGGT1_257360 -0.33 0.00 0.61 -0.14 -1.12 -1.21 -0.73 hypothetical protein
TGGT1_239810 -1.35 0.00 -0.55 -0.54 -0.82 -1.00 -0.73 hypothetical protein
TGGT1_308010 -0.93 0.00 0.02 -0.26 -0.94 -1.18 -0.75 hypothetical protein
TGGT1_319600 -0.32 0.00 0.11 -0.25 -0.91 -1.25 -0.75 putative alpha-tubulin N-acetyltransferase
TGGT1_213570 -0.57 0.00 -1.19 -1.00 0.03 0.00 -0.76 hypothetical protein
TGGT1_318470 -0.08 0.00 0.08 -0.32 -1.26 -1.41 -0.76 AP2 domain transcription factor AP2IV-4
TGGT1_212780 -0.28 0.00 -0.16 -0.58 -0.83 -1.15 -0.76 hypothetical protein
TGGT1_309810 0.55 0.00 -0.99 -1.02 0.61 0.73 -0.76 ribosomal protein RPP2
TGGT1_318632 -0.14 0.00 -1.14 -1.07 0.14 0.15 -0.76 hypothetical protein
TGGT1_310740 0.03 0.00 0.05 -0.26 -0.73 -1.03 -0.77 hypothetical protein
TGGT1_205360 -0.46 0.00 -0.10 -0.63 -1.06 -0.94 -0.79 hypothetical protein
TGGT1_226650 0.26 0.00 -1.01 -0.71 0.16 0.05 -0.79 hypothetical protein
TGGT1_279345 -0.19 0.00 -1.10 -0.96 0.47 0.39 -0.79 hypothetical protein
TGGT1_270760 -0.51 0.00 -0.17 -0.33 -0.65 -1.09 -0.79 asparagine synthase
TGGT1_221250 0.02 0.00 -0.12 -0.54 -0.69 -1.08 -0.79 hypothetical protein
TGGT1_252450 -0.80 0.00 0.57 0.31 -0.96 -1.52 -0.80 hypothetical protein
TGGT1_238410 -0.94 0.00 0.32 -0.47 -1.16 -1.23 -0.81 hypothetical protein
TGGT1_278390 1.22 0.00 -0.74 -1.02 -0.26 0.39 -0.81 Toxoplasma gondii family A protein
TGGT1_293050 0.35 0.00 -1.21 -1.05 0.00 -0.04 -0.82 sybindin family protein
TGGT1_295460 -0.07 0.00 -1.02 -0.76 -0.09 -0.34 -0.83 Got1 family protein
TGGT1_221850 0.15 0.00 -0.92 -1.04 0.10 0.12 -0.84 putative prohibitin family protein
TGGT1_200230 0.17 0.00 0.07 -1.26 -0.63 1.39 -0.84 microneme protein MIC17C
TGGT1_360740 -0.94 0.00 -0.06 -0.32 -0.80 -1.24 -0.84 hypothetical protein
TGGT1_315580 -0.22 0.00 -0.01 -0.31 -0.76 -1.25 -0.85 hypothetical protein
TGGT1_209000 -0.82 0.00 -0.05 -0.33 -1.39 -1.07 -0.85 HECT-domain (ubiquitin-transferase) domain-containing protein
TGGT1_306620 0.23 0.00 -0.01 -0.46 -0.86 -1.24 -0.85 AP2 domain transcription factor AP2IX-9
TGGT1_250760 -0.83 0.00 -0.35 -0.47 -0.85 -1.10 -0.85 pentatricopeptide repeat domain-containing protein
TGGT1_210345 -0.40 0.00 -0.05 -0.45 -1.14 -1.00 -0.86 hypothetical protein
TGGT1_222330 0.06 0.00 0.21 -0.26 -1.14 -1.41 -0.87 hypothetical protein
TGGT1_205340 -0.06 0.00 -1.00 -1.07 0.42 0.46 -0.87 ribosomal protein RPS12
TGGT1_215390 -0.29 0.00 -1.04 -0.92 0.74 0.58 -0.88 putative TIM10 family protein
TGGT1_291170 -0.38 0.00 0.09 -0.45 -1.15 -1.05 -0.91 hypothetical protein
TGGT1_269460 -0.41 0.00 -0.22 -0.36 -0.79 -1.13 -0.91 Ser/Thr phosphatase family protein
TGGT1_243910 -0.98 0.00 -1.08 -0.85 -0.27 -0.39 -0.92 Cof family hydrolase subfamily protein
TGGT1_263120 -1.31 0.00 -0.19 -0.28 -0.99 -1.30 -0.92 hypothetical protein
TGGT1_244130 -1.44 0.00 -0.43 -0.58 -1.01 -1.13 -0.92 hypothetical protein
TGGT1_409310 -1.09 0.00 -1.05 -1.16 -0.38 0.10 -0.92 tRNA-Met
TGGT1_213560 -0.49 0.00 -0.05 -0.87 -1.52 -0.75 -0.92 hypothetical protein
TGGT1_273530 -0.59 0.00 -1.11 -1.03 -0.32 -0.17 -0.93 flagellar associated protein
TGGT1_309080 -0.65 0.00 0.06 -0.44 -0.97 -1.08 -0.93 hypothetical protein
TGGT1_261220 -0.36 0.00 -0.99 -1.05 -0.17 -0.20 -0.96 transcription elongation factor SPT4
TGGT1_233720 0.33 0.00 -1.39 -1.20 0.18 0.09 -0.98 DNA-directed RNA polymerase II RPBABC8
TGGT1_322100 -1.51 0.00 -0.82 -1.04 0.07 0.19 -0.98 myosin-light-chain kinase
TGGT1_408250 1.11 0.00 0.15 0.15 -0.45 -1.10 -0.99 hypothetical protein
TGGT1_232320 -1.90 0.00 -0.06 -0.63 -1.01 -1.19 -1.00 hypothetical protein




TGGT1_273620 -0.02 0.00 -1.20 -0.98 0.15 0.12 -1.00 hypothetical protein
TGGT1_207875 -0.64 0.00 -0.46 -0.58 -0.08 0.20 -1.00 GCC2 and GCC3 domain-containing protein
TGGT1_294690 -0.28 0.00 -0.66 -0.80 -0.55 -0.73 -1.01 rhomboid protease ROM5
TGGT1_251490 -0.87 0.00 -0.75 -0.72 -0.54 -0.51 -1.01 ACR, COG2135 domain-containing protein
TGGT1_216610 -0.63 0.00 -0.87 -0.64 -0.13 0.66 -1.01 ribosomal RNA large subunit methyltransferase J protein
TGGT1_228175 -0.22 0.00 0.63 -0.41 -1.40 -1.27 -1.01 hypothetical protein
TGGT1_245630 -0.17 0.00 -0.64 -0.75 -0.15 -0.32 -1.01 hypothetical protein
TGGT1_243770 0.02 0.00 -1.06 -0.84 0.03 -0.10 -1.02 hypothetical protein
TGGT1_409250 -0.44 0.00 0.29 -0.17 -1.24 -1.00 -1.02 hypothetical protein
TGGT1_315260 0.60 0.00 -0.35 -0.59 -0.48 -0.37 -1.02 alanine dehydrogenase
TGGT1_286190 -0.54 0.00 -0.91 -0.91 -0.72 -0.70 -1.02 hypothetical protein
TGGT1_221410 -0.60 0.00 -0.77 -0.97 -0.33 -0.30 -1.02 actin-like protein ALP4
TGGT1_297643 0.64 0.00 -0.19 -0.32 -0.11 -0.35 -1.02 hypothetical protein
TGGT1_266980 0.23 0.00 -0.81 -0.61 -0.20 -0.39 -1.02 hypothetical protein
TGGT1_357490 0.37 0.00 -0.78 -0.97 -0.04 -0.19 -1.02 hypothetical protein
TGGT1_269630 -1.54 0.00 -0.71 -0.72 -0.87 -0.90 -1.03 hypothetical protein
TGGT1_315798 -0.51 0.00 -0.62 -0.19 0.07 1.04 -1.03 hypothetical protein
TGGT1_249380 -1.56 0.00 -0.66 -0.60 -0.96 -1.15 -1.03 DHHC zinc finger domain-containing protein
TGGT1_229910 0.11 0.00 -1.16 -1.01 -0.19 -0.33 -1.03 EF hand domain-containing protein
TGGT1_271060 -0.82 0.00 -0.71 -0.83 -0.45 -0.68 -1.03 Sec1 family protein
TGGT1_280540 -0.98 0.00 -0.19 -0.40 -0.89 -1.12 -1.03 HEAT repeat-containing protein
TGGT1_233960 -0.85 0.00 -0.47 -0.15 -0.42 1.33 -1.03 hypothetical protein
TGGT1_208722 -0.38 0.00 -1.05 -1.04 -0.44 -0.58 -1.03 hypothetical protein
TGGT1_280510 -0.59 0.00 0.08 -0.65 -0.45 -0.56 -1.04 Dpy-30 motif protein
TGGT1_272630 0.38 0.00 -1.24 -1.01 0.32 0.15 -1.04 putative U6 snRNA-associated Sm family protein LSm8
TGGT1_293290 0.98 0.00 -0.19 -0.80 -0.79 -0.65 -1.04 hypothetical protein
TGGT1_308050 -0.22 0.00 -0.84 -0.96 -0.06 -0.30 -1.04 thioredoxin domain-containing protein
TGGT1_229260 -0.34 0.00 -0.10 -0.64 -1.35 -1.63 -1.04 hypothetical protein
TGGT1_274040 1.00 0.00 0.07 -0.39 0.08 1.96 -1.04 hypothetical protein
TGGT1_356400 2.60 0.00 0.78 -0.75 -1.94 0.49 -1.05 cAMP-dependent protein kinase
TGGT1_231230 -0.97 0.00 -0.81 -0.87 -0.79 -0.99 -1.05 hypothetical protein
TGGT1_242100 -0.34 0.00 -0.21 -0.68 -0.12 0.42 -1.05 hypothetical protein
TGGT1_321360 -0.42 0.00 -0.88 -0.74 -0.35 -0.60 -1.05 clustered-asparagine-rich protein
TGGT1_248350 -0.05 0.00 0.01 -0.50 -0.66 -0.65 -1.05 hypothetical protein
TGGT1_268860 -0.72 0.00 1.18 -0.19 -1.48 -1.80 -1.05 enolase 1
TGGT1_261260A -1.08 0.00 -0.80 -0.86 -0.68 -0.80 -1.05 histone lysine demethylase JMJD6a
TGGT1_218955 -0.55 0.00 -0.92 -1.04 -0.53 -0.50 -1.06 hypothetical protein
TGGT1_267435 -1.94 0.00 -0.24 -0.29 -0.88 -0.32 -1.06 hypothetical protein
TGGT1_251750 -0.13 0.00 0.79 -0.46 -1.55 -0.13 -1.06 MORN repeat-containing protein
TGGT1_268350 -1.38 0.00 -0.87 -0.72 -0.61 -0.82 -1.06 hypothetical protein
TGGT1_232140 0.73 0.00 -0.27 -0.29 -0.62 -0.23 -1.06 hypothetical protein
TGGT1_321390 -0.20 0.00 0.17 -0.47 -0.66 -0.33 -1.07 hypothetical protein
TGGT1_247340 0.64 0.00 0.16 -0.56 -0.85 -0.26 -1.07 hypothetical protein
TGGT1_285825 0.42 0.00 -0.79 -0.58 -0.22 -0.64 -1.08 hypothetical protein
TGGT1_203175 -0.15 0.00 -0.48 -0.81 -0.67 -0.55 -1.08 hypothetical protein
TGGT1_299800 0.64 0.00 0.56 -0.19 -1.19 -1.24 -1.08 hypothetical protein
TGGT1_222188 0.74 0.00 -0.46 -0.78 -0.91 -0.06 -1.09 hypothetical protein
TGGT1_202850 -0.75 0.00 -0.39 -0.79 -0.85 -1.06 -1.09 ATP-binding domain-containing protein
TGGT1_246910 -0.40 0.00 -0.95 -0.77 -0.29 -0.26 -1.09 putative histone lysine methyltransferase, SET
TGGT1_318420 0.44 0.00 -1.25 -1.01 0.03 -0.06 -1.09 putative 30S ribosomal protein S16
TGGT1_269310 0.57 0.00 -0.42 -0.76 -0.77 -0.22 -1.09 hypothetical protein
TGGT1_227630 -0.02 0.00 0.32 -0.69 -1.35 -1.01 -1.09 hypothetical protein
TGGT1_237210 -0.79 0.00 -0.28 -0.65 -0.93 -1.18 -1.09 Tyrosine kinase-like (TKL) protein
TGGT1_205170 -0.79 0.00 -0.98 -0.96 -0.30 -0.35 -1.09 hypothetical protein
TGGT1_219370 -1.72 0.00 -0.26 -0.45 -0.08 0.27 -1.09 hypothetical protein
TGGT1_273750 -0.25 0.00 -0.78 -1.29 -0.22 0.66 -1.09 hypothetical protein
TGGT1_289490 -0.36 0.00 -0.77 -0.97 -0.89 -1.05 -1.10 serine/threonine specific protein phosphatase
TGGT1_294820 0.70 0.00 -0.76 -0.50 -0.56 1.40 -1.10 putative type I fatty acid synthase
TGGT1_206520 0.13 0.00 -0.75 -0.75 -0.37 -0.37 -1.11 hypothetical protein
TGGT1_250030 -0.91 0.00 -0.65 -0.79 -0.34 -0.59 -1.11 hypothetical protein
TGGT1_213580 0.51 0.00 -1.62 -1.48 1.03 0.84 -1.11 hypothetical protein
TGGT1_209985 2.40 0.00 0.78 -0.67 -1.98 0.30 -1.12 cAMP-dependent protein kinase
TGGT1_208760 0.47 0.00 -0.36 -0.74 -0.54 -0.64 -1.12 hypothetical protein
TGGT1_462964 0.10 0.00 -0.30 -0.62 -0.94 -1.45 -1.12 hypothetical protein
TGGT1_312680 0.00 0.00 -1.16 -1.07 -0.09 -0.16 -1.12 putative 60S ribosomal protein L27
TGGT1_261955B 0.02 0.00 -0.35 -0.84 -0.73 -0.91 -1.12 hypothetical protein
TGGT1_227980 0.32 0.00 -0.94 -0.93 -0.35 -0.39 -1.12 hypothetical protein
TGGT1_263110 -1.34 0.00 -0.27 -0.37 -0.79 -1.22 -1.13 hypothetical protein
TGGT1_267030 -2.19 0.00 -0.64 -0.38 -0.43 0.17 -1.13 ribonuclease type III Dicer
TGGT1_220580 -0.43 0.00 -1.19 -1.16 -0.23 -0.35 -1.13 hypothetical protein
TGGT1_261610 -1.89 0.00 -0.81 -0.70 -0.40 -0.38 -1.13 hypothetical protein
TGGT1_232240 -1.39 0.00 -0.72 -0.57 -0.89 -0.75 -1.13 hypothetical protein
TGGT1_236400 -1.07 0.00 -0.79 -0.79 -0.27 -0.16 -1.13 hypothetical protein
TGGT1_316670 0.02 0.00 -0.23 -0.51 -0.91 -0.73 -1.13 Toxoplasma gondii family D protein
TGGT1_238970 -0.70 0.00 -0.50 -0.35 -0.38 1.98 -1.13 hypothetical protein
TGGT1_239290 -2.20 0.00 -0.66 -0.36 -0.17 -0.59 -1.14 hypothetical protein
TGGT1_205230 -0.04 0.00 -0.63 -0.60 -0.09 -0.51 -1.14 hypothetical protein
TGGT1_243382 0.24 0.00 -0.57 -0.20 -0.38 0.68 -1.14 hypothetical protein
TGGT1_277070 -1.04 0.00 -0.59 -0.63 -0.99 -1.25 -1.14 SWI2/SNF2-containing protein
TGGT1_272680 -0.19 0.00 -0.30 -0.54 -0.60 -0.87 -1.14 hypothetical protein
TGGT1_306050 0.31 0.00 -0.48 -0.60 -0.72 -0.80 -1.15 hypothetical protein
TGGT1_209040 -0.17 0.00 0.04 -0.71 -1.00 -0.83 -1.15 hypothetical protein
TGGT1_264485 -0.16 0.00 -0.02 -0.46 -1.25 -1.22 -1.15 AP2 domain transcription factor AP2IX-3
TGGT1_248330 -0.29 0.00 -0.41 -0.45 -0.54 -1.17 -1.15 zinc finger, C3HC4 type (RING finger) domain-containing protein
TGGT1_312930 0.86 0.00 -0.07 -0.71 -0.82 -0.65 -1.15 putative cystathione gamma lyase
TGGT1_212910 0.23 0.00 -0.32 -0.02 -0.03 -0.51 -1.16 rhomboid protease ROM3




TGGT1_206650 -0.96 0.00 -0.64 -0.74 -0.78 -0.61 -1.16 zinc finger, c2h2 type domain-containing protein
TGGT1_271090 0.09 0.00 -0.40 -1.14 -0.76 -1.04 -1.17 hypothetical protein
TGGT1_250670 -0.28 0.00 -0.49 -0.68 -0.87 -0.98 -1.17 hypothetical protein
TGGT1_223025 -1.20 0.00 -0.77 -0.37 -0.32 -0.59 -1.17 hypothetical protein
TGGT1_236960 -0.07 0.00 -0.71 -0.95 -0.36 -0.19 -1.17 transporter, major facilitator family protein
TGGT1_285690 -0.23 0.00 0.34 0.09 -0.93 -0.88 -1.17 notch (dsl) domain-containing protein
TGGT1_221500 -0.63 0.00 -0.78 -0.74 -0.65 -0.80 -1.17 dual specificity phosphatase, catalytic domain-containing protein
TGGT1_232420 0.30 0.00 -0.21 -0.50 -0.91 -1.00 -1.17 hypothetical protein
TGGT1_280530 -0.41 0.00 -0.49 -0.45 -0.71 -1.07 -1.18 hypothetical protein
TGGT1_203770 -2.09 0.00 -0.11 -0.25 -0.38 -0.09 -1.18 hypothetical protein
TGGT1_242720 -0.94 0.00 -0.81 -0.90 -0.74 -0.88 -1.20 aspartyl protease ASP5
TGGT1_246010 -1.54 0.00 -0.80 -0.77 -0.74 -0.94 -1.20 hypothetical protein
TGGT1_213290 0.37 0.00 -0.23 -0.77 -0.66 -0.91 -1.20 hypothetical protein
TGGT1_285940 0.09 0.00 -0.14 -0.60 -1.16 -1.34 -1.20 hypothetical protein
TGGT1_201180B -0.23 0.00 -0.02 -0.48 -1.23 -1.12 -1.21 hypothetical protein
TGGT1_279440 -0.97 0.00 -0.61 -0.93 -0.04 -0.25 -1.21 PA14 domain-containing protein
TGGT1_251830 0.13 0.00 -0.51 -0.35 -0.37 -0.90 -1.21 hypothetical protein
TGGT1_265340 -0.50 0.00 -0.76 -0.90 -0.29 -0.63 -1.21 hypothetical protein
TGGT1_219110 0.14 0.00 0.03 -0.90 -1.33 -1.43 -1.21 hypothetical protein
TGGT1_258810 -0.20 0.00 -0.75 -0.16 -0.54 -0.34 -1.22 SAG-related sequence SRS27B
TGGT1_316560 0.30 0.00 0.34 -0.74 -1.49 -1.54 -1.22 Toxoplasma gondii family D protein
TGGT1_237490 -0.54 0.00 -0.61 -0.64 -0.60 0.58 -1.22 centrin family protein
TGGT1_204055 0.05 0.00 -0.99 -1.10 -0.40 -0.56 -1.22 hypothetical protein
TGGT1_213885 -0.02 0.00 -1.11 -1.06 -0.04 -0.12 -1.22 hypothetical protein
TGGT1_223725 0.20 0.00 -0.13 -0.40 -1.67 -0.73 -1.22 hypothetical protein
TGGT1_319510 0.14 0.00 -1.19 -1.13 -0.03 -0.16 -1.22 hypothetical protein
TGGT1_277705 0.07 0.00 -0.65 -0.37 -0.10 0.05 -1.23 hypothetical protein
TGGT1_321480 0.10 0.00 -0.33 -0.33 -0.08 -0.07 -1.23 SAG-related sequence SRS12B
TGGT1_268800 -0.63 0.00 -0.25 -0.83 0.26 0.09 -1.23 hypothetical protein
TGGT1_294400 -1.17 0.00 0.08 -0.04 -0.47 -0.38 -1.23 hypothetical protein
TGGT1_277950 -1.20 0.00 -0.46 -0.72 -0.73 -0.89 -1.24 lipase
TGGT1_290645 -0.28 0.00 -0.57 -0.70 -0.52 -1.05 -1.24 hypothetical protein
TGGT1_216415 0.32 0.00 -1.05 -1.14 -0.54 -0.25 -1.24 hypothetical protein
TGGT1_301470 -0.50 0.00 -0.74 -0.60 -0.54 -0.59 -1.24 hypothetical protein
TGGT1_273280 0.43 0.00 -0.14 -0.21 -0.95 -1.47 -1.24 hypothetical protein
TGGT1_309330 0.18 0.00 0.19 -0.85 -1.21 0.03 -1.25 SAG-related sequence SRS55F
TGGT1_275790 0.15 0.00 -0.05 -0.52 -1.06 0.14 -1.26 EGF family domain-containing protein
TGGT1_316580 -1.27 0.00 -0.68 -0.37 -0.44 -0.25 -1.26 hypothetical protein
TGGT1_320250 0.91 0.00 -0.14 -0.60 -0.79 0.65 -1.26 SAG-related sequence SRS15A
TGGT1_318610 -0.39 0.00 -0.04 -0.76 -0.73 -0.52 -1.26 AP2 domain transcription factor AP2IV-3
TGGT1_316190 -0.66 0.00 0.41 0.17 -0.67 -0.45 -1.26 superoxide dismutase SOD3
TGGT1_246160 -0.02 0.00 -0.53 -0.90 -0.88 -1.20 -1.26 hypothetical protein
TGGT1_272645 -0.12 0.00 -0.75 -0.89 -0.48 -0.56 -1.26 hypothetical protein
TGGT1_290585 -0.84 0.00 -0.10 -0.66 -0.82 2.41 -1.26 hypothetical protein
TGGT1_289610 -0.54 0.00 -0.86 -0.87 -0.22 -0.47 -1.27 hypothetical protein
TGGT1_206440 -0.96 0.00 -0.70 -0.62 -0.78 -1.45 -1.27 cpw-wpc domain-containing protein
TGGT1_365080 -0.51 0.00 -0.60 -0.88 0.03 -0.19 -1.27 rhoptry protein ROP7
TGGT1_245600 0.00 0.00 -0.50 -0.65 -1.04 -1.02 -1.27 hypothetical protein
TGGT1_301000 -0.11 0.00 -0.37 -0.55 -0.41 -0.33 -1.27 methyltransferase
TGGT1_238210 -2.18 0.00 -0.61 -1.15 -0.12 0.22 -1.28 EGF family domain-containing protein
TGGT1_239083 -0.79 0.00 -0.72 -1.03 -0.81 -0.82 -1.28 hypothetical protein
TGGT1_269400 0.40 0.00 0.73 -0.51 -1.00 -0.61 -1.28 oxidoreductase, short chain dehydrogenase/reductase family protein
TGGT1_218290 0.22 0.00 -0.60 -0.67 -0.66 -0.24 -1.28 WD domain, G-beta repeat-containing protein
TGGT1_217700 -0.37 0.00 -0.64 -1.16 -1.20 -1.79 -1.28 AP2 domain transcription factor AP2XII-2
TGGT1_282160 -0.08 0.00 -1.48 -1.43 -0.47 -0.57 -1.29 hypothetical protein
TGGT1_222080 1.78 0.00 -0.24 -0.15 0.03 0.01 -1.29 hypothetical protein
TGGT1_217490 -0.75 0.00 -0.27 -0.94 -0.83 -0.75 -1.29 hypothetical protein
TGGT1_305610 -0.14 0.00 -0.42 -0.34 -0.42 -0.67 -1.29 hypothetical protein
TGGT1_243330 -0.27 0.00 -0.80 -0.52 -0.59 0.29 -1.29 hypothetical protein
TGGT1_270273 0.17 0.00 0.02 -0.09 -0.83 -0.66 -1.30 hypothetical protein
TGGT1_293890 0.20 0.00 0.03 -0.61 -0.96 -1.03 -1.30 intraflagellar transport 80 family protein
TGGT1_214430 -1.25 0.00 0.14 -0.55 -1.37 -1.18 -1.30 hypothetical protein
TGGT1_218510 0.41 0.00 -0.21 -0.31 -0.51 -1.13 -1.30 hypothetical protein
TGGT1_209670 0.01 0.00 -1.40 -1.36 -0.18 -0.27 -1.30 hypothetical protein
TGGT1_268190 0.11 0.00 0.29 -0.51 -1.61 -1.02 -1.30 hypothetical protein
TGGT1_208380 0.17 0.00 0.23 -0.81 -1.16 -0.80 -1.30 hypothetical protein
TGGT1_305790 3.50 0.00 0.07 -0.22 -0.46 -0.33 -1.30 hypothetical protein
TGGT1_244726 -0.45 0.00 0.27 -0.31 -1.31 -0.56 -1.31 hypothetical protein
TGGT1_269270 -0.42 0.00 -0.02 -0.76 -0.43 -0.14 -1.31 leucine rich repeat-containing protein
TGGT1_255200 1.77 0.00 -0.52 -0.84 -1.07 -0.91 -1.31 putative Radial spoke head protein 9
TGGT1_411770 -1.22 0.00 -0.38 -0.80 -0.74 -0.70 -1.32 putative IgA-specific serine endopeptidase
TGGT1_266650 -0.06 0.00 0.21 -0.30 -0.60 -1.44 -1.32 hypothetical protein
TGGT1_306070 0.68 0.00 -0.60 -0.69 -0.59 -0.99 -1.32 hypothetical protein
TGGT1_293580 -0.41 0.00 -1.35 -1.23 -0.07 -0.31 -1.32 prefoldin subunit protein
TGGT1_306510 0.58 0.00 -0.59 -0.82 -0.76 -0.93 -1.32 hypothetical protein
TGGT1_294240 -1.74 0.00 -0.83 -0.36 -0.14 0.80 -1.33 hypothetical protein
TGGT1_243720 0.50 0.00 -0.57 -0.83 0.20 1.03 -1.34 peroxisomal biogenesis factor PEX11
TGGT1_240390 0.02 0.00 0.02 -1.05 -1.37 -0.84 -1.34 calcium-dependent protein kinase
TGGT1_208770 0.36 0.00 -0.19 -0.48 -0.66 -1.00 -1.34 hypothetical protein
TGGT1_293520 -0.33 0.00 -0.05 -0.68 -1.04 -1.12 -1.34 hypothetical protein
TGGT1_235010 -0.42 0.00 -0.13 -0.69 -0.63 0.28 -1.34 hypothetical protein
TGGT1_229405 0.41 0.00 -0.70 -1.05 -0.42 -0.49 -1.35 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_201690 4.10 0.00 -0.16 -0.45 -0.61 0.79 -1.35 BT1 family protein
TGGT1_262110 -0.26 0.00 -0.31 -0.90 -0.46 0.04 -1.35 hypothetical protein
TGGT1_267490 -1.55 0.00 0.19 -0.61 -1.01 -1.44 -1.35 putative preprocathepsin c precursor
TGGT1_227875 -0.44 0.00 -0.73 -0.74 -0.76 -1.07 -1.35 hypothetical protein




TGGT1_225105 -0.99 0.00 -0.06 -0.87 -1.05 -1.11 -1.36 hypothetical protein
TGGT1_255730 0.25 0.00 -0.31 -0.83 -0.67 -0.56 -1.36 hypothetical protein
TGGT1_314370 -1.11 0.00 -0.52 -0.72 -0.76 -1.11 -1.36 hypothetical protein
TGGT1_217860 -1.22 0.00 -0.87 -0.81 -0.60 0.39 -1.36 hypothetical protein
TGGT1_226220 -0.58 0.00 -0.51 -0.84 -0.99 -1.35 -1.36 alveolin domain containing intermediate filament IMC9
TGGT1_315495 0.10 0.00 -0.95 -1.03 -0.30 -0.22 -1.37 hypothetical protein
TGGT1_216200 -0.65 0.00 -0.10 -0.46 -0.76 -0.74 -1.37 hypothetical protein
TGGT1_220340 -1.15 0.00 -0.77 -0.98 -1.24 0.60 -1.37 hypothetical protein
TGGT1_225280 0.12 0.00 -0.18 -0.98 -1.06 -0.45 -1.37 hypothetical protein
TGGT1_259020 -0.33 0.00 0.35 -0.80 -0.83 -1.65 -1.37 bradyzoite antigen BAG1
TGGT1_410860 -2.51 0.00 -1.70 -1.68 -0.12 -0.47 -1.37 hypothetical protein
TGGT1_270670 -1.05 0.00 -0.81 -0.86 -0.76 -0.96 -1.37 hypothetical protein
TGGT1_237070 -1.14 0.00 -0.78 -0.64 0.41 3.29 -1.38 hypothetical protein
TGGT1_320540 0.10 0.00 0.01 -1.00 -1.48 -1.17 -1.38 hypothetical protein
TGGT1_318240 -0.13 0.00 -0.71 -0.45 -0.33 1.53 -1.39 Tubulin-tyrosine ligase family protein
TGGT1_264700 -1.14 0.00 -0.15 -0.58 -0.70 -0.76 -1.39 hypothetical protein
TGGT1_231900 0.60 0.00 -0.55 -0.92 -0.81 -1.09 -1.39 acyl-CoA dehydrogenase domain-containing protein
TGGT1_269020 -0.90 0.00 -0.66 -0.87 -0.72 -0.28 -1.39 hypothetical protein
TGGT1_318500 0.74 0.00 -0.98 -0.76 0.13 -0.10 -1.41 cpw-wpc domain-containing protein
TGGT1_209410 0.00 0.00 -0.13 -0.74 -1.17 -1.08 -1.41 hypothetical protein
TGGT1_203340 -0.60 0.00 -0.96 -0.77 -0.17 0.03 -1.41 metallo-beta-lactamase domain-containing protein
TGGT1_272265 -0.20 0.00 -0.62 -0.33 -0.39 -1.09 -1.41 hypothetical protein
TGGT1_228050 0.27 0.00 -0.08 -0.36 -0.39 -0.28 -1.41 hypothetical protein
TGGT1_310580 0.37 0.00 0.24 -0.56 -0.99 0.29 -1.42 1,3(4)-beta-glucanase
TGGT1_319360 0.80 0.00 -0.66 -0.74 -0.56 -0.98 -1.42 SAG-related sequence SRS17A
TGGT1_273740 -0.65 0.00 -0.09 -0.63 -0.45 0.40 -1.42 putative acetyl-CoA acyltransferase B
TGGT1_205590 -0.32 0.00 -1.10 -0.72 -0.24 0.90 -1.42 hypothetical protein
TGGT1_264178B -0.10 0.00 -0.10 -0.74 -1.48 -0.39 -1.42 flagellar associated protein
TGGT1_222700 -0.15 0.00 -0.13 -0.17 -0.83 0.35 -1.42 hypothetical protein
TGGT1_253480 0.05 0.00 0.10 -1.37 -1.42 -1.12 -1.42 putative topoisomerase VIA
TGGT1_240325 -1.20 0.00 0.31 -0.20 -1.22 -0.30 -1.43 Toxoplasma gondii family E protein
TGGT1_205450 -0.37 0.00 -1.48 -1.69 -0.07 0.08 -1.43 hypothetical protein
TGGT1_297920 -1.09 0.00 -0.33 -0.84 -1.30 -0.15 -1.43 hypothetical protein
TGGT1_277055 -1.17 0.00 -0.73 -1.06 -1.05 -1.20 -1.43 hypothetical protein
TGGT1_236880 -0.09 0.00 -0.10 -1.01 -1.03 -1.05 -1.43 hypothetical protein
TGGT1_408340 -0.06 0.00 -0.42 -0.67 -0.69 -0.85 -1.44 toxoplasma gondii family D protein
TGGT1_263135 -0.66 0.00 -0.20 -0.06 -0.40 -1.75 -1.44 hypothetical protein
TGGT1_247540 1.87 0.00 -0.41 -0.66 -0.61 -0.32 -1.44 ATP-binding cassette G family transporter ABCG107
TGGT1_410900 -1.78 0.00 0.17 -0.24 -0.30 1.97 -1.45 toxoplasma gondii family A protein
TGGT1_295740 -0.41 0.00 -0.65 -0.50 -1.18 1.08 -1.45 hypothetical protein
TGGT1_239365 -1.04 0.00 0.20 -0.62 -1.26 -0.25 -1.45 hypothetical protein
TGGT1_203230 -0.42 0.00 -0.64 -0.56 0.10 -0.13 -1.45 hypothetical protein
TGGT1_290590 -0.21 0.00 -0.36 -0.46 -0.93 1.86 -1.45 hypothetical protein
TGGT1_273915 -0.33 0.00 -1.41 -1.07 0.04 -0.23 -1.46 hypothetical protein
TGGT1_201190 0.10 0.00 -0.99 -0.81 0.18 -0.14 -1.46 hypothetical protein
TGGT1_262440 -0.33 0.00 -0.40 -0.72 -1.25 -0.67 -1.46 hypothetical protein
TGGT1_408330 -0.10 0.00 -0.67 -0.95 -0.81 -0.56 -1.46 toxoplasma gondii family D protein
TGGT1_269350 0.69 0.00 -0.14 -0.80 -0.52 0.42 -1.47 hypothetical protein
TGGT1_223870 -0.58 0.00 -0.80 -0.84 -1.06 -0.79 -1.47 hypothetical protein
TGGT1_294595 0.79 0.00 -0.12 -1.25 -0.84 -1.09 -1.48 hypothetical protein
TGGT1_323200 -1.40 0.00 -0.49 -1.03 -0.96 0.95 -1.48 OTU family cysteine protease
TGGT1_220460 -0.07 0.00 0.19 -0.78 -1.23 -1.04 -1.48 SNF7 family protein
TGGT1_222935 -0.38 0.00 -0.53 -0.69 -0.04 0.14 -1.49 hypothetical protein
TGGT1_273980 -0.05 0.00 -0.48 -1.09 -1.45 -1.70 -1.49 hypothetical protein
TGGT1_272540 0.34 0.00 0.22 -0.61 -1.23 -0.08 -1.50 protein kinase (incomplete catalytic triad)
TGGT1_214420 -1.13 0.00 -0.12 -0.84 -1.47 -1.52 -1.50 hypothetical protein
TGGT1_310680 0.46 0.00 -0.16 -0.91 -0.96 -0.36 -1.50 aminotransferase, class I/II superfamily protein
TGGT1_289040 0.14 0.00 0.41 -0.85 -1.30 -1.70 -1.51 Armadillo/beta-catenin family repeat-containing protein
TGGT1_213340 -2.10 0.00 -0.31 -1.12 -1.49 -1.19 -1.51 GMC oxidoreductase
TGGT1_318130A -1.04 0.00 -0.56 -1.40 -2.51 -0.76 -1.52 Toxoplasma gondii family E protein
TGGT1_411040 -0.57 0.00 -0.63 -0.99 -0.86 -0.93 -1.52 putative IgA-specific serine endopeptidase
TGGT1_231780 -1.58 0.00 0.01 -1.08 -1.13 -0.35 -1.52 hypothetical protein
TGGT1_410870 -1.49 0.00 -1.33 -1.30 -0.81 -0.86 -1.52 tRNA-Pro
TGGT1_319090 -0.81 0.00 -0.76 -1.04 -0.68 -0.72 -1.53 IgA-specific serine endopeptidase
TGGT1_218900 1.21 0.00 -1.42 -0.80 -0.23 1.81 -1.53 hypothetical protein
TGGT1_293258 0.42 0.00 -0.33 -0.62 -0.79 -1.11 -1.53 hypothetical protein
TGGT1_201180A 0.27 0.00 -0.36 -0.72 -1.04 -1.02 -1.53 hypothetical protein
TGGT1_224710 0.18 0.00 -0.12 -0.79 -1.09 -1.16 -1.54 hypothetical protein
TGGT1_238490 1.34 0.00 -1.06 -1.51 -1.02 -0.80 -1.54 SAG-related sequence SRS22E
TGGT1_243420 -0.36 0.00 -0.33 -0.97 -0.95 -1.17 -1.54 hypothetical protein
TGGT1_278878 -1.39 0.00 -1.15 -1.05 -0.59 -0.76 -1.55 GDA1/CD39 (nucleoside phosphatase) family protein
TGGT1_357300 0.15 0.00 -0.52 -0.44 -0.63 -0.79 -1.55 hypothetical protein
TGGT1_221265 -0.29 0.00 0.11 -1.10 -1.53 -1.14 -1.55 hypothetical protein
TGGT1_273940 -1.84 0.00 -0.73 -0.34 -0.49 1.94 -1.55 hypothetical protein
TGGT1_219450 0.04 0.00 -0.53 -0.59 -0.74 2.88 -1.56 WD domain, G-beta repeat-containing protein
TGGT1_206660 -1.12 0.00 -0.10 -0.81 -1.37 -1.42 -1.56 hypothetical protein
TGGT1_257910B -0.77 0.00 -0.30 -0.48 -1.07 2.20 -1.56 hypothetical protein
TGGT1_219660 -1.04 0.00 -0.90 -0.63 -0.83 -0.30 -1.56 hypothetical protein
TGGT1_301240 0.02 0.00 -0.76 -0.72 -0.15 -0.24 -1.56 hypothetical protein
TGGT1_289060 -2.56 0.00 -0.86 -0.86 -0.38 -0.33 -1.57 hypothetical protein
TGGT1_285665 -0.10 0.00 -0.24 -0.55 -0.61 -1.08 -1.57 hypothetical protein
TGGT1_257970 0.80 0.00 -0.49 -0.87 -0.91 -0.29 -1.57 hypothetical protein
TGGT1_295640 -0.74 0.00 0.11 -0.82 -1.09 -0.37 -1.57 peptidase family M13 protein
TGGT1_267410 -2.05 0.00 -0.27 -1.36 -1.32 -1.47 -1.58 scavenger receptor protein SR1 precursor
TGGT1_289240 -0.29 0.00 -0.58 -0.59 -0.36 1.90 -1.58 DnaJ domain-containing protein
TGGT1_229350 -1.09 0.00 -0.87 -1.14 -0.78 -0.96 -1.58 HEAT repeat-containing protein




TGGT1_259960 0.95 0.00 -0.87 0.16 0.03 3.18 -1.58 Nucleoside-diphosphatase
TGGT1_221895 -1.10 0.00 -0.28 -0.58 -0.50 0.28 -1.59 hypothetical protein
TGGT1_286460 0.22 0.00 -0.90 -0.93 -0.68 -0.89 -1.59 hypothetical protein
TGGT1_227350 -4.06 0.00 -1.11 -1.05 -1.17 -2.19 -1.59 hypothetical protein
TGGT1_203330 -1.31 0.00 -1.55 -1.37 -0.91 -0.59 -1.60 hypothetical protein
TGGT1_293030 -0.19 0.00 -0.07 -0.72 -0.99 0.53 -1.60 hypothetical protein
TGGT1_409850 1.21 0.00 0.01 -0.53 -1.67 -0.20 -1.60 SAG-related sequence protein SRS47A
TGGT1_204045 0.11 0.00 -0.71 -1.08 -0.58 -0.58 -1.60 hypothetical protein
TGGT1_270680 -1.24 0.00 -1.14 -1.06 -0.97 -1.12 -1.61 hypothetical protein
TGGT1_236290 -1.38 0.00 -0.76 -1.52 -0.49 0.16 -1.62 hypothetical protein
TGGT1_247970 -1.03 0.00 -0.29 -1.01 -1.69 -1.54 -1.62 hypothetical protein
TGGT1_252860 0.33 0.00 -0.35 -0.86 -1.52 -1.54 -1.62 hypothetical protein
TGGT1_300070 0.51 0.00 0.77 -1.30 -1.78 -1.62 -1.62 hypothetical protein
TGGT1_253120 0.41 0.00 -0.14 -0.76 -1.31 -0.77 -1.62 putative mandelonitrile lyase
TGGT1_233210 -1.55 0.00 -0.18 -0.70 -1.24 -0.98 -1.62 hypothetical protein
TGGT1_205020 -0.30 0.00 -1.10 -1.31 -0.53 -0.64 -1.63 hypothetical protein
TGGT1_250360 -0.65 0.00 -0.79 -1.09 -1.02 -0.68 -1.63 alpha/beta hydrolase fold domain-containing protein
TGGT1_301260 -0.37 0.00 -1.22 -1.26 -0.92 -1.17 -1.63 hypothetical protein
TGGT1_293250 0.42 0.00 -0.08 -0.50 -0.70 2.89 -1.64 hypothetical protein
TGGT1_316690 -1.35 0.00 -0.33 -1.18 -1.41 -0.19 -1.64 hypothetical protein
TGGT1_225400 0.14 0.00 -0.51 -0.74 0.00 0.58 -1.64 hypothetical protein
TGGT1_310260 0.13 0.00 -0.56 -0.62 0.26 1.09 -1.64 hypothetical protein
TGGT1_267160 -0.73 0.00 -0.90 -1.75 -1.60 -1.60 -1.64 SAG-related sequence SRS38D
TGGT1_210095 1.02 0.00 0.46 -0.88 -1.77 -0.65 -1.64 hypothetical protein
TGGT1_281600 0.74 0.00 -0.41 -1.08 -0.23 -0.03 -1.65 hypothetical protein
TGGT1_293500 2.23 0.00 -0.58 -1.16 -0.93 0.59 -1.66 hypothetical protein
TGGT1_240340A -0.50 0.00 -0.65 -0.68 -0.99 -0.23 -1.66 Toxoplasma gondii family E protein
TGGT1_238980 -0.98 0.00 -0.98 -1.09 -1.50 -1.80 -1.68 hypothetical protein
TGGT1_272360 0.45 0.00 -0.41 -1.33 -1.20 0.56 -1.68 EF hand family protein
TGGT1_225190 -0.73 0.00 -0.66 -1.03 -1.31 -1.46 -1.69 hypothetical protein
TGGT1_209300 -0.22 0.00 -0.48 -1.05 -1.38 -1.19 -1.69 WD domain, G-beta repeat-containing protein
TGGT1_318120 -0.92 0.00 -0.93 -1.07 -1.96 -1.15 -1.70 hypothetical protein
TGGT1_253150 -0.34 0.00 -0.17 -0.58 -1.16 2.85 -1.70 hypothetical protein
TGGT1_271892 -1.32 0.00 -0.45 -1.21 -1.11 -0.51 -1.70 hypothetical protein
TGGT1_205658 -2.11 0.00 -0.24 -0.92 -1.03 -0.11 -1.71 F5/8 type C domain-containing protein
TGGT1_292335 -0.79 0.00 -0.55 -1.11 -1.30 -1.97 -1.72 hypothetical protein
TGGT1_411550 -2.03 0.00 -0.05 -0.56 -0.36 1.85 -1.72 toxoplasma gondii family A protein
TGGT1_309030 -0.45 0.00 -0.05 -0.70 -0.63 0.44 -1.73 hypothetical protein
TGGT1_227880 -0.24 0.00 -0.99 -1.15 -0.48 -0.62 -1.73 hypothetical protein
TGGT1_210235 4.01 0.00 -1.18 -0.70 0.53 0.38 -1.73 hypothetical protein
TGGT1_209510 -1.09 0.00 0.73 -0.77 -2.12 -1.48 -1.73 hypothetical protein
TGGT1_315480 0.08 0.00 0.01 -0.62 -1.64 -1.09 -1.73 acyl-CoA dehydrogenase, middle domain-containing protein
TGGT1_211050 -0.14 0.00 -0.43 -1.30 -0.64 1.13 -1.74 ATPase, AAA family protein
TGGT1_248760 -0.09 0.00 -0.49 -0.60 -0.93 0.74 -1.74 subtilisin SUB7
TGGT1_218210 -0.17 0.00 -0.28 -0.86 -0.89 -0.61 -1.74 putative Chromosome-associated kinesin KLP1
TGGT1_269315 0.83 0.00 0.04 -0.84 -0.35 1.66 -1.75 hypothetical protein
TGGT1_255500 -0.06 0.00 -0.64 -1.14 -1.58 -0.35 -1.75 hypothetical protein
TGGT1_218340 -0.83 0.00 -0.83 -1.09 -0.97 0.97 -1.76 hypothetical protein
TGGT1_240370 -2.83 0.00 -0.31 -0.47 -1.14 -0.27 -1.76 Toxoplasma gondii family E protein
TGGT1_272020 0.24 0.00 -0.22 -0.64 -1.40 -1.26 -1.76 hypothetical protein
TGGT1_306480 1.95 0.00 -0.42 -1.28 -1.77 -1.15 -1.76 CAM kinase, CDPK family
TGGT1_281555 0.80 0.00 0.24 -1.24 -0.98 -0.12 -1.76 hypothetical protein
TGGT1_221665 -0.78 0.00 -0.05 -0.67 -0.90 0.72 -1.77 hypothetical protein
TGGT1_409760 0.36 0.00 0.20 -0.80 -1.29 -1.04 -1.77 putative transmembrane protein
TGGT1_243940 -0.70 0.00 -0.16 -0.78 -1.10 -0.95 -1.77 hypothetical protein
TGGT1_215670 -0.33 0.00 -0.20 -0.93 -1.23 1.44 -1.78 cAMP-dependent protein kinase
TGGT1_316130 0.27 0.00 -0.84 -1.11 -1.04 0.01 -1.78 hypothetical protein
TGGT1_270970 -1.40 0.00 -0.08 -0.94 -0.36 0.42 -1.78 hypothetical protein
TGGT1_205210 -0.60 0.00 -0.68 -1.13 -1.06 -0.58 -1.78 hypothetical protein
TGGT1_318675 0.78 0.00 -0.12 -1.06 -1.09 -0.54 -1.79 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_208020 -1.32 0.00 -0.41 -0.87 -1.17 -1.38 -1.79 AP2 domain transcription factor AP2Ib-1
TGGT1_312970 0.14 0.00 -0.27 -1.00 -1.04 0.93 -1.79 hypothetical protein
TGGT1_240730 -1.13 0.00 -1.01 -1.09 -0.71 -0.84 -1.79 hypothetical protein
TGGT1_289850 -0.50 0.00 -0.59 -0.85 -0.82 2.55 -1.80 hypothetical protein
TGGT1_265120 0.04 0.00 -0.42 -0.99 -1.78 -0.31 -1.80 putative rhoptry neck protein
TGGT1_220840 -0.49 0.00 -0.90 -0.72 -0.68 -1.39 -1.80 threonine synthase
TGGT1_258225 0.23 0.00 -0.80 -0.76 -0.77 -0.81 -1.80 hypothetical protein
TGGT1_234260 -0.72 0.00 -0.77 -0.97 -0.92 -0.98 -1.80 hypothetical protein
TGGT1_320090 -1.00 0.00 -0.65 -1.48 -1.53 -1.45 -1.81 hypothetical protein
TGGT1_224080 0.12 0.00 0.15 -0.15 -1.41 1.02 -1.82 Kazal-type serine protease inhibitor domain-containing protein
TGGT1_269640 -0.42 0.00 -0.90 -1.30 -1.30 -1.14 -1.82 hypothetical protein
TGGT1_228500 -1.28 0.00 0.05 -1.07 -1.41 -0.95 -1.82 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_202065 -0.70 0.00 -0.49 -0.61 -1.30 -0.71 -1.82 hypothetical protein
TGGT1_316550 0.79 0.00 -0.61 -0.92 -1.46 -1.00 -1.83 hypothetical protein
TGGT1_271980 -0.50 0.00 0.25 -0.89 -1.71 -1.62 -1.84 SAG-related sequence SRS32
TGGT1_221560 0.97 0.00 0.28 -0.68 -1.22 1.32 -1.84 hypothetical protein
TGGT1_221550 -0.08 0.00 -1.48 -0.78 -0.49 0.79 -1.86 CMGC kinase, MAPK family, MEK kinase-related (incomplete catalytic triad)
TGGT1_281675 -1.05 0.00 -0.45 -0.75 -1.27 -1.64 -1.86 putative protein kinase
TGGT1_203682 -2.51 0.00 -1.00 -1.64 -0.80 -0.35 -1.86 hypothetical protein
TGGT1_295662 -0.68 0.00 -0.64 -1.35 -1.33 -1.11 -1.87 hypothetical protein
TGGT1_279310 -1.30 0.00 -1.64 -1.45 -0.28 -0.54 -1.87 hypothetical protein
TGGT1_231060 -0.50 0.00 0.10 -0.55 -1.30 -0.17 -1.87 subtilisin SUB9
TGGT1_294210 -0.77 0.00 0.21 -0.94 -1.56 -0.65 -1.88 hypothetical protein
TGGT1_289840 -0.36 0.00 -0.39 -1.35 -1.27 1.60 -1.88 hypothetical protein
TGGT1_229660 -0.21 0.00 -1.10 -1.19 -0.30 -0.86 -1.89 hypothetical protein
TGGT1_276980 0.12 0.00 -1.06 -1.20 -0.65 -0.50 -1.90 hypothetical protein




TGGT1_202050 -1.15 0.00 -0.53 -0.76 -1.25 -0.68 -1.91 hypothetical protein
TGGT1_205140 -1.32 0.00 -0.07 -1.25 -1.87 0.51 -1.92 hypothetical protein
TGGT1_238915 0.10 0.00 0.15 -0.71 -1.46 -0.22 -1.92 hypothetical protein
TGGT1_218890 -0.37 0.00 -0.06 -1.42 0.03 2.95 -1.92 hypothetical protein
TGGT1_254890 -1.38 0.00 -0.86 -1.35 -1.42 -1.12 -1.93 hypothetical protein
TGGT1_315560 -1.11 0.00 -1.02 -1.35 -1.84 1.20 -1.93 ATP-binding cassette G family transporter ABCG77
TGGT1_268360 -1.22 0.00 -1.96 -1.31 -0.94 0.71 -1.93 hypothetical protein
TGGT1_305580 0.29 0.00 -0.64 -0.79 -1.56 -0.56 -1.93 ankyrin repeat-containing protein
TGGT1_269035 -0.18 0.00 -0.32 -0.68 -0.79 0.22 -1.93 nucleoside diphosphate kinase
TGGT1_321470 -2.05 0.00 -0.89 -0.73 0.09 0.48 -1.96 SAG-related sequence SRS12D
TGGT1_316380 0.70 0.00 -0.16 -0.14 -0.33 1.19 -1.96 hypothetical protein
TGGT1_260000 -0.21 0.00 -0.53 -1.23 -1.06 0.79 -1.96 hypothetical protein
TGGT1_203688 -2.30 0.00 -1.25 -1.93 -1.04 -0.47 -1.96 hypothetical protein
TGGT1_254750 -0.34 0.00 -0.03 -0.71 -1.25 1.04 -1.97 c3orf15 protein
TGGT1_201230 -1.47 0.00 -0.68 -1.22 -1.54 -1.49 -1.97 kinesin motor domain-containing protein
TGGT1_411250 0.16 0.00 -0.21 0.28 -0.50 1.07 -1.97 SAG-related sequence protein SRS22I
TGGT1_209485 -1.03 0.00 -0.62 -0.63 -0.59 2.14 -1.98 hypothetical protein
TGGT1_254160 -1.46 0.00 -1.11 -0.82 -0.61 0.60 -1.98 hypothetical protein
TGGT1_258575 1.08 0.00 -0.49 -2.31 -2.03 -2.70 -1.98 Dpy-30 motif protein
TGGT1_313250 -0.42 0.00 -1.24 -0.95 -0.22 -1.14 -1.98 hypothetical protein
TGGT1_246070 -1.25 0.00 -1.07 -1.38 -0.95 0.21 -1.99 SAG-related sequence SRS56
TGGT1_203250 -0.33 0.00 -0.21 -1.12 -0.90 1.50 -2.00 hypothetical protein
TGGT1_275590 0.10 0.00 -0.65 -1.02 -1.63 0.02 -2.00 mono- or diacylglycerol acyltransferase
TGGT1_274170 -0.65 0.00 -0.97 -1.30 -0.79 -0.31 -2.00 protein kinase (incomplete catalytic triad)
TGGT1_409630 -2.74 0.00 -0.60 -0.66 -1.05 -0.32 -2.01 toxoplasma gondii family E protein
TGGT1_269380 -1.56 0.00 -1.11 -0.94 -1.34 -1.00 -2.01 hypothetical protein
TGGT1_202400 -0.30 0.00 -0.04 -0.33 -0.86 1.19 -2.01 calcium binding egf domain-containing protein
TGGT1_249040 0.27 0.00 0.45 -0.39 -1.42 -0.95 -2.01 hypothetical protein
TGGT1_411540 -0.25 0.00 -1.52 -1.83 -0.39 -0.48 -2.01 hypothetical protein
TGGT1_233670 -0.46 0.00 0.28 -0.61 -0.66 0.00 -2.02 hypothetical protein
TGGT1_315345 -1.25 0.00 -0.59 -0.76 -1.58 -2.27 -2.02 SAG-related sequence SRS52F
TGGT1_286020 -0.05 0.00 -0.96 -1.29 -1.27 -1.27 -2.03 hypothetical protein
TGGT1_275798 0.21 0.00 -0.98 -1.34 -0.89 -1.41 -2.03 putative microneme protein
TGGT1_237894 -1.63 0.00 -0.75 -1.60 -1.58 -0.78 -2.04 OTU family cysteine protease
TGGT1_266330 -0.66 0.00 -0.14 -0.11 -0.39 1.74 -2.04 Toxoplasma gondii family A protein
TGGT1_275360 -0.03 0.00 -0.74 -0.87 -0.13 1.08 -2.04 SAG-related sequence SRS47B
TGGT1_231400A -0.88 0.00 -1.02 -0.87 -0.60 0.19 -2.04 tubulin/FtsZ family, GTPase domain-containing protein
TGGT1_267150 -0.30 0.00 -0.88 -1.13 -0.73 -0.39 -2.05 SAG-related sequence SRS38C
TGGT1_202445 -2.00 0.00 -1.09 -1.63 -1.48 -1.35 -2.05 hypothetical protein
TGGT1_204560 0.74 0.00 -0.53 -0.44 -1.17 1.43 -2.06 putative type I fatty acid synthase
TGGT1_319390 0.69 0.00 0.19 -1.26 -1.15 0.80 -2.06 hypothetical protein
TGGT1_272430 -0.34 0.00 0.14 -1.40 -1.55 0.47 -2.08 MAC/Perforin domain-containing protein
TGGT1_249150 0.43 0.00 -0.37 -0.96 -1.17 -0.58 -2.09 PAN domain-containing protein
TGGT1_243190 -0.74 0.00 -0.86 -1.27 -0.94 -0.72 -2.09 Toxoplasma gondii family A protein
TGGT1_411360 0.39 0.00 -0.65 -0.59 -0.92 0.07 -2.10 rhoptry kinase family protein
TGGT1_233180 -1.32 0.00 -1.20 -1.22 -1.00 -0.84 -2.10 hypothetical protein
TGGT1_258840 -0.33 0.00 -0.90 -0.96 -0.86 -0.74 -2.11 hypothetical protein
TGGT1_239430 -1.42 0.00 -0.94 -1.60 -1.78 -1.59 -2.11 EF hand domain-containing protein
TGGT1_204300 -0.84 0.00 -0.46 -1.62 -1.23 -1.10 -2.12 hypothetical protein
TGGT1_281660 -1.27 0.00 -0.86 -0.91 -1.60 -2.01 -2.14 hypothetical protein
TGGT1_311710 -1.56 0.00 -0.19 -1.37 -1.83 -2.14 -2.15 hypothetical protein
TGGT1_293020 0.08 0.00 -0.40 -1.11 -1.70 0.08 -2.15 hypothetical protein
TGGT1_218470 0.30 0.00 -1.73 -0.88 0.23 2.51 -2.16 putative protein disulfide-isomerase
TGGT1_240930 -1.29 0.00 -0.87 -1.06 -1.10 -1.21 -2.16 MoaC family protein
TGGT1_231470 2.41 0.00 -0.71 -1.30 0.02 2.08 -2.17 hypothetical protein
TGGT1_242740 -0.66 0.00 0.05 -1.16 -2.16 -2.22 -2.18 hypothetical protein
TGGT1_233405 -0.62 0.00 -0.42 -1.35 -1.24 -1.49 -2.19 hypothetical protein
TGGT1_231400B -1.13 0.00 -0.84 -0.81 -0.51 -0.01 -2.19 tubulin/FtsZ family, GTPase domain-containing protein
TGGT1_408360 -0.78 0.00 -0.45 -1.13 -1.09 -1.07 -2.19 tRNA-Glu
TGGT1_227370 -1.54 0.00 -0.24 -1.23 -1.55 -0.50 -2.22 hydrolase CocE/NonD family protein
TGGT1_297090 -0.58 0.00 -0.38 -1.75 -1.37 0.90 -2.22 hypothetical protein
TGGT1_217420 2.90 0.00 -0.45 -1.04 -1.24 -0.04 -2.23 hypothetical protein
TGGT1_364540 -0.30 0.00 -1.50 -0.27 -0.23 2.19 -2.24 putative type I fatty acid synthase
TGGT1_286465 -0.37 0.00 -1.44 -1.97 -1.08 -1.00 -2.24 hypothetical protein
TGGT1_219742 -0.06 0.00 -0.38 -1.08 -1.49 -0.21 -2.27 hypothetical protein
TGGT1_411630 -0.41 0.00 -2.61 -1.93 0.12 0.30 -2.28 disulfide-isomerase domain protein
TGGT1_278400 4.03 0.00 -1.29 -1.17 -0.63 0.86 -2.33 Toxoplasma gondii family A protein
TGGT1_228160 -1.68 0.00 -0.53 -1.25 -1.51 -1.74 -2.34 acid phosphatase
TGGT1_258910 -1.12 0.00 0.14 -0.95 -1.96 -1.89 -2.34 hypothetical protein
TGGT1_264805 -1.61 0.00 -1.18 -1.16 -1.56 -1.69 -2.35 hypothetical protein
TGGT1_295995 1.04 0.00 -0.22 -0.86 -1.05 -0.44 -2.35 hypothetical protein
TGGT1_227100 -2.77 0.00 -1.12 -1.44 -0.51 0.30 -2.35 hypothetical protein
TGGT1_299020 -0.79 0.00 -0.51 -1.34 -1.83 -1.87 -2.36 AP2 domain transcription factor AP2III-4
TGGT1_294410 0.29 0.00 -0.70 -1.26 -1.45 0.31 -2.37 hypothetical protein
TGGT1_239755 -0.44 0.00 -1.27 0.04 0.31 1.61 -2.37 hypothetical protein
TGGT1_271040 -0.73 0.00 -0.34 -1.50 -1.89 -1.22 -2.37 hypothetical protein
TGGT1_204290 -1.58 0.00 -0.66 -1.71 -1.86 -1.70 -2.38 hypothetical protein
TGGT1_258570 0.55 0.00 -0.11 -1.66 -1.44 -0.13 -2.41 hypothetical protein
TGGT1_226450 -0.65 0.00 -1.15 -1.32 -1.18 0.51 -2.42 hypothetical protein
TGGT1_257670 -0.46 0.00 -0.49 -1.08 -1.66 -2.00 -2.43 hypothetical protein
TGGT1_231880 -0.69 0.00 -0.85 -1.32 -1.27 -1.08 -2.44 hypothetical protein
TGGT1_264620 -1.81 0.00 -1.03 -1.71 -1.30 0.97 -2.45 hypothetical protein
TGGT1_274140 -0.42 0.00 -1.22 -1.01 -0.29 1.29 -2.46 hypothetical protein
TGGT1_256800 -0.10 0.00 -0.58 -1.30 -1.53 0.25 -2.46 hypothetical protein
TGGT1_215775 0.89 0.00 -0.39 -1.23 -1.78 -1.54 -2.48 rhoptry protein ROP8
TGGT1_312690 -1.02 0.00 -1.15 -1.76 -1.20 1.04 -2.49 hypothetical protein








TGGT1_236595 -0.97 0.00 -0.92 -1.09 -1.01 -0.88 -2.53 ankyrin repeat-containing protein
TGGT1_320240 0.35 0.00 0.29 -1.48 -2.09 0.35 -2.55 SAG-related sequence SRS15B
TGGT1_266270 -0.83 0.00 -1.19 -1.38 -0.90 -0.32 -2.56 short-chain-acyl-CoA dehydrogenase
TGGT1_235390 -1.06 0.00 -0.74 -1.39 -1.54 0.08 -2.57 PAN domain-containing protein
TGGT1_224010 -0.17 0.00 -0.02 -0.50 -0.96 2.19 -2.63 hypothetical protein
TGGT1_305220 0.39 0.00 -1.13 -0.97 -0.05 -0.16 -2.64 C-Myc-binding family protein
TGGT1_313940 -1.52 0.00 0.01 -1.23 -2.12 -2.27 -2.65 hypothetical protein
TGGT1_410600 1.54 0.00 0.33 -0.88 -2.04 -1.07 -2.66 putative cAMP-dependent protein kinase
TGGT1_277060 0.52 0.00 -0.68 -1.50 -1.57 -1.59 -2.67 hypothetical protein
TGGT1_411410 1.00 0.00 -0.10 -1.26 -2.10 -1.24 -2.72 putative transmembrane protein
TGGT1_252640 0.84 0.00 -1.58 -0.95 -0.73 0.98 -2.73 P-type ATPase PMA1
TGGT1_243655 0.37 0.00 -0.82 -1.55 -1.37 -0.22 -2.73 GMC oxidoreductase
TGGT1_217710 0.35 0.00 -0.36 -0.89 -0.99 1.89 -2.75 DnaJ domain-containing protein
TGGT1_410610 1.80 0.00 -0.57 -1.85 -1.89 -1.16 -2.76 hypothetical protein
TGGT1_314250 1.86 0.00 -0.32 -1.53 -2.04 -1.55 -2.77 bradyzoite rhoptry protein BRP1
TGGT1_301370 2.66 0.00 -1.14 -2.12 -0.82 -0.83 -2.78 DHHC zinc finger domain-containing protein
TGGT1_201650 -0.15 0.00 -1.51 -1.73 -2.05 -0.42 -2.79 hypothetical protein
TGGT1_411220 0.40 0.00 -0.80 -1.48 -2.40 -1.73 -2.82 hypothetical protein
TGGT1_297820 0.25 0.00 -0.55 -1.42 -0.67 0.97 -2.82 putative sperm associated antigen 6
TGGT1_203900 -0.65 0.00 -0.33 -1.48 -1.67 -1.66 -2.84 hypothetical protein
TGGT1_218192 -2.72 0.00 -1.71 -1.90 -1.30 -0.76 -2.85 hypothetical protein
TGGT1_237045 -2.02 0.00 -1.79 -1.22 -0.35 1.03 -2.85 hypothetical protein
TGGT1_201640 -0.47 0.00 -1.23 -1.41 -1.91 0.27 -2.86 hypothetical protein
TGGT1_410720 2.05 0.00 -1.69 -2.20 -1.74 -0.95 -2.86 putative protein kinase
TGGT1_306500 2.02 0.00 -0.69 -1.76 -1.44 0.02 -2.89 hypothetical protein
TGGT1_240365 -2.83 0.00 -0.56 -1.16 -1.49 -1.44 -2.90 hypothetical protein
TGGT1_320105 2.27 0.00 -1.03 -1.80 -1.38 -2.02 -2.90 hypothetical protein
TGGT1_217370 -0.97 0.00 -0.63 -0.80 -0.59 1.39 -2.95 hypothetical protein
TGGT1_203800 -1.05 0.00 -1.49 -1.75 -1.83 -0.89 -2.95 hypothetical protein
TGGT1_289930 -0.70 0.00 -0.70 -1.34 -1.68 -0.87 -2.98 putative phosphoenolpyruvate carboxykinase
TGGT1_306455 1.40 0.00 -0.56 -2.39 -2.30 -1.05 -2.99 hypothetical protein
TGGT1_410590 1.69 0.00 0.34 -0.90 -1.86 -0.80 -2.99 cAMP-dependent protein kinase
TGGT1_244620 0.06 0.00 -0.72 -1.83 -2.34 -1.51 -3.02 NEK kinase
TGGT1_410630 -1.33 0.00 -2.30 -2.69 -0.53 -1.80 -3.04 tRNA-Sec
TGGT1_409410 -2.00 0.00 -0.63 -1.50 -2.45 -2.11 -3.10 tRNA-Leu
TGGT1_278410 2.90 0.00 -0.91 -0.56 -1.28 0.40 -3.28 Toxoplasma gondii family A protein
TGGT1_205662 -2.48 0.00 -0.14 -1.83 -2.02 -2.24 -3.35 LCCL domain-containing protein
TGGT1_282200 -1.30 0.00 -1.25 -1.97 -1.73 -1.51 -3.44 ATPase, AAA family protein
TGGT1_247660 0.07 0.00 -2.16 -0.81 -0.43 0.27 -3.44 thioredoxin domain-containing protein
TGGT1_237893 -0.42 0.00 -1.38 -2.24 -0.77 -0.06 -3.48 hypothetical protein
TGGT1_305100 0.40 0.00 -0.03 -0.91 -0.85 2.14 -3.53 hypothetical protein
TGGT1_237585 0.09 0.00 -0.96 -2.15 -2.28 -1.71 -3.59 hypothetical protein
TGGT1_269120 0.11 0.00 0.28 -0.41 -0.02 3.45 -3.61 putative oxidoreductase
TGGT1_264630 -1.43 0.00 -1.34 -1.85 -1.22 -0.49 -3.87 hypothetical protein
TGGT1_291910 -2.80 0.00 -1.62 -1.95 -1.43 -1.12 -3.98 hypothetical protein
TGGT1_306450 1.82 0.00 -1.51 -2.73 -2.20 -1.08 -3.99 putative short chain dehydrogenase family protein
TGGT1_311700 -1.92 0.00 -1.43 -2.57 -2.23 -2.25 -4.02 hypothetical protein
TGGT1_207050 -0.99 0.00 -1.00 -2.24 -1.81 -2.44 -4.24 hypothetical protein
TGGT1_291920 -2.90 0.00 -1.76 -2.18 -1.62 -1.17 -4.24 hypothetical protein
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Table 4.5. Regression analysis identified 319 differentially expressed genes whose 
extracellular expression over time strongly correlated with GT1’s lab-adapting 
phenotypes  
The relationship between the 988 DEGs identified by TC-seq and our lab-adaptive 
phenotypes were examined by regression analysis (RA) in order to identify correlating 
DEGs. A total of 319 DEGs were identified as strongly correlating (R2 = ≥0.70; indicated 
by green text) with at least one lab-adaptive phenotype (extracellular survival, reinvasion 
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RH P11 P35 P55 P85 P148 P210 Plaque SizeReinv. Effic EC Surv.
TGGT1_409050 4.35 0.00 1.87 1.82 1.05 3.68 4.74 0.70 0.88 -0.08 hypothetical protein
TGGT1_264260 4.80 0.00 1.21 1.19 1.01 3.54 4.07 0.80 0.96 -0.10 hypothetical protein
TGGT1_249800 4.70 0.00 -0.30 0.17 0.60 3.17 3.98 0.84 1.00 0.04 hypothetical protein
TGGT1_262590 2.90 0.00 2.06 2.98 2.66 2.58 3.45 0.56 0.56 0.94 hypothetical protein
TGGT1_264240 4.35 0.00 -0.04 0.36 1.04 3.44 3.22 0.85 1.00 0.05 hypothetical protein
TGGT1_253330 0.10 0.00 0.91 0.62 1.84 3.04 2.73 0.85 1.00 0.05 Rhoptry kinase family protein
TGGT1_249810 3.35 0.00 0.14 0.24 0.10 1.68 2.60 0.77 0.96 0.00 putative activating signal cointegrator 1 complex subunit 3
TGGT1_262600 2.68 0.00 1.36 2.10 2.10 2.18 2.48 0.82 0.83 0.65 hypothetical protein
TGGT1_309930 0.98 0.00 1.18 1.01 1.79 2.37 2.21 0.82 0.97 0.05 melibiase subfamily protein
TGGT1_216680 5.19 0.00 0.29 0.76 1.22 1.64 2.17 0.85 1.00 0.05 ankyrin repeat-containing protein
TGGT1_304670 2.30 0.00 1.64 1.74 1.16 1.37 2.01 0.47 0.39 0.75 leucine rich repeat-containing protein
TGGT1_301210 3.35 0.00 0.34 0.87 0.93 2.93 2.01 0.68 0.87 0.05 putative NAD(P) transhydrogenase subunit beta
TGGT1_216335 2.82 0.00 0.78 1.44 1.85 0.58 1.95 0.06 0.00 0.78 hypothetical protein
TGGT1_315885 -0.09 0.00 0.79 1.23 1.04 1.49 1.94 0.85 1.00 0.05 putative glycosyltransferase
TGGT1_286420A 0.44 0.00 1.09 1.41 1.06 1.33 1.89 0.67 0.78 0.78 putative elongation factor 1-alpha (EF-1-ALPHA)
TGGT1_313640 0.89 0.00 0.42 0.92 1.61 1.87 1.87 0.77 0.93 0.05 hypothetical protein
TGGT1_277685 1.74 0.00 1.43 1.60 1.36 1.79 1.82 0.61 0.77 0.27 hypothetical protein
TGGT1_231992 2.21 0.00 1.32 1.35 1.02 1.00 1.80 0.41 0.26 0.75 hypothetical protein
TGGT1_289170 0.82 0.00 1.10 1.38 1.04 1.31 1.80 0.62 0.69 0.70 adenylate and guanylate cyclase catalytic domain-containing protein
TGGT1_230705 0.31 0.00 1.11 1.42 0.87 1.45 1.75 0.67 0.77 0.47 hypothetical protein
TGGT1_316700 0.04 0.00 0.80 0.80 1.19 2.00 1.72 0.85 1.00 0.05 uridine kinase
TGGT1_220420 1.64 0.00 1.03 1.09 0.99 1.74 1.68 0.70 0.91 0.06 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_224130 1.72 0.00 1.15 1.20 1.40 1.88 1.67 0.66 0.86 0.05 hypothetical protein
TGGT1_270840 1.15 0.00 1.13 1.34 1.80 2.42 1.66 0.46 0.71 0.05 poly(ADP-ribose) polymerase catalytic domain-containing protein
TGGT1_305980 0.19 0.00 0.31 0.90 1.88 1.47 1.65 0.85 1.00 0.05 pyruvate dehydrogenase complex subunit PDH-E3I
TGGT1_202970 -0.70 0.00 0.35 0.92 0.40 0.50 1.65 0.62 0.56 0.84 hypothetical protein
TGGT1_360830 -0.12 0.00 1.00 1.06 0.50 0.81 1.60 0.85 1.00 0.05 nucleoside-triphosphatase
TGGT1_247350 1.32 0.00 0.94 0.82 1.39 1.37 1.60 0.85 1.00 0.05 thioredoxin domain-containing protein
TGGT1_296020 -2.55 0.00 1.64 1.12 1.24 1.54 1.60 0.85 1.00 0.05 hypothetical protein
TGGT1_254820 1.03 0.00 0.50 0.83 1.32 1.60 1.59 0.85 1.00 0.05 hypothetical protein
TGGT1_408600 -2.23 0.00 1.40 1.48 0.65 0.94 1.59 0.85 1.00 0.05 hypothetical protein
TGGT1_222270 -0.24 0.00 0.80 1.15 1.48 1.61 1.57 0.81 0.96 0.05 hypothetical protein
TGGT1_318430 -1.20 0.00 0.56 0.76 1.16 1.23 1.56 0.85 1.00 0.05 malate dehydrogenase MDH
TGGT1_240610 0.92 0.00 0.43 0.87 1.34 1.45 1.55 0.47 0.76 0.05 hypothetical protein
TGGT1_240410 -0.36 0.00 0.75 0.78 0.75 0.96 1.55 0.85 1.00 0.05 protein kinase (incomplete catalytic triad)
TGGT1_285170 -0.09 0.00 0.16 0.97 1.30 1.60 1.54 0.67 0.86 0.05 putative ribosomal RNA large subunit methyltransferase I
TGGT1_289210 0.54 0.00 1.03 1.33 1.12 1.06 1.52 0.57 0.56 0.97 prefoldin subunit protein
TGGT1_297245 0.41 0.00 0.21 0.71 1.54 1.26 1.52 0.85 1.00 0.05 transporter, major facilitator family protein
TGGT1_200700 1.75 0.00 0.73 0.86 0.96 1.50 1.51 0.85 1.00 0.05 Toxoplasma gondii family C protein
TGGT1_217020 3.48 0.00 0.09 0.88 1.36 0.46 1.51 0.33 0.32 0.77 ATPase, AFG1 family protein
TGGT1_245670 -0.11 0.00 -0.49 -0.08 2.33 1.55 1.50 0.81 0.96 0.05 pyruvate dehydrogenase complex subunit PDH-E1Alpha
TGGT1_317720 0.24 0.00 0.71 0.98 0.73 0.92 1.49 0.71 0.82 0.79 putative eukaryotic translation initiation factor 3 subunit 7
TGGT1_214540 -1.06 0.00 0.29 0.76 1.23 1.25 1.47 0.85 1.00 0.05 hypothetical protein
TGGT1_213460 0.82 0.00 0.78 0.56 1.06 3.04 1.47 0.61 0.83 0.05 hypothetical protein
TGGT1_290580 0.55 0.00 0.27 0.84 1.67 1.93 1.46 0.44 0.70 0.05 ATP-binding cassette G family transporter ABCG89
TGGT1_231990 -0.49 0.00 1.17 1.42 1.10 1.12 1.42 0.11 -0.06 0.78 hypothetical protein
TGGT1_212735 0.08 0.00 0.87 0.76 1.17 1.32 1.41 0.85 1.00 0.05 hypothetical protein
TGGT1_211030 1.52 0.00 0.83 0.95 1.76 1.74 1.41 0.46 0.73 0.05 hypothetical protein
TGGT1_211060 0.21 0.00 1.01 1.36 0.66 0.53 1.40 0.18 -0.02 0.70 hypothetical protein
TGGT1_309860 0.87 0.00 1.00 1.24 0.77 1.39 1.39 0.62 0.76 0.26 hypothetical protein
TGGT1_222410 1.10 0.00 1.02 1.28 1.14 1.07 1.39 0.38 0.38 0.95 hypothetical protein
TGGT1_244700 3.33 0.00 0.27 0.43 0.20 0.50 1.39 0.74 0.96 0.21 NAD(+)/NADH kinase domain-containing protein
TGGT1_306470 1.49 0.00 0.77 0.88 1.00 1.07 1.39 0.85 1.00 0.05 isoprenylcysteine carboxyl methyltransferase (icmt) family protein
TGGT1_252210 0.07 0.00 0.15 0.21 0.32 1.35 1.36 0.85 1.00 0.05 pentatricopeptide repeat domain-containing protein
TGGT1_322110 2.95 0.00 -0.03 0.33 0.45 1.16 1.35 0.85 1.00 0.05 hypothetical protein
TGGT1_315900 1.44 0.00 0.76 0.75 0.46 0.90 1.35 0.67 0.73 0.21 hypothetical protein
TGGT1_278630 0.85 0.00 0.81 0.94 1.08 1.31 1.33 0.85 1.00 0.05 tetratricopeptide repeat-containing protein
TGGT1_230980 0.97 0.00 0.62 0.67 0.69 1.33 1.33 0.85 1.00 0.05 myosin I
TGGT1_248900 -0.51 0.00 0.90 0.87 0.53 1.16 1.32 0.85 1.00 0.05 hypothetical protein
TGGT1_247510 0.27 0.00 0.81 0.92 0.86 1.07 1.32 0.72 0.94 0.32 fructose-bisphospatase II
TGGT1_294990 0.88 0.00 0.83 1.02 0.60 0.90 1.31 0.85 1.00 0.05 hypothetical protein
TGGT1_361030 -1.74 0.00 0.91 0.98 0.91 1.16 1.30 0.85 1.00 0.06 hypothetical protein
TGGT1_252280 0.76 0.00 0.31 0.73 0.81 1.20 1.29 0.85 1.00 0.05 hypothetical protein
TGGT1_282150 0.27 0.00 0.99 0.84 1.30 1.53 1.29 0.51 0.76 0.05 hypothetical protein
TGGT1_240600 0.73 0.00 0.16 0.69 1.46 1.57 1.29 0.55 0.79 0.05 putative chaperonin cpn60
TGGT1_203450 0.64 0.00 0.62 0.96 0.97 0.87 1.29 0.86 0.84 0.40 DUF3228 domain-containing protein
TGGT1_273800 -0.72 0.00 0.73 0.84 0.51 1.11 1.29 0.85 1.00 0.05 WD domain, G-beta repeat-containing protein
TGGT1_292920 0.28 0.00 0.25 0.50 0.91 1.20 1.27 0.54 0.79 0.05 putative heat shock protein 75
TGGT1_286720 1.08 0.00 0.72 1.07 1.09 1.22 1.26 0.85 1.00 0.05 heat shock protein HSP28
TGGT1_305050 0.84 0.00 1.06 1.17 1.06 0.93 1.25 0.18 0.07 0.90 putative calmodulin
TGGT1_231140 0.36 0.00 0.75 0.90 0.95 1.04 1.25 0.85 1.00 0.05 ribosomal protein RPS25
TGGT1_409260 -0.24 0.00 0.19 0.44 1.16 1.50 1.24 0.75 0.91 0.05 hypothetical protein
TGGT1_267500 -0.28 0.00 1.05 1.21 0.64 0.55 1.23 0.31 0.14 0.74 hypothetical protein
TGGT1_230830 -1.41 0.00 0.51 0.78 0.79 1.13 1.23 0.82 0.97 0.05 ATPase family associated with various cellular activities (AAA) domain-containi
TGGT1_268010 -0.54 0.00 0.01 0.06 0.46 0.67 1.23 0.85 1.00 0.05 hypothetical protein
TGGT1_221470 0.95 0.00 0.68 0.71 1.04 1.32 1.22 0.85 1.00 0.05 hypothetical protein
TGGT1_219700 0.99 0.00 0.02 0.40 1.10 1.16 1.21 0.84 0.99 0.05 putative DNA replication licensing factor MCM4
TGGT1_264080 -0.48 0.00 0.08 0.40 1.50 1.30 1.21 0.62 0.84 0.05 acyl carrier protein ACP
TGGT1_265010 0.19 0.00 0.73 0.89 0.64 1.02 1.21 0.68 0.84 0.48 glutamate 5-kinase domain-containing protein
TGGT1_275770 0.26 0.00 0.99 1.16 0.68 0.66 1.20 0.42 0.30 0.80 hypothetical protein
TGGT1_262910 0.08 0.00 0.78 1.01 0.82 0.99 1.16 0.71 0.86 0.72 putative NADH-cytochrome b5 reductase 1
TGGT1_213350 0.34 0.00 0.58 0.68 0.90 1.21 1.16 0.79 0.94 0.05 ribosomal protein RPS15
TGGT1_231890 -0.08 0.00 0.18 0.66 1.34 1.41 1.16 0.49 0.75 0.05 putative beta-ketoacyl-acyl carrier protein synthase III
TGGT1_294980 0.72 0.00 0.60 0.78 0.42 0.73 1.15 0.85 1.00 0.05 hypothetical protein
TGGT1_292290 -0.09 0.00 1.01 0.92 0.68 1.13 1.15 0.68 0.80 0.40 hypothetical protein
TGGT1_245746A -1.84 0.00 0.80 0.84 0.49 0.68 1.14 0.50 0.41 0.77 hypothetical protein
TGGT1_258470 -0.12 0.00 0.83 0.79 0.61 1.17 1.13 0.65 0.82 -0.06 hypothetical protein








TGGT1_202850 -0.75 0.00 -0.39 -0.79 -0.85 -1.06 -1.09 0.62 0.83 0.05 ATP-binding domain-containing protein
TGGT1_227630 -0.02 0.00 0.32 -0.69 -1.35 -1.01 -1.09 0.76 0.92 0.05 hypothetical protein
TGGT1_237210 -0.79 0.00 -0.28 -0.65 -0.93 -1.18 -1.09 0.83 0.98 0.05 Tyrosine kinase-like (TKL) protein
TGGT1_208760 0.47 0.00 -0.36 -0.74 -0.54 -0.64 -1.12 0.85 1.00 0.05 hypothetical protein
TGGT1_263110 -1.34 0.00 -0.27 -0.37 -0.79 -1.22 -1.13 0.76 0.92 0.05 hypothetical protein
TGGT1_232240 -1.39 0.00 -0.72 -0.57 -0.89 -0.75 -1.13 0.85 1.00 0.05 hypothetical protein
TGGT1_239290 -2.20 0.00 -0.66 -0.36 -0.17 -0.59 -1.14 0.85 1.00 0.05 hypothetical protein
TGGT1_243382 0.24 0.00 -0.57 -0.20 -0.38 0.68 -1.14 0.92 0.97 0.23 hypothetical protein
TGGT1_277070 -1.04 0.00 -0.59 -0.63 -0.99 -1.25 -1.14 0.81 0.96 0.05 SWI2/SNF2-containing protein
TGGT1_272680 -0.19 0.00 -0.30 -0.54 -0.60 -0.87 -1.14 0.85 1.00 0.05 hypothetical protein
TGGT1_209040 -0.17 0.00 0.04 -0.71 -1.00 -0.83 -1.15 0.68 0.70 0.33 hypothetical protein
TGGT1_248330 -0.29 0.00 -0.41 -0.45 -0.54 -1.17 -1.15 0.85 1.00 0.05 zinc finger, C3HC4 type (RING finger) domain-containing protein
TGGT1_312930 0.86 0.00 -0.07 -0.71 -0.82 -0.65 -1.15 0.85 1.00 0.05 putative cystathione gamma lyase
TGGT1_262825 -0.73 0.00 -0.21 -0.50 -1.29 -1.30 -1.16 0.44 0.71 0.05 peptidase family c50 protein
TGGT1_206650 -0.96 0.00 -0.64 -0.74 -0.78 -0.61 -1.16 0.85 1.00 0.05 zinc finger, c2h2 type domain-containing protein
TGGT1_271090 0.09 0.00 -0.40 -1.14 -0.76 -1.04 -1.17 0.30 0.40 0.84 hypothetical protein
TGGT1_236960 -0.07 0.00 -0.71 -0.95 -0.36 -0.19 -1.17 0.37 0.25 0.94 transporter, major facilitator family protein
TGGT1_221500 -0.63 0.00 -0.78 -0.74 -0.65 -0.80 -1.17 0.65 0.71 0.64 dual specificity phosphatase, catalytic domain-containing protein
TGGT1_232420 0.30 0.00 -0.21 -0.50 -0.91 -1.00 -1.17 0.85 1.00 0.05 hypothetical protein
TGGT1_280530 -0.41 0.00 -0.49 -0.45 -0.71 -1.07 -1.18 0.85 1.00 0.05 hypothetical protein
TGGT1_242720 -0.94 0.00 -0.81 -0.90 -0.74 -0.88 -1.20 0.68 0.84 0.60 aspartyl protease ASP5
TGGT1_246010 -1.54 0.00 -0.80 -0.77 -0.74 -0.94 -1.20 0.75 0.96 0.25 hypothetical protein
TGGT1_321480 0.10 0.00 -0.33 -0.33 -0.08 -0.07 -1.23 0.85 1.00 0.05 SAG-related sequence SRS12B
TGGT1_294400 -1.17 0.00 0.08 -0.04 -0.47 -0.38 -1.23 0.85 1.00 0.05 hypothetical protein
TGGT1_277950 -1.20 0.00 -0.46 -0.72 -0.73 -0.89 -1.24 0.85 1.00 0.05 lipase
TGGT1_301470 -0.50 0.00 -0.74 -0.60 -0.54 -0.59 -1.24 0.78 0.98 0.12 hypothetical protein
TGGT1_273280 0.43 0.00 -0.14 -0.21 -0.95 -1.47 -1.24 0.68 0.87 0.05 hypothetical protein
TGGT1_318610 -0.39 0.00 -0.04 -0.76 -0.73 -0.52 -1.26 0.85 1.00 0.05 AP2 domain transcription factor AP2IV-3
TGGT1_246160 -0.02 0.00 -0.53 -0.90 -0.88 -1.20 -1.26 0.79 0.95 0.05 hypothetical protein
TGGT1_206440 -0.96 0.00 -0.70 -0.62 -0.78 -1.45 -1.27 0.79 0.92 0.03 cpw-wpc domain-containing protein
TGGT1_245600 0.00 0.00 -0.50 -0.65 -1.04 -1.02 -1.27 0.85 1.00 0.05 hypothetical protein
TGGT1_301000 -0.11 0.00 -0.37 -0.55 -0.41 -0.33 -1.27 0.68 0.82 0.44 methyltransferase
TGGT1_238210 -2.18 0.00 -0.61 -1.15 -0.12 0.22 -1.28 0.43 0.29 0.77 EGF family domain-containing protein
TGGT1_218290 0.22 0.00 -0.60 -0.67 -0.66 -0.24 -1.28 0.33 0.15 0.75 WD domain, G-beta repeat-containing protein
TGGT1_305610 -0.14 0.00 -0.42 -0.34 -0.42 -0.67 -1.29 0.85 1.00 0.05 hypothetical protein
TGGT1_243330 -0.27 0.00 -0.80 -0.52 -0.59 0.29 -1.29 0.87 0.99 0.14 hypothetical protein
TGGT1_214430 -1.25 0.00 0.14 -0.55 -1.37 -1.18 -1.30 0.72 0.89 0.05 hypothetical protein
TGGT1_218510 0.41 0.00 -0.21 -0.31 -0.51 -1.13 -1.30 0.85 1.00 0.05 hypothetical protein
TGGT1_208380 0.17 0.00 0.23 -0.81 -1.16 -0.80 -1.30 0.85 1.00 0.05 hypothetical protein
TGGT1_306510 0.58 0.00 -0.59 -0.82 -0.76 -0.93 -1.32 0.75 0.97 0.23 hypothetical protein
TGGT1_294240 -1.74 0.00 -0.83 -0.36 -0.14 0.80 -1.33 0.85 1.00 0.05 hypothetical protein
TGGT1_262110 -0.26 0.00 -0.31 -0.90 -0.46 0.04 -1.35 0.26 0.11 0.91 hypothetical protein
TGGT1_267490 -1.55 0.00 0.19 -0.61 -1.01 -1.44 -1.35 0.81 0.96 0.05 putative preprocathepsin c precursor
TGGT1_227875 -0.44 0.00 -0.73 -0.74 -0.76 -1.07 -1.35 0.85 1.00 0.05 hypothetical protein
TGGT1_203300 0.05 0.00 -0.29 -0.85 -1.02 -0.85 -1.36 0.85 1.00 0.05 hypothetical protein
TGGT1_225105 -0.99 0.00 -0.06 -0.87 -1.05 -1.11 -1.36 0.84 0.99 0.05 hypothetical protein
TGGT1_314370 -1.11 0.00 -0.52 -0.72 -0.76 -1.11 -1.36 0.85 1.00 0.05 hypothetical protein
TGGT1_217860 -1.22 0.00 -0.87 -0.81 -0.60 0.39 -1.36 0.85 1.00 0.05 hypothetical protein
TGGT1_226220 -0.58 0.00 -0.51 -0.84 -0.99 -1.35 -1.36 0.83 0.98 0.05 alveolin domain containing intermediate filament IMC9
TGGT1_216200 -0.65 0.00 -0.10 -0.46 -0.76 -0.74 -1.37 0.85 1.00 0.05 hypothetical protein
TGGT1_225280 0.12 0.00 -0.18 -0.98 -1.06 -0.45 -1.37 0.32 0.33 0.93 hypothetical protein
TGGT1_270670 -1.05 0.00 -0.81 -0.86 -0.76 -0.96 -1.37 0.69 0.91 0.34 hypothetical protein
TGGT1_318240 -0.13 0.00 -0.71 -0.45 -0.33 1.53 -1.39 0.85 1.00 0.05 Tubulin-tyrosine ligase family protein
TGGT1_269020 -0.90 0.00 -0.66 -0.87 -0.72 -0.28 -1.39 0.50 0.43 0.97 hypothetical protein
TGGT1_209410 0.00 0.00 -0.13 -0.74 -1.17 -1.08 -1.41 0.85 1.00 0.05 hypothetical protein
TGGT1_319360 0.80 0.00 -0.66 -0.74 -0.56 -0.98 -1.42 0.85 1.00 0.05 SAG-related sequence SRS17A
TGGT1_277055 -1.17 0.00 -0.73 -1.06 -1.05 -1.20 -1.43 0.85 1.00 0.05 hypothetical protein
TGGT1_236880 -0.09 0.00 -0.10 -1.01 -1.03 -1.05 -1.43 0.85 1.00 0.05 hypothetical protein
TGGT1_247540 1.87 0.00 -0.41 -0.66 -0.61 -0.32 -1.44 0.85 1.00 0.05 ATP-binding cassette G family transporter ABCG107
TGGT1_223870 -0.58 0.00 -0.80 -0.84 -1.06 -0.79 -1.47 0.85 1.00 0.05 hypothetical protein
TGGT1_323200 -1.40 0.00 -0.49 -1.03 -0.96 0.95 -1.48 0.75 0.73 0.52 OTU family cysteine protease
TGGT1_222935 -0.38 0.00 -0.53 -0.69 -0.04 0.14 -1.49 0.85 1.00 0.05 hypothetical protein
TGGT1_273980 -0.05 0.00 -0.48 -1.09 -1.45 -1.70 -1.49 0.45 0.72 0.05 hypothetical protein
TGGT1_213340 -2.10 0.00 -0.31 -1.12 -1.49 -1.19 -1.51 0.42 0.71 0.05 GMC oxidoreductase
TGGT1_411040 -0.57 0.00 -0.63 -0.99 -0.86 -0.93 -1.52 0.85 1.00 0.05 putative IgA-specific serine endopeptidase
TGGT1_319090 -0.81 0.00 -0.76 -1.04 -0.68 -0.72 -1.53 0.85 1.00 0.05 IgA-specific serine endopeptidase
TGGT1_293258 0.42 0.00 -0.33 -0.62 -0.79 -1.11 -1.53 0.85 1.00 0.05 hypothetical protein
TGGT1_201180A 0.27 0.00 -0.36 -0.72 -1.04 -1.02 -1.53 0.75 0.94 0.10 hypothetical protein
TGGT1_224710 0.18 0.00 -0.12 -0.79 -1.09 -1.16 -1.54 0.85 1.00 0.05 hypothetical protein
TGGT1_357300 0.15 0.00 -0.52 -0.44 -0.63 -0.79 -1.55 0.85 1.00 0.05 hypothetical protein
TGGT1_206660 -1.12 0.00 -0.10 -0.81 -1.37 -1.42 -1.56 0.73 0.90 0.05 hypothetical protein
TGGT1_219660 -1.04 0.00 -0.90 -0.63 -0.83 -0.30 -1.56 0.85 1.00 0.05 hypothetical protein
TGGT1_301240 0.02 0.00 -0.76 -0.72 -0.15 -0.24 -1.56 0.85 1.00 0.05 hypothetical protein
TGGT1_267410 -2.05 0.00 -0.27 -1.36 -1.32 -1.47 -1.58 0.52 0.78 0.05 scavenger receptor protein SR1 precursor
TGGT1_229350 -1.09 0.00 -0.87 -1.14 -0.78 -0.96 -1.58 0.63 0.70 0.74 HEAT repeat-containing protein
TGGT1_267670 -1.50 0.00 -0.63 -0.98 -0.65 -0.76 -1.58 0.85 1.00 0.05 hypothetical protein
TGGT1_286460 0.22 0.00 -0.90 -0.93 -0.68 -0.89 -1.59 0.78 0.92 0.54 hypothetical protein
TGGT1_227350 -4.06 0.00 -1.11 -1.05 -1.17 -2.19 -1.59 0.66 0.84 0.03 hypothetical protein
TGGT1_204045 0.11 0.00 -0.71 -1.08 -0.58 -0.58 -1.60 0.69 0.70 0.93 hypothetical protein
TGGT1_270680 -1.24 0.00 -1.14 -1.06 -0.97 -1.12 -1.61 0.85 1.00 0.06 hypothetical protein
TGGT1_233210 -1.55 0.00 -0.18 -0.70 -1.24 -0.98 -1.62 0.85 1.00 0.05 hypothetical protein
TGGT1_250360 -0.65 0.00 -0.79 -1.09 -1.02 -0.68 -1.63 0.92 0.96 0.25 alpha/beta hydrolase fold domain-containing protein
TGGT1_293500 2.23 0.00 -0.58 -1.16 -0.93 0.59 -1.66 0.85 1.00 0.05 hypothetical protein
TGGT1_225190 -0.73 0.00 -0.66 -1.03 -1.31 -1.46 -1.69 0.85 1.00 0.05 hypothetical protein
TGGT1_209300 -0.22 0.00 -0.48 -1.05 -1.38 -1.19 -1.69 0.85 1.00 0.05 WD domain, G-beta repeat-containing protein
TGGT1_271892 -1.32 0.00 -0.45 -1.21 -1.11 -0.51 -1.70 0.85 1.00 0.05 hypothetical protein
TGGT1_205658 -2.11 0.00 -0.24 -0.92 -1.03 -0.11 -1.71 0.85 1.00 0.05 F5/8 type C domain-containing protein
TGGT1_218210 -0.17 0.00 -0.28 -0.86 -0.89 -0.61 -1.74 0.71 0.81 0.81 putative Chromosome-associated kinesin KLP1
TGGT1_218340 -0.83 0.00 -0.83 -1.09 -0.97 0.97 -1.76 0.85 1.00 0.05 hypothetical protein
TGGT1_240370 -2.83 0.00 -0.31 -0.47 -1.14 -0.27 -1.76 0.85 1.00 0.05 Toxoplasma gondii family E protein
TGGT1_243940 -0.70 0.00 -0.16 -0.78 -1.10 -0.95 -1.77 0.85 1.00 0.05 hypothetical protein
TGGT1_316130 0.27 0.00 -0.84 -1.11 -1.04 0.01 -1.78 0.85 1.00 0.05 hypothetical protein
TGGT1_318675 0.78 0.00 -0.12 -1.06 -1.09 -0.54 -1.79 0.85 1.00 0.05 3'5'-cyclic nucleotide phosphodiesterase domain-containing protein
TGGT1_208020 -1.32 0.00 -0.41 -0.87 -1.17 -1.38 -1.79 0.85 1.00 0.05 AP2 domain transcription factor AP2Ib-1
TGGT1_240730 -1.13 0.00 -1.01 -1.09 -0.71 -0.84 -1.79 0.69 0.90 0.41 hypothetical protein
TGGT1_269640 -0.42 0.00 -0.90 -1.30 -1.30 -1.14 -1.82 0.78 0.97 0.27 hypothetical protein
TGGT1_281675 -1.05 0.00 -0.45 -0.75 -1.27 -1.64 -1.86 0.85 1.00 0.05 putative protein kinase
TGGT1_203682 -2.51 0.00 -1.00 -1.64 -0.80 -0.35 -1.86 0.22 0.03 0.78 hypothetical protein
TGGT1_276980 0.12 0.00 -1.06 -1.20 -0.65 -0.50 -1.90 0.58 0.50 0.83 hypothetical protein





TGGT1_254890 -1.38 0.00 -0.86 -1.35 -1.42 -1.12 -1.93 0.85 1.00 0.05 hypothetical protein
TGGT1_201230 -1.47 0.00 -0.68 -1.22 -1.54 -1.49 -1.97 0.85 1.00 0.05 kinesin motor domain-containing protein
TGGT1_246070 -1.25 0.00 -1.07 -1.38 -0.95 0.21 -1.99 0.85 1.00 0.05 SAG-related sequence SRS56
TGGT1_274170 -0.65 0.00 -0.97 -1.30 -0.79 -0.31 -2.00 0.52 0.43 0.97 protein kinase (incomplete catalytic triad)
TGGT1_409630 -2.74 0.00 -0.60 -0.66 -1.05 -0.32 -2.01 0.85 1.00 0.05 toxoplasma gondii family E protein
TGGT1_315345 -1.25 0.00 -0.59 -0.76 -1.58 -2.27 -2.02 0.63 0.84 0.05 SAG-related sequence SRS52F
TGGT1_286020 -0.05 0.00 -0.96 -1.29 -1.27 -1.27 -2.03 0.85 1.00 0.05 hypothetical protein
TGGT1_249150 0.43 0.00 -0.37 -0.96 -1.17 -0.58 -2.09 0.85 1.00 0.05 PAN domain-containing protein
TGGT1_233180 -1.32 0.00 -1.20 -1.22 -1.00 -0.84 -2.10 0.85 1.00 0.05 hypothetical protein
TGGT1_311710 -1.56 0.00 -0.19 -1.37 -1.83 -2.14 -2.15 0.73 0.90 0.05 hypothetical protein
TGGT1_240930 -1.29 0.00 -0.87 -1.06 -1.10 -1.21 -2.16 0.85 1.00 0.05 MoaC family protein
TGGT1_227370 -1.54 0.00 -0.24 -1.23 -1.55 -0.50 -2.22 0.85 1.00 0.05 hydrolase CocE/NonD family protein
TGGT1_228160 -1.68 0.00 -0.53 -1.25 -1.51 -1.74 -2.34 0.85 1.00 0.05 acid phosphatase
TGGT1_294410 0.29 0.00 -0.70 -1.26 -1.45 0.31 -2.37 0.85 1.00 0.05 hypothetical protein
TGGT1_257670 -0.46 0.00 -0.49 -1.08 -1.66 -2.00 -2.43 0.85 1.00 0.05 hypothetical protein
TGGT1_215775 0.89 0.00 -0.39 -1.23 -1.78 -1.54 -2.48 0.85 1.00 0.05 rhoptry protein ROP8
TGGT1_312690 -1.02 0.00 -1.15 -1.76 -1.20 1.04 -2.49 0.41 0.34 0.99 hypothetical protein
TGGT1_236595 -0.97 0.00 -0.92 -1.09 -1.01 -0.88 -2.53 0.75 0.97 0.15 ankyrin repeat-containing protein
TGGT1_266270 -0.83 0.00 -1.19 -1.38 -0.90 -0.32 -2.56 0.85 1.00 0.05 short-chain-acyl-CoA dehydrogenase
TGGT1_235390 -1.06 0.00 -0.74 -1.39 -1.54 0.08 -2.57 0.79 0.89 0.19 PAN domain-containing protein
TGGT1_313940 -1.52 0.00 0.01 -1.23 -2.12 -2.27 -2.65 0.84 1.00 0.05 hypothetical protein
TGGT1_277060 0.52 0.00 -0.68 -1.50 -1.57 -1.59 -2.67 0.85 1.00 0.05 hypothetical protein
TGGT1_410610 1.80 0.00 -0.57 -1.85 -1.89 -1.16 -2.76 0.82 0.99 0.08 hypothetical protein
TGGT1_314250 1.86 0.00 -0.32 -1.53 -2.04 -1.55 -2.77 0.85 1.00 0.05 bradyzoite rhoptry protein BRP1
TGGT1_411220 0.40 0.00 -0.80 -1.48 -2.40 -1.73 -2.82 0.82 0.99 0.05 hypothetical protein
TGGT1_218192 -2.72 0.00 -1.71 -1.90 -1.30 -0.76 -2.85 0.64 0.69 0.73 hypothetical protein
TGGT1_203800 -1.05 0.00 -1.49 -1.75 -1.83 -0.89 -2.95 0.88 0.84 0.54 hypothetical protein
TGGT1_289930 -0.70 0.00 -0.70 -1.34 -1.68 -0.87 -2.98 0.85 1.00 0.05 putative phosphoenolpyruvate carboxykinase
TGGT1_306455 1.40 0.00 -0.56 -2.39 -2.30 -1.05 -2.99 0.23 0.23 0.96 hypothetical protein
TGGT1_282200 -1.30 0.00 -1.25 -1.97 -1.73 -1.51 -3.44 0.85 1.00 0.05 ATPase, AAA family protein
TGGT1_237585 0.09 0.00 -0.96 -2.15 -2.28 -1.71 -3.59 0.85 1.00 0.05 hypothetical protein
TGGT1_291910 -2.80 0.00 -1.62 -1.95 -1.43 -1.12 -3.98 0.69 0.83 0.66 hypothetical protein
TGGT1_306450 1.82 0.00 -1.51 -2.73 -2.20 -1.08 -3.99 0.30 0.18 0.94 putative short chain dehydrogenase family protein
TGGT1_311700 -1.92 0.00 -1.43 -2.57 -2.23 -2.25 -4.02 0.90 0.96 0.22 hypothetical protein
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